European Academy of Allergy and Clinical Immunology June 2017 Helsinki, Finland. EAACI Congress 2017

Transcription

1 European Academy of Allergy and Clinical Immunology June 2017 Helsinki, Finland EAACI Congress 2017 Visit the website for more information On the Road to Prevention and Healthy Living #eaaci2017

2 WELCOME Contents Welcome...3 Addresses...5 Committees...7 Congress Venue Overview...8 General Information...10 Business Meetings...14 EAACI Meetings...19 Networking Events...19 Congress Scholarship Recipients / Fellowship...20 EAACI Awards Clinical Village...24 Description of Session Types...25 Scientific Programme Saturday, 17 June Sunday, 18 June Monday, 19 June Tuesday, 20 June Wednesday, 21 June Posters Speaker Index Sponsorship and Exhibition Industry Sessions Exhibition Floorplan Exhibitor List Exhibitor Editorials Hotels in Helsinki

3 WELCOME Dear Friends, Colleagues, Dear EAACI Friends, We very much look forward to hosting the EAACI Congress 2017, from June, and to wishing you a warm welcome to Finland and the beautiful city of Helsinki. The theme for the Helsinki Congress is On the road to prevention and healthy living. A unifying theme for EAACI, this represents the next step in making our patients lives healthy, despite their allergies. With more than half of all Europeans soon expected to suffer from allergy, ensuring our patients have a better quality of life, despite the allergy epidemic, is an obvious goal for EAACI. It is also a theme in the true Finnish Allergy Programme spirit: wishing good life for all people. The EAACI Congress 2017 is to be held in the Messukeskus Congress Center, which is easily reached from the city centre in just 5 minutes by train. This recently renovated venue offers the highest standards in conference facilities, with well-equipped and easy-to-find session rooms and a full digital environment. Helsinki itself is a modern city with all its attractions and services within walking distance. It has excellent hotels and restaurants for all budgets, monuments, parks, shopping, market squares and other places to visit, as well as the sea with picturesque boat rides in the Helsinki archipelago, a lively nightlife and even free bicycles provided by the city. Helsinki manages to combine big city life with the green and beautiful countryside in which it resides. With something for all tastes, Helsinki is a unique Nordic experience. On behalf of the European Academy of Allergy and Clinical Immunology it is my great pleasure to welcome you to Helsinki for the EAACI Congress Helsinki promises to be a wonderful Congress venue and offers an excellent opportunity for us to investigate, at close hand, the Finnish National Programme for Allergy a programme which is becoming a model for other EU countries to follow. Allergic diseases can be better managed with early diagnosis, and an awareness of allergy symptoms is crucial to this aim. Recognition of the value of the allergy specialty and national policies for the education of health professionals at all levels are essential to achieve progress in this area and to promote an effective understanding and awareness of allergic symptoms. We all have much to learn from the Finnish model. For many of you, this will be one of many similar conferences you have attended; for others, it will be the first. For all of us, the city of Helsinki and the friendly and open Nordic approach of its people will be the perfect context for our Congress, for sharing and discussing high level science, and translating that science into concrete initiatives for the benefit of allergy sufferers in Europe and across the world. Thank you for joining us. Welcome to Helsinki! Antti Lauerma EAACI Congress 2017 Chair Antonella Muraro EAACI President 3

4 WELCOME PAAM October 2017 London, United Kingdom 5th Pediatric Allergy and Asthma Meeting 4

5 ADDRESSES Important Addresses EAACI Headquarters Hagenholzstrasse 111 3rd Floor 8050 Zurich Switzerland Tel: EAACI - EU Liaison Office Rue du Luxembourg, Brussels Belgium Tel: EUoffice@eaaci.org Congress Venue Messukeskus Messuaukio Helsinki Finland Tel: The European Academy of Allergy and Clinical Immunology (EAACI) is a non-profit organisation active in the field of allergic and immunologic diseases such as asthma, rhinitis, eczema, occupational allergy, food and drug allergy and anaphylaxis. EAACI was founded in 1956 in Florence and has become the largest medical association in Europe in the field of allergy and clinical immunology. It includes over 10,000 members from 122 countries, as well as 60 national member societies. Visit for more information. DOWNLOAD THE EAACI CONGRESS APP Information at your fingertips during the 2017 Congress } Download using the free WiFi throughout the congress venue } Regular updates to the scientific programme } Use the app to vote during the sessions } Practical information about the venue } Submit questions to the speakers } Find exhibitors easily } Evaluate sessions } Access e-posters Can be downloaded at: Visit the Congress App Helpdesk in the entrance hall for more information. 5

6 WELCOME EAACI GOES GREEN Green in 2017 Greener in 2018 FIND OUT ABOUT EAACI S COMMITMENT TO SUSTAINABILITY AND OUR BIG PLANS FOR 2018 HELP US ACHIEVE PAPERLESS CONFERENCES IN THE FUTURE BY OPTING OUT OF BAGS & PRINTED PROGRAMMES Together WE can do MORE! By reducing the quantity of programmes, we can save up to*: 1.1 mil. sheets of paper 114,561 liters of water 6,258 kgs of waste 11,000 kgs of wood 4,951 kgs of co 2 emission Here are some additional ways EAACI is making its congresses sustainable: Pads and pens made from 100% recycled paper More digital & less printed signage Collaboration with committed exhibitors Tracking our sustainability Recycling stations Environmentally-friendly badges Find out more about the EAACI Goes Green Campaign at: * Calculated on the basis of 8,000 printed programmes copies with 140 sheets of paper. 6

7 COMMITTEES EAACI EXECUTIVE COMMITTEE EAACI BOARD OF OFFICERS EAACI SECTION MEMBERS AT LARGE ADJUNCT MEMBERS A. Muraro, President CHAIRPERSONS M. B. Bilò F. Braido, CME Committee Chair P. Hellings, Secretary General Ö. Kalayci, Asthma T. Chivato T. Frew, Ethics Committee M. Jutel, Treasurer C. Bindslev-Jensen, Dermatology K. Hoffmann-Sommergruber R. Gerth van Wijk, Specialty Committee Chair N. Papadopoulos, Past President R. Mösges, ENT M. Khaitov S. Halken, Scientific Programme Coordinator L. K. Poulsen, Vice-President L. O Mahony, Immunology S. Lau A. Lauerma, EAACI Congress 2017 Chair Congresses G. du Toit, Pediatrics G. Roberts C. Schmidt-Weber, Exam Committee Chair P. Schmid-Grendelmeier, Vice- O. Tsilochristou, Junior Members S. Smolinska, EAACI Web Editor President Education and Specialty I. Agache, President Elect and Vice-President Communications and EAACI INTEREST GROUP REPRESENTATIVES F. Timmermans, Patients Organisations Committee Chair O. Tsilochristou, EAACI Social Media Editor Membership S. Quirce T. Werfel, National Allergy Societies Sue C. C. Paredi, Executive Director I. Skypala Committee Chair LOCAL ORGANISING COMMITTEE (LOC) A. Lauerma, Finland, EAACI Congress 2017 Chair M. Mäkelä, Finland, EAACI Congress 2017 Secretary N. Fyhrquist, Finland, LOC Secretary T. Haahtela, Finland EAACI Congress 2017 Honorary President J. Karjalainen, Finland P. Kauppi, Finland M. Khaitov, Russia E. Melén, Sweden A. Pelkonen, Finland S. Plado, Estonia R. Renkonen, Finland A. Salava, Finland J. Savolainen, Finland S. Toppila-Salmi, Finland E. Valovirta, Finland SCIENTIFIC PROGRAMME COMMITTEE (SPC) S. Halken Scientific Programme Committee Coordinator A. Muraro EAACI President N. Papadopoulos EAACI Past President P. Hellings EAACI Secretary General L. K. Poulsen EAACI Vice-President Congresses O. Tsilochristou Junior Member Chair A. Lauerma EAACI Congress 2017 Chair M. Mäkelä EAACI Congress 2017 Secretary N. Fyhrquist EAACI Congress 2017 LOC Secretary T. Haahtela EAACI Congress 2017 Honorary President K. Hoffmann-Sommergruber EAACI Congress 2016 LOC Secretary Z. Szepfalusi EAACI Congress 2016 LOC Member SECTION SECRETARIES Z. Diamant Asthma S. Weidinger Dermatology P. Gevaert ENT J. Schwarze Immunology M. Alvaro Lozano Pediatrics INTEREST GROUP (IG) CHAIRS J. Buters Aerobiology and Pollution M. Kurowski Allergy, Asthma and Sports H. J. Hoffmann Allergy Diagnosis K. Grimshaw Allied Health O. Boyman Biologicals M. J. Torres Drug Allergy A. Straumann Eosinophilic Esophagitis C. Apfelbacher Epidemiology C. Mills Food Allergy R. Müller Comparative and Veterinary Allergology C. van Drunen Functional Genomics and Proteomics O. Pfaar Immunotherapy H. H. Smits Infections and Allergy G. Sturm Insect Venom Hypersensitivity J. Walusiak-Skorupa Occupational Allergy A. Leonardi Ocular Allergy D. Ryan Primary Care C. Agostini Primary Immunodefiencies

8 CONGRESS VENUE OVERVIEW 5a 5 5bc Prayer Room Virtual Congress Hub Bag Distribution Clinical Village EAACI Info ENTRANCE &B 1 Registration Conference Centre Coffee Station National Society Village 3c 3b 3a F&B 3g Lower Gallery 3f 3e 3d F&B F&B F&B Exhibition Poster Area Poster Area Shop Publishers Corner F&B Virtual Congress Hub & Seating Area Pro & Con Arena Holiday Inn Conference Centre Second floor a Speaker Service Centre Press Interview Room Press Room First floor a Ground floor Winter Garden 103b 103a 102 Winter Garden Cabinet Session Rooms Meeting Rooms 101 Holiday Inn Messukeskus, Expo and Convention Centr e Helsinki 8

9 WELCOME ISMA November 2017 Luxembourg 7th International Symposium on Molecular Allergology 9

10 GENERAL INFORMATION App Information The EAACI Events app is an innovative tool that redefines the way you visit and experience the EAACI Congress. Using the app, you can explore the event programme and exhibition at your fingertips. THE APP ALLOWS YOU TO: browse, search and personalise the entire event programme. search and locate exhibitors in the Exhibition Hall. access useful information about the Congress. access Congress abstracts (from 17 June 2017). access E-Posters (from 17 June 2017). evaluate speakers and sessions to provide your valuable feedback. vote in sessions that have polls. create and synchronise events with your personal calendar. The app is updated daily and allows users to access information offline to avoid roaming costs. It can be downloaded from your app store and works with ios and Android. Search your app store for EAACI Events; if you previously downloaded the EAACI Events App, just select EAACI Congress 2017 under All. A dedicated, free WiFi connection is provided throughout the Messukeskus. EAACI thanks Novartis for their sponsorship of the Congress App. Badges Each participant receives a name badge upon check-in at registration. This badge should be worn at all times in order to gain entrance to session rooms and other events. Please note that access to the Congress areas will not be possible without an official name badge. If you have lost your badge, a new one can be purchased (with proof of your original registration) at the Registration Assistance Desk for EUR 60. Your badge will be scanned at the entrance to session rooms: this is for internal EAACI statistical purposes and for CME accreditation. Bank, Cash Machines and Post Office The nearest bank - Nordea - is located around 700 meters from Messukeskus at Maistraatinportti 4, Helsinki. There are two cash machines in Messukeskus, located in the Glass Gallery (near the main entrance) and in the Lower Gallery. The nearest post office is located about 500 meters from Messukeskus at Asemapäällikönkatu 3, Helsinki. There is a mail box located next to the Holiday Inn entrance. Business Centre The closest business centre is in the Holiday Inn lobby next to Messukeskus. Certificate of Attendance Your Certificate of Attendance can be downloaded from the Congress website ( at the beginning of July. In order to download your certificate you will need your surname and unique name badge code (for example: ABC123) as printed on your name badge. For more details, please check the website or ask at the Registration Desk in the main Entrance Hall. Climate Helsinki s climate is typical of its northerly situation. Its intermediate climate combines characteristics of both a maritime and a continental climate. The proximity of the Arctic Ocean and the North Atlantic creates cold weather, while the Gulf Stream brings in warmer air. The summer in Helsinki is bright. The days are at their longest in the second half of June, when the sun stays above the horizon for 19 hours. Clinical Village The Clinical Village has been a huge success for the last two years and will be returning by popular demand in Helsinki. The Clinical Village will be open on Saturday, 17 June 2017 from 14:00-18:00 and on Sunday, 18 June 2017 from 12:00-16:00. Please find further information at Cloakroom A cloakroom is located in the Entrance Hall next to the EAACI Counter and Bag Distribution Counter. It is free of charge for Congress attendees, with the following opening hours: Saturday, 17 June 08:00-23:30 Sunday, 18 June 07:00-19:30 Monday, 19 June 06:30-19:30 Tuesday, 20 June 07:00-19:30 Wednesday, 21 June 08:00-14:00 Continuing Medical Education (CME) credits EAACI 2017 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS) in cooperation with the European Board of Accreditation in Allergy and Clinical Immunology (EBAACI) to provide the following CME activity for medical specialists: the Congress has been designated for 24 hours of European external CME credits (ECMECs). EACCME credits are recognised in Europe and by the American Medical Association (AMA) and the Royal College of Physicians and Surgeons of Canada towards the Physician s Recognition Award (PRA). To convert EACCME credits, please contact your respective national accreditation body for more information. Your badge will be scanned at the entrance of each session for CME accreditation. After the Congress, at the beginning of July, you will receive a link and detailed information to download your Certificate of CME. Congress Scholarships A Travel Reimbursement Form will be sent to scholarship winners and costs will be refunded by bank transfer. The original receipts together with the form should be handed in on site at the Speaker Registration Desk. Currency The local currency is the Euro (EUR). Dress code The dress code is informal throughout the Congress. EAACI Counter We invite you to visit the EAACI Counter located in the Entrance Hall, where information about the Academy, membership and future events is available. After the Congress, visit and catch up on the latest news about EAACI s activities and publications. Opening hours of the EAACI Counter: Saturday, 17 June 08:30-18:30 Sunday, 18 June 08:30-17:30 Monday, 19 June 08:30-17:30 Tuesday, 20 June 08:30-17:30 Wednesday, 21 June 08:30-12:00 General Assembly EAACI s General Assembly will take place in the Holiday Inn Conference Centre on the ground floor in session room 101 from 08:00-09:00 on Monday, 19 June. Only members are allowed to vote. Your membership number is printed on your badge. If you do not have your number on the badge and you are a member of EAACI, please contact the Registration Assistance Desk in the Entrance Hall to have a new badge issued. 10

11 GENERAL INFORMATION EAACI Membership EAACI gives its members priority status at EAACI Congresses, Focused Meetings, and at all other EAACI events and activities. Members receive a 25% discount on the registration fee. Junior members are entitled to register for the Congress at an even lower fee. EAACI offers free Junior membership to individuals aged 35 or less (with online access to the journals Allergy and Pediatric Allergy and Immunology). In addition, EAACI offers a 50% reduction of full membership fees to members from countries with a GNP of less than USD 10,000 per capita, with all membership benefits. As an EAACI member you will have access to all EAACI resources and be kept informed of latest research and developments through both the EAACI Newsletter and our official journals: Allergy, Pediatric Allergy and Immunology and Clinical Translational Allergy. These journals contain editorials, review articles, original articles, educational series and more. Why not join us and take part in the advancement of knowledge and the practice of allergy, asthma and immunology for optimal patient care? As a special offer during the EAACI Congress, apply for membership and save 50% on the 2017 fee. For more information and to apply for membership, please visit the EAACI Counter. EAACI Membership Services Desk Come and visit the Membership Services Desk at the EAACI Counter located in the Entrance Hall. We will be happy to answer any questions you have regarding EAACI membership, or to assist you if you simply want to pay your membership fee. EAACI Virtual Congress Hub This year, there are two EAACI Virtual Congress Hubs located: in the Exhibition Hall (open from 09:00-17:30 on June); and in front of Hall 5 on the first floor (open from 08:30-19:30 on June) At the Vitual Hubs you can: view webcasts of a selection of Congress sessions that you may have missed earlier in the Congress search for abstracts and E-posters take an opportunity to rate and comment on posters and webcasts search the Congress programme by topic or key words. Electricity The voltage in Finland is 230 volts. Round, European-style two-pin plugs are the common standard. Emergencies Please contact a member of Congress staff or security at the Messukeskus immediately in the case of an emergency. The European emergency number applies in Finland, and callers should dial: 112. Exhibition The EAACI Congress 2017 in Finland includes an exhibition that will be open from 09:00-17:30 on June. The Publishers Corner is located in the Exhibition Hall and the National Society Village can be found in front of tha session rooms in Hall 3. For more information regarding the exhibition and other sponsor opportunities, please visit the Congress website or use the Congress app, or ask any member of the Congress staff. First Aid There is a staffed First Aid Room at the Messukeskus which is located in the Gallery Corridor. Opening hours of the First Aid Room: Saturday, 17 June 08:00-23:00 Sunday, 18 June 07:00-19:00 Monday, 19 June 06:30-19:00 Tuesday, 20 June 07:00-19:00 Wednesday, 21 June 08:00-14:00 The closest hospital is the Haartman Hospital, Haartmaninkatu 4, Helsinki: Contact the General Information Desk in the Registration Area for more information. Flight Check-In Flight check-in terminals will be available to delegates in the Registration Area for online flight check-in. A printer will be available to print boarding passes. This service will be open from 15:00 on Tuesday, 20 June to 13:00 on Wednesday, 21 June. Food and Beverages Catering services are located in the Exhibition Hall. Coffee/tea and lunch are not included in the registration fee. EAACI Goes Green Initiative EAACI is going green. You can find out how we are making our Annual Congress more sustainable on page 6. Insurance/Liabilities and Disclaimer EAACI will not be held liable for personal injuries or for loss of or damage to property incurred by participants at the EAACI Congress Participants are encouraged to purchase insurance to cover loss incurred in the event of cancellation, medical expenses, or damage to or loss of personal effects when travelling outside of their own countries. EAACI cannot be held liable for any hindrance or disruption of the EAACI Congress 2017 proceedings arising from natural, political, social or economic events or other unforeseen incidents beyond its control. Registration of a participant implies acceptance of this condition. The materials presented at this continuing medical education activity are made available for educational purposes only. Internet Access For WiFi access, choose the EAACI free internet network. No password is required. Junior Members (JM) Programme The EAACI Junior Members (JM) Working Group promises several exciting events at the EAACI Congress 2017 in Helsinki! All our Junior Members qualify for sizeable discounts to take part in our profession s most stimulating educational opportunities. See the daily programme for details of JM activities. Language The official language of the Congress is English. Local Time The time zone in Helsinki is Central European Time CET +2. Lost and Found Please contact the General Information Desk in the Registration Area for personal belongings that have been lost or found. Mobile Phone Policy Please respect the Congress policy and keep mobile phones on silent in all meeting rooms, the Exhibition Hall and Poster Area. Please do not share any scientific data on social media. 11

12 GENERAL INFORMATION National Society Village National Societies have the opportunity to showcase their great work and upcoming meetings in the National Society Village. It is located in front of session rooms in Hall 3 and is open Sunday, 18 June - Tuesday, 20 June, from 09:00-17:30. We encourage you to visit their booths and learn more about other allergy, asthma and immunology societies. Parking Conference Parking is located near the Eastern Entrance. The closest access to the Congress is the Southern Entrance. The parking fee is EUR 12 for 24 hours. Parking fees can be paid at the parking cashier machines in cash or by debit or credit cards. Poster Exhibition Thematic Poster Sessions (TPS) are conducted with traditional paper posters. Thematic posters are displayed in the poster area in the Exhibition Hall. Posters will be displayed for a full day on either Sunday, Monday or Tuesday. Each day, the posters are organised in thematic groups of posters. At lunchtime, the presenters are required to stand by their posters and answer questions from delegates. During this time, two moderators per thematic group will also visit each poster and ask the presenters to briefly present their findings. Audio Thematic Poster Session (TPS) In order to increase the audio quality of presentations and discussions during the Thematic Poster Sessions (TPS), we will be implementing an Interactio app. The app is free, quick and easy to set up and use comfortably from your own mobile device. Headsets will be provided to participants. Further information is available on page 116. Poster Discussion Sessions (PDS) are conducted with E-Posters. They will take place in four designated PDS Zones in the Exhibition Hall. These posters will be presented in electronic format only. Moderators will lead a discussion with the audience. Visit the Poster Help Desk for assistance. Photographing and Recording Taking photographs or making any other form of electronic recording during the sessions in the meeting rooms is forbidden. An official photographer will be present for the entire event. Photos will be available for download on the Congress website: Please note, by registering to attend the EAACI Congress 2017, you acknowledge and agree that official photographs taken during the Congress may be used for future meeting promotional purposes. Prayer Room There is a Prayer Room located in the in the upper Gallery (next to Hall 5). Press Office The Press Office is located in the Holiday Inn Conference Centre on the first floor next to the Speakers Service Centre. Opening hours of the Press Office: Sunday, 18 June 08:30-17:30 Monday, 19 June 08:30-17:30 Tuesday, 20 June 08:30-17:30 Wednesday, 21 June 08:30-12:00 For all media enquires please contact: EAACI Headquarters Lena Geltenbort-Rost Publications, Public Relations and Public Affairs Manager Tel: lgr@eaaci.org Programme Search Tool (Online Programmme) A programme search tool is available online on the Congress website ( for the full programme of sessions, speakers, chairs and abstracts. The online programme has a search function with which you can find speakers, topics, session types and much more. The session details can be exported as a PDF or to your calendar in various systems (such as MS Outlook and Apple icalendar). It is also possible to find single abstracts. Alternatively, why not download the Congress app for full information on the Scientific Programme and more. Recycling Help support the EAACI s Goes Green Initiative by recycling using the containers located throughout Messukeskus. Badge recycling boxes will available in the Entrance Hall from Tuesday, 20 June. Registration Desk Hours Saturday, 17 June 08:00-20:00 Sunday, 18 June 07:00-18:00 Monday, 19 June 06:30-18:00 Tuesday, 20 June 07:00-18:00 Wednesday, 21 June 08:00-12:00 Registration Fee for Delegates The delegate registration fee includes: Admission to the Congress and the Exhibition Opening Ceremony/Welcome Reception Meeting Bag and Final Programme Opt-in This year EAACI is operating with an opt-in policy, whereby a meeting bag (EUR 10) and the 200 page printed programme (EUR 20) can be obtained at an extra charge. By making the most of the digital availability of the programme and further information via our website, the congress app and our virtual hub, you are kindly supporting the environment through the EAACI Goes Green initiative. This aims to print and produce less to save valuable resources (paper, water, cotton, transportation, etc.). Delegates who did not want to attend the Opening Ceremony and Welcome Reception benefited from a reduced registration fee of EUR 25 off the regular registration fee. Please note that the Welcome Reception fee cannot be refunded on site. Safety and Welfare Helsinki is a beautiful and generally very safe city. Yet, like most other major cities, there is petty crime. Therefore, please be aware of thieves and pick-pockets at all times. Do not wear your badge outside the Congress venue, and do not give it to anybody, even if you are leaving the Congress. If you are carrying valuables, always keep an eye on them. In the event of a theft, please contact the General Information Desk, who will call security. EAACI holds a very firm position against any form of discrimination or untoward behaviour by Congress participants. If any participant feels that they have been subjected to any inappropriate behaviour, please report it immediately to a senior member of Congress staff at the General Information Desk in the Registration Area and the matter will be referred to the local authorities for further investigation. Session Attendance Sessions may fill up quickly. Please arrive in good time for the start of a session. Due to security regulations, hosts and hostesses are instructed to restrict access once the maximum capacity of the room is reached. An overflow room (number 209) is located in the Holiday Inn Conference Centre on the first floor. 12

13 GENERAL INFORMATION Session Evaluation You can use the Congress app to evaluate the quality of a session and the faculty involved. Your feedback helps EAACI to constantly improve. Smoking Policy In accordance with EAACI policy, this is a nonsmoking event. Speaker Service Centre The Speaker Service Centre is located in the Holiday Inn Conference Centre next door to Messukeskus on the first floor next to the Press Room. The opening hours are: Saturday, 17 June 10:00-19:00 Sunday, 18 June 07:00-19:00 Monday, 19 June 06:30-19:00 Tuesday, 20 June 07:00-19:00 Wednesday, 21 June 08:00-12:00 Have a question? Lost? Need help? Ask one of the Congress staff in blue T-Shirts. Travelling to Messukeskus by Public Transport in Helsinki EAACI is pleased to provide delegates with a complimentary 5-day travel pass, offered courtesy of Helsinki Region Transport (HRT). Please order your travel pass during the registration process. Kindly note that the travel passes are valid for Helsinki, Vantaa, Espoo and Kauniainen and not for long distance trains. Registered delegates are entitled to one (1) free transportation pass. The EAACI 2017 name badge will include a voucher for the public transportation passes, which can be exchanged for the ticket at the Bag Distribution Counter. Messukeskus is located close to the centre of Helsinki, with excellent transport connections. It has two entrances: the Southern Entrance at Messuaukio 1 and the Northern Entrance on the same side as the car park. Trains: all local and long-distance trains stop at Pasila railway station, just a 300-metre walk from Messukeskus Trams: from the centre of Helsinki, take trams 7A, 7B and 9. Buses: use buses 506 and 69 to Messukeskus, and bus 551 from Espoo to Pasila railway station From the airport, take the I and P trains direct to Pasila railway station. The journey time is 30 minutes and trains leave every 10 minutes during the day. By taxi, you can reach Messukeskus in minutes. Further details can be found in the Journey Planner under

14 BUSINESS MEETINGS The Business Meetings of the EAACI Sections and Interest Groups are special meetings in which interested EAACI members can meet with other members in their area of interest. Each meeting starts with an academic lecture or debate led by a distinguished speaker. This is followed by interaction with the Board to plan the Section or Interest Group s activities and make proposals for future events. Sunday, 18 June :30-18:40 Business Meeting (BM 1) Room 103a IG Immunotherapy - Open to all attendees AIT from art to science Ulrich Wahn, Germany 17:30-18:40 Business Meeting (BM 2) Room 102 IG Allergy Diagnosis - Open to all attendees Still the same problems with IgE-diagnostics Were we too comfortable with the status quo? Nathalie Wojtalewicz, Germany 17:30-18:40 Business Meeting (BM 3) Room 103b IG Allergy, Asthma and Sports - Open to all attendees Beta-2 agonists in asthma and influence on sports performance: What do we know? What is the evidence? Morten Hostrup, Denmark 17:30-18:40 Business Meeting (BM 4) Room 201 IG Primary Care - Open to all attendees 17:30-18:40 Business Meeting (BM 5) Room 206 IG Insect Venom Hypersensitivity - Open to all attendees Maintenance intervals: 4 weeks or 6 months? What is the evidence? Constantinos Pitsios, Cyprus 17:30-18:40 Business Meeting (BM 6) Room 207 IG Allied Health - Open to all attendees Precautionary labelling - Past, present, future Katie Allen, Australia 17:30-19:00 Business Meeting (BM 7) Room 209 Junior Members (JMs) - Open to all attendees Fiction and reality of medical ethics Anthony Frew, United Kingdom 14

15 WELCOME Save the Date AAAAI/WAO Joint Congress 2-5 March 2018 ORLANDO, FLORIDA USA 15

16 BUSINESS MEETINGS Monday, 19 June, :25-13:35 Business Meeting (BM 8) Hall 3c Pediatric Section - Open to all attendees New approaches to the prevention and treatment of atopic dermatitis Carsten Flohr, United Kingdom 12:25-13:35 Business Meeting (BM 9) Hall 3d IG Food Allergy - Open to all attendees Infant Feeding Guidelines: How can results from allergy trials and cohorts influence global consensus? Michael Perkin, United Kingdom 17:30-18:40 Business Meeting (BM 10) Room 208 IG Epidemiology - Open to all attendees Allergy and sleep - in the dark? Jon Genuneit, Germany 17:30-18:40 Business Meeting (BM 11) Room 103b IG Drug Allergy - Open to all attendees Immunoreactions to checkpoint inhibitors treatment Werner Pichler, Switzerland 17:30-18:40 Business Meeting (BM 12) Room 201 IG Primary Immunodeficiency - Open to all attendees The IPEX syndrome Eleonora Gambineri, Italy 17:30-18:40 Business Meeting (BM 13) Room 206 IG Occupational Allergy - Open to all attendees New developments in work-related asthma Santiago Quirce, Spain 17:30-18:40 Business Meeting (BM 14) Room 207 IG Biologicals - Open to all attendees Desensitisations for IgE and non IgE mediated reactions to Monoclonal Antibodies: Are all biologicals candidates? Mariana Castells, United States 17:30-18:40 Business Meeting (BM 15) Room 209 IG Aerobiology and Pollution - Open to all attendees Climate change and airborne allergens Paul Beggs, Australia 16

17 BUSINESS MEETINGS Tuesday, 20 June, :10-13:20 Business Meeting (BM 16) Hall 3d Immunology Section - Open to all attendees The role of dendritic cells in respiratory inflammation Hamida Hammad, Belgium 12:10-13:20 Business Meeting (BM 17) Hall 3e Asthma Section - Open to all attendees Phenotyping from a clinician s point of view Johann Christian Virchow, Germany 12:10-13:20 Business Meeting (BM 18) Hall 3f Dermatology Section - Open to all attendees What s cooking in Omalizumab treatment of urticaria and other diseases? Marta Ferrer, Spain 12:10-13:20 Business Meeting (BM 19) Hall 3g ENT Section - Open to all attendees Pathogenic mechanisms in chronic rhinosinusitis Robert Schleimer, United States 15:30-17:00 Business Meeting (BM 20) Room 102 Patients Organisations Committee - Open to all attendees Food products and undeclared allergens causing accidental allergic reactions in daily life Marty Blom, The Netherlands 17:30-18:40 Business Meeting (BM 21) Room 102 IG Infections and Allergy - Open to all attendees Introductory lecture: Respiratory viral infections and asthma: A devastating combination? Chrysanthi Skevaki, Germany 17:30-18:40 Business Meeting (BM 22) Room 103b IG Comparative and Veterinary Allergology - Open to all attendees Comparing immediate type food allergy in humans and companion animals definition of knowledge gaps Isabella Pali-Schöll, Austria 17:30-18:40 Business Meeting (BM 23) Room 201 IG OMICS and Systems Medicine - Open to all attendees Single-cell RNA-seq and computational analysis using temporal mixture modelling resolves Th1/Tfh fate bifurcation in malaria Tapio Lonnberg, Finland 17:30-18:40 Business Meeting (BM 24) Room 206 IG on Eosinophilic Esophagitis - Open to all attendees Advances in genetics and pathophysiology in EoE Antonella Cianferoni, United States 17:30-18:40 Business Meeting (BM 25) Room 207 IG Ocular Allergy - Open to all attendees Characterisation of the microbiome on the ocular surface Mark Willcox, Australia 17

18 WELCOME a political call to action Policy Makers Patients Doctors Public health programmes Funding for research Sign before 30 th September Prevention and early diagnosis Root cause analysis of diseases Visit the EAACI counter for more information Personalised medicine Economic benefit SIGN 18 ONLINE #CallAllergyAsthma

19 EAACI MEETINGS PLEASE NOTE: THESE MEETINGS ARE BY INVITATION ONLY Friday, 16 June 08:30-18:00 EAACI Executive Committee Scandic Park Hotel Vision 2-3 Saturday, 17 June 08:30-13:00 EAACI Congress 2018 Scientific Programme Committee Scandic Park Hotel Explore 1 09:30-10:30 Newsletter Meeting Messukeskus 216a 10:30-11:30 Web and Social Media Meeting Messukeskus 216a Sunday, 18 June 11:00-12:00 CME Committee Meeting Messukeskus :00-13:00 EBAACI Meeting Messukeskus 307 Monday, 19 June 11:00-12:00 Exam Committee Meeting Messukeskus 203a 12:00-13:30 High-level Business Lunch on EU Health and Research Policies Messukeskus Winter Garden Tuesday, 20 June 08:00-09:00 EAACI Leadership Meeting with AAAAI Leadership Messukeskus :00-10:00 Web Committee Meeting Messukeskus :30-11:30 Communication Council Meeting Messukeskus :30-16:30 JM Working Group Business Meeting Messukeskus Winter Garden Cabinet 15:30-17:00 Ethics Committee Meeting Messukeskus :00-18:00 New Executive Committee Meeting Messukeskus Winter Garden Cabinet 18:00-19:00 Executive Committee & IG/Section Boards and TF Chairs Meeting Messukeskus Winter Garden NETWORKING EVENTS Opening Ceremony/Welcome Reception Saturday, 17 June at 19:00-23:00 PRICE: Included in the registration fee for registered delegates unless you opted out when registering. If you are sponsored by a company, they may be required to opt you out of the Opening Ceremony/Welcome Reception for pharmaceutical compliance reasons. Please contact the Registration Assistance Desk in the Entrance Hall if you require clarification. If you wish to attend the Opening Ceremony and Welcome Reception but have not yet paid, please contact the Registration Assistance Desk in the Entrance Hall prior to the start of the Opening Ceremony. The Opening Ceremony will take place in Hall 1 at Messukeskus at 19:00. The EAACI Congress 2017 Junior Member Poster Session will be located in the Foyer of Hall 5. Over 100 posters will be presented. After the official opening of the Congress, the Welcome Reception will take place. Do not miss this great opportunity for networking. Name badges are required. Junior Member Event Tuesday, 20 June at 20:30-00:30 PRICE: Included in the registration fee for Junior Members. If you wish to attend the JM Event, please visit the EAACI Counter in the Entrance Hall to pick up a ticket. All Junior Members are invited to join us for the Event. This event is exclusively for Junior Members name badge and ID are required. 19

20 CONGRESS SCHOLARSHIP RECIPIENTS Name, Country Name, Country Name, Country Suzanne Abbring, The Netherlands Velky Katerine Ahumada Contreras, Colombia Marcello Albanesi, Italy Natalia Aliakhnovich, Belarus Flore Amat, France Anand Kumar Andiappan, Singapore Siniavin Andrei, Russia Anne-Sofie Ballegaard, Denmark Ga young Ban, South Korea Aleksandra Barac, Serbia Amalia Bernad, Spain Alvise Berti, Italy Beatriz Cabanillas, Germany José Antonio Cañas, Spain Riccardo Castagnoli, Italy Zhuo Chen, China Anca Chiriac, Romania Francesco Cinetto, Italy Ana del Prado, Spain Denitsa Dimitrova, Bulgaria Sandra Ekström, Sweden Nerea Mendez-Barbero, Denmark Niloufar Farzan, Iran Mousavinasab Fatemehsadat, Iran Pawel Gajdanowicz, Poland María Garrido-Arandia, Spain Miguel González, Spain Vanessa Granger, France Katrine B. Graversen, Denmark Mindy Guo, Taiwan Pascal Haimerl, Germany Franziska Häring, Germany Zonne Hofman, The Netherlands Diana Hristova, Bulgaria Frederic Jabs, Germany Annika Jensen, Austria Anya Jones, Australia Marcelina Kocwin, Poland Olesya Koloskova, Russia Jonatan Leffler, Sweden Anita Leishangthem, India Agnieszka Lipinska-Ojrzanowska, Poland Juan Liu, China Daniel Lozano-Ojalvo, Spain Iana Markevych, Ukraine Nathan Marsteller, United States Klaudia Matysiak, Poland Leticia Mera, Spain Kyle Mincham, Australia Wat Mitthamsiri, Thailand Sheriene Moussa Afify, Egypt Manali Mukherjee, India Maria Nassiri, Germany Melanie Neeland, Australia Rita Nocerino, Italy Inês Paciência, Portugal Ines Padua, Portugal Maria Francisca Palomares Jerez, Spain Sara Peixoto, Portugal Natalia Pérez-Sánchez, Spain Nicole Pinto, Portugal Dominika Polak, Austria Federica Pulvirenti, Italy Tiago Rama, Portugal Francesca Rizzo, Italy Maria José Rodríguez, Spain Jorge Rojas, Chile João Rufo, Portugal Andres Sánchez, Colombia Gabriela Sánchez Acosta, Austria Maximilian Schiener, Germany Ann-Marie Malby Schoos, Denmark Polina Shahid, Bulgaria Manuprita Sharma, India Gaurab Sircar, India Tamar Smulders, The Netherlands Patricia Soares, Portugal Katherine Strong, United Kingdom Stella Taka, Greece Vladimir Tmusic, Serbia Gohar Tsakanova, Armenia Yanyi Tu, China Ceyda Tunakan Dalgiç, Turkey Estefania Vasquez Echeverri, Spain Maansi Vermani, India Evelina Vetskova, Bulgaria Alma Villaseñor Solis, Mexico Marlotte Vonk, The Netherlands Soh Wai Tuck, Malaysia Sabrina Wildner, Germany Cecil Wong, Philippines Jiakai Wu, United Kingdom Song-I Yang, South Korea Valerii Valerivich, Russia Li Zhao, China Yury Zhernov, Russia Jelena Živkovic, Croatia Odebode Adeyinka, Nigeria Sayyora Bazarova, Uzbekistan SCHOLARSHIPS TO JUNIOR REPRESENTATIVES FROM INTERNATIONAL ACADEMIES/SOCIETIES AAAAI, FIT Committee Christina Kwong, USA Vanessa Bundy, USA European Respiratory Society, Junior Members Assembly Sabine Bartel, Germany Alexander Mathioudakis, UK European Rhinology Society, Junior Members Board Pavol Surda, The Netherlands 20

21 Fel d 2 Fel d 7 Fel d 1 Fel d 8 Fel d 3 Fel d 4 Fel d 5 Fel d 6 POSITION PAPER T. Werfel 1, R. Asero 2, B. K. Ballmer-Weber 3, K. Beyer 4, E. Enrique 5, *, A. C. Knulst 6, A. Mari 7, 1 Department of Dermatology and Allergy, Hannover Medical University, Hannover, Germany; 2 Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Milan, Italy; 3 Allergy Unit, Department of Dermatology, University Hospital Z urich, Z urich, Switzerland; 4 Division of Paediatric Pneumology and Immunology, Charite University Hospital, Berlin, Germany; 5 Allergy Division, Hospital General de Castellon, Castellon, Spain; 6 Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands; 7 Associated Center for Molecular Allergology (CAAM), Latina, Italy; 8 The Referral Centre for Food Allergy Diagnosis and Treatment Veneto Region, Department of Mother and Child Health, University of Padua, Padua, Italy; 9 Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg and Department of Dermatology and Allergy, Biederstein, Technische Universit at M unchen (TUM), Munich, Germany; 10 Allergy Clinic Copenhagen University Hospital at Gentofte, Copenhagen, Denmark; 11 Division of Allergology, Paul-Ehrlich Institute, Langen, Germany; 12 Department of Dermatology and Allergy, of Charite - Universit atsmedizin Berlin, Berlin, Germany; 13 Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria Keywords To cite this article: Werfel T, Asero R, Ballmer-Weber BK, Beyer K, Enrique E, Knulst AC, Mari A, Muraro A, Ollert M, Poulsen LK, Vieths S, Worm M, Hoffmann-Sommergruber K. Position paper of the EAACI: food allergy due to immunological cross-reactions with common inhalant allergens. Allergy 2015; 70: Keywords inhalant; allergens; cross-reactive; food allergy; IgE; sensitization. Correspondence Assoc. Prof. Karin Hoffmann-Sommergruber, PhD, Department of Pathophysiology and Allergy Research, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. Tel.: Fax: karin.hoffmann@meduniwien.ac.at Allergy Abstract In older children, adolescents, and adults, a substantial part of all IgE-mediated food allergies is caused by cross-reacting allergenic structures shared by inhalants and foods. IgE stimulated by a cross-reactive inhalant allergen can result in diverse patterns of allergic reactions to various foods. Local, mild, or severe systemic reactions may occur already after the first consumption of a food containing a cross-reactive allergen. In clinical practice, clinically relevant sensitizations are elucidated by skin prick testing or by the determination of specific IgE in vitro. Component-resolved diagnosis may help to reach a diagnosis and may predict the risk of a systemic reaction. Allergy needs to be confirmed in cases of unclear history by oral challenge tests. The therapeutic potential of allergen immunotherapy with inhalant allergens in pollen-related food allergy is not clear, and more Allergy FELLOWSHIP AND JM QUIZZ WINNERS 2017 Name, Country Name, Country Name, Country Clinical Fellowships Marija Stankovic, Serbia Lucia Diaferio, Italy Kotryna Linauskiene, Lithuania Agne Ramonaite, Lithuania Medhat M. A. Elamawy, Egypt Alessandra Arcolaci, Italy Mariam Movsisyan, Armenia Kit Liang Gan, Malaysia Maria Teresa Gonzales, Peru Research Fellowships SHORT TERM RESEARCH FELLOWSHIP Anand Kumar Andiappan, Singapore Carla Mastrorilli, Italy Gyaviira Nkurunungi, Uganda Elisa Corsiero, United Kingdom Youcef Shahali, Iran MEDIUM TERM RESEARCH FELLOWSHIP Stefania Arasi, Italy Eva-Maria Rick, United Kingdom Africa Sanchez, Spain Omursen Yildirim, Turkey LONG TERM RESEARCH FELLOWSHIP Pattraporn Satitsuksanoa, Thailand Dries Paul Van Elst, Poland Galber Rodrigues Araujo, Brazil Ilean Maria Ghiordanescu, Romania Carmen Riggioni, Costa Rica EAACI JM Quizz Winners EAACI Juniors are eligible to win a travel grant of up to EUR 500 to attend the Annual Congress by taking part in the monthly JM Quizz. The months January to April have one winner with the exception of March during which the JM will select two winners to support the late breaking abstract submission. THE FIVE WINNERS ARE: January Mariam Movsisyan, Armenia February Madona Devidze, Georgia March Alba Angelina, Spain April Ozge Ozturk, Turkey Pavel Kolkhir, Russia EAACI SCIENTIFIC RESOURCES GUIDELINES JOURNALS CONSENSUS DOCUMENTS POSITION PAPERS MONOGRAPHS POSITION PAPER Impact Factor Position paper of the EAACI: food allergy due to immunological cross-reactions with common inhalant allergens T. Werfel 1, R. Asero 2, B. K. Ballmer-Weber 3, K. Beyer 4, E. Enrique 5, *, A. C. Knulst 6, A. Mari 7, A. Muraro 8, M. Ollert 9, L. K. Poulsen 10, S. Vieths 11, M. Worm 12 & K. Hoffmann-Sommergruber 13 Position paper of the EAACI: food allergy due to immunological cross-reactions with common inhalant allergens 1 Department of Dermatology and Allergy, Hannover Medical University, Hannover, Germany; 2 Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Milan, Italy; 3 Allergy Unit, Department of Dermatology, University Hospital Z urich, Z urich, Switzerland; 4 Division of Paediatric Pneumology and Immunology, Charite University Hospital, Berlin, Germany; 5 Allergy Division, Hospital General de Castellon, A. Muraro 8, M. Ollert 9, L. K. Poulsen 10, S. Vieths 11, M. Worm 12 & K. Hoffmann-Sommergruber 13 Impact Factor Castellon, Spain; 6 Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands; 7 Associated Center for Molecular Allergology (CAAM), Latina, Italy; 8 The Referral Centre for Food Allergy Diagnosis and Treatment Veneto Region, Department of Mother and Child Health, University of Padua, Padua, Italy; 9 Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg and Department of Dermatology and Allergy, Biederstein, Technische Universit at M unchen (TUM), Munich, Germany; 10 Allergy Clinic Copenhagen University Hospital at Gentofte, Copenhagen, Denmark; 11 Division of Allergology, Paul-Ehrlich Institute, Langen, Germany; 12 Department of Dermatology and Allergy, of Charite - Universit atsmedizin Berlin, Berlin, Germany; 13 Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria To cite this article: Werfel T, Asero R, Ballmer-Weber BK, Beyer K, Enrique E, Knulst AC, Mari A, Muraro A, Ollert M, Poulsen LK, Vieths S, Worm M, Open access online platform Hoffmann-Sommergruber K. Position paper of the EAACI: food allergy due to immunological cross-reactions with common inhalant allergens. Allergy 2015; 70: inhalant; allergens; cross-reactive; food allergy; IgE; sensitization. Correspondence Assoc. Prof. Karin Hoffmann-Sommergruber, PhD, Department of Pathophysiology and Allergy Research, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. Tel.: Fax: karin.hoffmann@meduniwien.ac.at *Present address: Allergy Division, Hospital de Sagunto, Sagunto, Spain Accepted for publication 4 June 2015 DOI: /all Abstract In older children, adolescents, and adults, a substantial part of all IgE-mediated food allergies is caused by cross-reacting allergenic structures shared by inhalants and foods. IgE stimulated by a cross-reactive inhalant allergen can result in diverse patterns of allergic reactions to various foods. Local, mild, or severe systemic reactions may occur already after the first consumption of a food containing a cross-reactive allergen. In clinical practice, clinically relevant sensitizations are elucidated by skin prick testing or by the determination of specific IgE in vitro. Component-resolved diagnosis may help to reach a diagnosis and may predict the risk of a systemic reaction. Allergy needs to be confirmed in cases of unclear history by oral challenge tests. The therapeutic potential of allergen immunotherapy with inhalant allergens in pollen-related food allergy is not clear, and m placebo-controlled studies are needed. As we are facing an i pollen allergies, a shift in sensitization patt and the occurrence of ne expected GLOBAL ATLASES USER GUIDES WEBCASTS WEBINARS HANDOUTS TEACHING SLIDES EA ACI MOLECULAR ALLERGOLOGY USER S GUIDE Published by the European Academy of Allergy and Clinical Immunology

22 EAACI AWARDS 2017 Each year, EAACI honours European researchers and clinicians who have contributed significantly to the development of innovative diagnostic and therapeutic strategies for control and prevention of allergic diseases, to the understanding of their pathophysiology and to the strengthening of allergology as a specialty in Europe. The EAACI Awards 2017 will be presented during the Opening Ceremony Saturday, 17th at 19:00. Miguel Blanca The 2017 Clemens von Pirquet Award for Clinical Research is awarded to Professor Miguel Blanca who has made an important contribution to the development of the specialty at both a national and international level. He is a specialist in allergy who trained at Malaga University Hospital University, and with a research stay at Middlesex University London. From 2000 to 2003 he was head of the allergy service, La Paz Hospital, and from 2003 to 2016 he was the head of the allergy department in the University Hospital of Malaga. From 2008 to 2016 Professor Blanca was coordinator of the National Network for the Study of Allergic Reactions to Drugs and Allergens (RIRAAF). He was also invited Professor at the University of Nancy (France). Miguel Blanca was one of the first scientists to make an in-depth study of the immunological mechanisms involved in the adverse reactions to drugs, especially beta-lactams and non-steroidal anti-inflammatory drugs. He is the author or co-author of more than 350 peer-reviewed publications including original articles, reviews and position papers, and his contributions have helped give a better understanding of the pathophysiology of the hypersensitivity reactions to drugs. He has also made important contributions in the fields of hymenoptera venom allergy, rhinitis and food allergy. Professor Blanca is a member of the EAACI Drug Allergy Interest Group (DAIG) and the European Network on Drug Allergy (ENDA), in which he has actively participated since their start. He was also a member of the American Academy of Allergy, Asthma and Immunology (AAAAI) s Adverse Reactions to Drugs, Biologicals and Latex Committee and has actively participated in Global Allergy and Asthma European Network (GA 2 LEN) projects. During his carrier he has formed more than six research independent groups located in different centres of Spain. Currently, he is scientific adviser of the Allergy Service, Hospital Infanta Leonor, Madrid, Spain. Sten Dreborg The Daniel Bovet Award for Treatment and Prevention is awarded to Professor Sten Dreborg. After finishing his specialisation in paediatrics at Uppsala Academic Hospital, Sten Dreborg served as head of the department of paediatrics, County Central Hospital, Boden, Sweden, from During that time, he concentrated on organising paediatrics in the most northern county of Sweden, on neonatology, publishing the first Swedish CPAP publication, and on the Norrbottnian type of Gaucher s disease, bringing about the first enzyme replacement by transplantation, and developing carrier and prenatal diagnosis. Between 1979 and 1989, he worked at Pharmacia Diagnostics as medical director, from 1985 scientific medical adviser, during which time he worked on allergen standardisation, freeze-dried extracts, immunotherapy, the Phazet needle and skin testing. In parallel, he worked at the Academic Hospital, Uppsala and later at the Linköping University Hospital, paediatric allergy department. In 1996 he was appointed professor of paediatric allergology at Voksentoppen National Paediatric Allergy and Asthma Institute, Oslo, Norway. He was a founder member of the group (1966) which developed into the Section on Child and Adolescent Allergology of the Swedish Paediatric Society. In 1984 he was a founder member of the Working Group on Paediatric Allergology and Clinical Immunology (WGPACI), within the European Society for Paediatric Research (ESPR) and in 1988 of the European Society of Paediatric Allergy and Clinical Immunology (ESPACI). Together with Arne Høst, he was the founder of the Paediatrics Section of EAACI in 1996, being chairman and adjunct member of the Executive Committee from 1997 to Presently, Professor Dreborg is affiliated to the Section on Child and Adolescent Allergology of Women s and Children s Health at Uppsala University. Furthermore, Sten Dreborg is presently a member of several editorial boards, among them JACI in Practice and the Annals of Allergy. 22

23 EAACI AWARDS 2017 Reto Crameri The Paul Ehrlich Award for Experimental Research is awarded to Professor Reto Crameri. After completing his bachelor s, master s and PhD degrees in 1981 at the Swiss Federal Institute of Technology (ETH) in Zürich, Reto Crameri moved to BiogenSA, Geneva, as senior scientist in molecular biology, where he stayed until Afterwards he worked at the Paul Scherrer Institute as principal investigator responsible for monitoring the natural radiation exposure of the Swiss population. Since 1990 Reto Crameri has been head of the molecular allergology department at the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos. His research interests have always been the development of novel molecular cloning systems based on phage surface display technologies, the production and structural characterisation of allergens, the development of novel vaccines and vaccination strategies aimed at curing allergic diseases, as well as studies on the basic mechanisms regulating IgE production. Reto Crameri has been involved in the task forces and networks of several EU projects including GA 2 LEN. He is a founding member of the Academia Raetica and the Graubünden Graduate School, and has supervised dozens of PhD students. Author of over 200 scientific publications himself, he serves as deputy editor of Mycoses and is an associate editor of Allergy. Petr Panzner The Charles Blackey Award for Promotion of the Allergy Speciality is awarded to Professor Petr Panzner. He is professor and head of the department of immunology and allergology, faculty of medicine in Pilsen, Charles University in Prague. Petr Panzner is vice-president of the Czech Society of Allergology and Clinical Immunology, member of the managing board and a faculty member of the Czech Initiative for Asthma, and is editor-in-chief of Current Opinion in Allergy and Clinical Immunology - Czech and Slovak digest. He was a member of the EAACI Executive Committee ( ) and is currently a member of the EAACI National Allergy Society Committee. He is also a board member of the UEMS Allergology Section. As vice-president of the UEMS Section and Board on Allergology he contributed significantly to the alignment of activities (blueprint, curriculum and quality criteria) between different allergy centres and countries. He also promoted activities meant to increase awareness of allergic diseases and allergology to national and international governmental bodies. Petr Panzner has a longstanding track record in allergy and immunology research focused on allergen immunotherapy, molecular diagnosis and insect venom hypersensitivity. He is a strong advocate for the implementation of a full medical specialty of allergology and clinical immunology throughout Europe. 23

24 CLINICAL VILLAGE CLINICAL VILLAGE The Clinical Village offers an excellent opportunity for attendees to try out different procedures and equipment used in the diagnosis and treatment of allergic diseases. It provides a perfect platform to explore a combination of both theoretical and practical topics, both for specialists-in-training as well as for clinicians wanting to update themselves on topics adjacent to their core business. WHEN CAN YOU VISIT THE CLINICAL VILLAGE? The Clinical Village will be open on Saturday, 17 June 2017 from 14:00-18:00 and on Sunday, 18 June 2017 from 12:00-16:00 at the Messukeskus. Admission is included in the registration fee and all registered attendees are invited to visit. The Clinical Village will be a particularly good complement to the EAACI postgraduate course running on Saturday afternoon, combining theory with practice. WHAT WILL YOU FIND IN THE CLINICAL VILLAGE? This year, there will be 15 individual stations served by specialists, Junior Members and staff from departments in local medical centres and hospitals. THE FOLLOWING TOPICS WILL BE COVERED: 1. Atopic dermatitis topical treatment 2. Practical Allergy Diagnosis based on Clinical Cases, a POC Role Play Activity 3. Anaphylaxis 4. Immunotherapy 5. Finnish Allergy Program Hot Topics in ENT Therapy and Diagnosis 7. Diagnosing and monitoring of Asthma in Young Children 8. Adult Onset Nonatopic Asthma 9. Food Allergy 10. Visual Diagnosis of Skin/Allergy Symptoms 11. Cutting Edge Allergy Laboratory Diagnosis 12. Skin Patch Testing 13. Historical Notes: Allergy 111 Years 14. Cosmetics Allergy Portal 15. Pollen Monitoring and Forecasting 24

25 DESCRIPTION OF SESSION TYPES Business Meetings (BM) Business Meetings of EAACI Sections and Interest Groups are special meetings in which interested EAACI members can meet with other members in their area of interest. Each meeting starts with an academic lecture or debate led by a distinguished speaker. This is followed by interaction with the Board to plan the Section or Interest Group s activities and make proposals for future events. Company Lunch Symposia (CLS) Company Lunch Symposia are sponsored symposia organised during the lunch breaks by the EAACI Founder Sponsors. The content of these sessions is proposed directly by the Founder Sponsors and approved by the Scientific Programme Committee prior to inclusion within the main programme. Company Sponsored Symposia (CSS) EAACI Platinum and Gold Founder Sponsors have a Company Sponsored Symposium within the main Congress programme. The content of these symposia is proposed directly by the Founder Sponsors and approved by the Scientific Programme Committee prior to inclusion within the main programme. Highlights Session Highlights Sessions are short and concise sessions which are compiled by the Scientific Programme Committee. The sessions highlight the most relevant talks of a certain topic and recap on significant results from other sessions. Hot Topic (HT) Hot Topic sessions consist of presentations followed by a discussion. Topics are selected close to the time of the Congress, with the goal of presenting new and exciting data in a more informal format than a typical session. Hot Topic sessions allow attendees to gain insights into the latest news and findings in the fields of allergy and clinical immunology. Learning Lounges Learning Lounges allow attendees to meet in a small group with outstanding researchers and clinicians. The format is designed to facilitate informal discussions, allowing participants to present their questions and gain new insights. Registration for these sessions is required. A separate registration fee applies. Oral Abstract Sessions (OAS) The most exciting work from abstracts submitted to the Congress will be honoured with a place in these sessions, which start with a brief introductory lecture. Each presenter shares their work and answers questions from attendees. Practical Allergy Management Workshop (PAMW) Global representatives of patient organisations will come together with other stakeholders in the field to share their experiences, as well as to discuss current issues. Plenary Symposia (PL) Plenary Symposia are at the core of Congress activities. These are exhaustive reviews of a major subject of the specialty, addressed to all Congress participants. Plenary Symposia are scheduled at prime time in the programme, with no crossover with other activities in order to enable maximum attendance. Two parallel symposia will be held, one primarily clinical and the other focused on basic science. Leading international speakers conduct these symposia. Postgraduate Courses (PG) Postgraduate Courses are half-day sessions proposed by the EAACI Sections or Interest Groups. They are designed to provide a thorough review in an area of special interest. Postgraduate courses can be at the basic level or advanced level, requiring background knowledge of that particular topic. Registration for these courses is required. A separate registration fee applies. Postgraduate Courses are merged with visits to the Clinical Village, where attendees can actively try out different procedures and equipment used in the diagnosis and treatment of allergic diseases. The courses are marked basic or advanced, relating to the participants knowledge of the topic. Poster Discussion Sessions (PDS) In these sessions, a group of thematically related posters is displayed. Presenters make a brief presentation of their poster with an E-Poster followed by questions and answers, facilitated by the session chairs. These sessions take place within the four Poster Discussion Zones, located in the Poster Exhibition Area. Pro & Con (P & C) The Pro & Con sessions allow speakers to debate controversial topics providing food for thought. These lunchtime sessions take place in the Exhibition Hall and you can participate by voting with the Congress app. Key Opinion Leader Insights Industry Key Opinion Leader Insights are an extension of the key talks presented at the Company Sponsored Symposia and Satellite Symposia. These sessions take place in the Pro & Con Arena in the Exibition Hall. Satellite Symposia (SAT) Satellite Symposia commence once the main programme has concluded for the day. These symposia are organised independently by sponsoring companies. Sister Society Symposia (SSS) EAACI has collaborated with a number of sister societies to develop symposia that represent regional or scientific areas common to EAACI and the sister society. This is your chance to expand your knowledge beyond the traditional limits. Symposia (SYM) Symposia are state-of-the-art educational sessions in which the speakers critically review diverse aspects of a specific topic. The target audience consists of delegates who are primarily interested in the subject or wish to update their knowledge in the area. Thematic Poster Sessions (TPS) Abstracts are grouped thematically into blocks of posters and displayed for a whole day. At lunchtime, presenters are available to discuss their work and answer questions from delegates and moderators alongside their posters. Workshops (WS) The Workshops format has been re-designed and features a broad range of new meeting set-ups and interactive approaches making them stand out from the more conventional session format of Symposia or Plenary Sessions. In a Workshop, the goal is more interaction, more discussion and more audience participation. The session set-up will be different from other sessions and the capacity of the meeting room will therefore be lower. Please arrive early to avoid disappointment. Year in Review (YIR) The Year in Review sessions are complete and authoritative reviews focused on the highlights published during the previous year on a specific topic. Topic Tracks Each session in the scientific programme belongs to one or more topic tracks. All sessions are marked in the Programme at a Glance with one of the following topic codes: A Asthma AH Allied Health BA Basic Allergology BI Biologicals CA Clinical Allergology CI Clinical Immunology D Dermatology DA Drug Allergy DI Allergy Diagnosis ENT Ear, Nose, Throat FA Food Allergy I Immunology IT Immunotherapy OA Ocular Allergy P Pediatrics PC Allergy management in Primary Care 25

26 PROGRAMME AT A GLANCE SATURDAY 17 JUNE 2017 SATURDAY 09:00 09:30 Gallery + Registration Lobby Foyer of Hall 5 Clinical Village Hall 1 Hall 5a Hall 3a Hall 3d Hall 3g Room 103a Room :00 10:30 11:00 P.28 Exam 10th EAACI/ UEMS 11:30 Examination in Allergology and Clinical 12:00 Immunology 12:30 13:00 13:30 14:00 P.28 P.28 P.29 P.29 P.29 Clinical Village Russian Day in Russian language Allied Health Day 14:30 15:00 PG 1 Management of drug hypersensitivity - Basic PG 2 Contact dermatitis in childhood - Basic 15:30 P.32 Talent Development Programme 16:00 for Junior Members: Standing out 16:30 as a leader: A mind-opening journey 17:00 17:30 A, IT, P A, AH, FA, PC DA D, P 18:00 18:30 19:00 P.33 Opening Ceremony 20:00 P.33 P.33 Welcome Reception Poster Sessions (JMs) 21:00 Junior Members 22:00 23:

27 PROGRAMME AT A GLANCE SATURDAY 17 JUNE 2017 Room 208 Room 103b Room 206 Room 201 Room 204 Room 207 Room 102 Room :00 09:30 SATURDAY 10:00 10:30 11:00 11:30 12:00 12:30 13:00 13:30 P.30 P.30 P.30 P.31 P.31 P.31 P.32 P.32 14:00 PG 3 Postgraduate PG 4 Recent PG 5 Food Allergy PG 6 Tools to enhance PG 7 Diagnostic tools in PG 8 Omic PG 9 Allergy Diagnosis PG 10 Allergy for Primary Course developments in beyond childhood the value of examination of the technologies in 2017: Novel Care doctors: Immunotherapy - gastrointestinal - Basic clinical research in nose - Basic immunology - dimensions in English language 14:30 Advanced food allergy - Basic Advanced ex vivo allergy hypersensitivity - diagnostics - Basic Advanced 15:00 15:30 16:00 16:30 IT FA FA, P CA ENT I DI, CA PC 17:00 17:30 18:00 18:30 19:00 20:00 SESSION GUIDE PG Postgraduate Course JM Junior Members Programme TOPIC TRACKS A Asthma AH Allied Health BA Basic Allergology BI Biologicals CA Clinical Allergology CI Clinical Immunology D Dermatology DA Drug Allergy DI Allergy Diagnosis ENT Ear, Nose, Throat FA Food Allergy I Immunology IT Immunotherapy OA Ocular Allergy P Pediatrics PC Allergy management in Primary Care 21:00 22:

28 SATURDAY 17 JUNE 2017 SATURDAY SOME SESSIONS FILL UP QUICKLY. ARRIVE EARLY TO GUARANTEE YOUR ENTRY. IF YOU HAVE MISSED A SESSION, YOU CAN CATCH UP ON IT AT THE VIRTUAL CONGRESS HUB IN THE EXHIBITION HALL. PROGRAMME IS STILL SUBJECT TO CHANGE. PLEASE REFER TO THE CONGRESS APP FOR LATEST UPDATE. EAACI/UEMS EXAM 11:00-14:00 10th EAACI/UEMS Examination in Allergology and Clinical Immunology Hall 5a EAACI administers the annual European Knowledge Examination for Allergy and Clinical Immunology which will take place for the tenth time at the EAACI Congress 2017 in Helsinki. The exam includes about 100 multiple-choice questions in English and candidates have 3 hours to complete it. It does not replace or substitute for any currently existing national examinations that are regularly held by national bodies. The hope is that this examination will help to further increase standards in the fields of allergy and clinical immunology in Europe, and everyone has the opportunity to use it as a tool for self evaluation. CLINICAL VILLAGE 14:00-18:00 Clinical Village The Clinical Village offers an excellent opportunity for attendees to try out different procedures and equipment used in the diagnosis and treatment of allergic diseases. It provides a perfect platform to explore a combination of both theoretical and practical topics, both for specialists-in-training as well as for clinicians wanting to update themselves on topics adjacent to their core business. The Clinical Village will be a particularly good complement to the EAACI postgraduate courses running on Saturday afternoon, combining theory with practice. OPENING HOURS: Saturday, 17 June 2017: 14:00-18:00 Sunday, 18 June 2017: 12:00-16:00 SPECIAL SESSIONS 14:00-17:30 Russian Day - A comprehensive course held in the Russian language. Please note: No translation into English will be provided. Hall 3a Chairs: Rakhim Khaitov, Russia Musa Khaitov, Russia The burden of allergy and asthma Natalia Ilina, Russia Optimising diagnostics and treatment of allergic diseases in children: How to be more effective? Leyla Namazova-Baranova, Russia Allergen Immunotherapy today and tomorrow Marek Jutel, Poland Coffee break Development of novel approaches in the treatment of allergic diseases Musa Khaitov, Russia Severe asthma in children: Possible pathways and control tools Andrei Kamaev, Russia Primary Immunodeficiency in adults where are we now? Elena Latysheva, Russia 28

29 SATURDAY 17 JUNE 2017 SPECIAL SESSIONS 14:00-17:30 Allied Health Day Hall 3d Chairs: Kate Grimshaw, United Kingdom Inger Kull, Sweden The changing face of food allergy in adults Isabel Skypala, United Kingdom SATURDAY OTE e-resources to help patients/carers manage food allergy James Gardner, United Kingdom Asthma and Allergy Clinics in Primary Care Inger Kull, Sweden Coffee break Patient educational programs and knowledge-based follow up Anne Trollvik, Norway Do Inter-professionel teams improve the care of allergic patients? Discussion session chaired by Nicolette de Jong, The Netherlands POSTGRADUATE COURSE (PG 1) 14:00-17:30 Management of drug hypersensitivity - Basic Chairs: Knut Brockow, Germany Patrizia Bonadonna, Italy Room 103a A patient with an acute reaction: Recognise, document and treat Knut Brockow, Germany The importance of the clinical history: Is there a need for investigation? Andreas Bircher, Switzerland Coffee break / visit to the clinical village Skin tests and drug provocation tests: Which ones and when? Maria J. Torres, Spain The contribution of the laboratory Gülfem Çelik, Turkey General principles of drug desensitisation Josefina Rodrigues Cernadas, Portugal POSTGRADUATE COURSE (PG 2) 14:00-17:30 Contact dermatitis in childhood - Basic Room 209 Chairs: Flora B. de Waard-van der Spek, The Netherlands Charlotte G. Mortz, Denmark Contact dermatitis: Definitions and classification Flora B. de Waard-van der Spek, The Netherlands Epidemiology Charlotte G. Mortz, Denmark Photo-allergic dermatitis Razvigor Darlenski, Bulgaria Contact dermatitis versus contact urticaria Clive Grattan, United Kingdom Coffee break / visit to the clinical village Immediate type contact allergy Wolfgang Uter, Germany Discussion Flora B. de Waard-van der Spek, The Netherlands 29

30 SATURDAY 17 JUNE 2017 SATURDAY POSTGRADUATE COURSE (PG 3) 14:00-17:30 Postgraduate Course Immunotherapy - Advanced Room 208 Chairs: Oliver Pfaar, Germany Lars Jacobsen, Denmark Allergen Exposure Chambers in AIT Oliver Pfaar, Germany Biomarkers in AIT- an update Mohamed Shamji, United Kingdom AIT in polysensitised patients Carmen Vidal, Spain Coffee break / visit to the clinical village Absolute and relative contraindications in AIT Hans-Jørgen Malling, Denmark Recent advances of AIT in children and adolescents Eva-Maria Varga, Austria POSTGRADUATE COURSE (PG 4) 14:00-17:30 Recent developments in gastrointestinal food hypersensitivity - Basic Room 103b Chairs: Alex Straumann, Switzerland Anna Nowak-Wegrzyn, United States Eosinophilic gastrointestinal disorders Alex Straumann, Switzerland The spectrum of wheat hypersensitivity Frits Koning, The Netherlands Coffee break / visit to the clinical village Food protein-induced enterocolitis syndrome Anna Nowak-Wegrzyn, United States Food hypersensitivity and functional gastrointestinal disorders Alberto Ravelli, Italy Treatment of EoE: Drugs or diet? Carina Venter, United Kingdom POSTGRADUATE COURSE (PG 5) 14:00-17:30 Food Allergy beyond childhood - Basic Room 206 Chairs: Tilo Biedermann, Germany Clare Mills, United Kingdom Adult food allergy: A clinical overview Barbara Ballmer-Weber, Switzerland Update on diagnostics in food allergy André Knulst, The Netherlands Coffee break / visit to the clinical village Special faces of adult food allergy: alfa-gal, exercise induced reactions, hydrolysates, kernels, ltp Tilo Biedermann, Germany Managing food allergy in adolescents Jonathan Hourihane, Ireland What is the right treatment in adulthood in 2017? Elide Pastorello, Italy 30

31 SATURDAY 17 JUNE 2017 POSTGRADUATE COURSE (PG 6) 14:00-17:30 Tools to enhance the value of clinical research in allergy - Basic Room 201 Chairs: Christian Apfelbacher, Germany Alberto Alvarez-Perea, Spain Transparency and accuracy in reporting allergy research Christian Apfelbacher, Germany SATURDAY Reporting guideline for RCTs: The CONSORT statement Michael Perkin, United Kingdom Guideline for reporting systematic reviews and meta-analyses: The PRISMA statement Jon Genuneit, Germany Coffee break / visit to the clinical village Guidelines for reporting observational research: The STROBE statement Alberto Alvarez-Perea, Spain POSTGRADUATE COURSE (PG 7) 14:00-17:30 Diagnostic tools in examination of the nose - Basic Room 204 Chairs: Michael Rudenko, United Kingdom Peter Valentin Tomazic, Austria Nasal endoscopy/rhinoscopy Peter Valentin Tomazic, Austria Nasal function: Nasal peak flow, rhinomanometry, acoustic rhinometry Michael Rudenko, United Kingdom Nasal challenge Ralph Mösges, Germany Nasal hyperresponsiveness to Cold Dry Air Valerie Hox, Belgium Nasal inflammation: NO, secretions, biopsies Ludger Klimek, Germany Coffee break / visit to the clinical village Hands on nasal peak flow, rhinomanometry, acoustic rhinometry, cold dry air, nasal secretions, nasal NO POSTGRADUATE COURSE (PG 8) 14:00-17:30 Omic technologies in immunology - Advanced Room 207 Chairs: Cornelis van Drunen, The Netherlands Mikael Benson, Sweden Introductory lecture: How omics are applied in immunology Cornelis van Drunen, The Netherlands Functional genomics and proteomics: Understanding the dynamic aspects of immune diseases Mikael Benson, Sweden Coffee break / visit to the clinical village Pitfalls and development of standardised protocols Risto Renkonen, Finland Future; new perspectives within immunology Claudio Rhyner, Switzerland 31

32 SATURDAY 17 JUNE 2017 SATURDAY POSTGRADUATE COURSE (PG 9) 14:00-17:30 Allergy Diagnosis 2017: Novel dimensions in ex vivo allergy diagnostics - Advanced Room 102 Chairs: Hans-Jürgen Hoffmann, Denmark Markus Ollert, Luxembourg Implementing component research diagnostics in allergy diagnosis Markus Ollert, Luxembourg Molecular profiling of allergic patients by multiplex testing Paolo Matricardi, Germany Cellular tests for diagnosing and monitoring of allergy Edward Knol, The Netherlands Coffee break / visit to the clinical village A new framework for the interpretation of IgE sensitisation tests Graham Roberts, United Kingdom Discussion: How to implement these novel diagnostics in routine allergy diagnostics: Chaired by Hans-Jürgen Hoffmann, Denmark; Markus Ollert, Luxembourg POSTGRADUATE COURSE (PG 10) 14:00-17:30 Allergy for Primary Care doctors: English language Room 205 The EAACI Primary Care Interest Group (PCIG) invites you to the Postgraduate Course for Primary Care doctors. PCIG is a Specialist Interest Group of WONCA Europe. Learn and develop a diagnostic and therapeutic pathway in a relaxed environment The Postgraduate Course for Primary Care doctors is designed to reproduce real situations in a virtual and safe medical setting. The purpose is for GPs and specialists to work together on challenging cases as an example of integrated care and interactive learning. Course participants will get to explore various decision points similar to during a regular consultation. Moderators: Dermot Ryan, United Kingdom Elizabeth Angier, United Kingdom Johannes Ring, Germany Scenarios: 27 year old man with complaints of cough 6 year old child with severe symptoms during birthday party 36 year old female patient with intermittent itchy rash The course is held in English and will be CME accredited. TALENT DEVELOPMENT PROGRAMME 15:30-17:00 Talent Development Programme for Junior Members Hall 3g The President of EAACI is pleased to launch an exciting programme for Junior Members. The objective of the session is to help the Junior Members acknowledge and develop certain aspects of their personality which would make them stand out as current and future leaders in a group of people with similar qualifications. Course Leader: Valerie Ryder 32

33 SATURDAY 17 JUNE 2017 OPENING CEREMONY 19:00-20:00 Opening Ceremony Hall 1 WELCOME RECEPTION 20:00-23:00 Welcome Reception Gallery + Registration Lobby SATURDAY JUNIOR MEMBERS (JMS) - POSTER PRESENTATION 20:00-21:15 Junior Members (JMs) Foyer of Hall 5 BENEFITS FOR EAACI MEMBERS SPECIAL OFFER JOIN AS A FULL MEMBER DURING THE EAACI CONGRESS AND RECEIVE A 50% DISCOUNT* COMPLETE THE APPLICATION FORM ONLINE AT OR AT THE EAACI COUNTER * Membership will be valid until 31 December 2017 BENEFITS Members Junior Members** Subscription to Allergy, European Journal of Allergy and Clinical Immunology Yes Online access only Subscription to PAI, Pediatric Allergy and Immunology Journal Yes Online access only 25% discount on registration to all EAACI events Yes Yes Printed EAACI Newsletter Yes Yes Access to the EAACI Members Area including the Membership Directory, Membership Certificate, Guidelines, Monographs, Yes Yes Webcasts, Slide Kits and more 50% discount on the EAACI/UEMS Knowledge Examination Yes Yes Eligibility for election to the Executive Committee and steering board of Sections and Interest Groups Yes Yes Full voting rights Yes Yes Fellowship Programme Yes FEES Annual Fee EUR 150 Free Members from countries with a GNP of less than USD 10,000 EUR 75 EAACI Allied Health Interest Group Members EUR 75 EAACI Allied Health Interest Group Members from countries with a GNP less than USD 10,000 EUR 40 EAACI/AAAAI Dual Membership (-20%) EUR 120 EAACI/ACAAI Dual Membership (-20%) EUR 120 EAACI/European Respiratory Society Dual Membership (-15%) EUR 128 EAACI/European Rhinologic Society Dual Membership (-10%) EUR 135 ** Individuals 35 years of age 33 Junior fee with printed Allergy and PAI Journals Subscription: EUR 60

34 PROGRAMME AT A GLANCE SUNDAY 18 JUNE 2017 SUNDAY Clinical Village Hall 1 Hall 5bc Hall 5a Hall 3a Hall 3b Hall 3c Hall 3d Hall 3e Hall 3f Hall 3g Session Roo 08:30 P.37 P.37 09:00 09:30 PL 1 Allergy prevention: The broad perspective PC, FA, A, P PL 2 Systems allergology: Involving molecular cell models in understanding the complex immunology in allergy BA, CA, D, A 10:00 10:30 P.178 P.38 P.38 P.38 P.38 P.38 P.39 P.39 P.40 P.40 CSS 1 SYM 1 SYM 2 SYM 3 SYM 4 SYM 5 SSS 1 OAS 1 OAS 2 OAS 3 Company Women in New anti- Treatment of Regulation Fatty acid and AAAAI: Food allergy Biomarkers in IgE and Sponsored Science inflammatory rhinosinusitis: and standardisation lipid signaling Environmental mechanisms Asthma allergens 11:00 Symposium Symposium treatments of State of the in asthma and climate and asthma and art of allergen and allergic impact on biomarkers allergy immunotherapy inflammation allergic disease 11:30 products CI, DI, D, P A, CA ENT, PC IT, CA, PC I, BA A, CA, ENT, P FA A I 12:00 P.44 Clinical Village P.248 CLS 1 12:30 Company Lunch Symposium Lunch and Poster Viewing in the Poster Area 13:00 13:30 P.44 P.46 P.44 P.178 P.45 P.45 P.45 P.46 P.46 P.46 SYM 6 EAACI Guidelines HT 2 The united SYM 7 New frontiers CSS 2 Company SYM 8 Important SYM 9 Airborne SYM 10 Tree nut SSS 2 SLAAI: What OAS 6 Updates in OAS 7 Immune for Clinical airways in atopic Sponsored aspects of pollutants and allergy in causes allergic rhino- deficiency and 14:00 14:30 practice on Allergen Immunotherapy: Controversies and challenges microbiome dermatitis therapy Symposium insect venom allergies allergy Europe allergies in Latin America and how we deal with them? conjunctivitis autoimmunity IT, A, P, ENT A, CI, ENT, P D, CA, P CA, DI, P CA, A, ENT, PC FA, CA, P CA, IT ENT I 15:00 15:30 P.52 P.51 P.51 P.51 P.51 P.51 P.52 P.52 P.53 P.53 YIR 1 SYM 11 OAS 11 United airways Anaphylaxis Lymphocytes 16:00 16:30 SYM 12 Inflammometric biomarkers in asthma SYM 13 Clinical immune tolerance: From fantasy to reality? SYM 14 Management of drug hypersensitivity in children SYM 15 Prevention of occupational allergy: A multidisciplinary approach SSS 3 APAPARI: The epidemic of food allergies: Lessons from around the world JM Sci One airway, one disease: Can the allergic march be halted? OAS 12 AIT biomarkers and persistence of immune response A, ENT FA, P, CA, PC A, CA BI, CA, CI, BA DA, P, CA CA, A, ENT FA,P A, ENT, IT, P I IT 17:00 17:30 P.184 P.184 P.184 P.184 P :00 SAT 1 Company Sponsored Satellite Symposium SAT 2 Company Sponsored Satellite Symposium SAT 3 Company Sponsored Satellite Symposium SAT 4 Company Sponsored Satellite Symposium SAT 5 Company Sponsored Satellite Symposium 18:

35 PROGRAMME AT A GLANCE SUNDAY 18 JUNE 2017 m: Hall 3g Room 101 Room 103a Room 208 Room 102 Pro & Con Arena Poster Discussion Zone 1 SESSION GUIDE SSS Sister Society Symposium OAS Oral Abstract Session PDS Poster Discussion Session JM Junior Members Programme LB PDS Late Breaking Poster Discussion Session P & C PL SYM WS HT YIR Pro & Con Session Plenary Symposium Symposium Workshop Hot Topic Session Year in Review Session TOPIC TRACKS A Asthma AH Allied Health BA Basic Allergology BI Biologicals CA Clinical Allergology CI Clinical Immunology D Dermatology DA Drug Allergy DI Allergy Diagnosis ENT Ear, Nose, Throat FA Food Allergy I Immunology Poster Discussion Zone 2 IT Immunotherapy OA Ocular Allergy P Pediatrics PC Allergy management in Primary Care Poster Discussion Zone 3 Poster Discussion Zone 4 SISTER SOCIETIES AAAAI American Academy of Allergy, Astma & Immunology APAPARI Asia-Pacific Association of Pediatric Allergy, Respirology and Immunology SLAAI Latin American Society of Allergy, Asthma and Immunology 08:30 09:00 09:30 10:00 SUNDAY P.39 P.40 P.39 P.41 P.41 P.42 P.43 P.42 10:30 HT 1 New clinical OAS 4 Allergy WS 1 Practical OAS 5 What's new in PDS 1 Urticaria and PDS 2 Immunotherapy LB PDS 1 Drug allergy: PDS 3 Autoimmunity insights in allergy epidemiology: approaches insect venom angioedema - From epidemiology, and immune and immunology Early life and to feeding the allergy? immune response diagnosis and deficiency 11:00 environment food allergic to real clinical aspect child life treatment 11:30 CI, D, DI A, D, P AH, P, FA, PC CA D IT DA I 12:00 Lunch and Poster Viewing in the Poster Area P.44 Pro & Con 1 Macrolides should be considered for the treatment of asthma A P.44 Pro & Con 2 Can drug provocation be done without skin testing first? DA Lunch and Poster Viewing in the Poster Area 12:30 13:00 P.47 P.47 P.45 P.48 P.49 P.48 P.49 P.50 13:30 OAS 8 Food allergy epidemiology OAS 9 Environment and allergic WS 2 Challenges in asthma OAS 10 Drug allergy: From pathomechanism LB PDS 2 Allergy diagnosis PDS 4 Biomarkers in asthma PDS 5 Aeroallergens: exposure and LB PDS 3 Allergy in children, - a world of difference diseases in children diagnosis and management to the management health impact prevention and risk factors 14:00 14:30 FA P A, P, PC, AH DA DI A CA, ENT, OA P P :00 KOL 1 Key Opinion Leader Insights Session P.178 P.53 P.52 P.54 P.54 P.55 P.55 P.56 15:30 CSS 3 OAS 13 WS 3 OAS 14 PDS 6 PDS 7 PDS 8 PDS 9 Company Management Managing Asthma Asthma immunopathology Food allergy Innate immune News in Sponsored of atopic allergic Mechanisms / diagnosis response immunotherapy Symposium dermatitis conjunctivitis in Inflammation / and varia 16:00 daily practice Mechanism 16:30 D OA, CA, PC A A FA I IT 17:00 P :30 SAT 6 Company Sponsored Satellite 18:00 Symposium 18:

36 LEARNING LOUNGES AND BUSINESS MEETINGS LEARNING LOUNGES Room 218 Room 217 Room 204 Room :30-08:15 P.37 07:30-08:15 P.37 07:30-08:15 P.37 07:30-08:15 P.37 LL 1 LL 2 LL 3 LL 4 Rare allergens: Problems in diagnosis Is BAT/CRD useful for diagnosis of food Ocular allergy: Differential diagnosis Perioperative hypersensitivity: What to and AIT allery? that you need to be aware of do when tests are negative IT, DI FA, DI, P, CA OA, P, CA, PC DI, CA, DA SUNDAY BUSINESS MEETINGS Room 103a Room 102 Room 103b Room 201 Room 206 Room 207 Room :30-18:40 P.57 17:30-18:40 P.57 17:30-18:40 P.57 17:30-18:40 P.57 17:30-18:40 P.57 17:30-18:40 P.57 17:30-19:00 P.57 BM 1 BM 2 BM 4 BM 6 IG Immunotherapy - Open to all attendees IG Allergy Diagnosis - Open to all attendees IG Primary Care - Open to all attendees IG Allied Health - Open to all attendees BM 3 IG Allergy, Asthma and Sports - Open to all attendees BM 5 IG Insect Venom Hypersensitivity - Open to all attendees BM 7 Junior Members (JMs) - Open to all attendees SESSION GUIDE LL Learning Lounge BM Business Meeting of EAACI Sections and Interest Groups TOPIC TRACKS CA Clinical Allergology DA Drug Allergy DI FA Allergy Diagnosis Food Allergy IT Immunotherapy OA Ocular Allergy P Pediatrics PC Allergy management in Primary Care SYMPOSIUM Chairs: Susanne Halken, Denmark, Antonella Muraro, Italy Sunday :30 12:00 Hall 5bc WOMEN IN SCIENCE Early intervention in allergy prevention Kari Christine Nadeau United States Role of CRD in prevention and early management of allergic diseases Verena Niederberger Austria Role of the skin in immunomodulation Stefanie Eyerich Germany 36

37 SUNDAY 18 JUNE 2017 SOME SESSIONS FILL UP QUICKLY. ARRIVE EARLY TO GUARANTEE YOUR ENTRY. IF YOU HAVE MISSED A SESSION, YOU CAN CATCH UP ON IT AT THE VIRTUAL CONGRESS HUB IN THE EXHIBITION HALL. PROGRAMME IS STILL SUBJECT TO CHANGE. PLEASE REFER TO THE CONGRESS APP FOR LATEST UPDATE. LEARNING LOUNGE 07:30-08:15 Learning Lounges are early morning sessions. Pre-registration & sperarate payment required, limited spaces. Learning Lounge (LL 1) Room 218 Rare allergens: Problems in diagnosis and AIT Ludger Klimek, Germany SUNDAY Learning Lounge (LL 2) Room 217 Is BAT/CRD useful for diagnosis of food allergy? Alexandra Santos, United Kingdom Learning Lounge (LL 3) Room 204 Ocular allergy: Differential diagnosis that you need to be aware of Osmo Kari, Finland Learning Lounge (LL 4) Room 205 Perioperative hypersensitivity: What to do when tests are negative Lene Heise Garvey, Denmark PLENARY SYMPOSIUM (PL 1) 08:30-10:00 Allergy prevention: The broad perspective Hall 1 Chairs: Ioana Agache, Romania Tari Haahtela, Finland Food allergy prevention: Lessons from the last decades Antonella Muraro, Italy Early introduction of foods: How early Gideon Lack, United Kingdom The Finnish prevention campaign Mika Mäkelä, Finland PLENARY SYMPOSIUM (PL 2) 08:30-10:00 Systems allergology: Involving molecular cell models in understanding the complex immunology in allergy Hall 5bc Chairs: Lars K. Poulsen, Denmark Carsten Schmidt-Weber, Germany Systems medicine: An overview of the implications for allergology Juha Kere, Sweden Atopic dermatitis: Systems, pathways, and genes Emma Guttman Yassky, United States Systems allergology to individualise treatment Ian Adcock, United Kingdom 37

38 SUNDAY 18 JUNE 2017 SYMPOSIUM (SYM 1) 10:30-12:00 Women in Science Symposium Hall 5bc Chairs: Antonella Muraro, Italy Susanne Halken, Denmark Early intervention in allergy prevention Kari Christine Nadeau, United States SUNDAY OTE Role of CRD in prevention and early management of allergic diseases Verena Niederberger, Austria Role of the skin in immunomodulation Stefanie Eyerich, Germany SYMPOSIUM (SYM 2) 10:30-12:00 New anti-inflammatory treatments of asthma and allergy Chairs: Liam Heaney, United Kingdom Sven-Erik Dahlén, Sweden OTE Hall 5a Peptides for mycobacterium: Towards the prevention of allergy? Clive Page, United Kingdom Dual PDE3/4 inhibitor: Novel treatment options for asthma Leif Bjermer, Sweden CRTH2 antagonists and blockers of the 5-lipoxygenase pathway Zuzana Diamant, The Netherlands SYMPOSIUM (SYM 3) 10:30-12:00 Treatment of rhinosinusitis: State of the art Hall 3a Chairs: Peter Valentin Tomazic, Austria Valerie Hox, Belgium OTE Chronic rhinosinusitis Claire Hopkins, United Kingdom Nasal polyps Ludger Klimek, Germany Biologicals Claus Bachert, Belgium SYMPOSIUM (SYM 4) 10:30-12:00 Regulation and standardisation of allergen immunotherapy products Hall 3b Chairs: Roy Gerth van Wijk, The Netherlands Oliver Pfaar, Germany OTE Allergen products in the EU: Regulatory requirements and standardisation Stefan Vieths, Germany US FDA requirements for allergen regulation Ronald Rabin, United States New regulatory approaches Sergio Bonini, Italy SYMPOSIUM (SYM 5) 10:30-12:00 Fatty acid and lipid signaling in asthma and allergic inflammation Hall 3c 38 Chairs: Liam O Mahony, Switzerland Eva Untersmayr, Austria OTE Modulating allergy with short chain fatty acids? Remo Frei, Switzerland Arachidonic acid metabolism in allergic inflammation Grzegorz Woszczek, United Kingdom Sphingolipids in allergic inflammation Stefan Worgall, United States

39 SUNDAY 18 JUNE 2017 WORKSHOP (WS 1) 10:30-12:00 Arrive early to guarantee your entry, limited spaces. Practical approaches to feeding the food allergic child Room 208 Chairs: Carina Venter, United Kingdom Nicolette de Jong, The Netherlands Knowing what infants and young children actually eat and how this can help in food allergy management Emilia Vassilopoulou, Cyprus Normalising food intakes to improve nutritional status and social life Jenny van Odijk, Sweden SUNDAY SISTER SOCIETY SYMPOSIUM (SSS 1) 10:30-12:00 AAAAI: Environmental and climate impact on allergic disease Hall 3d Chair: David B. Peden, United States OTE Global climate change, pollution and environmental allergens Gennaro D Amato, Italy Epigenetic Impact of pollutants in allergy Gurjit Khurana-Hershey, United States Interventions to reduce the impact of pollutants on allergic disease David B. Peden, United States HOT TOPIC (HT 1) 10:30-12:00 New clinical insights in allergy and immunology Room 101 Chairs: Nanna Fyhrquist, Sweden Ralf Müller, Germany OTE Antigen-specific regulatory T cells directing tolerance or allergy to aeroallergens Petra Bacher, Germany Prausnitz-Küstner test revisited Anja Pahlow Mose, Denmark Prophylaxis of hereditary angioedema Marco Cicardi, Italy ORAL ABSTRACT SESSION (OAS 1) 10:30-12:00 Food allergy mechanisms and biomarkers Chair: Alexandra Santos, United Kingdom Session roadmap Alexandra Santos, United Kingdom 0001 Innate immune hyperactivation in paediatric food allergy Melanie R Neeland, Murdoch Childrens Research Institute, Australia 0002 Genetic variation at the Th2 immune gene IL13 is associated with IgE -mediated paediatric food allergy Sarah Elizabeth Ashley, Max-Delbrück-Centrum für Molekulare Medizin, Germany 0003 A proposal for the adverse outcome pathway (AOP) for food sensitization Jolanda Hubertina Maria Van Bilsen, TNO, The Netherlandss Hall 3e 0004 Metabolomic phenotyping based biomarkers in food allergy linked to respiratory allergy Alma Villaseñor, San Pablo CEU University, Spain 0005 Nutritional wheat alpha-amylase/trypsin inhibitors but not a control storage protein from corn exacerbate allergeninduced gut and lung inflammation in humanized mice Joachim Saloga, Department of Dermatology, University Medical Center of the Johannes Gutenberg-University Mainz, Germany 0006 Tri-pentamers in galacto-oligosaccharide mixture induce galectin-9 release in CpG dna-primed activated human intestinal epithelial cells Linette Willemsen, Utrecht University, The Netherlands 39

40 SUNDAY 18 JUNE 2017 ORAL ABSTRACT SESSION (OAS 2) 10:30-12:00 Biomarkers in asthma Hall 3f 0067 Control of asthma by omalizumab: the role of CD4+Foxp3+ regulatory T cells Flore Amat, Hôpital d Enfants Armand Trousseau, France 0070 Asthma symptoms, medication use, and lung function before and after an asthma exacerbation Hanne Hedegaard Villesen, Global Medical Affairs, ALK, Denmark SUNDAY 0068 Quantification of histamine-secreting microbes from the gut differentiates obese versus non-obese asthma patients Weronika Barcik, SIAF, Switzerland 0069 Decreased lung function relates to increased type-2 inflammation in asthma subjects from the swedish ga2len study Ida Mogensen, Uppsala University, Sweden 0071 Nocturnal variabilities of tidal airflow and heart rate show mutual association in young children with asthma symptoms Ville-Pekka Seppä, Biomeditech, Tampere University of Technology, Finland 0072 Phenotypes related with the clinical improvement of patients treated with omalizumab in routine clinical practice. Fenoma study Paloma Campo, Hospital Regional Universitario Carlos Haya, Spain ORAL ABSTRACT SESSION (OAS 3) 10:30-12:00 IgE and allergens Chairs: Claudio Rhyner, Switzerland Mohamed Shamji, United Kingdom Session roadmap: Claudio Rhyner, Switzerland 0133 Human ige monoclonal antibodies with natural heavy and light chain pairing and specificity for asthma-associated allergens Anna Pomés, Indoor Biotechnologies, Inc., United States 0134 Bet v 1 microarray: recognition pattern of serum allergenspecific IgEs Jaana Haka, Desentum Oy, Finland Hall 3g 0136 Identification and immunological characterization of the ligand of pru p 3 María Garrido-Arandia, Centre for Plant Biotechnology and Genomics, (UPM-INIA), Technical University of Madrid, Spain 0137 Clonality and mast cell activation Hans Jürgen Hoffmann, Aarhus University Hospital, Denmark 0138 An anti-ige single domain antibody disrupts the interaction of IgE with fceri by acting as functional high affinity mimic of cd23 Frederic Jabs, Department of Engineering, Aarhus University, Denmark 0135 Identification of novel oyster allergens using a combined transcriptomic and proteomic approach for improved diagnosis of oyster allergy Andreas L Lopata, Department of Molecular and Cell Biology, James Cook University, Australia ORAL ABSTRACT SESSION (OAS 4) 10:30-12:00 Allergy epidemiology: Early life and environment Chairs: Jon Genuneit, Germany Session roadmap: Jon Genuneit, Germany 0169 Does leukocyte telomere length play a role as a candidate biomarker for prenatal stress exposure and the risk of atopic dermatitis development? Dong In Suh, Seoul National University Children s Hospital, South Korea 0170 Late preterm birth protects against atopies in adulthood Pieta Näsänen-Gilmore, National Institute for Health and Welfare, Finland Room 103a 0171 Influence of early feeding patterns on eczema development in high-risk infants Mimi Tang, Royal Children s Hospital, Murdoch Children s Research Institute, University of Melbourne, Australia 0172 Farmhouse-like indoor microbiota protects children from asthma also away from farms Pirkka V. Kirjavainen, THL, Finland 0173 Indoor microbiome and asthma: a case-control study within ecrhs Juha Pekkanen, University of Helsinki, Finland 0174 Perinatal probiotics decreased eczema up to 10 years of age but at 5 10 years allergic rhino conjunctivitis was increased Päivi Peldan, Children s Hospital, University of Helsinki and Helsinki University Hospital, Finland 40 Full abstract author lists are available on the official Congress website.

41 SUNDAY 18 JUNE 2017 ORAL ABSTRACT SESSION (OAS 5) 10:30-12:00 What s new in insect venom allergy? Room 102 Chairs: Beatrice Biló, Italy Dario Antolin Amerigo, Spain Session roadmap: Beatrice Biló, Italy 0175 Role of cytokine gene polymorphisms in hymenoptera venom allergy Betül Ayse Sin, Division of Immunology & Allergy, Ankara University School of Medicine, Turkey 0176 Polistes venom allergy: identification and immunological characterization of novel allergens Maximilian Schiener, Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, Germany 0177 Component-resolved allergen content of therapeutic honeybee venom extracts Dennis Russkamp, Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, Germany 0178 Can tests distinguish between acute patients, VIT treated patients, and asymptomatically sensitized subjects? Christoph Schrautzer, Department of Dermatology, Austria 0179 CD63 and CD203c expression during specific immunotherapy (SIT) for wasp venom allergy using basophile activation test (BAT): Results after 3 years and correlation to sting challenge test Nadine Reiß, Institut für Klinische Chemie und Laboratoriumsmedizin, Universitätsklinikum Carl Gustav Carus, Germany 0180 Understanding health care system settings and funding structures in European countries in management of patients with Hymenoptera venom allergy Ewa Cichocka-Jarosz, Jagiellonian University Medical College, Department of Pediatrics, Poland SUNDAY POSTER DISCUSSION SESSION (PDS 1) 10:30-12:00 Urticaria and angioedema Poster Discussion Zone 1 Chair: Clive Grattan, United Kingdom 0205 Cleaved high molecular weight kininogen in plasma from patients with hereditary angioedema due to C1 inhibitor deficiency Daniel J Sexton, Shire, United States 0206 G protein coupled receptor kinase 2 (GRK2) regulates endothelial permeability induced by Bradykinin Stefania Loffredo, Department of Translational Medical Sciences and Center for Basic and Clinical immunological Research (CISI), University of Naples Federico II, Italy 0207 Proteomic analysis of contact system activation in plasma from patients with hereditary angioedema Dan J Sexton, Shire, United States 0208 Pharmacokinetics (PK) and pharmacodynamics (PD) of c1 esterase inhibitor (c1-ihn) for prophylaxis of angioedema attacks in patients (PTS) with hereditary angioedema (HAE) Yi Wang, Shire, United States 0209 Gender analysis of baseline characteristics and treatment outcomes in patients (pts) with hereditary angioedema type I/II: findings from the icatibant outcomes survey Marcus Maurer, Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité Universitätsmedizin Berlin, Germany 0210 Efficacy, safety and pharmacokinetics of icatibant for acute attacks in japanese adults with type I or type II hereditary angioedema: results of a phase 3, open-label study Jennifer Schranz, Shire, United States 0211 Evaluation of IL-17 serum level in patients with chronic idiopathic urticaria based on the autologous skin test compared to the control group Rasool Nasiri Kalmarzi, Cellular & Molecular Research Center, Kurdistan University of Medical Sciences, Iran 0212 Guide clinical history for chronic urticaria: an easy tool Iván Chérrez Ojeda, Universidad Espíritu Santo, Ecuador 0213 Clinical and diagnostic features in acquired cold urticaria patients in a Coruña sanitary area, Spain Beatriz Veleiro Pérez, Complexo Hospitalario Universitario A Coruña, Spain 0214 Healthcare resource utilisation due to chronic urticaria in Europe, South America, and Central America: findings from visit 1 of the worldwide aware study Marcus Maurer, Department of Dermatology and Allergy, Allergie-Centrum-Charité/ECARF, Charité Universitätsmedizin, Germany 0215 Early impact of anti-ige therapy on FceRI-expressing basophils in patients with chronic urticaria correlates with improved disease control Michèle Myriam Rauber, Clinical & Experimental Allergology, Department of Dermatology and Allergology, Philipps University Marburg, Germany 0216 Omalizumab in patients with severe active chronic spontaneous urticaria (CSU) heavily treated with corticosteroids and cyclosporine. Zev Sthoeger, The Israeli Chronic Urticaria study group., Israel 41

42 SUNDAY 18 JUNE Dimers correlation to response to treatment in chronic spontaneous urticaria (UAS7 score): Results from the sunrise study Annick Barbaud, dermatologie et allergologie, Hôpital Tenon, France 0218 Markers for systemic inflammation (CRP, ESR, IL-6, IL-10, IL- 33, CCL2/MCP-1), and the disease severity in patients with chronic spontaneous urticaria Anna Valerieva, Medical University of Sofia, Bulgaria SUNDAY POSTER DISCUSSION SESSION (PDS 2) 10:30-12:00 Immunotherapy - From immune response to real life treatment Poster Discussion Zone 2 Chairs: Lars Jacobsen, Denmark Carmen Vidal, Spain 0343 Immunological modulation of allergic cell responses by Prup3-enriched-sublingual immunotherapy. María Francisca Palomares, Research Laboratory, IBIMA, Regional University Hospital of Malaga, UMA., Spain 0344 Crucial role of Langerhans cells in epicutaneous immunotherapy Vincent Dioszeghy, DBV-Technologies, France 0345 Successful allergen-specific immunotherapy decreases group 2 innate lymphoid cells in house dust mite allergic patients Wat Mitthamsiri, Division of Allergy and Clinical Immunology, Department of Medicine, Phramongkutklao Hospital, Thailand 0346 Epicutaneous immunotherapy (EPIT) prevents anaphylaxis to egg in sensitized mice Sophie Wavrin, DBV Technologies, France 0347 Induction of functional Foxp3+ regulatory T cells, butyric acid and galectin-9 by oral immunotherapy in combination with a fructo-oligosaccharide supplemented diet in a murine model Marlotte M Vonk, Utrecht University / Nutricia Research, The Netherlands 0348 Safety and feasibility of slow low-dose oral immunotherapy Shiro Sugiura, Aichi Children s Health and Medical Center, Japan 0349 Safety and tolerability of the SQ grass SLIT-tablet in the paediatric grazax asthma prevention (GAP) trial Maria Abildgaard Steffensen, Global Pharmacovigilance and Clinical Development, ALK, Denmark 0350 Local adverse effects and adherence to grass allergy sublingual immunotherapy with tablets in real life Erminia Ridolo, Clinical and Experimental Deprtment, University of Parma, Italy 0351 Preliminary results of a tolerability study with polimerized depot mixture (100/100) of olea europaea and phleum pratense pollen extract. Vanesa Sánchez Moreno, Hospital Universitario de Henares. Alergology Service, Spain 0352 Quality of life improvement in patients with rhinoconjuntivitis with or without asthma, after one-year immunotherapy treatment. preliminary results of an observational prospective study (ícara). Javier Cuesta Herranz, IIS-Fundación Jiménez Díaz. Allergy department., Spain 0353 Modalities of use and tolerance of a 300IR 5-grass pollen tablet treatment in real life in patients consulting allergology specialists in France Michel Migueres, Clinique de l Union, France POSTER DISCUSSION SESSION (PDS 3) 10:30-12:00 Autoimmunity and immune deficiency Poster Discussion Zone 4 Chair: Jan Gutermuth, Belgium 0479 Detection of neutrophil elastase protease activity by using a highly sensitive FRET reporter Reza Akbarzadeh, Institute of Anatomy, University of Lübeck, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Germany 0480 Hypoxia-inducible MiR-342-3p is critical for dendritic cells and C5a-associated inflammatory pathogenesis in rheumatoid arthritis Cheng Qian, National Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, China 0481 Investigating the expression of Sfpi-1 transcription factor and its regulation by targeting mirnas in an animal model of MS and stimulated macrophages with LPS Leila Shakerian, Tehran University of Medical Science, Department of Immunology, Iran 0482 Endothelial activation markers are associated with vasculopathy severity in patients with systemic sclerosis Roxana Sfrent-Cornateanu, Dept of Immunology and Physiopathology, Carol Davila University of Medicine and Pharmacy, Romania 0483 Aberrant expression of circulating Th22 cells and serum level of IL-22 in patients with ulcerative colitis Hassan Nikoueinejad, Baqiyatallah University of Medical Sciences, Iran 42 Full abstract author lists are available on the official Congress website.

43 SUNDAY 18 JUNE Eye manifestations of patients with muckle-wells syndrome Sükrü Çekiç, Uludag University Faculty of Medicine, Pediatric Allergy and Clinical Immunology, Turkey 0485 Antiretroviral activity of the conjugates 3 -azido- 3 deoxythymidine and derivatives of 1,3-diacylglycerides Andrei Siniavin, NRC Institute of Immunology FMBA of Russia, Russia 0486 Humic substance-based antivirals: antiretroviral activity, mechanisms of action, and impact on mucosal immunity Yury V. Zhernov, National Research Center Institute of Immunology Federal Medical-Biological Agency of Russia, Russia 0487 Functional characterization of T helper cells in a cohort of common variable immunodeficiency patients Tomas Milota, 2nd Faculty of Medicine Charles University and University Hospital in Motol, Czech Republic 0488 Bone mineralisation defect in patients with hax-1 deficiency Sara Sebnem Kiliç, Uludag University Faculty of Medicine, Pediatric Allergy and Clinical Immunology, Turkey 0489 The role of cytokine status and substance P in frequently ill children Maleyka Knyaz Karimova, Azerbaijan Medical University, Azerbaijan SUNDAY LATE BREAKING POSTER DISCUSSION SESSION (LB PDS 1) 10:30-12:00 Drug allergy: epidemiology, diagnosis and clinical aspect Poster Discussion Zone Evaluation of the improvement in the quality of registry in the opening of the electronic medical records of drugs allergy (first visit). Dorimar Cristina Brugaletta Matheus, Hospital Universitario de Torrevieja, Spain 1450 Is it atopy a risk factor for drug hypersensitivity? Jenny Badas, Hospital São João, Portugal 1451 A predictive model for the diagnostis of allergic drug reactions Beatriz Hierro, Hospital Ciudad de Coria, Spain 1452 IgE dependent immediate hypersensitivity to monoclonal antibodies: do they occur as frequently as we have expected? Ceyda Tunakan Dalgiç, Ege University Medical Faculty, Department of Allergy and Clinical Immunology, Turkey 1453 A new causative agent for symmetrical drug-related intertriginous and flexural exanthema Tamar Kinaciyan, DIAID, Dept. of Dermatology, Medical University of Vienna, Austria 1454 Skin tests with PPL and MDM in Betalactam allergy diagnosis - Do we need to reconsider? Ana Margarida Romeira, Immunoallergy Department, Dona Estefânia Hospital, Centro Hospitalar de Lisboa Central, EPE, Portugal 1455 Concentrations of dilutions used in quinolone skin testing in Greek population - Irritant or not? Maria Konstantakopoulou, General Hospital of Athens Laiko, Greece 1456 Fixed drug erupción induced by metamizole Dorimar Cristina Brugaletta Matheus, Hospital Universitario del Vinalopó, Spain 1457 Lymphocyte transformation test in the diagnostic approach of severe drug hypersensitivity reactions Lise Brosseron, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal 1458 Hypersensitivity reaction during anaesthesia: evaluation of 27 patients in an outpatient allergy clinic Kavitha Garuna Murthee, Singapore General Hospital, Singapore 1459 Prevalence and clinical features of hypersensitivity reactions to antiepileptic drugs in children: A prospective study Hakan Guvenir, Ankara Children s Hematology Oncology Training and Research Hospital, Department of Pediatric Allergy and Immunology, Turkey 1460 Clinical pattern and assesment of drug causality in drug reaction with eosinophilia and systemic symptoms (DRESS) patients Sri Awalia Febriana, Department of Dermatology and Venereology Faculty of Medicine Universitas Gadjah Mada / Dr. Sardjito Academic Hospital, Indonesia 1461 Experience on desensitization to chemotherapeutic agents at Clinica Alemana de Santiago, Chile. Lorena Jiusan, Immunology and Allergy Unit, Medicine Department, Clinica Alemana de Santiago, Chile 1462 Changing trends in perioperative anaphylaxis: A review of 20 years of data from a regional anaesthetic reaction clinic in the UK Shuayb Elkhalifa, Central Manchester NHS Foundation Trust, United Kingdom 43

44 SUNDAY 18 JUNE 2017 CLINICAL VILLAGE 12:00-16:00 Clinical Village SUNDAY The Clinical Village offers an excellent opportunity for attendees to try out different procedures and equipment used in the diagnosis and treatment of allergic diseases. It provides a perfect platform to explore a combination of both theoretical and practical topics, both for specialists-in-training as well as for clinicians wanting to update themselves on topics adjacent to their core business. OPENING HOURS: Saturday, 17 June 2017: 14:00-18:00 Sunday, 18 June 2017: 12:00-16:00 PRO & CON SESSION (PRO & CON 1) 12:15-12:45 Macrolides should be considered for the treatment of asthma Pro & Con Arena Chair: Ömer Kalayci, Turkey OTE Pro Michael Edwards, United Kingdom Con PRO & CON SESSION (PRO & CON 2) 12:45-13:15 Can drug provocation be done without skin testing first? Pro & Con Arena Chair: Andreas Bircher, Switzerland OTE Pro Lene Heise Garvey, Denmark Con Knut Brockow, Germany SYMPOSIUM (SYM 6) 13:30-15:00 EAACI Guidelines for Clinical practice on Allergen Immunotherapy: Controversies and challenges Hall 1 Chairs: Antonella Muraro, Italy Graham Roberts, United Kingdom OTE Preventing allergy with AIT: The start of a new era? Susanne Halken, Denmark Is AIT an option for treating asthma and when? Ioana Agache, Romania Can we use regulations to enhance AIT? Stefan Vieths, Germany SYMPOSIUM (SYM 7) 13:30-15:00 New frontiers in atopic dermatitis therapy Hall 5a Chairs: Ralf Mueller, Germany Jonathan White, United Kingdom OTE Keratinocyte-microbiome interactions Joost Schalkwjik, The Netherlands Insights from veterinary medicine Tim Nuttall, United Kingdom New drugs in the pipeline Stephan Weidinger, Germany 44

45 SUNDAY 18 JUNE 2017 SYMPOSIUM (SYM 8) 13:30-15:00 Important aspects of insect venom allergy Hall 3b Chairs: Beatrice Biló, Italy Wolfgang Hemmer, Austria Component resolved diagnosis 2017: All problems fixed? Thilo Jakob, Germany OTE Myths and pitfalls in insect venom allergy Gunter Sturm, Austria Clonal mast cell disorders and insect venom allergy: What do we know today? Patrizia Bonadonna, Italy SUNDAY SYMPOSIUM (SYM 9) 13:30-15:00 Airborne pollutants and allergies Hall 3c Chairs: Domingo Barber, Spain Gennaro D Amato, Italy OTE Outdoor air exposure and allergic diseases Jeroen Titus Buters, Germany Indoor air exposure and allergic diseases Dick Heederik, The Netherlands Work place exposure and allergic disease Gianna Moscato, Italy SYMPOSIUM (SYM 10) 13:30-15:00 Tree nut allergy in Europe Hall 3d Chairs: Carsten Bindslev-Jensen, Denmark Anastasios Panagiotis Konstantinopoulos, Greece OTE Walnut: An emerging food allergen Barbara Ballmer-Weber, Switzerland Cross-reactive tree nut allergies Margitta Worm, Germany Effect of food matrix and processing Clare Mills, United Kingdom WORKSHOP (WS 2) 13:30-15:00 Arrive early to guarantee your entry, limited spaces. Challenges in asthma diagnosis and management Room 208 Chairs: Ömer Kalayci, Turkey Dermot Ryan, United Kingdom Mis-diagnosis of asthma Enrico Heffler, Italy Underutilisation of lung function measurements Arzu Bakirtas, Turkey Adequate management of patients with suspected asthma Silvia Sanchez-Garcia, Spain 45

46 SUNDAY 18 JUNE 2017 SISTER SOCIETY SYMPOSIUM (SSS 2) 13:30-15:00 SLAAI: What causes allergies in Latin America and how we deal with them? Hall 3e Chairs: Edgardo Jares, Argentina Patricia Latour, Dominican Republic Allergen sensitisation profile Susana Repka, Paraguay SUNDAY OTE Immunotherapy peculiarities in the region João Negreiros Tebyriçá, Brazil Allergic reactions while vacationing in Latino countries Maximiliano Gomez, Argentina HOT TOPIC (HT 2) 13:30-15:00 The united airways microbiome Chairs: Ulrich Wahn, Germany Michael J Cox, United Kingdom OTE Hall 5bc Interaction between genetics and the upper airways microbiome Elina M Toskala, United States The respiratory microbiome in severe asthma Sebastian Johnston, United Kingdom The role of microbiome in the development of childhood asthma Erika von Mutius, Germany ORAL ABSTRACT SESSION (OAS 6) 13:30-15:00 Updates in allergic rhinoconjunctivitis Chair: Cemal Cingi, Turkey Sanna Toppila-Salmi, Finland Session roadmap: Cemal Cingi, Turkey 0181 Conjunctival redness at allergen provocation with photodocumentation: influence of missing values on the therapeutic effect Anatoli Astvatsatourov, University Hospital of Cologne, Germany 0182 Conjunctival transcriptome in vernal keratoconjunctivitis Oren Mark Feuerman, Department of Neuroscience, Ophthalmology Unit, University of Padua, Italy Hall 3f 0184 A novel method of measuring nasal specific IgE in local allergic rhinitis patients Paloma Campo, Allergy Unit, IBIMA, Regional University Hospital of Malaga, UMA, Spain 0185 Frequency of local allergic rhinitis diagnosed by high dose nasal allergen provocation Martin Wagenmann, Düsseldorf University Hospital, Germany 0186 Probiotics-impregnated bedding covers in house dust mite allergic rhinitis patients: A double-blind, randomised, placebo-controlled, crossover clinical trial Margot Berings, Ghent University, Belgium 0183 Expert interpretation of the allergic rhinitis clinical decision support system (AR CDSS): results of a survey monkey of allergic rhinitis experts Jean Bousquet, MACVIA-LR, EIP on AHA Reference Site, France ORAL ABSTRACT SESSION (OAS 7) 13:30-15:00 Immune deficiency and autoimmunity Chairs: Carlo Agostini, Italy Manuel Rial Prado, Spain Session roadmap: Carlo Agostini, Italy 0187 PGM3-deficiency associated hyper IgE syndrome: from molecular basis to intervention approaches. Mohamed-Ridha Barbouche, Institut Pasteur de Tunis, Tunisia Hall 3g 0188 Serum free light chains as a possible diagnostic tool in primary hypogammaglobulinemia: a multicentric study on 344 CVID patients Francesca Rizzo, Dipartimento di Medicina - DIMED, Università degli Studi di Padova, Italy 46 Full abstract author lists are available on the official Congress website.

47 SUNDAY 18 JUNE Sustained natural killer cell expansion in virologically suppressed HIV+ individuals on antiretroviral therapy: a phenotypic study Chiara Tontini, Università Politecnica delle Marche, Italy 0191 Different serum cytokine profiles reflect anti-neutrophil cytoplasmic antibodies (ANCA)-specificity in patients with anca-associated vasculitis Alvise Berti, San Raffaele Scientific Institute, Italy 0190 Dysfunctions of neutrophilic granulocytes in 0192 Gestational age at birth and the risk of type 1 diabetes immunocomromised children with viral coinfections: chronic Petteri Hovi, National Institute for Health and Welfare, Finland herpes-viral and recurrent respiratory viral infections Irina V. Nesterova, People s Friendship University of Russia, Russia ORAL ABSTRACT SESSION (OAS 8) 13:30-15:00 Food allergy epidemiology: A world of difference Room 101 SUNDAY Chairs: Maria Montserrat Fernandez-Rivas, Spain Katie Allen, Australia Session roadmap: Maria Montserrat Fernandez-Rivas, Spain 0193 Prevalence of childhood food allergy among older order mennonites (OOM) in Western New York, introduction of foods and breastfeeding Kirsi M Jarvinen, University of Rochester School of Medicine and Dentistry, United States 0194 Evaluation of the financial costs of healthcare services for people with peanut allergy vs matched controls in the United Kingdom Laura Allison Scott, Cardiff University, United Kingdom 0195 Frequency of food allergy up to and at school age across Europe first results from the ifaam birth cohort Linus B Grabenhenrich, Charité - Universitätsmedizin Berlin, Germany 0196 Prognosis of symptoms and IgE reactivity to cow s milk in Swedish children from early life to adolescence Jennifer Lisa Penner Protudjer, Karolinska Institutet, Sweden 0197 Lipid transfer protein allergy in UK adults characterisation and comparison to adults with pollen-food syndrome Isabel Janet Skypala, Royal Brompton & Harefield NHS Foundation Trust, United Kingdom 0198 Prevalence of food allergy in Vietnam: the first populationbased study Thu Thi Kieu Le, James Cook University, Australia ORAL ABSTRACT SESSION (OAS 9) 13:30-15:00 Environment and allergic diseases in children Chair: Arne Høst, Denmark Session roadmap: Arne Høst, Denmark 0199 Development of atopic sensitization in Finnish and Estonian children a latent class analysis in a multicenter cohort Felicitas Maria Schmidt, Dr. von Hauner Children s Hospital, Germany 0200 Changes in sensitization pattern in allergic brazilian children: first results from 2 cross-sectional studies 12 years apart (proal I & II) Carolina Sanchez Aranda, Federal University of São Paulo, Brazil Room 103a 0201 Indoor microbiota and the development of asthma by age 10.5 years: A birth cohort study Juha Pekkanen, University of Helsinki and National Institute for Health and Welfare (THL), Finland 0202 Differences in the immune profiles and asthma risk in urban and rural children Yu Han Xing, Chinese University of Hong Kong, China 0203 Rural-urban differences in the prevalence and comorbidity of asthma and allergic disorders in Belarus and Poland. Grzegorz Marek Brozek, Medical University of Silesia in Katowice, School of Medicine in Katowice, Department of Epidemiology, Poland 0204 The association between asthma and type 1 diabetes in children and adolescents - a case-cohort study in Finland Johanna Metsälä, National Institute for Health and Welfare, Finland 47

48 SUNDAY 18 JUNE 2017 ORAL ABSTRACT SESSION (OAS 10) 13:30-15:00 Drug allergy: From pathomechanism to management Room 102 SUNDAY Chairs: Werner Pichler, Switzerland Josefina Rodrigues Cernadas, Portugal Session roadmap: Werner Pichler, Switzerland 0007 Elevated expression of Ikaros Family Zinc Finger 1 (IKZF1) exacerbates mucocutaneous inflammation Mayumi Ueta, Kyoto Prefectural University of Medicine, Japan 0008 Genetic polymorphisms of costimulatory molecules and maculopapular eruption induced by antituberculosis drugs Sang-Heon Kim, Hanyang University College of Medicine, South Korea 0009 Biotinylated clavulanic acid as a tool for identifying serum proteins target of haptenation by clavulanic acid in the context of allergy studies Angela Martín-Serrano, BIONAND, Research Laboratory IBIMA-UMA, Spain 0010 Serum procalcitonin for differentiating dress syndrome from bacterial infection Young-Hee Nam, Department of Internal Medicine, College of Medicine, Dong-A University, South Korea 0011 Desensitization for drug hypersensitivity (allergen immunotherapy-like) Marcello Albanesi, University of Bari-Aldo Moro, Italy day desensitization protocol with oral chemotherapeutics for non-immediate hypersensitivity reactions: experience of a single center Semra Demir, Istanbul University, Istanbul Faculty of Medicine, Adult Allergy Clinic, Turkey POSTER DISCUSSION SESSION (PDS 4) 13:30-15:00 Biomarkers in asthma Poster Discussion Zone 2 Chairs: Konstantinos Kostikas, Switzerland Helena Pite, Portugal 0518 Folliculin-induced epithelial cell activation in aspirinexacerbated respiratory disease Hoang Kim Tu Trinh, Ajou University School of Medicine, South Korea 0519 Raised CCL22 chemokine levels during infancy are associated with increased sensitization to house dust mite and asthma in early childhood Kuo-Wei Yeh, Chang Gung Memorial Hospital at Linkuo, Taiwan 0520 Serum periostin is not a biomarker for pediatric asthma Naofumi Suzuki, Mie National Hospital, Japan 0521 Clinical, biochemical and radiological factors for response to aspirin desensitization in patients with aspirin exacerbated respiratory disease- pilot study. Katarzyna Ewa Tyrak, II Chair of Internal Medicine, Jagiellonian University Medical College, Poland 0522 Association of circulating micrornas with asthma and the disease control Malgorzata Ewa Pawelczyk, Department of Immunology, Rheumatology and Allergy, Medical University of Lodz, Poland 0523 Periostin and IL-17a: serum levels in adult patients with moderate to severe bronchial asthma Denitsa Dimitrova, Clinical center of pulmonary diseases, SHATPD St. Sofia, Medical University, Bulgaria 0524 Point-of-care blood eosinophils count in a severe asthma clinic setting Giuseppe Picardi, University of Catania - Respiratory Medicine and Allergology, Italy 0525 Upregulation of total ige in non-allergic asthma with nasal polyps José A. Castillo, Hospital Universitario Quirón Dexeus, Spain 0526 Effect of omalizumab treatment on serum periostin levels in asthma Jakub Novosad, Institute of Clinical Immunology and Allergy, Czech Republic 0527 Usefulness of serum pteridines as a biomarker for childhood asthma Saki Kasuga, Department of Pediatrics, Osaka City University Graduate School of Medicine, Japan 0528 Eicosanoid metabolites of induced sputum supernatants in patients with asthma and normal control subjects Ji-Yong Moon, Department of Internal Medicine, College of Medicine, Hanyang University, South Korea 0529 Serum periostin in asthma is related to disease severity, eosinophilia and IL-33 Brigita Sitkauskiene, Central Manchester NHS Foundation Trust, Lithuania 0530 Leukotriene receptor antagonists in managing severe uncontrolled asthma Elena Jovanovska Janeva, PHI University Clinic of Pulmonology and allergology, Macedonia, Former Yugoslav Republic of 48 Full abstract author lists are available on the official Congress website.

49 SUNDAY 18 JUNE Changes in fractional exhaled nitric oxide levels after aspirin bronchial challenge. Marta Sánchez-Jareño, Department of Allergy Hospital Universitario La Paz IdiPAZ, Spain POSTER DISCUSSION SESSION (PDS 5) 13:30-15:00 Aeroallergens: Exposure and health impact Poster Discussion Zone 3 Chairs: Michel Thibaudon, France Jordina Belmonte, Spain 0532 Aeroallergens: A comparative study of two monitoring methods Carmen Galán, University of Córdoba, Spain 0533 Pollen allergy potency for the main urban plants Michel Thibaudon, RNSA, France 0538 Clinical and diagnostic profile of patients sensitized to Alt a 6 in a sample of 94 patients sensitized to alternaria. Amalia Alonso Bernad, Clínica Universidad de Navarra, Spain 0539 Identification, purification and quantification of 20.2 kd IgE binding major allergen of aspergillus fumigatus for quality control Maansi Vermani, Amity University Uttar Pradesh, India SUNDAY 0534 Impact of weed pollination versus tree and grass pollination on sales of antihistamines in central Ukraine Victoria Rodinkova, Vinnitsa National Pirogov Memorial Medical University, Ukraine 0535 Signification of skin sensitization to plantago lanceolata (plantain) in north eastern France Gabriele Gadermaier, Université de Salzbourg, Austria 0536 Sensitisation to peach tree pollen in a highly exposed population Natalia Pérez-Sánchez, Research Laboratory, IBIMA, Regional University Hospital of Malaga, UMA, Spain 0537 Detection of Ole e1 allergens in the atmosphere and its correlation with olive pollen counts Nihat Sapan, Uludag University, Turkey 0540 Comparison of cat and dog allergen concentrations on electrostatic dust collectors in offices and homes Ingrid Sander, Institut für Prävention und Arbeitsmedizin der DGUV, Institut der Ruhr-Universität Bochum, IPA, Germany 0541 Comparison of quality of life and local inflammatory/atopy markers in smoking vs non smoking patients with allergic rhinitis. R Maximiliano Gomez, Fundación Ayre, Argentina 0542 Anti-allergic effect of intranasal vitamin D treatment by inhibiting dendritic cell activation in the allergic rhinitis mouse model Sung-Woo Cho, Seoul National University College of Medicine, South Korea 0543 Appropriate treatment can reduce vitamin D deficiency in children with vernal keratoconjunctivitis Daniele Giovanni Ghiglioni, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Italy LATE BREAKING POSTER DISCUSSION SESSION (LB PDS 2) 13:30-15:00 Allergy diagnosis Poster Discussion Zone Evaluation of a scanner based allergy lateral flow assay system for the determination of specific IgE within 20 minutes Nadine Offermann, Dr. Fooke Laboratorien GmbH, Germany 1464 Faber IgE test: A standard multiplex diagnostic tool to explore allergic sensitization across different European regions: Romania, Croatia, Italy Adriano Mari, Centri Associati di Allergologia Molecolare, Italy 1465 Misleading allergens in the diagnosis of latex allergy Nihal Mete Gokmen, Ege University Faculty of Medicine, Department of Internal Medicine, Division of Allergy and Immunology, Turkey 1466 Artificial human sera (ARTHUS) as a tool for validation and standardization of bee and wasp specific in-vitro diagnostic systems Nadine Offermann, Dr. Fooke Laboratorien GmbH, Germany 1467 Profile of IgE sensitization to house dust mite allergens in gabonese asthmatic children determined with micro-arrayed allergens Gabrielle Pauli, Faculté de médecine, Université de Strasbourg, France 1468 Der p 23, the new player in house dust mite allergy Filipa Matos Semedo, Centro Hospitalar de Setúbal and Faculdade de Ciências da Saúde, Universidade da Beira Interior, Portugal 1469 Increased occurrence of ash trees in the Vienna area is associated with increasing rates of sensitization to the major ash pollen allergen Victoria Garib, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria, Austria 49

50 SUNDAY 18 JUNE Are pollen allergens more stable and/or more abundant than non-allergens from Phleum pratense and Ambrosia artemisifolia? Geoffrey Andrew Mueller, NIEHS, United States 1473 A comparison of the blinding of peanut in different oral food challenge matrices used for diagnosis of food allergy Martin Sean John Wickham, Reacta Biotech Limited, United Kingdom SUNDAY 1471 IgE and IgG4 ImmunoCAP ISAC 112 profiles in peanut sensitized children and adolescents Riikka Tuuli Ilona Uotila, Helsinki University Hospital, The Skin and Allergy Hospital, Finland 1472 Role of component resolved diagnosis (CDR) in predicting the outcome of DBPCFC with peanut Roberta Bonaguro, Food Allergy Referral Centre, Veneto Region, University Hospital of Padua, Department of Women and Child Health, Padua Italy, Italy 1474 The importance of component resolved diagnosis in seafood allergic children undergoing oral food challenges to shrimp, squid and mussel Carmen Riggioni Víquez, Allergy And Clinical Immunology Department, Hospital Sant Joan De Deu Barcelona, Spain LATE BREAKING POSTER DISCUSSION SESSION (LB PDS 3) 13:30-15:00 Allergy in children, prevention and risk factors Poster Discussion Zone Influenza vaccination of children with atopic bronchial asthma Vilya Bulgakova, National Scientific and Practical Center of Children s Health, Russia 1476 Cord blood immunoglobulin E predicts allergic rhinitis in children: a cohort study Chung-Chieh Hung, Department of Pediatrics, Chang Gung Memorial Hospital, Taiwan 1477 Common causal factors in human and dog allergies? Jenni Lehtimäki, University of Helsinki, Finland 1478 Predictive value of early life food and aero-allergen sensitisation for school age asthma and allergic rhinitis in the paps cohort Siri Rossberg, Charité - Universitätsmedizin Dep. f. Pediatric Pneumology and Immunology, Germany 1479 Environmental exposures, farming and asthma in childhood Susanne Elfriede Karolina Mueller-Rompa, Klinikum der Universität München, Dr von Hauner Children s Hospital, Germany 1480 Is use of tobacco products by 18 weeks pregnancy outdated in Scandinavia? Ina Kreyberg, University of Oslo/Oslo University Hospital, Norway 1481 Neonatal antibiotic treatment is associated with an increased risk for wheezing and allergic sensitization in the first year of life Berthe Cornelie Oosterloo, Emma Children s Hospital, AMC, The Netherlands 1482 When do young people with food allergy carry their medication and what is their perception of risk in different situations? Christina Jane Jones, Brighton & Sussex Medical School, United Kingdom 1483 Changes in allergy manifestations, sensibilisation and gut microbiota in estonian children Anneli Larionova, Children s Clinic of Tartu University Hospital, Estonia 1484 A pilot study to investigate the influence of common viral infections on food sensitivity Sofia Kostoudi, Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University, Greece 1485 Immunomodulating properties of whey fermented with yoghurt cultures fortified with L. plantarum W42 and B. lactis Bi30 in vivo analysis Barbara Wróblewska, Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, Poland 1486 Partially hydrolyzed whey proteins suppress clinical symptoms in a cow s milk allergy mouse model and enhance treg and breg frequency Gea Kiewiet, University medical centre Groningen, The Netherlands 1487 LEAP in practice - A regional center experience Anjum Grewal, Sheffield Childrens Hospital, United Kingdom 1488 Detection of egg and milk residues on work surfaces in school canteens in the Hortaleza District, Madrid and their relevance to children with allergies to these food groups Martha Cabrera, Servicio de Alergia. Hospital Los Madroños. Brunete, Spain 1489 Parental perception of seafood as being highly allergenic, could lead to unnecessary diet restriction George Raptis, Royal Hospital for Children, United Kingdom 50 Full abstract author lists are available on the official Congress website.

51 SUNDAY 18 JUNE 2017 SYMPOSIUM (SYM 11) 15:30-17:00 Anaphylaxis Hall 5bc Chairs: Margitta Worm, Germany Graham Roberts, United Kingdom What s new in pathophysiology? Peter Vadas, Canada New elicitors of anaphylaxis OTE Tilo Biedermann, Germany Why don t we treat anaphylaxis with adrenaline? Charlotte G. Mortz, Denmark SYMPOSIUM (SYM 12) 15:30-17:00 Inflammometric biomarkers in asthma Hall 5a SUNDAY Chairs: Leif Bjermer, Sweden Jussi Karjalainen, Finland OTE Biomarkers of type 2 high and type 2 low inflammation in asthma Liam Heaney, United Kingdom Biomarker of airway remodelling Sven-Erik Dahlén, Sweden Biomarker-driven asthma management Konstantinos Kostikas, Switzerland SYMPOSIUM (SYM 13) 15:30-17:00 Clinical immune tolerance: From fantasy to reality? Hall 3a Chairs: Onur Boyman, Switzerland Edward Knol, The Netherlands OTE Immune tolerance induction in allergy Mübeccel Akdis, Switzerland Low-dose IL-2 therapy in autoimmunity David Klatzmann, France Novel interventions for the establishment of immune tolerance Onur Boyman, Switzerland SYMPOSIUM (SYM 14) 15:30-17:00 Management of drug hypersensitivity in children Hall 3b Chair: Mariana Castells, United States OTE Approaches to suspected drug allergy in children Marina Atanaskovic-Markovic, Serbia The role of viruses in suspected drug allergy in children Ingrid Terreehorst, The Netherlands Desensitisation in children Josefina Rodrigues Cernadas, Portugal SYMPOSIUM (SYM 15) 15:30-17:00 Prevention of occupational allergy: A multidisciplinary approach Hall 3c Chairs: Santiago Quirce, Spain Gianna Moscato, Italy OTE Prevention of respiratory allergy in the workplace Jolanta Walusiak-Skorupa, Poland The impact of contact allergies on public health Wolfgang Uter, Germany Exposure assessment and preventive strategy for food processing Berit Elisabeth Bang, Norway 51

52 SUNDAY 18 JUNE 2017 WORKSHOP (WS 3) 15:30-17:00 Arrive early to guarantee your entry, limited spaces. Managing allergic conjunctivitis in daily practice Room 208 Chairs: Virginia Calder, United Kingdom Serge Doan, France Allergic and non-allergic conjunctivitis in daily practice Banu Bozkurt, Turkey SUNDAY Management of vernal keratoconjunctivitis Andrea Leonardi, Italy Management of severe atopic keratoconjunctivitis Osmo Kari, Finland SISTER SOCIETY SYMPOSIUM (SSS 3) 15:30-17:00 APAPARI: The epidemic of food allergies: Lessons from around the world Hall 3d Chairs: Gary Wong, Hong Kong SAR Jing-Long Huang, Taiwan OTE Wheat as a major cause of food allergy: Lessons from Asia Pakit Vichyanond, Thailand Primary prevention of food allergy: Translating trial findings into the real world George du Toit, United Kingdom Phenotypes of Shellfish Allergy from the Tropics Lynette Shek, Singapore YEAR IN REVIEW (YIR 1) 15:30-17:00 United airways Hall 1 Chairs: Philippe Gevaert, Belgium Arzu Bakirtas, Turkey OTE Allergic rhinitis Stephen Durham, United Kingdom Asthma Ioana Agache, Romania Allergic rhinitis and its impact on asthma Jean Bousquet, France JUNIOR MEMBERS (JM SCI) 15:30-17:00 JM Scientific Symposium: One airway, one disease: Can the allergic march be halted? Hall 3e Chair: Peter Hellings, Belgium OTE Allergic rhinitis and asthma: The epidemiologic link Pavol Surda, The Netherlands Allergic rhinitis and asthma: The pathophysiologic link Christina Kwong, United States Pharmacologic interventions against the allergic march Alexander Mathioudakis, United Kingdom Allergen specific immunotherapy interventions against the allergic march Ibon Eguiluz Gracia, Spain 52 Full abstract author lists are available on the official Congress website.

53 SUNDAY 18 JUNE 2017 ORAL ABSTRACT SESSION (OAS 11) 15:30-17:00 Lymphocytes Hall 3f Chairs: Risto Renkonen, Finland Jürgen Schwarze, United Kingdom Session roadmap: Risto Renkonen, Finland 0013 Preconception OVA immunization can induce IL-10 producing B cells in offspring: A potential main role for maternal IgG Jefferson Russo Victor, LIM-56 - School of Medicine - University of Sao Paulo (FM-USP), Brazil 0014 Th22 cells form a distinct th lineage from Th17 cells in vitro with unique transcriptional properties and Tbet-dependent Th1 plasticity Maximilian W Plank, The University of Newcastle, Australia 0015 The cannabinoid receptors agonist WIN55,212-2 promotes anti-inflammatory responses in dendritic cells: implications for allergic diseases Alba Angelina, Department of Biochemistry and Molecular Biology I, School of Chemistry, Complutense University of Madrid, Spain 0016 Circulating CCR10+ ILC2 frequencies and CCL27 plasma concentrations reflect asthma severity Vincent Lombardi, Stallergenes Greer, France 0017 Type 2 ILC2 in the blood of asthma and copd patients share characteristics of tissue resident cells Suzanne Marleen Bal, Academic Medical Center, The Netherlands 0018 Increases in group 2 innate lymphoid cells are inhibited by glucocorticoid treatment in asthma patients via stat signaling pathways Qiu-Ning Yu, Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen University, China SUNDAY ORAL ABSTRACT SESSION (OAS 12) 15:30-17:00 AIT biomarkers and persistence of immune response Chairs: Mohamed Shamji, United Kingdom Erika Jensen-Jarolim, Austria Session roadmap: Mohamed Shamji, United Kingdom 0019 Interference into JAK/stat signaling - a concept for improved allergen-specific immunotherapy? Anke Graessel, Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, Germany 0020 IgG4, but not IgG1, repolarizes pro-allergic M2a macrophages to a tolerogenic M2b-like phenotype: implications for allergen immunotherapy-mediated immune tolerance. Rodolfo Bianchini, Dept. of Comparative Medicine, The interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Austria Hall 3g 0021 Identification of novel biomarkers in the assessment of grass pollen slit response Maria M Escribese, San Pablo CEU University, Spain 0022 Persistent induced regulatory T-cell response to grass tablet sublingual immunotherapy is linked to lower specific immunoglobulin-e and clinical benefit Carlos Blanco, Servicio de Alergia, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IP), Spain 0023 Changes in T-regulatory cells activity during dermatophagoides pteronyssinus immunotherapy Miguel González, Research laboratory IBIMA-UMA, Spain 0024 Long-term suppression of allergen-induced basophil activation upon treatment with subcutaneous house dust mite immunotherapy: a prospective study Margot Berings, Ghent University, Belgium ORAL ABSTRACT SESSION (OAS 13) 15:30-17:00 Management of atopic dermatitis Chair: Ana Giménez-Arnau, Spain 0025 Burden of illness in adults with atopic dermatitis: Analysis of national health and wellness survey data from France, Germany, Italy, Spain, and the UK Laurent Eckert, Sanofi, France Room 103a 0026 Use of topical treatment of eczema among adolescents - data from a population-based birth cohort (BAMSE) Susanne Lundin, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden0027 Immuno-modulatory effects of prebiotics, probiotics and active microbial structures on human primary epithelial cells Carolin Schlumprecht, Chair and Institute of Environmental Medicine, UNIKA-T, Technical University of Munich and Helmholtz Zentrum München German Research Center for Environmental Health (GmbH), Germany 53

54 SUNDAY 18 JUNE 2017 SUNDAY 0028 Optimizing outcome on azathioprine treatment in patients with atopic dermatitis and/or chronic hand/foot eczema by co-prescription of allopurinol Floor Garritsen, University Medical Center, The Netherlands 0029 Efficacy and safety of dupilumab in adult patients with atopic dermatitis and an inadequate response, intolerance, or contraindication to cyclosporine: pooled analysis of two 16-week phase 3 trials Marjolein S. De Bruin-Weller, Department of Dermatology & Allergology, University Medical Center Utrecht, The Netherlands 0030 Efficacy and safety of dupilumab in adult patients with atopic dermatitis and a history of inadequate response, intolerance, or contraindication to cyclosporine: subgroup analysis from a 1-year trial Marjolein S. De Bruin-Weller, Department of Dermatology & Allergology, University Medical Center Utrecht, The Netherlands ORAL ABSTRACT SESSION (OAS 14) 15:30-17:00 Asthma mechanisms Room 102 Chairs: Susanne Vijverberg, The Netherlands Enrico Heffler, Italy Session roadmap: Susanne Vijverberg, The Netherlands 0031 Eosinophil-derived exosomes from asthmatics modify functionality on airway structural cells. José Antonio Cañas, Department of Immunology, IIS- Fundación Jiménez Díaz-UAM; CIBER de Enfermedades Respiratorias (CIBERES), Spain 0032 Impaired fibrinolysis and lower levels of plasma a2- macroglobulin are associated with an increased risk of severe asthma exacerbations Agnieszka Cybulska, Department of Internal Medicine, Jagiellonian University Medical College, Poland 0033 Regulation of suppressor of cytokine signalling 1 (SOCS1) expression in asthma Katherine Anne Strong, Imperial College London, United Kingdom 0034 Activation of inflammatory cells during asthma exacerbations is initiated prior to their migration to the lung Anya C Jones, Telethon Kids Institute, The University of Western Australia, Australia 0035 The effects of allergen derived proteases on airway epithelial cells obtained from asthmatic and healthy individuals and associated mechanisms Esra Birben, Hacettepe University, School of Medicine, Pediatric Allergy Unit, Turkey 0036 Maternal exposures influence asthma severity in offspring: gleaning mechanistic insights from animal models. Ian Paul Lewkowich, Cincinnati Children s Hospital, United States POSTER DISCUSSION SESSION (PDS 6) 15:30-17:00 Asthma immunopathology / inflammation / mechanism Poster Discussion Zone 1 Chair: Ellen Tufvesson, Sweden 0544 The significance of selected smad proteins in the mediation of inflammation in asthma in response to a specific and nonspecific triggers. Marcelina Kocwin, Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz Norbert Barlicki University Hospital No 1, Poland 0545 Deletion of NFATc1 in T lymphocytes affects Th2 and Th17 cell differentiation as well as IL-9-mediated mast cell activation in allergic asthma Sonja Koch, Department of Molecular Pneumology, University Hospital Erlangen, Germany 0546 Efficiency of the use of nitric oxide donors for the treatment of bronchial asthma Sayyora Bazarova, Center of therapy, Uzbekistan 0547 Clinical and immunological characteristics of fungal sensitive asthma and allergic bronchopulmonary Aspergillosis Peiyan Zheng, Guangzhou Institute of Respiratory Diseases,First Affiliated Hospital of Guangzhou Medical University, China 0548 Self-reported allergic rhinitis and/or allergic conjunctivitis associate with IL13 Rs20541 genotypes in Finnish adult asthma patients Annika Luukkainen, Haartman Institute, University of Helsinki and Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Finland 0549 Immunoregulatory role of nfat-interacting protein (NIP) 45 in adaptive and innate immune responses in allergic asthma Sonja Koch, Department of Molecular Pneumology, University Hospital Erlangen, Germany 54 Full abstract author lists are available on the official Congress website.

55 SUNDAY 18 JUNE Serum IL-6, IL-17a and periostin levels in different clusters of adult patients with moderate to severe asthma Denitsa Dimitrova, Clinical center of pulmonary diseases, SHATPD St. Sofia, Medical University, Bulgaria 0552 Dynamics of cytokines in blood and sputum cytology in patients with different bronchial asthma phenotypes Sayyora Abdubasitovna Bazarova, Center of therapy, Uzbekistan 0551 Eosinophil activation with autophagy and extracellular DNA 0553 Association of serum cortisol levels with the ige immune traps is involved in severe asthma response in poor pediatric allergy asthma patients from the Duy Le Pham, University of Medicine and Pharmacy, Viet Nam Caribbean Colombian area: A pilot study Eduardo Egea, Universidad del Norte, Colombia POSTER DISCUSSION SESSION (PDS 7) 15:30-17:00 Food allergy diagnosis Poster Discussion Zone 2 SUNDAY Chairs: Marianne van Hage, Sweden Pınar Uysal, Turkey 0554 BP14, an allergen from cupressus sempervirens pollen related to the family of snakin/gibberellin-regulated proteins Pascal Poncet, Institut Pasteur, France 0555 Identification of genetic biomarkers useful for the prediction of severe pollen-mediated food reactions. Leticia Mera, Institute of Applied Molecular Medicine (IMMA), CEU San Pablo University, Spain 0556 Is testing for different allergen components useful in diagnosing IgE-mediated allergy to freshwater and seawater fishes? Nicki Y H Leung, Department of Paediatrics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 0557 Immunoprofile of a-gal- and B-antigen-specific responses reveals differences between red meat allergic patients and healthy individuals Danijela Apostolovic, Karolinska Institutet and University Hospital, Sweden 0558 Purification and characterization of a novel allergenic walnut vicilin-like protein Pawel Dubiela, Medical University of Vienna, Austria 0559 FABER IgE diagnostic test: the most comprehensive view on IgE sensitization to milks and meats Claudia Alessandri, CAAM - Centri Associati di Allergologia Molecolare, Italy 0560 Eosinophil cationic protein and eosinophil derived neurotoxin levels in children with food allergy. Tatyana Sentsova, Federal Research Centre of Nutrition and Biotechnology, Russia 0561 Is mealworm food allergy indicative for food allergy to other insects? Kitty Catharina Maria Verhoeckx, TNO, The Netherlands 0562 Fx5: Is it really worth asking for? Cátia Alves, Immunoallergology Department, Hospital D. Estefânia, CHLC, Portugal 0563 Variability of the allergen pattern in different pomegranate cultivars Claudia Alessandri, CAAM - Centri Associati di Allergologia Molecolare, Italy 0564 Eosinophilic esophagitis: diagnostic work-up and follow-up - a single center experience Filipe Benito-Garcia, Immunoallergy Department, CUF Descobertas Hospital, Portugal POSTER DISCUSSION SESSION (PDS 8) 15:30-17:00 Innate immune response Poster Discussion Zone 3 Chairs: Grzegorz Woszczek, United Kingdom Sven Seys, Belgium 0565 The effects of urban air particulate matter and farm dust on children s immune responses in vitro Marjut Roponen, Department of Environmental and Biological Sciences, University of Eastern Finland, Finland 0566 Role of the carbohydrate A10 (CA10) from ehrlich tumor cells targeting dendritic cells in the generation of functional regulatory T cells Leticia Martín-Cruz, Dpt. of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Spain 0567 Assessment of changes in expression of immune system biomarkers to assist the differential diagnosis of acute bacterial infections A Hancharou, Republican Research-Practical Center for Epidemiology and Microbiology, Belarus 0568 Phenotypic changes of blood monocytes in kidney transplant recipients. Ilja Striz, Institute for Clinical and Experimental Medicine, Czech Republic 55

56 SUNDAY 18 JUNE Enhancement of thioredoxin production by histamine H1 receptor antagonists in vitro and in vivo Tomomi Mizuyoshi, Department of Otorhinolaryngology, School of Medicine, Showa University, Japan 0573 The chemical penetration enhancer oleic acid aggravate immune responses in the skin Ellen Namork Namork, Norwegian Institute of Public Health, Norway SUNDAY 0570 Progranulin-dependent regulation of th2 airway inflammation by house dust mite allergen Jun-Pyo Choi, Division of Allergy and Clinical Immunology, Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, South Korea 0571 Can acute stress dampen allergic reactions? Epinephrine induces a regulatory M2b-like macrophage phenotype, which attenuates cord blood-derived mast cell (CBMC) IgEmediated degranulation Jelena Gotovina, The Interuniversity Messerli Research Institute of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Austria 0572 Impact of a high carbohydrate diet on select cytokines and chemokines which are related to immune responses and inflammation Roman Khanferyan, Federal Center for Nutrition and Biothechnology, Russia 0574 Hypertonic seawater solutions comprising algae extracts exhibit anti-inflammatory action and improve nasal cell function in epithelial cell cultures isolated from allergic and normal human donors. Kostas Alevizopoulos, Gerolymatos International SA, Greece 0575 Significantly reduced plasma levels of the bioactive sphingolipid S1P in lung transplanted cystic fibrosis patients are associated with gastrointestinal symptoms Eva Untersmayr, Medical University of Vienna, Institute of Pathophysiology and Allergy Research, Austria 0576 Polybacterial mucosal stimulation in lymphoproliferative syndromes with recurrent infections: a new complementary strategy Marta Tejera-Alhambra, Inmunotek, S.L., Spain 0577 Sublingual therapeutic immunotherapy with a polyvalent bacterial preparation in preschool children with recurrent respiratory tract infections Blanca Selva, La Fe Hospital, Spain POSTER DISCUSSION SESSION (PDS 9) 15:30-17:00 News in immunotherapy and varia Poster Discussion Zone 4 Chair: Oscar Palomares, Spain 0578 AP205 bacteriophage-based virus-like particle displaying der P 2 for novel house dust mite allergen specific immunotherapy Alain Jacquet, Chulalongkorn University, Thailand 0579 Utilization of ultrahigh-resolution native mass spectrometry in the analysis of allergens Merja Niemi, University of Eastern Finland, Finland 0580 Characterization of QM1S, a hybrid recombinant hypoallergen from house dust mite allergens, Der p 1 and Der p 2 Juan Andrés Asturias, ROXALL España, R&D Department, Spain 0581 A comprehensive analysis of the proteome and allergome of house dust mites (dermatophagoides pteronyssinus and d. farinae) uncovers the presence of novel allergens Emmanuel Nony, Stallergenes Greer, France 0582 Novel development of bilayer sublingual tablets containing purified allergen extract of cockroach and parthenium for sublingual immunotherapy (SLIT) Anita Leishangthem, Bengaluru Allergy Centr, India 0583 Epitope specificity of monoclonal antibodies 5B4 and 6H4 used in the reference Bet v 1 quantification ELISA Emmanuel Nony, Stallergenes Greer, France 0584 Foxp3+ regulatory t cells mediate the amelioration of shrimp allergy in mouse in a hypoallergen-encoding DNA vaccine immunotherapy Christine Yee Yan Wai, School of Life Sciences; Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR 0585 Chemical modification of a ragweed extract results in an increased safety profile while immunogenicity is maintained Hanneke Van Der Kleij, HAL Allergy B.V., The Netherlands 0586 Microcrystalline Tyrosine (MCT): a depot adjuvant used in allergy offers new opportunities in infectious disease Matthew D Heath, Allergy Therapeutics, United Kingdom 0587 Subcutaneous venom immunotherapy in children: efficacy and safety Pinar Gür çetinkaya, Hacettepe University School of Medicine, Turkey 0588 Selection of the optimal dose for an ultra-short course subcutaneous immunotherapy for rhinoconjunctivitis for birch allergic patients. EUDRACT number Tim Higenbottam, Allergy Therapeutics, United Kingdom 0589 Prospective adherence to specific immunotherapy in Europe (paste) - a three year survey Melina Makatsori, Imperial College London, National Heart and Lung Institute, United Kingdom 56 Full abstract author lists are available on the official Congress website.

57 SUNDAY 18 JUNE 2017 BUSINESS MEETING (BM 1) 17:30-18:40 IG Immunotherapy - Open to all attendees Room 103a AIT from art to science Ulrich Wahn, Germany BUSINESS MEETING (BM 2) 17:30-18:40 IG Allergy and Diagnosis - Open to all attendees Room 102 Still the same problems with IgE-diagnostics Were we too comfortable with the status quo? Nathalie Wojtalewicz, Germany SUNDAY BUSINESS MEETING (BM 3) 17:30-18:40 IG Allergy, Asthma and Sports - Open to all attendees Room 103b Beta-2 agonists in asthma and influence on sports performance: What do we know? What is the evidence? Morten Hostrup, Denmark BUSINESS MEETING (BM 4) 17:30-18:40 IG Primary Care - Open to all attendees Room 201 BUSINESS MEETING (BM 5) 17:30-18:40 IG Insect Venom Hypersensitivity - Open to all attendees Room 206 Maintenance intervals: 4 weeks or 6 months? What is the evidence? Constantinos Pitsios, Cyprus BUSINESS MEETING (BM 6) 17:30-18:40 IG Allied Health - Open to all attendees Room 207 Precautionary labelling Past, present, future Katie Allen, Australia BUSINESS MEETING (BM 7) 17:30-19:00 Junior Members (JMs) - Open to all attendees Room 209 Fiction and reality of medical ethics Anthony Frew, United Kingdom 57

58 PROGRAMME AT A GLANCE MONDAY 19 JUNE 2017 Hall 1 Hall 5bc Hall 5a Hall 3a Hall 3b Hall 3c Hall 3d Hall 3e Hall 3f Hall 3g Session Roo 08:00 08:30 MONDAY 09:00 P.61 P.61 PL 3 New insights PL 4 The 09:30 into the microbiome pathophysiology in health of upper and lower and allergic disease 10:00 airways BA, A, I, ENT BA, D, A, FA 10:30 11:00 11:30 12:00 YIR 2 Year in Review: Asthma P.63 P.62 P.180 P.62 P.62 P.62 P.63 P.64 P.64 P.64 SYM 16 IgE 50 years A BA, CI, CA, DI CSS 4 Company Sponsored Symposium SYM 17 EAACI-AAAAI Practall Symposium A, D, CA SYM 18 Early childhood asthma A, P, CA, PC SYM 19 Fish and shell fish allergy FA, P, CA SSS 4 WAO World Allergy Forum: Mechanisms and complications of severe asthma A, CA, CI OAS 15 Inflammatory skin diseases: Mechanisms and associations D HT 3 Hot topics in immunology CI, I OAS 16 What do animals teach us about asthma? A 12:30 13:00 Lunch and Poster Viewing in the Poster Area 13:30 14:00 14:30 P.69 P.69 P.69 P.180 P.69 P.70 P.70 P.71 P.70 P.71 SYM 21 Systems medicine approaches in allergic disease SYM 22 Challenges of severe asthma in childhood SYM 23 There is something in the air: Pollens CSS 5 Company Sponsored Symposium SYM 24 Obesity and allergy SYM 25 Treatment and monitoring of eosinophilic esophagitis SSS 5 ACAAI: The challenge of chronic cough JM Educational Session YIR 3 Year in Review: ENT PAMW 1 Statement of the problem 15:00 CA, BA A, P, PC CA, PC, ENT PC, A, CA, P FA, CA, P A, ENT, P ENT A, PC 15:30 16:00 16:30 SYM 26 Pediatric allergy as seen in Primary Care P.75 P.75 P.75 P.75 P.77 P.77 P.180 P.78 P.78 P.76 SYM 27 SYM 28 SYM 29 OAS 20 CSS 6 OAS 22 LB OAS 2 PAMW 2 Ophthalmology Controversies Novel roles Managing Company What's new Asthma - Patient Driven for in sports and of dendritic asthma from Sponsored in aerobiology genetics, immu- Solutions allergists asthma cells infancy to Symposium neresponse and adolescence management OAS 21 New approaches to the diagnosis and management of food allergy 17:00 P, PC, AH, FA OA, CA, IT A, CA BA, A, P P FA A, ENT, I, D A 17:30 P.81 P.186 P.186 P.188 SSS 7 IRINE: Immunology 18:00 SAT 7 Company SAT 8 Company SAT 9 Company Research Institute of New Sponsored Sponsored Sponsored England Symposium 2017: New Satellite Satellite Satellite Symposium models for analysis 18:30 Symposium Symposium of allergic diseases CA, CI, DA, ENT 19:

59 PROGRAMME AT A GLANCE MONDAY 19 JUNE 2017 m: Hall 3g Room 101 Room 103a Room 208 Room 102 Pro & Con Arena Poster Discussion Zone 1 EAACI General Assembly - EAACI members only Poster Discussion Zone 2 Poster Discussion Zone 3 Poster Discussion Zone 4 P.61 08:00 SESSION GUIDE BM Business Meeting of EAACI Sections and Interest Groups SYM WS SSS Sister Society Symposium HT OAS Oral Abstract Session YIR PDS Poster Discussion Session PAMW JM Junior Members Programme LB PDS Late Breaking Poster Discussion Session P & C Pro & Con Session PL Plenary Symposium Symposium Workshop Hot Topic Session Year in Review Session Practical Allergy Management Workshop TOPIC TRACKS A Asthma AH Allied Health BA Basic Allergology BI Biologicals CA Clinical Allergology CI Clinical Immunology D Dermatology DA Drug Allergy DI Allergy Diagnosis ENT Ear, Nose, Throat FA Food Allergy I Immunology IT Immunotherapy OA Ocular Allergy P Pediatrics PC Allergy management in Primary Care SISTER SOCIETIES ANS African National Societies ACAAI American College of Allergy, Asthma & Immunology IRINE Immonulogy Research Institute of New England WAF World Allergy Forum 08:30 09:00 09:30 10:00 P.63 P.65 P.63 P.65 P.65 P.66 P.67 P.67 SYM 20 Treatment of rhinitis: Current standards and new concepts OAS 17 Factors influencing the development of allergic diseases WS 4 Insect venom allergy in practice LB OAS 1 Food allergy - Epidemiology and mechanism PDS 10 Rhinoconjunctivitis PDS 11 Anaphylaxis: From epidemiology to management LB PDS 4 Allergen immunotherapy: Vaccines and clinical PDS 12 Daily management of drug allergy 10:30 11:00 11:30 MONDAY ENT, CA, P, IT P CA, P, IT FA ENT FA IT DA 12:00 YIR 4 Year in Review: Immunology A, CI, FA, ENT Lunch and Poster Viewing in the Poster Area P.68 12:30 Pro & Con 3 A, P, PC Beta2 agonists should be used as a chronic preventive treatment for exercise induced bronchoconstriction Lunch and Poster Viewing P.68 in the Poster Area 13:00 Pro & Con 4 I, CI Bregs are as important as Tregs for allergen tolerance 13:30 P.71 P.71 P.70 P.72 P.72 P.73 P.73 P.74 OAS 18 OAS 19 PDS 13 PDS 14 PDS 15 PDS 16 Immunotherapy: Diagnostic From adaptive Food allergy Occupational The spectrum Measures tools in food immune epidemiology allergy - of pediatric and Outcomes allergy response to what's new? skin and drug mast cells allergy IT WS 5 Illustrating the use of Component Resolved Diagnosis and Basophil testing in allergy diagnosis DI, CA, P, DA FA I FA A, D, CA P 14:00 14:30 15:00 P.192 Highlights Session 1 15:30 SYM 30 Molecular tools for allergen immunotherapy P.76 P.76 P.76 P.78 P.79 P.79 P.80 P.80 SSS 6 PDS 17 PDS 18 PDS 20 Allergies in Primary immunodeficiency Pediatric food Asthma Africa allergy genetics WS 6 Patch testing in specific situations OAS 23 Novel mechanisms in rhinitis and rhinosinusitis PDS 19 Epidemiology, risk factors and clinical aspects of drug allergy 16:00 16:30 DI, IT, CA, P A, CA, CI, FA D, DI, DA ENT CI FA, P DA A 17:00 17:30 P.188 P.190 SAT 10 SAT 11 Company Company Sponsored Sponsored Satellite Satellite Symposium Symposium 18:00 18:30 19:

60 LEARNING LOUNGES AND BUSINESS MEETINGS LEARNING LOUNGES Room 218 Room 217 Room 204 Room :00-07:45 P.61 07:00-07:45 P.61 07:00-07:45 P.61 07:00-07:45 P.61 LL 5 LL 6 LL 7 LL 8 Exercise-induced respiratory symptoms in athletes Practical approaches to the diagnosis of hypersensitivity to Nonsteroidal Anti- Inflammatory Drugs Drug allergy in children Human innate lymphoid cells: Where are they and how can we detect them? A, P, PC DA, DI, CA DA, P, CA BA BUSINESS MEETINGS MONDAY Hall 3c Hall 3d 12:25-13:35 P.68 12:25-13:35 P.68 BM 8 BM 9 Pediatric Section - Open to all attendees IG Food Allergy - Open to all attendees Room 208 Room 103b Room 201 Room 206 Room 207 Room :30-18:40 P.81 17:30-18:40 P.81 17:30-18:40 P.82 17:30-18:40 P.82 17:30-18:40 P.82 17:30-18:40 P.82 BM 10 BM 11 BM 13 BM 14 IG Epidemiology - Open to all attendees IG Drug Allergy - Open to all attendees IG Occupational Allergy - Open to all attendees IG Biologicals - Open to all attendees BM 12 IG Primary Immunodeficiency - Open to all attendees BM 15 IG Aerobiology and Pollution - Open to all attendees SESSION GUIDE LL Learning Lounge BM Business Meeting of EAACI Sections and Interest Groups TOPIC TRACKS CA Clinical Allergology DA Drug Allergy DI FA Allergy Diagnosis Food Allergy IT Immunotherapy OA Ocular Allergy P Pediatrics PC Allergy management in Primary Care EAACI WEBCASTS A practical resource in an interesting format! Over 180 webcasts to choose from Exclusive to all EAACI members Access to sessions of EAACI s major meetings 24-hour access to experts and outstanding researchers work For more information visit 60

61 MONDAY 19 JUNE 2017 SOME SESSIONS FILL UP QUICKLY. ARRIVE EARLY TO GUARANTEE YOUR ENTRY. IF YOU HAVE MISSED A SESSION, YOU CAN CATCH UP ON IT AT THE VIRTUAL CONGRESS HUB IN THE EXHIBITION HALL. PROGRAMME IS STILL SUBJECT TO CHANGE. PLEASE REFER TO THE CONGRESS APP FOR LATEST UPDATE. LEARNING LOUNGE 07:00-07:45 Learning Lounges are early morning sessions. Pre-registration & sperarate payment required, limited spaces. Learning Lounge (LL 5) Room 218 Exercise-induced respiratory symptoms in athletes Marcin Kurowski, Poland Learning Lounge (LL 6) Room 217 Practical approaches to the diagnosis of hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs Marek Kowalski, Poland MONDAY Learning Lounge (LL 7) Room 204 Drug allergy in children Marina Atanaskovic-Markovic, Serbia Learning Lounge (LL 8) Room 205 Human innate lymphoid cells: Where are they and how can we detect them? Jenny Mjösberg, Sweden EAACI GENERAL ASSEMBLY (GA) 08:00-09:00 EAACI General Assembly - EAACI members only Room 101 PLENARY SYMPOSIUM (PL 3) 09:00-10:30 New insights into the pathophysiology of upper and lower airways Hall 1 Chairs: Peter Hellings, Belgium Nikolaos Papadopoulos, Greece Common mechanisms in late onset asthma and chronic rhinosinusitis Wytske Fokkens, The Netherlands Th2-driven versus ILC2s-driven airway inflammation in unified airways disease Cezmi Akdis, Switzerland Revisiting the role of mast cells in in the pathophysiology of persistent asthma and chronic rhinitis Jonas Erjefalt, Sweden PLENARY SYMPOSIUM (PL 4) 09:00-10:30 The microbiome in health and allergic disease Hall 5bc Chairs: Antti Lauerma, Finland Susanne Halken, Denmark The respiratory microbiome Michael J Cox, United Kingdom Diet and the microbiome Benjamin Marsland, Switzerland The skin microbiome Harri Alenius, Finland 61

62 MONDAY 19 JUNE 2017 SYMPOSIUM (SYM 16) 10:45-12:15 IgE 50 years Hall 5bc Chairs: Barbara Bohle, Austria Paolo Matricardi, Germany OTE The discovery of IgE S.G.O. Johansson, Sweden IgE immunology Lars K. Poulsen, Denmark IgE-based diagnosis Jörg Kleine-Tebbe, Germany SYMPOSIUM (SYM 17) 10:45-12:15 MONDAY EAACI-AAAAI Practall Symposium Chairs: Antonella Muraro, Italy Thomas Fleisher, United States OTE Asthma and the microbiome: Mechanistic insights Benjamin Marsland, Switzerland Hall 3a The role of the microbiome in asthma: Clinical studies, challenges, needs Yvonne J. Huang, United States The role of the microbiome in atopic dermatitis Donald Leung, United States SYMPOSIUM (SYM 18) 10:45-12:15 Early childhood asthma Hall 3b Chairs: Adnan Custovic, United Kingdom Mika Mäkelä, Finland OTE Genetics of asthma in determining childhood phenotype John Holloway, United Kingdom Early childhood wheezing: Connecting physiology to phenotypes with lung function testing Pekka Malmberg, Finland Do separate asthma phenotypes require unique treatment regimens? Robert Lemanske, United States SYMPOSIUM (SYM 19) 10:45-12:15 Fish and shell fish allergy Hall 3c Chairs: Clare Mills, United Kingdom Barbara Ballmer-Weber, Switzerland OTE Allergens in fish and shell fish Andreas Ludwig Lopata, Australia Fish intake: Protective or allergenic? Anna Bergström, Sweden Novel cross reactivity between shell fish and insects André Knulst, The Netherlands 62

63 MONDAY 19 JUNE 2017 SYMPOSIUM (SYM 20) 10:45-12:15 Treatment of rhinitis: Current standards and new concepts Room 101 Chairs: Paul van Cauwenberge, Belgium Ralph Mösges, Germany OTE Allergic rhinitis Sanna Toppila-Salmi, Finland Non-allergic rhinitis Paloma Campo, Spain Immunotherapy: From evidence to practice Oliver Pfaar, Germany WORKSHOP (WS 4) 10:45-12:15 Arrive early to guarantee your entry, limited spaces. Insect venom allergy in practice Room 208 Chairs: Beatrice Biló, Italy Identifying the relevant venom for VIT: For you to decide Gunter Sturm, Austria Markus Ollert, Luxembourg Difficult cases in venom allergy: To treat or not to treat? Arthur Helbling, Switzerland MONDAY Who would you prescribe an emergency kit to? Making your decision Hanneke Oude-Elberink, The Netherlands SISTER SOCIETY SYMPOSIUM (SSS 4) 10:45-12:15 WAO World Allergy Forum: Mechanisms and complications of severe asthma Hall 3d Chairs: Mario Sanchez-Borges, Venezuela Peter Hellings, Belgium OTE Fungal interference in severe asthma David B. Corry, United States TSLP and IL-33 basic immunology/biology in severe asthma Steven Ziegler, United States Steroids and Vitamin D in severe asthma Catherine Hawrylowicz, United Kingdom YEAR IN REVIEW (YIR 2) 10:45-12:15 Year in Review: Asthma Hall 1 Chairs: Tari Haahtela, Finland Zuzana Diamant, The Netherlands OTE Treatable traits of asthma for precision medicine William Busse, United States Airway imaging in precision medicine for asthma Asthma endotypes and precision medicine Stylianos Loukides, Greece 63

64 MONDAY 19 JUNE 2017 HOT TOPIC (HT 3) 10:45-12:15 Hot topics in immunology Hall 3f Chairs: Bettina Margrethe Jensen, Denmark Ibon Eguiluz Gracia, Spain OTE A helminth-derived inhibitor of interleukin-33 Henry McSorley, United Kingdom The amazing plasticity of innate lymphocytes Suzanne Bal, The Netherlands Neutrophils in allergy and the type-2 cytokine / IL-17 balance Onur Boyman, Switzerland ORAL ABSTRACT SESSION (OAS 15) 10:45-12:15 MONDAY Inflammatory skin diseases: Mechanisms and associations Hall 3e Chairs: Thomas Werfel, Germany 0040 Intra-transcriptome interactions between interleukins and Antti Lauerma, Finland tight junctions, reveals widespread barrier dysregulation in atopic dermatitis lesions Association of atopic dermatitis with cardiovascular risk Can Altunbulakli, Swiss Institute of Allergy and Asthma factors and diseases. Research (SIAF), University of Zurich, Davos, Switzerland. Marie Standl, Institute of Epidemiology I, Helmholtz Zentrum Christine Kühne- Center for Allergy Research and Education München German Research Center for Environmental Health, (CK-CARE), Switzerland Germany 0041 Toll-like receptor 7 and interleukin 17 are possible targets for 0038 Atopic dermatitis is not independently associated with intervention in allergic contact dermatitis. cardiovascular or autoimmune comorbidities in the general Joanna Wallengren, Unit of Dermatology, Department of population: Results from the LIFE-adult-study Clinical Sciences, Skåne University Hospital, Lund University, Regina Treudler, Universität Leipzig, Dept. of Dermatology, Sweden Venereology and Allergology, Germany 0042 Evidence for a role of eosinophils in blister formation in 0039 Is there an increased risk of non-melanoma skin cancer bullous pemphigoid in patients with atopic dermatitis treated with oral Dagmar Simon, Dept. of Dermatology, Inselspital, Bern immunosuppressive drugs? University Hospital, Switzerland Floor Garritsen, University Medical Center, The Netherlands ORAL ABSTRACT SESSION (OAS 16) 10:45-12:15 What do animals teach us about asthma? Chairs: Sven Seys, Belgium Luis Caraballo, Colombia Session roadmap: Sven Seys, Belgium 0043 Pulmonary delivery In vivo if SiRNA-based therapeutic approach for PI3K-delta isoform successfully improves HDM-induced asthmatic features via the regulation of NLRP3 inflammasome So RI Kim, Chonbuk National University Medical School, South Korea 0044 Raw cow s milk prevents the development of airway inflammation in a murine house dust mite-induced asthma model Suzanne Abbring, Utrecht University, Utrecht Institute of Pharmaceutical Sciences, Pharmacology, The Netherlands 0045 Differences of the role of NLRP3 inflammasome between two types of fungal allergen-induced asthma Yong Chul Lee, Chonbuk National University Medical School, South Korea Hall 3g 0046 Distinct roles for the cytokines IL5 and IL13 in pulmonary inflammation and asthma pathophysiology Rajita Pappu, Genentech, United States 0047 The metabolite D-tryptophan from probiotic bacteria ameliorates allergic airway disease and influences the gut microbiome Sabine Bartel, Division of Experimental Asthma Research, Research Center Borstel, Leibniz-Center for Medicine and Biosciences, Borstel, Germany, Member of the German Center for Lung Research (DZL), Germany 0048 Exacerbation of experimental asthma regulated by IL-17 producing NK cells depends on IL-6 but not on IL-23 or rorgt Lars Lunding, Division of Asthma Exacerbation & Regulation, Priority Area Asthma and Allergy, Research Center Borstel, Airway Research Center North, Member of the German Center for Lung Research, Germany 64 Full abstract author lists are available on the official Congress website.

65 MONDAY 19 JUNE 2017 ORAL ABSTRACT SESSION (OAS 17) 10:45-12:15 Factors influencing the development of allergic diseases Chairs: Tuomas Jartti, Finland Bodo Niggemann, Germany Session roadmap: Tuomas Jartti, Finland Room 103a 0052 The cost-effectiveness of polyvalent mechanical bacterial lysate treatment in children with asthma Anna Bodajko-Grochowska, Dept. of Paediatric Pneumonology and Rheumatology, Medical University, Poland 0049 Airway microbial dysbiosis in pre-school children associates with respiratory symptoms Tamar Smulders, AMC-UvA, The Netherlands 0050 Viral infections in preschool children with wheezing Vojko Berce, University Medical Centre Maribor, Slovenia 0051 Eating fish as infant and living on a farm decreased the risk of allergic rhinitis at 12 years of age Styliana Vasileiadou, Department of Paediatrics, University of Gothenburg, Queen Silvia Children s Hospital, Sweden 0053 Food diversity during first year of life and allergic diseases until 15 years: results from lisaplus birth cohort Iana Markevych, University Hospital of Munich (LMU); Institute of Epidemiology I, Helmholtz Zentrum München - German Research Center for Environmental Health, Germany 0054 Preventive effect of human milk against food allergy: New insights into butyrate activities Rosita Aitoro, University of Naples Federico II, Italy MONDAY LATE BREAKING ORAL ABSTRACT SESSION (LB OAS 1) 10:45-12:15 Food allergy - Epidemiology and mechanism Room Maternal carriage of prevotella during pregnancy is associated with decreased food allergy in the offspring Peter J Vuillermin, Deakin University, Australia 1420 Infant food allergy phenotypes predict the allergic march of early childhood Katrina J Allen, Murdoch Childrens Research Institute, Department of Allergy and Immunology and Department of Pediatrics, Royal Children s Hospital, Australia 1421 The prevalence of food sensitization has remained stable across two high-risk Melbourne cohorts recruited 15 years apart Katrina J Allen, Murdoch Childrens Research Institute, Department of Allergy and Immunology and Department of Pediatrics, Royal Children s Hospital, Australia 1422 Replication of the association of the STAT6 gene with food allergy, as diagnosed by DBPCFC Cornelia Doriene Van Ginkel, Department of Paediatric Pulmonology and Paediatric Allergy, University Medical Center Groningen, Groningen Research Institute on Asthma and COPD, University of Groningen, The Netherlands 1423 Europrevall outpatient clinic survey: Clustering approaches of allergen microarray data Alessandra Van Ree, University of Amsterdam, The Netherlands 1424 Peripheral basopenia during peanut-induced allergic reactions a protective response? Paul J Turner, Imperial College London, United Kingdom POSTER DISCUSSION SESSION (PDS 10) 10:45-12:15 Rhinoconjunctivitis Poster Discussion Zone 1 Chairs: Ludger Klimek, Germany Valerie Hox, Belgium 0219 The regulatory effect of mir-125a-3p on mast cell activation in an allergic rhinitis mouse model Yaoshu Teng, Department of Otorhinolaryngology Head and Neck Surgery, Hangzhou First People s Hospital, Nanjing Medical University, China 0220 Decreased frequency of adenoidectomy with 12-week nasal budesonide treatment Haiyu Hong, Department of Otolaryngology and Head Neck Surgery of 5th Hospital Affiliated with Sun Yat-sen University, China 0221 Plasma IL-33 level as a potential indicator of corticosteroid sensitivity in chronic rhinosinusitis with nasal polyps Haiyu Hong, Department of Otolaryngology and Head Neck Surgery of 5th Hospital Affiliated with Sun Yat-sen University, China 0222 Correlation between chronic cough and chronic rhinosinusitis in adults: nationwide, population-based, and cross-sectional study Sea-Yuong Jeon, Gyeongsang National University Hospital, South Korea 0223 Down-regulation of hypoxia-inducible factor-2a is associated with increased vascular permeability in nasal polyps Yanyi Tu, The Second Hospital of Shandong University, China 65

66 MONDAY 19 JUNE Increased DNAH5 mis-localization in cilia of nasal polyps Yang Peng, Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 0225 The association of Th17 cells with Th2 cytokine in patients with nasal polyps Li Zhao, Department of Otolaryngology, the Second Hospital of Shandong University, Shandong University, China 0226 Are there any specific signs of allergic fungal rhinosinusitis visible by computed tomography scan? Aleksandra Barac, Clinic for Infectious and Tropic Diseases Clinical Centre of Serbia, Serbia 0230 Mast cells promote collagen lattice contraction mediated by conjunctival fibroblasts by up-regulating matrix metalloproteinase production Tatsuma Kishimoto, Kochi Medical School, Japan 0231 Role of interleukin-10 in immunoglobulin e-mediated immediate hypersensitivity in the conjunctiva of mice Waka Ishida, Department of Ophthalmology, Kochi Medical School, Japan 0232 Corneal crosslinking treatment for keratoconus in children with vernal keratoconjunctivitis Banu Bozkurt, Selcuk University Faculty of Medicine, Department of Ophthalmology, Turkey MONDAY 0227 Expression profiles of regulatory and helper T-cellassociated genes in antrochoanal polyp Peng Jin, The Second Hospital of Shandong University, China 0228 Olfactory change pattern after endoscopic sinus surgery in chronic rhinosinusitis with olfactory dysfunction XiaoXue Zi, Department of Otolaryngology, The Second Affiliated Hospital Of Shandong University, China, China 0229 The effect of HGF, TGF-ß1, and PGE2 in allergic rhinitis mouse model Ji-Hun Mo, Dankook University College of Medicine, South Korea 0233 Systemic associations in VKC affected children: analysis and considerations of last 7 years clinical records in our tertiary referral center. Pia Allegri, Lavagna (Genoa) Hospital, Italy 0234 Allergic inflammation and its link to epithelial remodeling in nasal polyposis Cira Rosario García De Durango, Institute of Applied Molecular Medicine (IMMA), San Pablo CEU University, Spain 0235 Is specific immunotherapy effective in subjects suffering from VKC? A tertiary referral center ten years experience. Pia Allegri, Rapallo (Genova) Hospital - Ophthalmological Dep., Italy POSTER DISCUSSION SESSION (PDS 11) 10:45-12:15 Anaphylaxis: From epidemiology to management Poster Discussion Zone Analysis of the French national anaphylaxis data, : focus on pediatric anaphylaxis fatalities. Guillaume Pouessel, Department of Pediatrics, Children s Hospital, France 0237 Trends in incidence of hospital and emergency department admission for anaphylaxis in Hong Kong paediatric population from 2001 to 2015 Yichao Wang, Murdoch Childrens Research Institute, Parkville; Department of Paediatrics, The University of Melbourne, Parkville, Australia 0238 Prevalence of anaphylaxis and prescription rates of epinephrine self-injector in Korea based on national health insurance data Hyunseok Cho, Department of Emergency Medicine, Hwacheon Health Center and County Hospital, South Korea 0239 Impact of allergic disorders and anaphylaxis in mastocytosis: Preliminary data from a study of the European Competence Network on Mastocytosis (ECNM) registry Marek Niedoszytko Niedoszytko, Medical University of Gdansk Dep of Allergology, Poland 0240 Factors influencing anaphylaxis severity Raif Coskun, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Allergy, Turkey 0241 Serum levels of 9a,11ß-PGF2 in combination with apolipoprotein A1 or cys-leukotriens are reliable biomarkers of anaphylaxis Maria Nassiri, Allergy-Center-Charité, Department of Dermatology and Allergy, Charité- Universitätsmedizin Berlin, Germany 0242 Estimation of the long-term biological variation of tryptase using chronic disease models Douwe De Boer, Maastricht University Medical Centre, The Netherlands 0243 Hypersensitivity reactions to synthetic hemodialysis membranes. Study of the differences in ex vivo response Gemma Vilà-Nadal, La Paz University Hospital, Spain 0244 Co-factors affect time and size of reaction in a passive cutaneous anaphylaxis model of egg allergy in humans. Esben Eller, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Denmark 0245 Evaluating the management of anaphylaxis in emergency departments: A multicentre survey Sébastien Lefevre, Unit of Allergy - CHR Metz-Thionville, France 66 Full abstract author lists are available on the official Congress website.

67 MONDAY 19 JUNE Global review of epinephrine availability and anaphylaxis management practices amongst patient organization countries Susan Waserman, Division of Clinical Allergy and Immunology, Department of Medicine, McMaster University, Canada 0247 Knowledge, perception and attitudes of paramedics students of anaphylaxis. Joanna Lange, Department of Pediatric Pneumonology and Allergy, Medical University, Poland 0248 Implementation of stock epinephrine (stock epi) program in malls and food service establishments: a pilot implementation study Susan Waserman, Department of Medicine, Clinical Immunology and Allergy, McMaster University, Canada 0249 Optimal needle length for epinephrine prefilled syringe in children Wiparat Manuyakorn, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand POSTER DISCUSSION SESSION (PDS 12) 10:45-12:15 Daily management of drug allergy Poster Discussion Zone 4 Chair: Marina Atanaskovic-Markovic, Serbia 0250 Multiple drug hypersensitivity syndrome to antihistamines, corticosteroids and nonsteroidal anti-inflammatories in a patient with asthma and urticaria. Joana Barradas Lopes, Centro Hospitalar Vila Nova de Gaia/ Espinho, EPE, Portugal 0251 Assessment of oral provocation test results with alternative iron salts among patients who have oral iron hypersensitivity Özge Öztürk Aktas, Hacettepe University School of Medicine, Department of Chest Diseases, Division of Allergy and Clinical Immunology, Ankara, Turkey, Turkey 0252 Natural evolution in patients with NSAIDs-induced urticaria/ angioedema Maria Jose Torres, Allergy Unit, Spain 0253 Real life data about safety and advantage of hacettepe method (double/triple test) Ebru Celebioglu, Hacettepe University School of Medicine, Department of Chest Diseases, Division of Allergy and Clinical Immunology, Turkey 0254 A nursing protocol of assistance in the desensitization schedules of antineoplastic agents in an allergy daily unit Antonia Rojas Crespo, Infanta Leonor University Hospital, Spain 0255 Long term clinical effects of aspirin desensitization in patients with nerd: comparison of maintanence doses of 300 mg versus 600 mg aspirin Ömür Aydin, Ankara University School of Medicine Department of Chest Diseases Division of Immunology and Allergy, Turkey 0256 Intradermal test is a relevant biomarker of the outcome of rapid desensitization in penicillin allergy Juliana Fóes Bianchini Garcia, University of São Paulo, Brazil 0257 Utility of basophil activation test for monitoring the acquisition of clinical tolerance after subcutaneous desensitization to brentuximab-vedotin in two patients Diego Gutiérrez Fernández, UGC Neumología-Alergia, Hospital Universitario Puerta del Mar, Spain 0258 Safe and successful desensitization protocol to chemotherapy agents without premedication Anna Sala-Cunill, Hospital Universitari Vall d Hebron, Spain 0259 Rapid desensitization for the management of hypersenzitivity reaction to biologicals - infliximab and adalimumab in inflammatory bowel disease patients Bronislava Novotna, University Hospital Brno, Czech Republic 0260 Management of patients with a history of penicillin allergy: barriers to best practice and strategies to overcome them Shuayb Elkhalifa, Central Manchester University Hospitals, United Kingdom MONDAY LATE BREAKING POSTER DISCUSSION SESSION (LB PDS 4) 10:45-12:15 Allergen immunotherapy: Vaccines and clinical Poster Discussion Zone Safety of oral immunotherapy during maintenance phase: the effect of counseling on appearance of adverse events Lucia Caminiti, Department of Pediatrics - Allergy Unit - University of Messina, Italy 1491 The next generation of products for allergy treatment Louis-Philippe Vezina, ANGANY Genetics, Canada 1492 Two grass pollen tablets commercially available for allergy immunotherapy display different IgE epitope repertoires Thierry Batard, Stallergenes Greer, France 1493 The recombinant B cell epitope-based grass pollen vaccine BM32 induces antibodies protecting against hepatitis B virus (HBV) infection. Rainer Henning, Biomay AG, Vienna, Austria 1494 Evidence for long term effects of treatment with recombinant B cell epitope-based grass pollen allergy vaccine BM32 Raffaela Campana, Medical University of Vienna, Austria 1495 Immunotherapy with the recombinant B cell epitope-based grass pollen vaccine, BM32, does not induce IgE responses and may be suitable for prophylactic vaccination Verena Niederberger, Medical University of Vienna, Austria 67

68 MONDAY 19 JUNE 2017 MONDAY 1496 Sublingual allergen specific immunotherapy of polysensitization children under 5 years. Olena Sharikadze, Shupyk National Medical Academy of postgraduate education, Ukraine 1497 The SQ tree SLIT-tablet reduces rhinoconjunctivitis symptoms during challenge with birch pollen in an environmental exposure chamber Maria Abildgaard Steffensen, Global Pharmacovigilance & Clinical Development, ALK Abelló A/S, Denmark 1498 The SQ tree SLIT-tablet containing allergen extract from birch pollen reduces rhinoconjunctivitis symptoms caused by oak pollen - A proof of concept trial Maria Abildgaard Steffensen, Global Pharmacovigilance & Clinical Development, ALK Abelló A/S, Denmark 1499 Subcutaneous immunotherapy with depigmentedpolymerized allergen extracts: A systematic review and meta-analysis Jaime Sánchez-López, Laboratorios LETI, S.L.U., Spain 1500 Efficacy of a 3-week subcutaneous immunotherapy course in patients with grass pollen-induced rhinoconjunctivitis: Results of a phase-3 study Ralph Mösges, Institute of Medical Statistics, Informatics and Epidemiology (IMSIE), Germany 1501 Clinical efficacy of cat or dog allergen immunotherapy - A real life study Silvia A Uriarte, Fundación Jiménez Díaz, Spain 1502 Treatment with grass pollen slit tablets is associated with long-term relief of allergic rhinitis: A retrospective real-life dataset analysis Ulrich Wahn, Department for Pediatric Pneumology and Immunology, Charité Medical University, Germany 1503 Grass pollen sublingual immunotherapy (SLIT) tablets treatment is associated with reduction of new onset and progression of asthma Philippe Devillier, UPRES EA 220, France 1504 Safety of an accelerated build up phase with pollen allergoids. A retrospective study Cristiano Caruso, Allergy Unit, C.I. Columbus, Rome, Italy BUSINESS MEETING (BM 8) 12:25-13:35 Pediatric Section - Open to all attendees Hall 3c New approaches to the prevention and treatment of atopic dermatitis Carsten Flohr, United Kingdom BUSINESS MEETING (BM 9) 12:25-13:35 IG Food Allergy - Open to all attendees Hall 3d Infant Feeding Guidelines: How can results from allergy trials and cohorts influence global consensus? Michael Perkin, United Kingdom PRO & CON SESSION (PRO & CON 3) 12:30-13:00 Beta2 agonists should be used as a chronic preventive treatment for exercise induced bronchoconstriction Pro & Con Arena Chair: Zuzana Diamant, The Netherlands OTE Pro Pascale Kippelen, United Kingdom Con Vibeke Backer, Denmark PRO & CON SESSION (PRO & CON 4) 13:00-13:30 Bregs are as important as Tregs for allergen tolerance Pro & Con Arena Chair: Carsten Schmidt-Weber, Germany Pro OTE Con Barbara Bohle, Austria 68 Full abstract author lists are available on the official Congress website.

69 MONDAY 19 JUNE 2017 SYMPOSIUM (SYM 21) 13:45-15:15 Systems medicine approaches in allergic disease Hall 1 Chairs: Mikael Benson, Sweden Cornelis van Drunen, The Netherlands OTE Integrated epigenome and transcriptome mapping in allergic disease Michael Kabesch, Germany Integrated microbiome and transcriptome mapping in allergic disease Multiomics data integration for biomarker discovery in allergy Dario Greco, Finland SYMPOSIUM (SYM 22) 13:45-15:15 Challenges of severe asthma in childhood Hall 5bc Chairs: Susanne Lau, Germany Nikolaos Papadopoulos, Greece Burden of severe asthma in children and adolescents Antonio Nieto Garcia, Spain MONDAY OTE Differences in diagnosis and phenotypes in adult severe asthma Sejal Saglani, United Kingdom Differences in treatment of adult severe asthma Ömer Kalayci, Turkey SYMPOSIUM (SYM 23) 13:45-15:15 There is something in the air: Pollens Hall 5a Chairs: Jeroen Titus Buters, Germany Tomás Chivato, Spain OTE Using pollen counts in clinics and practice Karl-Christian Bergmann, Germany Automation of pollen monitoring networks Bernard Clot, Switzerland Prediction of pollen and symptoms Mikhail Sofiev, Finland SYMPOSIUM (SYM 24) 13:45-15:15 Obesity and allergy Hall 3b Chairs: Katie Allen, Australia Jürgen Schwarze, United Kingdom OTE Obesity and allergy: The evidence Liam O Mahony, Switzerland Obesity and asthma Gert-Jan Braunstahl, The Netherlands Weight loss management in allergy practice Rosan Meyer, United Kingdom 69

70 MONDAY 19 JUNE 2017 SYMPOSIUM (SYM 25) 13:45-15:15 Treatment and monitoring of Eosinophilic Esophagitis Chairs: Ingrid Terreehorst, The Netherlands Hans-Uwe Simon, Switzerland OTE Hall 3c Non-invasive instruments for monitoring eosinophilic esophagitis: CRD, IgG4 and free light chains, string- or sponge tests Arjan Bredenoord, The Netherlands Food elimination in eosinophilic esophagitis: 4 foods, 6 foods or no foods? Carina Venter, United Kingdom Monitoring of eosinophilic esophagitis patients Alex Straumann, Switzerland MONDAY WORKSHOP (WS 5) 13:45-15:15 Arrive early to guarantee your entry, limited spaces. Illustrating the use of Component Resolved Diagnosis and Basophil testing in allergy diagnosis Room 208 Chair: Ronald van Ree, The Netherlands Cases of food allergy illustrating the use of Component Resolved Diagnosis Anna Kaarina Kukkonen, Finland Cases of drug allergy illustrating the use of Basophil testing in diagnosis Paul Rouzaire, France Cases of food allergy illustrating the use of Basophil testing Alexandra Santos, United Kingdom SISTER SOCIETY SYMPOSIUM (SSS 5) 13:45-15:15 ACAAI: The challenge of chronic cough Hall 3d Chair: Stephen Tilles, United States OTE Chronic cough in the pediatric patient Bradley Chipps, United States Upper airway causes of chronic cough Michael S. Blaiss, United States Chronic cough: Distinguishing asthma from paradoxical laryngeal obstruction Stephen Tilles, United States YEAR IN REVIEW (YIR 3) 13:45-15:15 Year in Review ENT Hall 3f Chairs: Paloma Campo, Spain Peter Valentin Tomazic, Austria OTE Nasal hyperreactivity: From mechanisms to treatment Christine Segboer, The Netherlands Alcohol hyperreactivity in airway inflammation Els De Schryver, Belgium Laryngeal hyperreactivity Martin Wagenmann, Germany 70

71 MONDAY 19 JUNE 2017 YEAR IN REVIEW (YIR 4) 13:45-15:15 Year in Review: Immunology Room 101 Chairs: Carsten Schmidt-Weber, Germany Hideaki Morita, Japan OTE Skin immunology Jan Gutermuth, Belgium Gut immunology Calum Bain, United Kingdom Airway immunology Christian Taube, The Netherlands JUNIOR MEMBERS (JM EDU) 13:45-15:15 JM Educational Session Chairs: Olympia Tsilochristou, United Kingdom Anke Graessel, Germany OTE Guidelines for clinical practice: What s their value for junior members? Antonella Muraro, Italy How to handle our junior years to become a proactive senior member Ioana Agache, Romania Hall 3e MONDAY How to write a scientific paper and choose the best references? Jean Bousquet, France What editors want: Being a good reviewer makes you a good author Cezmi Akdis, Switzerland PRACTICAL ALLERGY MANAGEMENT WORKSHOP (PAMW 1) 13:45-15:15 Statement of the problem Chairs: Frans Timmermans, The Netherlands Ibon Eguiluz Gracia, Spain OTE Changes of pollen patterns worldwide: Impact on the allergy diagnosis Todor Popov, Bulgaria Allergy clinical trials in children: The ethicist s perspective Tanja Krones, Switzerland Hall 3g Preliminary results from EAACI POC s supported study on the availability of emergency medication in anaphylaxis: Are your patients prepared? Laurie Harada, Canada ORAL ABSTRACT SESSION (OAS 18) 13:45-15:15 Immunotherapy: Measures and outcomes Chairs: Lars Jacobsen, Denmark Stefan Vieths, Germany Session roadmap: Lars Jacobsen, Denmark 0055 High correlation between the total symptom score measured in a pollen chamber and the combined symptom medication score measured during the grass pollen season in grass pollen allergic patients Pieter Jan De Kam, HAL Allergy BV, Clinical Development & Pharmacovigilance Department, The Netherlands Room 103a 0056 A randomized clinical trial of passive immunotherapy with single-dose anti-fel d1 monoclonal antibodies REGN in cat-induced rhinoconjunctivitis: exploratory efficacy endpoints, safety, and Stephen Durham, Imperial College, United Kingdom 0057 Long-term sustained reduction of allergic rhinoconjunctivitis in children with grass pollen allergy results from an asthma prevention (GAP) trial Susanne Halken, Hans Christian Andersen Children s Hospital, Denmark 71

72 MONDAY 19 JUNE Peanut oral immunotherapy during omalizumab protection; a clinical trial on severely peanut allergic adolescsents Josef Brandström, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet and Sachs Children and Youth Hospital, Sweden 0059 Clinical validation of environmental exposure chamber in strasbourg (alyatec ) with mite in asthmatic patients Frédéric De Blay, Chest Disease Department Hôpitaux Universitaires, France 0060 Factors influencing compliance to specific subcutaneous immunotherapy(scit) Gokten Bulut, Ege University Medical Faculty, Department of Allergy and Clinical Immunology, Turkey ORAL ABSTRACT SESSION (OAS 19) 13:45-15:15 Diagnostic tools in food allergy Room 102 MONDAY 0061 FABER IgE diagnostic test: the most comprehensive view on IgE sensitization to egg and poultry allergens Claudia Alessandri, CAAM - Centri Associati di Allergologia Molecolare, Italy 0062 The variability of the egg specific cut-off IgE levels to predict clinical reactivity by total IgE, age and types of oral food challenge tests Ebru Arik Yilmaz, Hacettepe University School of Medicine, Department of Pediatric Allergy, Turkey 0063 A novel human mast cell activation test for peanut allergy Alexandra F. Santos, King s College London / Guy s & St Thomas Hospital, United Kingdom 0064 Re-analysis of a new luminex-based peptide assay (LPA) to identify different degrees of milk allergic reactivity Cansin Sackesen, Division of Pediatric Allergy, Koc University School of Medicine, Turkey 0065 Using IgG4 for cow s milk proteins to define risk of eosinophilic esophagitis in the community Alexander J. Schuyler, University of Virginia, United States 0066 Skin prick test preparations for seafood allergy: A molecular and immunological assessment Andreas L. Lopata, James Cook University, Australia POSTER DISCUSSION SESSION (PDS 13) 13:45-15:15 From adaptive immune response to mast cells Poster Discussion Zone 1 Chairs: Eva Untersmayr, Austria Inge Kortekaas Krohn, Belgium 0261 Immunisation of mice with protein antigen and microcrystalline tyrosine (MCT) depot adjuvants stimulate strong antibody and Th1-like immune responses in mice Matthew D Heath, Allergy Therapeutics, United Kingdom 0262 The regulatory role of germinal center maturation during the early B cell response to inhalant allergens investigated in the PIAMA cohort using the MeDALL allergen microarray Rob C Aalberse, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands 0263 Synthetic allergoid consisted of PLGA nanoparticles covered with synthetic peptides from Bet v1 Sergey Andreev, NRC Institute of Immunology FMBA, Russia 0264 Effect of sublingual fungal immunostimulation on the proliferative capacity and cytokine production of splenocytes from immunized mice Carmen María Diez-Rivero, Inmunotek, S.L., Spain 0265 Mechanism of inhibition of IgE-mediated mast cell degranulation by essential oil derived eugenol Linette Willemsen, Utrecht University, The Netherlands 0266 Aryl hydrocarbon receptor regulates sphingolipid homeostasis in mast cell Hsueh-Chun Wang, Department of Medical Research, China Medical University Hospital, Taiwan 0267 The function of MiR-125a-3p in mast cells in response to IgE-mediated activation Yaoshu Teng, Department of Otorhinolaryngology Head and Neck Surgery, Hangzhou First People s Hospital, Nanjing Medical University, China 0268 Dose-dependent effect of the n(epsilon)-carboxymethyllysine on proliferation in an in vitro Th2-induced model Carine Delayre-Orthez, Institut Polytechnique UniLaSalle, Nutrition and Health Department, EGEAL Unit, France 0269 Peptide cytokine mimetics for immune modulation of allergy Galber R Araujo, University of Salzburg, Austria 0270 Differential innate antiviral responses between atopics and non atopics from birth to adulthood Anastasia Georgountzou, Unit of Allergy and Clinical Immunology, 2nd Department of Pediatrics, National and Kapodistrian University of Athens, Greece 72 Full abstract author lists are available on the official Congress website.

73 MONDAY 19 JUNE A systems-immunology approach identifies a set of micrornas in shaping the th2 phenotype in allergic airway inflammation. Ayse Kilic, Institute of Laboratory Medicine, Philipps University Marburg, Germany 0272 Mouse-specific T cell responses in allergic and asthmatic patients Veronique Schulten, La Jolla Institute, United States POSTER DISCUSSION SESSION (PDS 14) 13:45-15:15 Food allergy epidemiology Poster Discussion Zone 2 Chairs: Isabel Skypala, United Kingdom Montserrat Alvaro, Spain 0273 Construction and analysis of a database of plant-based food allergy patient data Francisca Gomez, Allergy Unit, IBIMA, Regional University Hospital of Malaga, UMA, Spain 0274 Ige sensitization to cow s milk and its allergen in a large pediatric cohort Davide Paolo Caimmi, CHRU de Montpellier, Allergy Unit and Cystic Fibrosis center, France 0275 Cockroach is the major cross-reactive allergen in shrimpsensitized rural children in south China Zhaowei Yang, Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, China 0276 Molecular recognition profiles and clinical patterns of PR-10 sensitization in a birch free Mediterranean area Enrico Scala, IDI IRCCS, Italy 0277 Food protein induced enterocolitis syndrome a case series David Pina Trincão, Immunoallergology Department, Hospital Dona Estefânia, Centro Hospitalar de Lisboa Central, E.P.E., Portugal 0278 A multicenter retrospective study of 2,901 cases with immediate-type food allergy in Korean children Kyunguk Jeong, Department of Pediatrics, Ajou University School of Medicine, South Korea 0279 Cows milk allergy in children: Natural course and factors predicting the prognosis Pinar Gür çetinkaya, Hacettepe University School of Medicine, Pediatric Allergy Department, Turkey 0280 Bullying in Australian children and adolescents with food allergies Andrew Timothy Fong, University of New South Wales, Australia 0281 Dietary intake of adults with eosinophilic oesophagitis: a comparison with Dutch dietary guidelines and intake levels of the general population Simone R.B.M. Eussen, Nutricia Research, Nutricia Advanced Medical Nutrition, The Netherlands 0282 Impaired health-related quality of life in children and teenagers with food allergies Tina Vesel, University Children s Hospital, Slovenia 0283 Fruit allergy in the Mediterranean area - Description of 45 pediatric patients using inmunocap isac microarray Patricia López De Los Santos, Ramón y Cajal University Hospital, Spain MONDAY POSTER DISCUSSION SESSION (PDS 15) 13:45-15:15 Occupational allergy: What s new? Poster Discussion Zone 3 Chairs: Santiago Quirce, Spain Jolanta Walusiak-Skorupa, Poland 0284 Sensitisation in Norwegian crab processing workers Marte Renate Thomassen, Department of Occupational and Environmental Medicine, University Hospital of North Norway, Norway 0285 Skin symptoms, burnout, and sensitization to latex in surgery clinic employees Dragan Mijakoski, Institute of Occupational Health, WHO Collaborating Center and GA2LEN Collaborating Center, Macedonia, Former Yugoslav Republic of 0286 Occupational respiratory disease and anaphylaxis in a baker sensitized to plant-food allergens Raphaëlle Bazire, Department of Allergy, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Spain 0287 Lung function decline in food preparation and distribution workers Giulia Paolocci, Section of Occupational Medicine, Respiratory Diseases and Toxicology, Italy 0288 Prevalence of wood dust sensitization in occupationally exposed workers in Germany What can be tested? Sabine Kespohl, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Germany 0289 Respiratory health status among Norwegian fish production workers on board fishing trawlers Cecilie Thon Heidelberg, University Hospital of North Norway, Department of Occupational and Environmental Medicine, Norway 73

74 MONDAY 19 JUNE Airways inflammation in work-related asthma due to high and low molecular weight agents Agnieszka Anna Lipinska-Ojrzanowska, Nofer Institute of Occupational Diseases, Poland 0291 Occupational asthma to epoxy compounds Hille Suojalehto, Finnish Institute of Occupational Health, Finland 0292 Occupational allergy in hairdressing apprentices clinical manifestations and evaluation of the hypersensitivity to occupational allergens Marta Wiszniewska, Nofer Institute of Occupational Medicine, Poland 0293 Risk factors associated with allergic sensitization and asthma phenotypes among poultry farm workers in South Africa Dorothy Ngajilo, Division of Occupational Medicine and Centre for Environmental and Occupational Health Research, School of Public Health and Family Medicine, University of Cape Town, South Africa 0294 Workplace pef monitoring with a smartphone application Irmeli Lindström, Finnish Institute of Occupational Health, Finland 0295 Diversity vs. level of occupational exposure and the risk of ige sensitization Anders Ingemann Larsen, Novozymes A/S, Denmark MONDAY 0296 Does common enzymatic activity predict cross-reactivity? a study of phospholipase A1 in different species Katrine T. Callesen, Allergy Clinic, Herlev and Gentofte University Hospital, Denmark POSTER DISCUSSION SESSION (PDS 16) 13:45-15:15 The spectrum of pediatric skin and drug allergy Poster Discussion Zone 4 Chairs: Charlotte G. Mortz, Denmark Philippe Eigenmann, Switzerland 0297 Symptoms of food allergy in children with atopic dermatitis and different types of feeding Julia Boguslavskaya, I.M.Sechenov First Moscow State Medical University, Moscow, Russia 0298 Mastocytosis in children! Petronela Popa-Colbu, Emergency Hospital for children, Romania 0299 Atopic dermatitis in children from Russian and Englishspeaking families in Russia and other countries Asya Kudryavtseva, I.M.Sechenov First Moscow State Medical University, Russia 0300 Associations between skin diseases in parents and responses to skin prick tests in their infants Miwa Shinohara, Department of Pediatrics, Japan 0301 Polyvalent IgE-mediated allergy yn infants and young children with atopic dermatitis. Beata Cudowska, Department of Pediatrics, Gastroenterology and Allergology; Medical University of Bialystok, Poland 0302 Severity and quality of life in children with atopic dermatitis Nurul Iman Nilam Sari, Harapan Kita Women and Children Hospital, Indonesia 0303 Obsessive compulsive symptoms in the atopic dermatitis patients mothers Velat Celik, Trakya University Medical Faculty, Turkey 0304 A retrospective review of case notes & referral letters to analyse management of paediatric eczema by primary care in the United Kingdom and the reasons for referral to paediatric allergy clinic. Tushar Kanti Banerjee, County Durham and Darlington NHS Foundation Trust, United Kingdom 0305 Analysis of potential contact allergens in cosmetics intended to use in newborns and infants Karolina Dumycz, Department of Pediatric Respiratory Diseases and Allergy, The Medical University Children s Hospital, The Medical University of Warsaw, Poland 0306 Frequency of nonsteroid anti-inflammatory drug hypersensitivity in asthmatic children Hakan Guvenir, Ankara Children s Hematology Oncology Training and Research Hospital, Department of Pediatric Allergy and Immunology, Turkey 0307 Adverse drug reactions in Korean children : an analysis of KAERS database on Eun Hee Chung, Department of Pediatrics, Chungnam National University School of Medicine, South Korea 0308 Assessment of the results of the drug provocation tests in children with history of multiple drug allergies Hakan Guvenir, Ankara Children s Hematology Oncology Training and Research Hospital, Department of Pediatric Allergy and Immunology, Turkey 74 Full abstract author lists are available on the official Congress website.

75 MONDAY 19 JUNE 2017 SYMPOSIUM (SYM 26) 15:45-17:15 Pediatric allergy as seen in Primary Care Hall 1 Chair: Anna Kaarina Kukkonen, Finland OTE An approach to the wheezy infant in Primary Care Patrick Bindels, The Netherlands Gut symptoms and food allergy in infants Laura Merras-Salmio, Finland Meeting the allergy burden/challenge in the community Isobel El-Shanawany, United Kingdom SYMPOSIUM (SYM 27) 15:45-17:15 Ophthalmology for allergists Chairs: Andrea Leonardi, Italy Jean-Luc Fauquert, France OTE The ocular immune system Virginia Calder, United Kingdom The spectrum of ocular allergy Serge Doan, France Hall 5bc MONDAY Immunotherapy for allergic conjunctivitis Ken Fukuda, Japan SYMPOSIUM (SYM 28) 15:45-17:15 Controversies in sports and asthma Chairs: Mariana Couto, Portugal Kai-Håkon Carlsen, Norway OTE Hall 5a Ambient conditions, air pollutants and airway inflammation: Why outdoor activity is not always beneficial Valérie Bougault, France Is asthma under or overdiagnosed in athletes? Marcin Kurowski, Poland Asthma in athletes: An occupational disease? Stefano Del Giacco, Italy SYMPOSIUM (SYM 29) 15:45-17:15 Novel roles of dendritic cells Hall 3a Chairs: Mübeccel Akdis, Switzerland Lars K. Poulsen, Denmark OTE Dendritic cells in allergic rhinitis Frode Jahnsen, Norway Dendritic cell based endotypes of severe RSV bronchiolitis? Jürgen Schwarze, United Kingdom New ways of analysing dendritic cell subsets 75

76 MONDAY 19 JUNE 2017 SYMPOSIUM (SYM 30) 15:45-17:15 Molecular tools for allergen immunotherapy Room 101 Chairs: Rudolf Valenta, Austria Victoria Cardona, Spain OTE Molecular allergology in food allergy immunotherapy Ronald van Ree, The Netherlands Improving allergen immunotherapy prescription Paolo Matricardi, Germany Molecular based allergen immunotherapy Marek Jutel, Poland MONDAY WORKSHOP (WS 6) 15:45-17:15 Arrive early to guarantee your entry, limited spaces. Patch testing in specific situations Room 208 Chair: Johannes Ring, Germany Patch testing in drug reactions Jussi Liippo, Finland Contact allergy in patients with atopic dermatitis Tove Agner, Denmark Contact allergy to cosmetic ingredients An Goossens, Belgium SISTER SOCIETY SYMPOSIUM (SSS 6) 15:45-17:15 Allergies in Africa Chairs: Habib Douagui, Algeria Di Hawarden, South Africa OTE Room 103a Protection against food sensitisation and challenge proven food allergy in rural African children Michael Levin, South Africa Inhalant food allergens and asthma in the African workplace Mohamed Jeebhay, South Africa Do allergy and malaria involve common signalling pathways: implications toward the design of an experimental malaria vaccine Salah Mecheri, France PRACTICAL ALLERGY MANAGEMENT WORKSHOP (PAMW 2) 15:45-17:15 Patient Driven Solutions Chairs: Mary Jane Marchisotto, United States Susanne Lau, Germany OTE Hall 3g European advocacy in allergy: What s been done and what s still needed Frans Timmermans, The Netherlands Perspectives on may contain : Update from the ifaam Consortium Clare Mills, United Kingdom How to maximise adherence to therapy: The role of patients Giselle Mosnaim, United States 76 Full abstract author lists are available on the official Congress website.

77 MONDAY 19 JUNE 2017 ORAL ABSTRACT SESSION (OAS 20) 15:45-17:15 Managing asthma from infancy to adolescence Hall 3b Chair: Alberto Alvarez-Perea, Spain 0073 Breast-milk microbiome and risk of asthma by 6 years of age Inka Hämynen, National Institute for Health and Welfare, Finland 0074 Sex-shift of respiratory multimorbidity prevalence during adolescence pooled analyses of longitudinal european birth cohort data from medall Theresa Keller, Institute of Social Medicine, Epidemiology and Health Economics, Charité Universitätsmedizin Berlin, Germany 0075 Patients with rhinovirus a or c species induced severe bronchiolitis are at increased risk of using asthma control medication 4 years later. Matilda Aakula, Department of Pediatrics, Turku University Hospital, Turku, Finland 0076 Rhinovirus and respiratory syncytial virus genome load and the post-bronchiolitis use of asthma controller medication: prospective 4-year follow-up study Eija Bergroth, Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland and Department of Pediatrics, Central Hospital of Central Finland, Finland 0077 Exercise-induced bronchoconstriction in children with asthma: an observational cohort study in Taiwan Li-Lun Lin, Division of Allergy, Asthma, and Rheumatology, Department of Pediatrics, Chang Gung Children s Hospital, Taiwan 0078 The influence of polyvalent mechanical bacterial lysate on immunological parameters in asthmatic children Malgorzata Bartkowiak-Emeryk, Chair and Dept. of Clinical Immunology, Medical University, Poland MONDAY ORAL ABSTRACT SESSION (OAS 21) 15:45-17:15 New approaches to the diagnosis and management of food allergy Hall 3c Chairs: Karin Hoffmann-Sommergruber, Austria Kirsten Beyer, Germany Session roadmap: Karin Hoffmann-Sommergruber, Austria 0079 Treatment of human dendritic cells with STAT6-IP inhibits proliferation of lymphocytes from peanut allergic donors and reduces TH2 cytokines: a novel approach for treatment of food allergies. Christine T Mccusker, McGill University Health Center Research Institute, Canada 0080 A hypoallergenic hydrolysate of ovalbumin with pepsin exerts preventive and therapeutic effects in a mouse model of egg allergy Daniel Lozano-Ojalvo, Instituto de Investigación en Ciencias de la Alimentación (CIAL, CSIC-UAM), Spain 0081 Phenotypical characterization of peanut allergic children with differences in cross-allergy to tree nuts and other legumes Mathias Cousin, MD in Unité d allergologie, Département de Pneumologie et Addictologie, Hôpital Arnaud de Villeneuve, CHRU de Montpellier, France and Service d Allergologie et d Education Thérapeutique, Hôpital Saint-Vincent de Paul, France 0082 Food products and undeclared allergens causing accidental allergic reactions in daily life W. Marty Blom, TNO, Netherlands Organization for Applied Scientific Research, The Netherlands 0083 Food allergens recalls on rapid alert system for food and feed (rasff) portal from the EU Commission: analysis Ines Padua, Faculty of Nutrition and Food Sciences, University of Porto, Portugal 0084 A randomized, double-blind, placebo-controlled, pivotal multicenter trial with budesonide orodispersible tablets for treatment of active eosinophilic esophagitis (eos-1) Stephan Miehlke, Center for Digestive Diseases Eppendorf, Germany 77

78 MONDAY 19 JUNE 2017 ORAL ABSTRACT SESSION (OAS 22) 15:45-17:15 What s new in aerobiology Chairs: Jeroen Titus Buters, Germany Carmen Galán, Spain Session roadmap: Jeroen Titus Buters, Germany 0085 The inventory of the pollen monitoring networks worldwide: results of the TF (ig aerobiology & pollution) Celia Antunes Antunes, ICT Institute of Earth Sciences, IIFA & Dep. Chemistry, ECT, University of Evora, Portugal Hall 3e 0087 School neighbouring affects lung function and the autonomic nervous system in children Inês Paciência, Faculty of Medicine, University of Porto, Portugal 0088 Effect of nitrogen dioxide on childhood airway hyperresposiveness and incident asthma Song-I Yang, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, South Korea MONDAY 0086 Towards automatic, real-time pollen monitoring for allergic patients: need for health information services? Franziska Häring, Chair and Institute of Environmental Medicine, UNIKA-T, Technical University of Munich and Helmholtz Zentrum München, Germany - German Research Center for Environmental Health, Germany 0089 Environmental determinants of exhaled breath condensate ph in children. Tiago Rama, Immunoallergology unit, Centro Hospitalar São João, Portugal 0090 Cross-reactivity between tropomyosin allergens from aedes aegypti and dermatophagoides pteronyssinus involves B and T epitopes Jose Fernando Cantillo, Institute for Immunological Research/ University of Cartagena, Colombia ORAL ABSTRACT SESSION (OAS 23) 15:45-17:15 Novel mechanisms in rhinitis and rhinosinusitis Room 102 Chair: Ruby Pawankar, Japan Session roadmap: Ruby Pawankar, Japan 0091 Transdifferentiated ILC2s promote neutrophilic airway inflammation in nasal polyps of CRSwNP in cystic fibrosis K. Golebski, Academic Medical Center, University of Amsterdam, The Netherlands 0092 Association between type 2 innate lymphoid cells increasement and allergy in patients with chronic rhinosinusitis and asthma Xun Meng, ENT Department Guangzhou Oversea Chinese Hospital, China 0093 Increased expression of SMAD7 in persistent allergic rhinitis Aarif O Eifan, Allergy and Clinical Immunology, Imperial College London, United Kingdom 0094 Targeted metabolomics reveals novel lipid and amino acid metabolism alterations in aspirin-exacerbated respiratory disease Pascal Haimerl, ZAUM - Center for Allergy & Environment Munich, Technical University and Helmholtz Center Munich, Germany 0095 TLR2 and TLR4 signalling is responsible for impaired epithelial barrier in chronic rhinosinusitis with nasal polyps Brecht Steelant, KU Leuven, Belgium 0096 The construction of related gene expression profile of allergic rhinitis and screening the pathogenic genes Zhuo Chen, Department of Otolaryngology Head & Neck Surgery, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China LATE BREAKING ORAL ABSTRACT SESSION (LB OAS 2) 15:45-17:15 Asthma - genetics, immuneresponse and management Hall 3f 1425 Association of vitamin D receptor taqi gene variant in exon 9 and apai in intron 8 with adult asthma in ireland. Katrina Hutchinson, School of Chemistry, National University of Ireland, Ireland 1426 Rs IL4 polymorphism could be a genetic biomarker linked with nonatopic uncontrolled wheeze Flore Amat, AP-HP, UPMC, INSERM, France 1427 MicroRNA-146a modulates immune responses to human rhinoviruses in primary bronchial epithelial cells. Ana Rebane, University of Tartu, Estonia 1428 Hallmarks of autoimmunity and inflammatory phenotypes in bronchial asthma and copd Anna Konishcheva, Mechnikov Research Institute for vaccines and sera, Russia 78 Full abstract author lists are available on the official Congress website.

79 MONDAY 19 JUNE Smoking asthma endotype is associated with low expression of tnf and reduced macrophages in sputum Sven F Seys, KU Leuven, Belgium 1430 Beliefs about medicines and medication adherence: A prospective study in persons with asthma Christian Joachim Apfelbacher, Medical Sociology, Germany POSTER DISCUSSION SESSION (PDS 17) 15:45-17:15 Primary immunodeficiency Poster Discussion Zone 1 Chair: Anna Sediva, Czech Republic 0309 Evaluation of health-related quality of life using CVID_QoL questionnaire: impact of clinical, immunological and therapyrelated factors on burden of disease in common variable immunodeficiency Federica Pulvirenti, Dpt of Molecular Medicine Sapienza University, Italy 0310 Antibiotic prophylaxis in primary antibody deficiency patients: study design Cinzia Milito, Sapienza Dpt of Molecular Medicine, Italy 0311 IgM and IgA anti-pneumococcal capsular polysaccharides as prognostic tool for common variable immunodeficiency: a longitudinal study. Federica Pulvirenti, Dpt of Molecular Medicine Sapienza University, Italy 0312 Subcutaneous ig replacement therapy in primary and secondary hypogammaglobulinemia: A retrospective single centre study of 203 patients Francesco Cinetto, Department of Medicine - DIMED, University of Padova, Italy 0313 Central nervous system involvement in adult patients with primary antibody deficiencies Veronica Pedini, Clinical Medicine, Polytechnic University of Marche and Ospedali Riuniti, Italy 0314 Cellulitis and campylobacter jejuni bacteremia in a patient with x-linked agammaglobulinemia: case report Mara Fernandes, Immunoallergology Department, Hospital de Santa Maria (HSM), Centro Hospitalar Lisboa Norte EPE; Immunoallergology Unit, Hospital Dr. Nélio Mendonça, SESARAM, EPE, Funchal, Portugal 0315 Analysis of three genes (CD40L, AID and CD40) in Iranian HIGM patients Marzieh Mazinani, Immunology, Asthma & Allergy Research Institute, Tehran University of Medical Sciences, Iran 0316 Report of a novel deletion-insertion in UNC13D gene in a prenatal diagnosis Marzieh Mazinani, Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Iran 0317 Treatment of granulomas in patients with ataxia telangiectasia Sandra Woelke, Department for Children and Adolescents, Division of Allergology, Pulmonology and Cystic fibrosis, Goethe University Hospital, Frankfurt, Germany, Germany 0318 Progressive liver disease in patients with ataxia telangiectasia Sandra Woelke, Department for Children and Adolescents, Division of Allergology, Pulmonology and Cystic fibrosis, Goethe University Hospital, Germany MONDAY POSTER DISCUSSION SESSION (PDS 18) 15:45-17:15 Pediatric food allergy Poster Discussion Zone 2 Chair: Cansin Sackesen, Turkey 0319 Influential factors in tolerance acquisition of IgE-mediated egg allergy in children Jong Deok Kim, Severance Hospital, South Korea 0320 Evaluation of pollen-food syndrome in children Hakan Guvenir, Ankara Children s Hematology Oncology Training and Research Hospital, Department of Pediatric Allergy and Immunology, Turkey 0321 Does anaphylaxis (with administration of adrenaline) during in-hospital food challenges impact adversely on healthrelated quality of life? Nandinee B Patel, Imperial College London, United Kingdom 0322 Donkey s milk is well accepted and tolerated by infants with cow s milk food protein-induced enterocolitis syndrome Simona Barni, Anna Meyer Children Hospital, Italy 0323 Donkey s milk tolerability and palatability in cow s milk allergic children Simona Barni, Anna Meyer Children Hospital, Italy 0324 The effects of the elimination diet on the growth of a child with cow s milk allergy systematic review Anni Piekkala, University of Tampere, Finland 0325 Cost-effectiveness of molecular allergology in children with suspected hazelnut allergy compared to double blind placebo controlled food challenge and skin prick test Barbara Mascialino, Thermo Fisher Scientific - ImmunoDiagnostics, Sweden 0326 Prevalence of pollen-food allergy syndrome among schoolage children Yosuke Fujii, Department of Pediatric Acute Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan 79

80 MONDAY 19 JUNE Immune profile after OIT in children with cow s milk allergy Magna Correia, Immunoallergy Department, CUF Descobertas Hospital, Lisbon, Portugal, Portugal 0328 Desensitization and tolerance in cow s milk allergy Nursen Cigerci Gunaydin, Ege University, Faculty of Medicine, Department of Pediatric Allergy and Immunology, Turkey POSTER DISCUSSION SESSION (PDS 19) 15:45-17:15 Epidemiology, risk factors and clinical aspects of drug allergy Poster Discussion Zone 3 Chair: Erik Melén, Sweden 0329 Incidences and risk factors of adverse drug reactions of gadolinium-based contrast media Sunyoung Kim, Department of Internal Medicine, Yonsei University College of Medicine, South Korea 0336 Outpatient collaboration between allergist and pharmacists results in long-term increase in ß-Lactam antibiotic prescriptions among patients with a history of penicillin allergy Miguel Park, Mayo Clinic, United States MONDAY 0330 Hyperuricemia: A new risk factor for NSAIDS allergy? Our 7 years experience Darío Antolín-Amérigo, ESI-Alergia. Hospital Universitario Príncipe de Asturias. Departamento de medicina y especialidades médicas. Universidad de Alcalá, Spain 0331 Incidence of beta lactam antibiotics hypersensitivity according to data of Vilnius University Hospital Santariskiu Klinikos Ingrida Maciulaityte, Vilnius University, Department of Infectious and Chest Diseases, Dermatovenereology and Allergology, Center of Pulmonology and Allergology, Lithuania 0332 Assessment of local anesthetic drug allergy diagnosis and treatment in Ukraine: A survey to optimize patient care Igor Kaidashev, Ukrainian Medical Stomatological Academy, Ukraine 0333 Are patients prone to using penicillin after testing negative for penicillin allergy at a specialist centre? Marianne Eriksson, Dept. of Allergology, Sahlgrenska University Hospital, Sweden 0334 Utility of nasal challenge with l-asa for the diagnosis of nsaids-induced skin reactions. pronasa study Adriana Izquierdo-Dominguez, Clinica Diagonal, Spain 0337 Case series with single NSAID induced acute reactions Ali Aydin, Recep Tayyip Erdogan University School Of Medicine Department of Internal Medicine Division of Immunology and Allergic Diseases, Turkey 0338 Airway nitric oxide levels in drug provocation test; a new diagnostic tool? Ayse Baccioglu, Kirikkale University Faculty of Medicine, Division of Immunology and Allergic Diseases, Turkey 0339 Characterization of subjects experiencing blended hypersensitivity reactions to non-steroidal anti-inflammatory drugs Esther Barrionuevo, Allergy Unit, Regional University Hospital of Malaga-IBIMA, Spain 0340 Hypersensitivity reactions to NSAIDs in children vs adolescents. Natalia Blanca-López, Infanta Leonor University Hospital, Spain 0341 Epidemiology of pediatric adverse drug reactions (ADRs) in Korea; using big data of 48.1 million south Korean healthcare records and KAERS (Korea adverse event reporting system) database Gwang-Cheon Jang, NHIS ILSAN Hospital, South Korea 0335 Psychological evaluation of patients from a drug allergy unit: are there differences between patients with confirmed or excluded drug allergy? Eunice Dias De Castro, Allergy and Clinical Immunology Department, Portugal 0342 Toxoallergic reactions caused by medicines- one year retrospective study Julia Petrunov Radenkova-Saeva, UMHATEM, Bulgaria POSTER DISCUSSION SESSION (PDS 20) 15:45-17:15 Asthma genetics Poster Discussion Zone 4 Chair: Michael Kabesch, Germany 0354 Genetic effects on production of arachidonic acid metabolites related with asthma pathogenesis Ga-Young Ban, Ajou University School of Medicine, South Korea 0355 The lncrnas involved in murine airway allergic inflammation following induced pluripotent stem cell-mesenchymal stem cell treatment Shu-Yue Wang, Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen University, China 80 Full abstract author lists are available on the official Congress website.

81 MONDAY 19 JUNE The construction of related gene expression profile of allergic rhinitis with asthmas and screening the pathogenic genes Zhuo Chen, Department of Otolaryngology Head & Neck Surgery, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China q21 gene variation increases the risk of exacerbations in asthmatic children treated with inhaled corticosteroids: a meta-analysis in the multi-ethnic pica consortium Niloufar Farzan, Department of Respiratory Medicine, Academic Medical Center (AMC). University of Amsterdam, The Netherlands 0358 Homozygous status for the Arg16 variant is associated with increased prescribing of controller asthma medication Patricia Soares, Academic Department of Paediatrics, Brighton & Sussex Medical School, Royal Alexandra Children s Hospital, United Kingdom 0359 PTGDR influences cytokine levels in the A549 cell line Ignacio Dávila, Department of Biomedical and Diagnostic Sciences. University of Salamanca, Spain 0360 C-159t polymorphism of the CD14 gene in adult patients with fixed and reversible airflow obstructive asthma in Crimea, Ukraine Y Bisyuk, Bogomolets National Medical University, Ukraine 0361 Association of CD14 C159t promoter polymorphism with regulatory cytokine response in indian children with atopic asthma Amit Agarwal, Postgraduate Institute of Medical Education and Research, India 0362 The disbalance of TLR2, TLR4 gene expression and cytokines production in children with bronchial asthma. Oxana Anatolievna Svitich, Mechnikov Research Institute of Vaccines and Sera, Russia MONDAY SISTER SOCIETY SYMPOSIUM (SSS 7) 17:30-19:00 IRINE: Immunology Research Institute of New England Symposium 2017: New models for analysis of allergic diseases Hall 3f Chairs: Leonid Titov, Belarus Yuri Bisyuk, Ukraine Lawrence DuBuske, United States OTE Development of mouse models of allergic rhinitis and allergic asthma: Impact of allergen immunotherapy Alexander Alexandrovich Babakhin, Russia Lawrence DuBuske, United States New models for prediction of pollen season: Impact of global warming in Ukraine Victoria Rodinkova, Ukraine Survey of current patterns of assessment of drug allergy in Ukraine: Optimizing diagnosis Igor Kaidashev, Russia Modeling the impact of intense exercise on immune function in elite athletes Roman Khanferyan, Russia Questions & Answers BUSINESS MEETING (BM 10) 17:30-18:40 IG Epidemiology - Open to all attendees Room 208 Allergy and sleep in the dark? Jon Genuneit, Germany BUSINESS MEETING (BM 11) 17:30-18:40 IG Drug Allergy - Open to all attendees Room 103b Immunoreactions to checkpoint inhibitors treatment Werner Pichler, Switzerland 81

82 MONDAY 19 JUNE 2017 BUSINESS MEETING (BM 12) 17:30-18:40 IG Primary Immunodeficiency - Open to all attendees Room 201 The IPEX syndrome Eleonora Gambineri, Italy BUSINESS MEETING (BM 13) 17:30-18:40 IG Occupational Allergy - Open to all attendees Room 206 New developments in work-related asthma Santiago Quirce, Spain MONDAY BUSINESS MEETING (BM 14) 17:30-18:40 IG Biologicals - Open to all attendees Room 207 Desensitisations for IgE and non IgE mediated reactions to monoclonal antibodies: Are all biologicals candidates? Mariana Castells, United States BUSINESS MEETING (BM 15) 17:30-18:40 IG Aerobiology and Pollution - Open to all attendees Room 209 Climate change and airborne allergens Paul Beggs, Australia 82

83 MONDAY 19 JUNE 2017 VISIT US ONLINE Join the EAACI virtual community EAACI Website Your platform for great resources: } Clean layout for easier navigation } All EAACI events in one place } Available on smartphones and tablets MONDAY Follow us and stay informed about all EAACI activities! #eaaci

84 PROGRAMME AT A GLANCE TUESDAY 20 JUNE 2017 Hall 1 Hall 5bc Hall 5a Hall 3a Hall 3b Hall 3c Hall 3d Hall 3e Hall 3f Hall 3g Session Roo 08:30 P.87 P.87 09:00 PL 5 Eosinophil disorders: From mechanism to treatment PL 6 Innate lymphoid cells in allergy and chronic inflammatory 09:30 diseases 10:00 FA, CA, BI, P BA, CI, D, A TUESDAY 10:30 P.88 P.89 P.182 P.88 P.88 P.88 P.89 P.90 P.90 P.91 SYM 31 Non IgE gastrointestinal YIR 5 Year in Review: CSS 7 Company Sponsored SYM 33 Real life data for allergy SYM 34 New ways of coping with HT 4 Nature: Friend or foe? OAS 24 Allergens and immunotherapy OAS 25 Innate immune 11:00 disease in the allergy clinic Pediatrics Symposium research cat allergy response in mucosal tissues 11:30 SYM 32 Autoinflammation: From molecular mechanisms to new treatment strategies SSS 8 Ga 2 len: Practical approach to phenotypes and endotypes in nasal inflammatory diseases AH, FA, P, PC FA, IT, P CI, I CA, D IT, P, A, ENT ENT A, CA, CI IT I 12:00 12:30 Lunch and Poster Viewing in the Poster Area 13:00 13:30 P.95 P.97 P.95 P.97 P.96 P.97 P.96 P.98 P.98 SYM 36 Nutritional interventions HT 5 Innovative intervention SYM 37 House dust mite in OAS 27 Advances in hereditary SYM 38 Basophils in drug allergy Ethics Session: Ethical SYM 39 Mast cell diseases: An OAS 28 Managing food allergy in OAS 29 Asthma Immunopathology/ 14:00 for allergy prevention asthma and allergic rhinitis angioedema diagnosis aspects of food allergy: update children inflammation We are what 14:30 we eat FA, AH, P CA, FA, D A, ENT, P D DA, DI, CA AH, FA, P D, CA FA, P A 15:00 15:30 P.102 P.102 P.102 P.102 P.103 P.103 P.104 P.104 P.104 P.182 SYM 41 SYM 42 SYM 43 SYM 44 SYM 45 SSS 9 OAS 31 OAS 32 LB OAS 3 CSS 8 Interventional Novel insights Properties of Primary National GARD: Cellular and AIT in children Anaphylaxis, Company studies for the in virus allergens that immune Allergy Tackling molecular and adults venom and drug Sponsored 16:00 prevention of food allergy induced bronchiolitis and asthma account for sensitisation, cross deficiency and allergy: What is Societies Forum allergies and chronic respiratory diagnostic techniques allergy: From diagnosis to treatment Symposium 16:30 reactivity and relationship? diseases in severity low income FA, AH, P, PC I, A, P DI, CA CI, CA countries A, CA DI IT DA 17:00 17:30 P.190 P :00 SAT 12 Company Sponsored Satellite Symposium SAT 13 Company Sponsored Satellite Symposium 18:30 19:

85 PROGRAMME AT A GLANCE TUESDAY 20 JUNE 2017 m: Hall 3g Room 101 Room 103a Room 208 Room 102 Pro & Con Arena Poster Discussion Zone 1 SESSION GUIDE BM Business Meeting of EAACI Sections and Interest Groups P & C PL SSS Sister Society Symposium SYM OAS Oral Abstract Session WS PDS Poster Discussion Session HT JM Junior Members Programme YIR LB PDS Late Breaking Poster Discussion Session PAMW Pro & Con Session Plenary Symposium Symposium Workshop Hot Topic Session Year in Review Session Practical Allergy Management Workshop TOPIC TRACKS A Asthma AH Allied Health BA Basic Allergology BI Biologicals CA Clinical Allergology CI Clinical Immunology D Dermatology DA Drug Allergy DI Allergy Diagnosis ENT Ear, Nose, Throat FA Food Allergy I Immunology IT Immunotherapy OA Ocular Allergy P Pediatrics PC Allergy management in Primary Care Poster Discussion Zone 2 Poster Discussion Zone 3 Poster Discussion Zone 4 SISTER SOCIETIES GA²LEN Global Allergy and Asthma European Network GARD The Global Alliance against Respiratory Diseases 08:30 09:00 09:30 10:00 SYM 35 Asthma challenges in clinical practice P.89 P.91 P.89 P.90 P.92 P.92 P.93 P.94 10:30 OAS 26 WS 7 Junior PDS 21 PDS 22 PDS 23 Insights and Drug allergy Members Immunotherapy Mechanism Rhinitis and advances anaphylaxis: - Case - news and diagnosis Rhinosinusitis in chronic Risk factors and Reports from the of drug 11:00 urticaria management Session clinic allergy LB PDS 5 Asthma in children and adults: Biomarkers, epidemiology and management 11:30 A, P, PC, AH D DA, CA, FA IT DA ENT A, P 12:00 Lunch and Poster Viewing in the Poster Area P.95 Pro & Con 5 Can a computer diagnose allergy? 12:30 Lunch and Poster Viewing P.95 in the Poster Area Pro & Con 6 Immunotherapy can be performed in 13:00 the community, not only in hospitals TUESDAY SYM 40 Biologicals in daily practice of allergy treatment BI, A, DA, P P.96 P.99 P.96 P.99 P.100 P.100 P :30 OAS 30 PDS 24 PDS 25 Drug allergy: Pediatric Infection and Diagnosis Asthma allergy DA WS 8 New immunological concepts in allergen-specific immunotherapy: Immune regulation beyond regulatory T cells? I, IT, BA Highlights Session 2 P.192 A, P I, A, P PDS 26 Atopic dermatitis and other inflammatory skin conditions D PDS 27 Translational approaches to food allergy P.103 P.105 P.103 P.105 P.106 P.106 P :30 YIR 6 Year in Review: Dermatology LB OAS 4 Food allergy - diagnosis and management WS 9 When the athlete knocks on your door: PDS 28 Biologicals in respiratory and PDS 29 Functional genomics and PDS 30 Food allergy - supporting patients from PDS 31 Innovative allergy diagnostics 16:00 Hints for optimal cutaneous proteomics bench to management? diseases bedside FA 14:00 14:30 15:00 16:30 D, P FA A, IT, CA A, BI, D, I I FA DI 17:00 P :30 SAT 14 Company Sponsored Satellite 18:00 Symposium 18:30 19:

86 LEARNING LOUNGES AND BUSINESS MEETINGS LEARNING LOUNGES Room 218 Room 217 Room 204 Room :30-08:15 P.87 07:30-08:15 P.87 07:30-08:15 P.87 07:30-08:15 P.87 LL 9 LL 10 LL 11 LL 12 A child with recurrent respiratory tract infections P, CI, PC, AH How a chest physician approaches suspected occupational work-related airway disease A, ENT, DI, PC Anti IgE for the treatment of chronic urticaria D, P, BI Are oral food challenges still necessary for diagnosing food allergy? FA, P, DI, CA BUSINESS MEETINGS Hall 3d Hall 3e Hall 3f Hall 3g 12:10-13:20 P.94 12:10-13:20 P.94 12:10-13:20 P.94 12:10-13:20 P.95 BM 16 BM 17 BM 18 BM 19 Immunology Section - Open to all attendees Asthma Section - Open to all attendees Dermatology Section - Open to all attendees ENT Section - Open to all attendees Room :30-17:00 P.105 BM 20 Patients Organisations Committee - Open to all attendees TUESDAY Room 102 Room 103b Room 201 Room 206 Room :30-18:40 P :30-18:40 P :30-18:40 P :30-18:40 P :30-18:40 P.108 BM 21 BM 22 BM 23 BM 24 BM 25 IG Infections and Allergy - Open IG Comparative and Veterinary IG OMICS and Systems IG on Eosinophilic Esophagitis IG Ocular Allergy - to all attendees Allergology - Open to all attendees Medicine - Open to all attendees - Open to all attendees Open to all attendees SESSION GUIDE LL Learning Lounge BM Business Meeting of EAACI Sections and Interest Groups TOPIC TRACKS CA Clinical Allergology DA Drug Allergy DI Allergy Diagnosis FA Food Allergy IT Immunotherapy OA Ocular Allergy P Pediatrics PC Allergy management in Primary Care 86

87 TUESDAY 20 JUNE 2017 SOME SESSIONS FILL UP QUICKLY. ARRIVE EARLY TO GUARANTEE YOUR ENTRY. IF YOU HAVE MISSED A SESSION, YOU CAN CATCH UP ON IT AT THE VIRTUAL CONGRESS HUB IN THE EXHIBITION HALL. PROGRAMME IS STILL SUBJECT TO CHANGE. PLEASE REFER TO THE CONGRESS APP FOR LATEST UPDATE. LEARNING LOUNGE 07:30-08:15 Learning Lounges are early morning sessions. Pre-registration & sperarate payment required, limited spaces. Learning Lounge (LL 9) Room 218 A child with recurrent respiratory tract infections Susanne Lau, Germany Learning Lounge (LL 10) Room 217 How a chest physician approaches to suspected occupational work-related airway disease Enrico Heffler, Italy Learning Lounge (LL 11) Room 204 Anti IgE for the treatment of chronic urticaria Torsten Zuberbier, Germany Learning Lounge (LL 12 ) Room 205 Are oral food challenges still necessary for diagnosing food allergy? Philippe Eigenmann, Switzerland TUESDAY PLENARY SYMPOSIUM (PL 5) 08:30-10:00 Eosinophil disorders: From mechanism to treatment Hall 1 Chairs: Peter Schmid-Grendelmeier, Switzerland Marek Jutel, Poland Eosinophilic syndrome: Anything new? Hans-Uwe Simon, Switzerland Molecular, cellular and genetic pathogenesis of Eosinophilic Esophagitis Marc Rothenberg, United States Biologicals in the treatment of Eosinophil-driven diseases? Philippe Gevaert, Belgium PLENARY SYMPOSIUM (PL 6) 08:30-10:00 Innate lymphoid cells in allergy and chronic inflammatory diseases Hall 5bc Chairs: Cezmi Akdis, Switzerland Edward Knol, The Netherlands Function and subsets of ILCs in human Rudi W. Hendriks, The Netherlands Human ILCs in intestine and skin Jenny Mjösberg, Sweden The role of ILCs in allergy and asthma Hideaki Morita, Japan 87

88 TUESDAY 20 JUNE 2017 SYMPOSIUM (SYM 31) 10:30-12:00 Non IgE gastro-intestinal disease in the allergy clinic Hall 1 Chair: Michael Levin, South Africa OTE Lactose intolerance Kaija-Leena Kolho, Finland FODMAPS: Bacterial overgrowth and fermentable carbohydrates Heidi Staudacher, Australia Non-coeliac gluten sensitivity Marco Silano, Italy SYMPOSIUM (SYM 32) 10:30-12:00 Autoinflammation: From molecular mechanisms to new treatment strategies Hall 3a Chairs: Marek Jutel, Poland Grzegorz Woszczek, United Kingdom OTE Mechanisms leading to autoinflammatory diseases Lori Broderick, United States Clinical manifestations of autoinflammatory diseases Helen Lachmann, United Kingdom TUESDAY Diagnosis and management of recurrent fever syndromes Nienke ter Haar, The Netherlands SYMPOSIUM (SYM 33) 10:30-12:00 Real life data for allergy research Hall 3b Chairs: Margitta Worm, Germany Carsten Flohr, United Kingdom OTE Allergy registries across Europe: State of the art Christian Apfelbacher, Germany How to set up an international high quality registry? The TREatment of ATopic Eczema (TREAT) registry Phyllis Spuls, The Netherlands Routinely collected data for allergy research David Price, United Kingdom SYMPOSIUM (SYM 34) 10:30-12:00 New ways of coping with cat allergy Hall 3c Chairs: Marianne van Hage, Sweden Mübeccel Akdis, Switzerland OTE Epidemiology of allergy to cat and other pets Magnus Wickman, Sweden Allergen Immunotherapy in cat allergy patients: Skipping the molecule from extracts to peptides Mark Larché, Canada Change of concept: Vaccinating the cat Thomas Kündig, Switzerland 88

89 TUESDAY 20 JUNE 2017 SYMPOSIUM (SYM 35) 10:30-12:00 Asthma challenges in clinical practice Room 101 Chairs: Silvia Sanchez-Garcia, Spain Matteo Bonini, Italy OTE Inhaler devices: A critical step Sinthia Bosnic-Anticevich, Australia How can we improve asthma medication adherence? Kathy Hetherington, Ireland Ehealth coaches in asthma management Jacob Sont, The Netherlands WORKSHOP (WS 7) 10:30-12:00 Arrive early to guarantee your entry, limited spaces. Drug allergy anaphylaxis: Risk factors and management Room 208 Chairs: Werner Pichler, Switzerland Maria J. Torres, Spain Drug allergy as a co-factor of food allergy Victoria Cardona, Spain Mast cell disorders as risk factors of anaphylaxis Knut Brockow, Germany ACE inhibitors as risk factors Werner Aberer, Austria SISTER SOCIETY SYMPOSIUM (SSS 8) 10:30-12:00 Ga 2 len: Practical approach to phenotypes and endotypes in nasal inflammatory diseases Hall 3d TUESDAY Chairs: Torsten Zuberbier, Germany Jean Bousquet, France OTE From a concept to reality in nasal allergy G. Walter Canonica, Italy Epidemiologic evidence Claus Bachert, Belgium Clinical implications Peter Hellings, Belgium Remote monitoring of the concept Benoit Pugin, Belgium YEAR IN REVIEW (YIR 5) 10:30-12:00 Year in Review: Pediatrics Chairs: Montserrat Alvaro, Spain Olympia Tsilochristou, United Kingdom OTE Hall 5bc Natural history of food allergy: Lessons from birth cohort studies Kirsten Beyer, Germany Besides early introduction of foods, what else can prevent food allergy? Fish oil, probiotics, Vitamin D.? Cansin Sackesen, Turkey Oral immunotherapy for food allergy Robert Wood, United States 89

90 TUESDAY 20 JUNE 2017 HOT TOPIC (HT 4) 10:30-12:00 Nature: Friend or foe? Hall 3e Chairs: Antonella Muraro, Italy Paul Beggs, Australia OTE Microbiome Nanna Fyhrquist, Sweden Thunderstorm asthma Gennaro D Amato, Italy Indirect effects of climate changes on air pollution: A special look at the Mediterranean region Isabella Annesi-Maesano, France JUNIOR MEMBERS (JMS) JM CASE REPORT SESSION 10:30-12:00 JM Case Report Session Room 102 TUESDAY 1078 Acquired angioedema in a patient with adrenal insufficiency and marginal zone lymphoma: A challenging diagnosis and management Alice Corsi, SOD Immunologia Clinica, Università Politecnica delle Marche, Ancona, Italy 0914 The dark side of The poppaea S soap Matteo Martini, Allergy Unit, Department of Internal Medicine, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, Italy 1027 A unique presentation of pulmonary disease in advanced systemic mastocytosis, proven by the presence of mast cells in broncheoalveolar lavage. Maud Hermans, Erasmus MC, Rotterdam, Netherlands 0989 Dynamics of cytokines in exhaled breath condensate and serum in patients with bronchial asthma under the influence of l-arginine Sayyora Bazarova, Center of therapy, Tashkent, Uzbekistan 0629 Allergic keratoconjunctivitis treatment: experience with omalizumab Amyra Ali Azamar Jacome, Instituto Nacional de Pediatría, Ciudad De México, Mexico 0770 Anaphylaxis secondary to progesterone hypersensitivity successfully treated with omalizumab Rossella Intravaia, University of Catania - Respiratory Medicine and Allergology, Catania, Italy 1250 Omalizumab as adjuvant treatment during venom immunotherapy in mast cell disorders Paula Vázquez-Revuelta, Hospital Universitario Ramón y Cajal, Madrid, Spain 0924 Tropomyosin from vertebrates as an allergen case report Sara Peixoto, Pediatric Department of Centro Hospitalar de Trás-os-Montes e Alto Douro (CHTMAD),Vila Real, Portugal 1001 Delayed hypersensitivity reactions to beta-lactams in children: challenging diagnostic Joana Cosme, Immunoallergology Department, Hospital de Santa Maria Northern Lisbon Hospital Center, Lisbon, Portugal 1308 Angioedema attacks related to endometrial hyperplasia in a case of estrogen dependent FXII-hereditary angioedema Dasha Roa Medellín, Allergy Department. Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain ORAL ABSTRACT SESSION (OAS 24) 10:30-12:00 Allergens and immunotherapy Chairs: Jörg Kleine-Tebbe, Germany Ronald van Ree, The Netherlands Session roadmap: Jörg Kleine-Tebbe, Germany 0097 Development of novel class of rationally-designed hypoallergens: Bet V 1 variant for the specific immunotherapy of birch pollen allergy Pekka Mattila, Desentum Oy, Finland 0098 Minor allergens in birch pollen allergen products - insights into pollen and processing Julia Zimmer, Paul-Ehrlich-Institut, Germany Hall 3f 0099 ICH validation of the quantification of grass pollen and house dust mite major allergens by mass spectrometry Emmanuel Nony, Stallergenes Greer, France 0100 Improvement of symptoms and allergen tolerance in local allergic rhinitis patients treated with depigmented polymerized Phleum pratense extract immunotherapy, a double-blind placebo-controlled trial Carmen Rondon, Allergy Unit, IBIMA, Regional University Hospital of Malaga, UMA, Spain 90 Full abstract author lists are available on the official Congress website.

91 TUESDAY 20 JUNE Aluminium hydroxide impairs tolerogenic properties imprinted by allergoids conjugated to nonoxidized mannan in dendritic cells Cristina Benito-Villalvilla, Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Spain 0102 High correlation between validated Rhinoconjunctivitis Quality Of Life (RQLQ) and EAACI recommended Combined Symptom Medication Score (CSMS) as clinical outcome measure in allergen immunotherapy trial Oliver Pfaar, Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim Heidelberg University, and Center for Rhinology and Allergology, Germany ORAL ABSTRACT SESSION (OAS 25) 10:30-12:00 Innate immune response in mucosal tissues Hall 3g Chair: Liam O Mahony, Switzerland 0103 Differences in dendritic cell allergen sampling, migration and subsequent T cell differentiation separate induction of mucosal tolerance versus sensitisation Jonatan Leffler, Telethon Kids Institute, University of Western Australia, Australia 0104 Rhbdd3 controls innate inflammatory diseases via negatively regulating TLR signaling Juan Liu, National Key Laboratory of Medical Immunology, Institute of Immunology, Second Military Medical University, China 0105 Monocytes accumulate in the airways of children with fatal asthma Ibon Eguiluz Gracia Eguiluz Gracia, Allergy Department and Research Laboratory. Regional University Hospital of Malaga and Biomedical Research Institute of Malaga, Spain 0106 Differential expression of rna-binding proteins in airway epithelium in chronic lung inflammation Luca Ricciardi, Department of Medicine, Surgery and Dentistry Scuola Medica Salernitana, University of Salerno, Italy 0107 Systemic mastocytosis associates with cardiovascular events despite lower plasma lipid levels Paul L.A. Van Daele, Erasmus MC, The Netherlands TUESDAY 0108 RNA is the key element of the th1-promoting and allergyprotective activation of dendritic cells by the cowshed bacterium lactococcus lactis G121 Holger Heine, Research Center Borstel, Germany ORAL ABSTRACT SESSION (OAS 26) 10:30-12:00 Insights and advances in chronic urticaria Chairs: Clive Grattan, United Kingdom Carsten Bindslev-Jensen, Denmark Session roadmap: Clive Grattan, United Kingdom 0109 Chronic inducible urticaria (CIndU) in Europe, Central America, and South America: findings from visit 1 of the worldwide aware study Marcus Maurer, Department of Dermatology and Allergy, Allergie-Centrum-Charité/ECARF, Charité Universitätsmedizin, Germany 0110 Causal association between IgE anti-tpo and chronic urticaria. Jorge Sánchez, Group of Clinical and Experimental Allergy, University of Antioquia, Colombia Room 103a 0112 Can basophil histamine release assay predict response and time of response to omalizumab in chronic spontaneous urticaria? Kok Loong Ue, Guy s and St Thomas NHS Foundation Trust, United Kingdom 0113 Omalizumab improves angioedema-related quality of life impairment in chronic spontaneous urticaria patients: results from the X-ACT study Karsten Weller, Charité - Universitätsmedizin Berlin, Germany 0114 Exploring demographic and clinical differences among omalizumab responders and non-responders: Interim results from a 48-week, phase IV study of omalizumab in chronic idiopathic/spontaneous urticaria Thomas B Casale, University of South Florida, United States 0111 Chronic spontaneous/idiopathic urticaria patients with moderate activity have similar burden of disease as those with severe activity - results from the ASSURE-CSU study Alexander Marsland, Salford Royal Hospital & University of Manchester, United Kingdom 91

92 TUESDAY 20 JUNE 2017 POSTER DISCUSSION SESSION (PDS 21) 10:30-12:00 Immunotherapy: News from the clinic Poster Discussion Zone 1 TUESDAY Chairs: Roy Gerth van Wijk, The Netherlands Lone Winther, Denmark 0363 Characterisation of subjects clinical phenotypes in a paediatric asthma prevention (GAP) trial Erkka Valovirta, Department of Lung Disease and Clinical Allergology, University of Turku and Terveystalo Turku, Allergy Clinic, Finland 0364 Sustained reduction in risk of experiencing asthma symptoms and using asthma medication in years following grass SLIT-tablet treatment results from the paediatric GAP trial Adam Fox, Department of Paediatric Allergy, Guy s & St Thomas Hospitals NHS Foundation Trust, United Kingdom 0365 Clinical effect of intra-lymphatic immunotherapy: three years follow up from a double blind placebo controlled trail. Søren Helbo Skaarup, Department of respiratory medicine and allergy, Aarhus University Hospital, Denmark, Denmark 0366 Increased lcn2-levels after sublingual immunotherapy against house dust mites is associated with amelioration of symptoms. Franziska Roth-Walter, Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Austria 0367 Treatment-start early in life reduces the Number Needed to Treat (NNT) results from an Asthma Prevention (GAP) trial Susanne Halken, Hans Christian Andersen Children s Hospital, Odense University Hospital, Denmark 0368 Sublingual immunotherapy with a liquid birch pollen extract is similarly effective for younger and older patients with birch pollen induced allergic rhinitis/rhinoconjunctivitis Heleen Moed, HAL Allergy BV, Clinical Development & Pharmacovigilance department, The Netherlands 0369 The effect of grastek on birch pollen induced allergic rhinitis symptoms in dually sensitized grass and birch allergic patients a pilot evaluation utilizing controlled allergen challenge Anne K. Ellis, Queen s University, Canada 0370 A house dust mite SLIT-tablet reduces symptoms of house dust mite allergic rhinitis in adolescents pooled subgroup analysis of results from two DBPC trials Brian Sonne Stage, Global Clinical Development, ALK A/S, Denmark 0371 Clinical and immunologic characteristics of european patients screened for palisade (peanut allergy oral immunotherapy study of AR101 for desensitization in children and adults). Andrea Vereda, Aimmune Therapeutics, United States 0372 Efficacy of 300ir 5-grass pollen sublingual tablet: improvement in subjects with grass pollen-induced allergic rhinoconjunctivitis based on well days and severe days evaluation Detlef Brehmer, Private ENT Clinic Goettingen, Witten/ Herdecke University, Faculty of Medicine, Germany 0373 Predisposing factors of adverse events in subcutaneous allergen immunotherapy- results from a long-term observation Piotr Lacwik, Medical University of Lodz, Department of Internal Medicine, Asthma and Allergy, Poland 0374 Component-resolved diagnostics in cow s milk oral immunotherapy - long-term follow-up Tiina Kauppila, University of Helsinki, Skin and Allergy Hospital, Children s Hospital, Finland 0375 Allergen immunotherapy - Real life experience in a hospitalbased allergy clinic Ilan Asher, Kapaln Medical Center, Israel 0376 Metabolomic profiling of serum during allergy immunotherapy in asthmatic children Peiyan Zheng, Guangzhou Institute of Respiratory Diseases, China year-analysis of serious adverse reactions occurred with depigmented polymerized allergen immunotherapy in Germany Daniela Neumeyr, LETI Pharma GmbH, Germany POSTER DISCUSSION SESSION (PDS 22) 10:30-12:00 Mechanism and diagnosis of drug allergy Poster Discussion Zone 2 Chair: Cristobalina Mayorga, Spain 0378 Decreased surfactant protein D level in patients with aspirinexacerbated respiratory disease. Youngwoo Choi, Ajou University School of Medicine, South Korea 0379 What happens to basophils and mediators of tryptase, lxa4, and cyslt during aspirin desensitization? Gülfem Elif Çelik, Ankara University School of Medicine Department of Chest Diseases Division of Immunology and Allergy, Turkey 0380 Desensitization to acetylsalicylic acids in patients with SAPHO syndrome Rocio Candon Morillo, Hospital General Mancha Centro, Spain 92 Full abstract author lists are available on the official Congress website.

93 TUESDAY 20 JUNE Full course drug provocation tests to penicillins do we really need them? Filipa Matos Semedo, Hospital de São Bernardo, Centro Hospitalar de Setúbal E.P.E.; Faculdade de Ciências da Saúde, Universidade da Beira Interior, Portugal 0382 Do skin tests predict next perioperative allergic reaction after perioperative anaphylaxis? Ceyda Tunakan Dalgiç, Ege University Medical Faculty,Department of Allergy and Clinical Immunology, Turkey 0383 The utility of the basophil activation test in diagnosing sugammadex-induced anaphylaxis Tatsuo Horiuchi, Department of Anesthesiology, Gunma University Hospital, Japan 0384 Contribution of basophil activation test in diagnosis of hypersensitivity reactions to oxaliplatin Cristina Ornelas, Imunoallergology Department, Centro Hospitalar Lisboa Norte, Hospital Santa Maria, Portugal 0385 Retrospective analysis of ten cases of hypersensitivity to proton pump inhibitors Elleni Sofia Vaia, CHU Brugmann Immuno-Allergology Clinic, Belgium 0386 An unusual diagnosis in children: amoxicillin-induced multiple fixed eruption Leticia Herrero-Lifona, Hospital Quironsalud Campo de Gibraltar, Spain 0387 Hypersensitivity to non-steroid anti-inflammatory in Alicante, Spain Victor Soriano-Gomis, Allergy Section. General Hospital Alicante. ISABIAL, Spain 0388 Clinical features of 31 patients with dress syndrome Jaume Martí Garrido, Hospital Universitari i Politècnic La Fe, Spain 0389 SCARs in a district hospital Maria Isabel Mascarenhas, Hospital Beatriz Ângelo, Portugal POSTER DISCUSSION SESSION (PDS 23) 10:30-12:00 Rhinitis and rhinosinusitis Poster Discussion Zone 3 Chairs: Paloma Campo, Spain Michael Rudenko, United Kingdom 0390 Topical ciclosporin A 1 mg/ml cationic emulsion in the treatment of active severe vernal keratoconjunctivitis (VKC): results of the phase 3 vektis study Andrea Leonardi, Department of Neuroscience, Ophthalmology Unit, Italy 0391 Role of nasal nitric oxide in the diagnostic evaluation of rhinitis (EPONA study) Lorena Soto-Retes, Asthma and Allergy Unit, Pneumology Department, Hospital de la Santa Creu i Sant Pau, Spain 0392 Is nasal nitric oxide is always a good biomarker in allergic rhinitis? A. Fusun Kalpaklioglu, Kirikkale University Faculty of Medicine Department of Allergic Diseases, Turkey 0393 Taste dysfunction analysis of allergic rhinitis Jichao Sha, China-Japan Union Hospital of Jilin University, China 0394 What patients want from an allergic rhinitis treatment assessed by discrete choice experiment: Australia vs UK Peter Smith, Griffith University, Australia 0395 Suppressive activity of histamine H1 receptor antagonists, desloratadine and levocetirizine, on the production of periostin in vitro. Masayo Asano, Department of Otolaryngology, School of Medicine, Showa University, Japan 0396 Validation of an allergic rhinitis control test in teenagers Lisa Izquierdo, University of Montpellier, France 0397 Role of vitamin D and effect of montelukast in patients with asthma and seasonal alergic rhinitis in eastern India. Manuprita Sharma, ICARE Institute of Medical Sciences and Research, India 0398 Local allergic rhinitis in a mediterranean area population Javier Fernández, Allergy Section. General HospitaI Alicante. ISABIAL-UMH, Spain 0399 A new approach in treatment of allergic rhinitis without the use of corticosteroids and antihistamines - Three years experience with the nasal application of alpha-tocopherol acetate spray Juergen Lamprecht, University Duesseldorf, ENT, Germany year follow-up study of local allergic rhinitis Ana Prieto, Pediatric Unit, Regional University Hospital of Malaga., Malaga, Spain, Spain 0401 Extent of sinus involvement in patients with bilateral nasal polyposis (NP): baseline sinus ct scan results from a phase 2a study Claus Bachert, Ghent University Hospital, Belgium TUESDAY 93

94 TUESDAY 20 JUNE 2017 LATE BREAKING POSTER DISCUSSION SESSION (LB PDS 5) 10:30-12:00 Asthma in children and adults: Biomarkers, epidemiology and management Poster Discussion Zone Metabolic phenotyping of saliva and urine in children with atopic asthma Helena Pite, CUF Descobertas Hospital and CUF Infante Santo Hospital & CEDOC, Chronic Diseases Research Center, NOVA Medical School / Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Portugal 1506 The bone mineral density among children with asthma Vera A Revyakina, Federal Research Centre of Nutrition, Biotechnology and Food Safety, Russia 1507 Physical development of children and adolescents with bronchial asthma Vilya Bulgakova, National Scientific and Practical Center of Children s Health, Russia 1508 Correlative analysis between psychological characteristics and coping style amongst children Na Cui, China-Japan Unite Hospital of Jilin University, China 1511 Economic costs of severe asthma in patients treated with omalizumab - Fenoma study Paloma Campo, Hospital Regional Universitario Carlos Haya, Spain 1512 Asthma severity in nonsmoking asthmatics - Prevalence, clinical characteristics and risk factors Roxana Mincheva, Krefting Research Centre, University of Gothenburg, Sweden 1513 Impact of patient education on medication on health outcomes and adherence in patients with asthma Byoung Whui Choi, Chung-Ang University Hospital., South Korea 1514 Role of objective parameters in assessment of asthma control Melek Ergin, Abant Izzet Baysal University Medical School, Turkey TUESDAY 1509 Investigating the causal association of smoking with hay fever and asthma: a mendelian randomization meta-analysis in the CARTA consortium Allan Linneberg, The Capital Region of Denmark, Research Centre for Prevention and Health, Denmark 1510 Allergic sensitization patterns among asthma patients in the US National Health and Nutrition Examination Survey (NHANES) David Hinds, Real World Evidence & Epidemiology, GlaxoSmithKline, United States 1515 Do patients who develop cough within two weeks after initiation of angiotensin converting enzyme inhibitors have asthma? Insu Yilmaz, Erciyes University School of Medicine Department of Chest Dieseases, Division of Immunology and Allergy, Turkey 1516 Does world asthma day activity have an impact on the knowledge level of family physicians? Ilknur Bostanci, Healthy Science University, Dr Sami Ulus Maternity and Children Training & Research Hospital, Department of Pediatric Immunology and Allergy, Turkey BUSINESS MEETING (BM 16) 12:10-13:20 Immunology Section - Open to all attendees Hall 3d The role of dendritic cells in respiratory inflammation Hamida Hammad, Belgium BUSINESS MEETING (BM 17) 12:10-13:20 Asthma Section - Open to all attendees Hall 3e Phenotyping from a clinician s point of view Johann Christian Virchow, Germany BUSINESS MEETING (BM 18) 12:10-13:20 Dermatology Section - Open to all attendees Hall 3f What s cooking in Omalizumab treatment of urticaria and other diseases? Marta Ferrer, Spain 94 Full abstract author lists are available on the official Congress website.

95 TUESDAY 20 JUNE 2017 BUSINESS MEETING (BM 19) 12:10-13:20 ENT Section - Open to all attendees Hall 3g Pathogenic mechanisms in chronic rhinosinusitis Robert Schleimer, United States PRO & CON SESSION (PRO & CON 5) 12:15-12:45 Can a computer diagnose allergy? Pro & Con Arena Chair: Adnan Custovic, United Kingdom OTE Pro Lauri-Ann van der Poel, United Kingdom Con Bodo Niggemann, Germany PRO & CON SESSION (PRO & CON 6) 12:45-13:15 Immunotherapy can be performed in the community, not only in hospitals Pro & Con Arena Chair: Anthony Frew, United Kingdom OTE Pro Elizabeth Angier, United Kingdom Con Désirée Larenas-Linnemann, Mexico TUESDAY SYMPOSIUM (SYM 36) 13:30-15:00 Nutritional interventions for allergy prevention Hall 1 Chairs: Vanessa Garcia-Larsen, United Kingdom Katie Allen, Australia OTE Importance of dietary patterns vs single nutrients? Kate Grimshaw, United Kingdom Dietary modification of the gut microbiota Catarina Simoes, Portugal Immunomodulatory effect of nutrition Mairead Kiely, Ireland SYMPOSIUM (SYM 37) 13:30-15:00 House dust mite in asthma and allergic rhinitis Hall 5a Chairs: Sanna Toppila-Salmi, Finland Arne Høst, Denmark OTE How do house dust mite allergens induce allergy? Wayne Thomas, Australia Primary and secondary prevention of house dust mite allergy Adnan Custovic, United Kingdom Management of house dust mite allergy Ralph Mösges, Germany 95

96 TUESDAY 20 JUNE 2017 SYMPOSIUM (SYM 38) 13:30-15:00 Basophils in drug allergy diagnosis Hall 3c Chairs: Gülfem Çelik, Turkey Hans-Jürgen Hoffmann, Denmark OTE Can a basophil activation test beat provocations? Cristobalina Mayorga, Spain Which drugs can be used in a basophil activation test? Didier G. Ebo, Belgium What about old-fashioned histamine release? Bettina Margrethe Jensen, Denmark SYMPOSIUM (SYM 39) 13:30-15:00 Mast cell diseases: An update Hall 3e Chairs: Patrizia Bonadonna, Italy Peter Schmid-Grendelmeier, Switzerland OTE Comorbidities in mastocytosis Sigurd Broesby-Olsen, Denmark What s the difference(s) between acute and chronic urticaria Torsten Zuberbier, Germany TUESDAY MCAS: A new disease entity? Cem Akin, United States SYMPOSIUM (SYM 40) 13:30-15:00 Biologicals in daily practice of allergy treatment Room 101 Chairs: Sevim Bavbek, Turkey Onur Boyman, Switzerland OTE Beneficial effects of biologicals in allergy treatment Sevim Bavbek, Turkey Adverse effects and hypersensitivity to biologicals Alessandra Vultaggio, Italy New therapies and biosimilars Adam Chaker, Germany WORKSHOP (WS 8) 13:30-15:00 Arrive early to guarantee your entry, limited spaces. New immunological concepts in allergen-specific immunotherapy: Immune regulation beyond regulatory T cells? Room 208 Chairs: Edward Knol, The Netherlands Cezmi Akdis, Switzerland B cells (Bregs) and IgG4 antibodies in allergen-specific immunotherapy Hermelijn Smits, The Netherlands Regulatory T cells in allergen-specific immunotherapy Oscar Palomares, Spain 96 Full abstract author lists are available on the official Congress website.

97 TUESDAY 20 JUNE 2017 SPECIAL SESSIONS 13:30-15:00 Ethical aspects of food allergy: We are what we eat Chairs: Anthony Frew, United Kingdom Jacques Gayraud, France Ethicist discussant: Habib Chabane, France OTE Hall 3d Banning nuts on aircraft: Is it necessary and whose risk/interests predominate? Carsten Bindslev-Jensen, Denmark Restaurants and anaphylaxis Helen Smith, United Kingdom Milk products and allergy Susanne Lau, Germany Whose responsibility is it when we advise to reintroduce foods? Isabel Skypala, United Kingdom HOT TOPIC (HT 5) 13:30-15:00 Innovative intervention Hall 5bc Chairs: Luís Delgado, Portugal Lars K. Poulsen, Denmark Hypoallergenic interventions in food allergy Nikolaos Papadopoulos, Greece OTE Can we prevent contact allergy? Ana Giménez-Arnau, Spain Reducing exposure: Genetically modified allergen sources Karin Hoffmann-Sommergruber, Austria TUESDAY ORAL ABSTRACT SESSION (OAS 27) 13:30-15:00 Advances in hereditary angioedema Chairs: Marco Cicardi, Italy Anja Pahlow Mose, Denmark Session roadmap: Marco Cicardi, Italy 0115 Metabolomic analysis of contact system activation in plasma from patients with hereditary angioedema Dan J Sexton, Shire, United States 0116 Kallikrein-cleaved kininogen as a stable and specific biomarker for bradykinin release in hereditary angioedema Zonne Lm Hofman, University Medical Center Utrecht, The Netherlands 0117 Longitudinal natural history of patients with type I or II hereditary angioedema: data from the icatibant outcome survey Marcus Maurer, Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, Germany Hall 3b 0118 Immunogenicity profile of lanadelumab, a fully human monoclonal antibody plasma kallikrein inhibitor, for the prevention of angioedema attacks in patients with hereditary angioedema Marcus Maurer, Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité Universitätsmedizin Berlin, Germany 0119 Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of Hereditary Angioedema (HAE) attacks: First findings from the COMPACT extension study Hilary Longhurst, Barts Health NHS Trust, United Kingdom 0120 The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children Henriette Farkas, Hungarian Angioedema Center, 3rd Department of Internal Medicine, Semmelweis University, Hungary 97

98 TUESDAY 20 JUNE 2017 ORAL ABSTRACT SESSION (OAS 28) 13:30-15:00 Managing food allergy in children Chair: Montserrat Alvaro, Spain Session roadmap: Montserrat Alvaro, Spain 0121 Understanding predictors for severe allergies in pediatric food allergy natural history registry Jesse Alexander Blumenstock, Northwestern University, United States 0122 Amino acid-based formula including specific synbiotics modifies the gut microbiota and reduces clinical symptoms in non-ige mediated cow s milk allergic infants Louise J Michaelis, Great North Children s Hospital, United Kingdom Hall 3f 0123 Peanut epitope-specific IgE binding in the first 2 years of life can predict clinical peanut allergy Sampson A Sampson, Icahn School of Medicine at Mount Sinai, United States 0124 Peanut, tree-nut and sesame seed allergies: do children allergic to a nut or sesame seed need to avoid all nuts? Helen Annaruth Brough, King s College London, United Kingdom 0125 Long-time evolution of oral immunotherapy in highly sensitized milk allergy children María Del Carmen Lillo, Paediatric Allergy Department. Hospital Materno-Infantil Gregorio Marañón. Madrid, Spain 0126 Improved quality of life and less diet restrictions if CRD is used: simulation analysis in a prospective food allergy study among school children Barbara Mascialino, Thermo Fisher Scientific - ImmunoDiagnostics, Sweden TUESDAY ORAL ABSTRACT SESSION (OAS 29) 13:30-15:00 Asthma immunopathology/inflammation Hall 3g Chair: Inge Kortekaas Krohn, Belgium Session roadmap: Inge Kortekaas Krohn, Belgium 0127 Neutrophil extracellular traps are associated with asthma severity and neutrophilic phenotype Vanessa Granger, APHP, Hôpital Bichat, Immunologie, Paris, France/UMR996 - Inflammation Chimiokines et Immunopathologie, INSERM, Fac. de pharmacie - Univ.Paris- Sud, Université Paris-Saclay, France 0128 Type 1 interferon alpha (IFN-a) regulation by respiratory viruses in pediatric asthma Susetta Finotto, Department of Molecular Pneumology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Universitätsklinikum Erlangen, Germany 0130 Tgf-beta regulation and regulated anti-rhinovirus (RV) immune responses in asthma Susetta Finotto, Department of Molecular Pneumology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Universitätsklinikum Erlangen, Germany 0131 Dupilumab efficacy in severe asthma exacerbations by different baseline patient characteristics in patients with uncontrolled persistent asthma Leonardo M Fabbri, Università degli Studi di Modena e Reggio Emilia, Italy 0132 FoxP3+ regulatory B cells were higher in sputum and blood, but lower in bone marrow following whole lung allergen challenge in allergic asthmatics John-Paul Oliveria, McMaster University, Canada 0129 Increase of systmic and local regulatory B cells coincides with a shift in T cell subpopulations in and out of grass pollen season Ulrich M. Zissler, Center of Allergy and Environment (ZAUM), Technical University Munich and Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Germany 98 Full abstract author lists are available on the official Congress website.

99 TUESDAY 20 JUNE 2017 ORAL ABSTRACT SESSION (OAS 30) 13:30-15:00 Drug allergy: Diagnosis Chair: Werner Aberer, Austria Session roadmap: Werner Aberer, Austria 0139 Eicosanoid mediators levels in patients with NSAIDs-induced acute urticaria/angioedema José Antonio Cornejo-García, Research Laboratory, IBIMA, Regional University Hospital of Malaga, Spain 0140 Diagnostic value of T cell analysis of CD69 up regulation and in vitro release of interleukins in patients with nonimmediate hypersensitivity to amoxicillin Mihaela Zidarn, University Clinic of Pulmonary and Allergic Diseases, Slovenia 0141 Surveillance of severe cutaneous adverse reactions in Korea based on a nationwide registry Kyoung-Hee Sohn, Departement of Internal Medicine, Seoul National University College of Medicine, South Korea Room 103a 0142 Basophil activation using synthetic antigenic determinants for diagnosing immediate hypersensitivity to clavulanic acid Tahia Diana Fernandez, IBIMA-Regional University Hospital of Malaga-UMA, Spain 0143 Penicillin major and minor determinants: are they still relevant? Leonard Quok Chean Siew, Guy s and St Thomas NHS Foundation Trust, United Kingdom 0144 Drug provocation tests with beta-lactams in patients with nonimmediate reactions: comparison of two protocols Nicole Pinto, Immunoallergology Department, Hospital de Dona Estefânia, Centro Hospitalar de Lisboa Central, E.P.E., Portugal POSTER DISCUSSION SESSION (PDS 24) 13:30-15:00 Pediatric asthma Poster Discussion Zone The influence of polyvalent mechanical bacterial lysate on 0408 Respiratory virus infection and house dust mite sensitization clinical course of asthma in children may be associated with childhood asthma exacerbation in Andrzej Emeryk, Dept. of Paediatric Pneumonology and the fall: a single center study Rheumatology, Medical University, Poland Song-I Yang, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, South Korea 0403 Higher parental education reduced the risk of uncontrolled asthma 0409 Long-term follow-up outcomes of clinical remission and Emma Goksör, Department of pediatrics, Institution of Clinical pulmonary function following early anti-inflammatory therapy Sciences, University of Gothenburg, Queen Silvia Children s for asthma in children under 2 years old hospital, Sweden Masanori Ikeda, Department of Pediatric Acute Medicine, Okayama University Graduate School of Medicine, Dentistry 0404 Adolescent asthma in relation to severity and gender data and Pharmaceutical Sciences, Japan from a prospective population based cohort study Maria Ödling, Department of Clinical Science and Education, 0410 Values of fractional exhaled nitric oxide in diagnosis and Södersjukhuset, Karolinska Institutet, Sweden treatment of children with chronic cough Wujun Jiang, Children s Hospital of Soochow University, China 0405 New approach shows no clear relation of maternal milk Ffatty acid composition to childhood wheeze or asthma 0411 Real-time biofeedback and target minute ventilation in Jon Genuneit, Institute of Epidemiology and Medical Biometry, eucapnic voluntary hyperventilation test in children aged 10- Ulm University, Germany 16 years Janne Burman, Skin and Allergy Hospital, Department of 0406 Sensitization to house dust mites as a risk factor for asthma pediatrics, Finland exacerbation in the fall Beom Joon Kim, College of Medicine, The Catholic University 0412 Evaluation of reversibility with classical spirometry and of Korea, South Korea impluse oscilometry in children with atopic asthma Ozge Yilmaz, Celal Bayar University Medical Faculty, Dept. of 0407 Human rhinovirus is the major cause of asthma exacerbation Pediatric Allergy and Pulmonology, Turkey and acute lower respiratory tract infections among hospitalized children in Hong Kong 0413 Computer bronchophonography - frequency analysis of the Ting Fan Leung, Department of Paediatrics, The Chinese respiratory cycle. University of Hong Kong, Hong Kong SAR Anita Robertovna Denisova, I.M. Sechenov First Moscow State Medical University, Russia TUESDAY 99

100 TUESDAY 20 JUNE 2017 POSTER DISCUSSION SESSION (PDS 25) 13:30-15:00 Infection and allergy Poster Discussion Zone 2 TUESDAY Chair: Wojciech Feleszko, Poland 0414 House dust mite and ascaris IgE sensitization in a birth cohort from the tropics: Follow-up to 6 years in the FRAAT study Velky Ahumada, Institute for Immunological Research, University of Cartagena, Colombia 0415 Synthetic cationic peptides with linear helical and dendrimeric structures effectively reduce respiratory virus infection in vitro Mariia S Sundukova, National Research Center - Institute of Immunology, FMBA of Russia, Russia 0416 Human neutrophils process and present antigens to cd4+ T cells Dominika Polak, Medical University of Vienna, Austria 0417 IL-33 demonstrate strong upregulation in asthmatics with respiratory virus infections Igor Petrovich Shilovskiy, National Research Center - Institute of Immunology, FMBA of Russia, Russia 0418 Staphylococcus aureus accelerates inflammation on the asthmatic patient s primary epithelial cells. Mi Kyung Park, Division of Allergy and chronic Respiratory Diseases, Center for Biomedical Sciences, Korea National Institute of Health, Korea Center for Disease Control and prevention, South Korea 0419 Immuno-clinical investigation of IgE-mediated cross reactivity of major nosocomial fungal allergens: a serious health hazard in Barasat District Hospital Mouli Saha, Basirhat College, India 0422 Human umbilical cord derived mesenchymal stem cells decreased T helper 17 immune response in skin draining lymph node of atopic dermatitis-like skin lesions induced by aspergillus fumigatus Sungsu Jung, Department of Pediatrics, Asan Medical Center, University of Ulsan, College of Medicine, South Korea 0423 A comparative in vitro nasal model for rhinovirus infection: a model for understanding rhinovirus immune activation in the nasal epithelium Hsiao Hui Ong, Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 0424 Allergy development during the first 10 years of life in a Swedish prospective birth cohort is preceded by a lack of early lactobacilli-colonization and a skewed plasma chemokine-profile Sophia Björkander, Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Sweden 0425 Targeting CD151 reduces severity of influenza a virus infection by promoting innate immune system and interrupting viral proteins nuclear export Yongkang Qiao, National University of Singapore, Singapore 0426 In vitro human nasal epithelial cells model as a complementary model for population level transcriptomic profiling of emerging respiratory infectious disease Kai Sen Tan, Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 0420 Interleukin-37 expression is up-regulated in peripheral blood mononuclear cells from patients with virus induced asthma exacerbation Alina R Gaisina, National Research Center - Institute of Immunology, Russia 0421 Gut microbiota development in healthy and allergic children: a prospective study from infancy to school age Christina E West, Clinical Sciences, Pediatrics, Sweden 0427 Short interfering ribonucleic acids targeted to interleukin-33 decrease airway hyperresponsiveness and lung inflammation in a mouse model of virus induced asthma exacerbation Valerii Valerievich Smirnov, National Research Center - Institute of Immunology, Russia POSTER DISCUSSION SESSION (PDS 26) 13:30-15:00 Atopic dermatitis and other inflammatory skin conditions Poster Discussion Zone Yogurt culture lactobacilus delbrueckii subsp. Bulgaricus modulates the secretion of Th1/Th2 and treg cell-related cytokines by PBMCs from patients with atopic dermatitis Abdolkarim Sheikhi, Department of Immunology, Dezful University of Medical Sciences, Iran 0429 Associations between fetal ultrasound-based anthropometrics and atopic dermatitis by age 3: results of the Ulm SPATZ health study. Jon Genuneit, Institute of Epidemiology and Medical Biometry, Ulm University, Germany 0430 Zonulin, the physiological protein to regulate intercellular tight junctions of epithelial cells, is closely associated with disease severity in children with atopic dermatitis Joo Young Song, CHA University, South Korea 0431 Eosinophil derived neurotoxin as a bio-marker of disease severity in severe atopic dermatitis Jin-Tack Kim, Department of Pediatrics, South Korea Full abstract author lists are available on the official Congress website.

101 TUESDAY 20 JUNE Distinctive clinical response to lactobacillus plantarum CJLP133 in children with atopic dermatitis Jihyun Kim, Samsung Medical Center, South Korea 0433 The use of the online patient portal for atopic dermatitis patients in daily practice; characteristics of portal users and non-users Lieneke Francis Marleen Ariens, UMC Utrecht, The Netherlands 0434 Dietary intervention with a synbiotic mixture of scgos/ lcfos with bifidobacterium breve M-16V in infants with atopic dermatitis shows beneficial immunological changes in chemokine profiles Lies Hulshof, Emma Children s Hospital Academic Medical Center, Department of Pediatric Respiratory Medicine and Allergy, The Netherlands 0435 Metal sequestering dermal cream exhibits beneficial effects in patients with dyshidrotic eczema associated with nickel induced allergic contact dermatitis - a pilot study Malena Gergovska, Medical University, Bulgaria 0437 Emollient therapy alters barrier function and skin microbes in infants at risk for developing atopic dermatitis Martin Glatz, Dermatology Branch, Center for Cancer Research, NCI, NIH, United States 0438 Preliminary blinded study on the use of emollient products and detergents based on Sacha Inchi oil, in children affected by mild-moderate atopic dermatitis Sonia Musumeci, Pediatric Allergology, Hospital San Pietro Fatebenefratelli, Italy 0439 Long-term treatment with low-dose medicine in chronic childhood eczema. A double-blind two-stage randomized control trial Rossella Carello, Department of Pediatric Allergy, San Pietro Hospital Fatebenefratelli,, Italy 0440 The overnight use of a temperature-controlled laminar airflow (TLA) device has sustained benefit for children with severe eczema Claudia Gore, Imperial College Healthcare NHS Trust, United Kingdom 0436 Optimized growth conditions for malassezia Spp. improves research on its role in atopic dermatitis Martin Glatz, Allergy Unit, Department of Dermatology, University and University Hospital of Zurich, Switzerland 0441 Treatment of chronic spontaneous urticaria and angioedema with 5 aminosalicylate Colin Mackenzie Barber, University of Manitoba, Canada TUESDAY POSTER DISCUSSION SESSION (PDS 27) 13:30-15:00 Translational approaches to food allergy Poster Discussion Zone Tolerogenic mechanisms elicted by extensively hydrolysed casein formula with L. Rhamnosus GG Lorella Paparo, University of Naples Federico II, Italy 0443 MicroRNA-sequencing in a mouse model of peanut sensitized mice treated by EPIT identifies early changes in microrna expression influencing T-cell plasticity and Th2 cytokine production Jorg Tost, CEA-IG, CNG, France 0444 Receptor mediated uptake of peanut proteins in dendritic cells. Joost J Smit, IRAS, Utrecht University, The Netherlands 0445 Sensitising capacity of unmodified and acid hydrolysed gluten through the skin a comparative study in naïve versus tolerant brown norway rats Anne-Sofie R. Ballegaard, National Food Institute, Technical University of Denmark, Denmark 0446 Proteomic analysis of food allergen transport into the bloodstream in a mouse model Philip Johnson, University of Nebraska, United States 0447 IgA to cow s milk differs between breast milk and serum for its epitope specificity Antti E Seppo, University of Rochester Medical Center, United States 0448 Diverse effects of thermal processing on walnut proteins Jeongmin Lee, Department of Pediatrics, Ajou University School of Medicine (Department of pediatrics, Yonsei university Wonju college of medicine), South Korea 0449 Thermal processing effects on cashew and pistachio allergenicity Beatriz Cabanillas, Department of Dermatology and Allergy, University of Bonn Medical Center, Germany 0450 Evaluation of gut microbiota and fecal butyrate concentration in children affected by non-ige-mediated cow s milk allergy Rita Nocerino, University of Naples Federico II, Italy 0451 Non-digestible oligosaccharides can influence IgE-mediated basophil degranulation in whole blood of peanut allergic patients S. M. Hayen, UMC Utrecht, The Netherlands 0452 Combined exposure of intestinal epithelial cells to the dietary oligosaccharide mixture ScFOS/LcFOS and CpG DNA enhances the Th1 and regulatory IL-10 response in an allergen-specific co-culture model S. M. Hayen, UMC Utrecht, The Netherlands 0453 Severe pollen-mediated food reactions correlate with oral mucosa integrity and effector cell sensitivity. Domenico Rosace, Institute of Applied Molecular Medicine (IMMA), San Pablo CEU University, Spain 101

102 TUESDAY 20 JUNE Tree nut responsive IL-5+ Th cells dominate in allergic and asymptomatically sensitized but not in non-sensitized tolerant subjects Lars Heede Blom, 1. Department of Dermatology and Allergy, Allergy Clinic, Denmark 0455 Correlation of the allergenicity and tolerogenicity of two cow s milk protein products with intestinal uptake Katrine B. Graversen, National Food Institute, Technical University of Denmark, Denmark 0456 Enumeration of regulatory T cells in esophageal tissue of patients with eosinophilic esophagitis in comparison to patients with gastroesophageal reflux disease and control group. Fatemahsadat Mousavinasab, Shahid Beheshti University of Medical Science, Iran SYMPOSIUM (SYM 41) 15:30-17:00 Interventional studies for the prevention of food allergy Hall 1 Chairs: Kate Grimshaw, United Kingdom Susanne Halken, Denmark OTE Single food interventions Johanna Bellach, Germany Multiple food interventions Michael Perkin, United Kingdom Integration in clinical practice Sasha Watkins, South Africa TUESDAY SYMPOSIUM (SYM 42) 15:30-17:00 Novel insights in virus induced bronchiolitis and asthma Hall 5bc Chair: William Busse, United States OTE Short- and long-term outcomes of virus induced early wheeze Tuomas Jartti, Finland Virus-epithelial cell interactions in pulmonary immune regulation Irene Heijink, The Netherlands Epigenetic modulation of DC function in RSV infection Nick Lukacs, United States SYMPOSIUM (SYM 43) 15:30-17:00 Properties of allergens that account for sensitisation, cross reactivity and severity Hall 5a Chair: Jeroen Titus Buters, Germany OTE LTP as a primary sensitiser Maria Montserrat Fernandez-Rivas, Spain Cross reactivity patterns and their clinical relevance Marianne van Hage, Sweden Structural and biological evidence for good and bad allergens Rudolf Valenta, Austria SYMPOSIUM (SYM 44) 15:30-17:00 Primary immune deficiency and allergy: What is the relationship? Hall 3a OTE Hyper IgE syndromes Ellen Renner, Germany Treg cell deficiencies and IPEX (immunodysregulation polyendocrinopathy enteropathy X-linked syndrome) Eleonora Gambineri, Italy Impaired DNA demethylation in primary immunodeficiencies Esteban Ballestar, Spain Full abstract author lists are available on the official Congress website.

103 TUESDAY 20 JUNE 2017 SYMPOSIUM (SYM 45) 15:30-17:00 National Allergy Societies Forum Hall 3b Chair: Thomas Werfel, Germany OTE Development of the allergy and asthma programs over the past decade in Kazakhstan Zhannat Ispayeva, Kazakhstan Towards recognition of full speciality status for allergology in France Jean-Luc Fauquert, France Promoting allergy centres and the allergy specialty by the Danish Society of Allergology Lone Winther, Denmark WORKSHOP (WS 9) 15:30-17:00 Arrive early to guarantee your entry, limited spaces. When the athlete knocks on your door: Hints for optimal management? Room 208 Chairs: Stefano Del Giacco, Italy Marcin Kurowski, Poland Assessing bronchial hyperreactivity: What can we learn from studies in athletes? Kai-Håkon Carlsen, Norway Targeting symptoms and inflammation of exercise induced bronchoconstriction: Is there a rationale for anticholinergics and cromones? Pascale Kippelen, United Kingdom TUESDAY Allergen immunotherapy in recreational athletes Matteo Bonini, Italy SISTER SOCIETY SYMPOSIUM (SSS 9) 15:30-17:00 GARD: Tackling allergies and chronic respiratory diseases in low income countries Hall 3c Chairs: Nikolai Khaltaev, Switzerland José Rosado Pinto, Portugal OTE Allergic conditions in the new international classification of diseases (ICD) Moisés Calderón, United Kingdom Poverty as a risk factor for asthma and poor outcomes Arzu Yorgancioglu, Turkey Management of Asthma-COPD Overlap in the real world Alvaro Cruz, Brazil Improving lung health: GARD projects Nils E. Billo, Switzerland YEAR IN REVIEW (YIR 6) 15:30-17:00 Year in Review: Dermatology Room 101 Chairs: Radoslaw Spiewak, Poland Clive Grattan, United Kingdom OTE Urticaria Marcus Maurer, Germany Contact dermatitis Tove Agner, Denmark Atopic dermatitis Marjolein Saskia de Bruin-Weller, The Netherlands 103

104 TUESDAY 20 JUNE 2017 ORAL ABSTRACT SESSION (OAS 31) 15:30-17:00 Cellular and molecular diagnostic techniques Chairs: Paolo Matricardi, Germany Bettina Margrethe Jensen, Denmark Session roadmap: Paolo Matricardi, Germany 0145 Generation of enriched mature basophil cultures from CD34+ haematopoietic stem cells highly responsive to allergen stimulation upon sensitization Jiakai Wu, University of Manchester, United Kingdom 0146 Recombinant basophil activation test and fingerprint modeling of allergenic activity Mira Šilar, University Clinic of Respiratory and Allergic Diseases Golnik, Slovenia Hall 3d 0147 Dipeptidyl peptidase I is stored in secretory granules and released on mast cell activation Rana Abadalkareem, United Kingdom 0148 Specific ige to alpha-gal in cow s milk allergic children: prevalence, quantification and relationship with meat allergy Caroline Klingebiel, France 0149 IgE against 2S albumin Ara h 7 has a diagnostic value comparable to Ara h 2 and 6 Mark Alexander Blankestijn, The Netherlands 0150 Introducing a multiplex IgE diagnostic test, a new nanobead-based tool for allergy diagnosis: reporting on IgE reactivity of single allergen preparations and reproducibility performances Adriano Mari, CAAM - Centri Associati di Allergologia Molecolare, Italy TUESDAY ORAL ABSTRACT SESSION (OAS 32) 15:30-17:00 AIT in children and adults Hall 3e Chairs: Graham Roberts, United Kingdom 0153 Real-world treatment pattern from a French cohort study Hanneke Oude-Elberink, The Netherlands Patrick Blin, Université de Bordeaux, Bordeaux PharmacoEpi Session roadmap: INSERM CIC Bordeaux CIC1401, ADERA, France Graham Roberts, United Kingdom 0154 Health related quality of life among children and adolescents 0151 Subcutaneous allergen immunotherapy evaluation in a treated with allergen immunotherapy (AIT) pediatric population Camilla Söderqvist Elinder, Sachs children an youths hospital, Cátia Alves, Immunoallergology Department, Hospital D. Södersjukhuset, Sweden Estefânia, CHLC, Portugal 0155 House dust mite SLIT-tablet is well tolerated in patients with 0152 A grass SLIT-tablet is well tolerated in the paediatric house dust mite respiratory allergic disease population Waltraud Emminger, Allergy Outpatient Clinic, Rennweg, Erkka Valovirta, Department of Lung Disease and Clinical Austria Allergology, University of Turku and Terveystalo Allergy Clinic, 0156 Intralymphatic immunotherapy (ilit) with both grass and birch Finland allergen- a randomized double-blind placebo controlled trial Eric Hjalmarsson, Karolinska Institutet, Sweden LATE BREAKING ORAL ABSTRACT SESSION (LB OAS 3) 15:30-17:00 Anaphylaxis, venom and drug allergy: From diagnosis to treatment Hall 3f 1431 Statistical Validation of International Consensus Equation for Acute Serum Trytase in Mast Cell Activation in Suspected Perioperative Anaphylaxis Richard Lawrence Baretto, Heart of England NHS Foundation Trust, United Kingdom 1432 CCL2 measurement in sera as a novel biomarker of anaphylaxis Romana Vantur, University Hospital of Respiratory and Allergic Diseases Golnik, Slovenia 1433 Recombinant phospholipase A1 from polybia paulista (hymenoptera: vespidae) for specific diagnosis and immunotherapy of venom allergy Amilcar Perez-Riverol, Department of Biology, Institute of Biosciences. University of Sao Paulo State (UNESP), Brazil 1434 Oral dissolvable film containing dexamethasone: a promising novel alternative to tablets for rescue applications in allergy Zuzana Diamant, Dept of Respiratory Medicine & Allergology, Institute for Clinical Science, Skåne University Hospital, Sweden Full abstract author lists are available on the official Congress website.

105 TUESDAY 20 JUNE Survey on the proper use of an adrenaline auto-injector in 551 Japanese outdoor workers after hymenoptera stings Naruo Yoshida, Dokkyo Medical University Koshigaya Hospital, Japan 1436 The current state of follow up care in patients with a history of hymenoptera venom anaphylaxis in southwest germany Sabine Müller, Department of Dermatology, Allergy Research Group, Medical Center University of Freiburg, Germany LATE BREAKING ORAL ABSTRACT SESSION (LB OAS 4) 15:30-17:00 Food allergy - diagnosis and management Room 103a 1437 Characterization of the differential IgE-binding features of lupinus angustifolius recombinant major allergen (Lup An 1) for potential uses in sweet lupin allergy diagnosis and therapy Jose C. Jimenez-Lopez, Spanish National Research Council (CSIC), Estacion Experimental del Zaidin, Dept. Biochemistry, Cell & Molecular Biology of Plants; and The UWA Institute of Agriculture, The University of Western Australia, Spain 1438 Mast cell activation test distinguishes between sensitisation and clinical reactivity with improved diagnostic characteristics compared to other diagnostic techniques including basophil activation Paul J Turner, Imperial College London, United Kingdom 1439 Immunological response to peanut oral immunotherapy - Results of a randomized, placebo-controlled trial Valérie Trendelenburg, Department of Pediatric Pneumology and Immunology, Charité Universitätsmedizin Berlin, Germany 1440 Short beta-lactoglobulin-derived peptides loaded in PLGA nanoparticles for the prevention of cow s milk allergy Atanaska I. Kostadinova, Utrecht University and Nutricia Research, The Netherlands 1441 Efficacy, safety and quality of life in a multi-center, randomized, placebo-controlled trial on peanut oral immunotherapy in peanut allergic children Katharina Blumchen, Department of Paediatric and Adolescent Medicine, Paediatric Allergology, Pulmonology and Cystic Fibrosis, University Hospital Frankfurt, Germany 1442 Feasibility of desensitising children with severe peanut allergy by OIT. Tonje Reier-Nilsen, Division of Paediatrics and Adolescent Medicine, Norway TUESDAY BUSINESS MEETING (BM 20) 15:30-17:00 Patients Organisations Committee - Open to all attendees Room 102 Food Products And Undeclared Allergens Causing Accidental Allergic Reactions In Daily Life Marty Blom, The Netherlands POSTER DISCUSSION SESSION (PDS 28) 15:30-17:00 Biologicals in respiratory and cutaneous diseases Poster Discussion Zone 1 Chairs: Sevim Bavbek, Turkey Alexia Chatzipetrou, Greece 0457 Could anti-cd38 (daratumumab) be used in the management of severe allergic diseases? Mark Alexander Blankestijn, University Medical Center Utrecht, The Netherlands 0458 Home self-administration of omalizumab for chronic spontaneous urticaria Tariq El-Shanawany, University Hospital of Wales, United Kingdom 0459 Omalizumab for the treatment of chronic idiopathic/ spontaneous urticaria in children Riccardo Castagnoli, Clinica Pediatrica - Policlinico San Matteo - Università degli studi di Pavia, Italy 0460 Mepolizumab: anti-asthmatic but not anti-allergic? Karl-Christian Bergmann, Allergy-Centre-Charité, Charité- Universitätsmedizin Berlin, Germany 0461 Hyperamylasemia among patients treated with omalizumab Gul Karakaya, Hacettepe University School of Medicine, Department of Chest Disease, Division of Allergy and Clinical Immunulogy, Turkey 0462 Omalizumab, lights and shadows of our experience Veronica Lopez Couso, Hospital Univesitario Puerta de Hierro, Spain 0463 Omalizumab treated patients experience good subjective effect on symptoms and quality of life- results from a nurse initiated real-life interview investigation Lene Mølgaard Pedersen, Department of Respiratory Medicine and Allergy, Aarhus University Hospital, Denmark 0464 Distance to treatment centre has an impact on number of patients treated with omalizumab results from a nurse initiated real-life cohort study. Anne Devantier, Department of Respiratory Medicine and Allergy, Aarhus University Hospital, Denmark 105

106 TUESDAY 20 JUNE Phenotypic characterization of severe atopic asthma patients treated with mepolizumab Charlene M Prazma, GlaxoSmithKline, United States 0466 Phenotypic characterization of severe OCS-dependent atopic asthma patients treated with mepolizumab Charlene M Prazma, GlaxoSmithKline, United States 0467 IgG4 production against infliximab in treated patients Alessandra Vultaggio, Immunoallergology Unit, Department of Biomedicine, Careggi Hospital, Italy 0468 Omalizumab retreatment of patients with chronic idiopathic urticaria / chronic spontaneous urticaria following return of symptoms: Primary results of the optima study Gordon Sussman, Department of Medicine, University of Toronto, Canada 0469 Omalizumab administration in non-atopic chronic spontaneous urticaria patients prevents respiratory illnesses George N Konstantinou, Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Greece 0469A Omalizumab prevents anaphylaxis and improves symptoms and quality of life in systemic mastocytosis Sigurd Broesby-Olsen, Odense University Hospital, Odense, Denmark POSTER DISCUSSION SESSION (PDS 29) 15:30-17:00 Functional genomics and proteomics Poster Discussion Zone 2 TUESDAY Chairs: Cornelis van Drunen, The Netherlands Claudio Rhyner, Switzerland 0470 Molecular fingerprinting of complex grass allergoids: size assessments reveal new insights in epitope repertoires and functional capacities Sviatlana Starchenka, Allergy Therapeutics, United Kingdom 0471 Liposomes modified by carbohydrates for targeted sirna delivery into the liver cells Olesya Koloskova, NRC Institute of Immunology FMBA and Moscow Technological University (campus MITHT), Russia 0472 Sialylated fetuin-a is a candidate predictive biomarker for successful grass pollen allergen immunotherapy Vincent Lombardi, Stallergenes Greer, France 0473 Cytogenetic analysis of tumor cultures for preparation of personified antitumor vaccines against bladder cancer Tatiana Slavyanskaya, RUDN University, Russia 0474 M1 and M2 macrophage gene methylation profiles in patients with kawasaki disease Mindy Ming-Huey Guo, Kaohsiung Chang Gung Memorial Hospital, Taiwan 0475 Genome-wide identification of allergic rhinitis-related gene networks using blood transcriptomics in a tropical urban environment Anand Kumar Andiappan, Singapore Immunology Network (SIgN),Agency for Science, Technology and Research, Singapore 0476 Unique transcriptomic signature of allergen-specific CD4 T cells and regulatory T cells during allergen-specific immunotherapy Milena Sokolowska, Swiss Institute of Asthma and Allergy Research, University of Zurich, Switzerland 0477 The relationship between genetic polymorphisms of Beta2 adrenergic receptors And efficiency of the broncholytic therapy among russian children with bronchial asthma Vilya Bulgakova, National Scientific and Practical Center of Children s Health, Russia 0478 Multi-approach analysis for the identification of proteases within birch pollen Olivia Eve Mckenna, Universität Salzburg, Austria POSTER DISCUSSION SESSION (PDS 30) 15:30-17:00 Food allergy: Supporting patients from bench to bedside Poster Discussion Zone 3 Chair: Elide Pastorello, Italy 0490 Frequency and causes of reintroduction failure after negative food challenge in adults Astrid Versluis, University Medical Center Utrecht, The Netherlands 0491 Development and validation of a novel multiplex immunoassay for the simultaneous quantification of food allergen proteins Maria Oliver, Indoor Biotechnologies Ltd, United Kingdom 0492 Clinical and immunological evolution of patients who failed milk-oral immunotherapy Estefania Vasquez-Echeverri, 1 Hospital Infantil Universitario Niño Jesús, 2 Grupo de Inmunodeficiencias Primarias. Facultad de medicina. Universidad de Antioquia., Spain 0493 Recombinant fish parvalbumin Gad c 1 as a prognostic marker of fish allergy João Marcelino, Immunoallergology Department, Santa Maria Hospital, Centro Hospitalar Lisboa Norte, Portugal 0494 Development of a web-based educative intervention for schools and restaurants: Food allergy community program (FAC Program) Ines Padua, Faculty of Nutrition and Food Sciences, University of Porto, Portugal 0495 Development of parallel reaction monitoring (PRM) methods for soy and milk detection: consideration of allergen-derived ingredients Melanie Downs, University of Nebraska-Lincoln, United States Full abstract author lists are available on the official Congress website.

107 TUESDAY 20 JUNE Milk ingestion in daily diet after OIT in cma patients Alice Toniolo, Food Allergy Referral Centre, Veneto Region, University Hospital of Padua, Department of Women and Child Health, Italy 0497 Frozen-defrosted dried skimmed milk is a suitable product for sublingual immunotherapy for cow s milk allergy Marta Vazquez-Ortiz, Imperial College London, United Kingdom 0498 Randomized controlled trial of the efficacy of low dose ingestion of egg in children with egg allergy aged less than 36 months Mayu Shimizu, Showa University School of Medicine, Japan 0499 Another brick in the wall: toward a national food allergy strategy for canada Susan J Elliott, University of Waterloo, Canada 0500 Component resolved diagnostics reduces diet restrictions by half among Finnish school children Johannes Savolainen, University of Turku, Finland 0501 Omalizumab treatment for severe food allergy caused by lipid transfer protein: a preliminary case series Adriano Mari, CAAM - Centri Associati di Allergologia Molecolare, Italy 0502 Oral immunotherapy with peach-juice in lipid transfer protein (LTP) allergy: is it possible to reach tolerance? Eladia Alarcon Gallardo, Servei d Allergia. Hospital Universitari Dexeus. Grupo Quirón Salud. UAB., Spain POSTER DISCUSSION SESSION (PDS 31) 15:30-17:00 Innovative allergy diagnostics Poster Discussion Zone Molecular allergy diagnostics refines the characterization of children allergic to dog Ulrika Käck, Dep of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden 0504 Sensitisation to Fel d 2, 4 and 7 is associated with type-2 inflammation in young asthmatics Nikolaos Tsolakis, Uppsala University, Women s and Children s Health, Sweden 0505 Complete sequence and recombinant production of horse dander allergen Equ c 2 Jonas Lidholm, Thermo Fisher Scientific, Sweden 0506 Component resolved diagnosis using guinea-pig allergens elucidates allergen sensitization profiles in allergy to furry animals Kyra Swiontek, Luxembourg Institute of Health, Luxembourg 0507 Characterization of a major allergen from mongolian oak, quercus mongolica, a dominant species of oak in Korea Kyoung Yong Jeong, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, South Korea 0508 Sensitization to the pollen of different olive tree cultivars in a group of Portuguese patients Ruben Duarte Ferreira, Immunoallergology Department, Northern Lisbon Hospital Centre, Portugal 0509 Structural and immunological comparison of heat treated pru p 3 and art v 3, the non-specific lipid transfer proteins of peach and mugwort pollen Sabrina Wildner, Christian Doppler Laboratory for Innovative Tools for the Characterization of Biosimilars, University of Salzburg, Austria 0511 IgG, IgE and IgG4 specific antibodies to molecular allergens of aspergillus fumigatus Thomas Romain, Assistance Publique Hôpitaux de Marseille, Hôpital de La Conception, Laboratoire d Immunologie, France 0512 Personalized and rapid food allergy test using natural allergenic extracts Mikaël Frossard, Laboratoire d Électrochimie Physique et Analytique, EPFL Valais Wallis, École Polytechnique Fédérale de Lausanne, Switzerland 0513 Prediction of atopy at 6 years of age by cord blood IgE Fang-Yu Chang, Department of Pediatrics, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taiwan 0514 Alternative method in allergy diagnosis by thermographic imaging Artemii Bogomolov, Vinnitsa national Pirogov memorial medical university, Ukraine 0515 Basophil activation test (BAT) as a measure of passive sensitization following plasma transfusion Kjetil Børve Lund, Haukeland University Hospital, Norway 0516 Evaluation and validation of a salivary interleukin-3 immunosorbent assay for the evaluation of chronic urticaria exacerbated by a salicylate rich diet Eulitty Gumunyu, University Hospital Southampton, United Kingdom 0517 Allergorithm: allergy algorithm to increase pre-test probability of allergic disease Snjezana Kos, Maasstad Hospital, The Netherlands TUESDAY 0510 Blo t 5-der p 2 hybrid molecule allows detecting most of house dust mite allergic patients. Leonardo Puerta, Institute for Immunological Research, University of Cartagena, Colombia 107

108 TUESDAY 20 JUNE 2017 BUSINESS MEETING (BM 21) 17:30-18:40 IG Infections and Allergy - Open to all attendees Room 102 Respiratory viral infections and asthma: A devastating combination? Chrysanthi Skevaki, Germany BUSINESS MEETING (BM 22) 17:30-18:40 IG Comparative and Veterinary Allergology - Open to all attendees Room 103b Comparing immediate type food allergy in humans and companion animals definition of knowledge gaps Isabella Pali-Schöll, Austria BUSINESS MEETING (BM 23) 17:30-18:40 IG OMICS and Systems Medicine - Open to all attendees Room 201 Single-cell RNA-seq and computational analysis using temporal mixture modelling resolves Th1/Tfh fate bifurcation in malaria Tapio Lonnberg, Finland TUESDAY BUSINESS MEETING (BM 24) 17:30-18:40 IG on Eosinophilic Esophagitis - Open to all attendees Room 206 Advances in genetics and pathophysiology in EoE Antonella Cianferoni, United States BUSINESS MEETING (BM 25) 17:30-18:40 IG Ocular Allergy - Open to all attendees Room 207 Characterisation of the microbiome on the ocular surface Mark Willcox, Australia 108

109 TUESDAY 20 JUNE 2017 AIT GUIDELINES LAUNCH TUESDAY It is our pleasure to launch the latest addition to the EAACI Guideline series } Visit the EAACI counter to preview the Allergen Immunotherapy Guidelines 109

110 TUESDAY 20 JUNE 2017 EDUCATIONAL ACTIVITIES EAACI sees growing demand for its two smaller meeting formats which encourage and enable more interactive, hands on learning. Allergy Schools These training courses focus on a specific topic within allergy and are build to offer a solid foundation in this area. They are therefore attractive for fellows in training and EAACI junior members, as well as professionals with a particular interest in the chosen topic. Participation is limited to a maximum of 120 attendees. For more information visit Master Classes Covering both clinical and transitional topics of a particular field, EAACI Master Classes aim to delve deeper and therefore target professionals and specialist with a higher level of experience, but do not give bias to age. Conducted in intimate workshop formats, they offer an excellent platform for the exchange of knowledge. Participation is limited to a maximum of 60 attendees

111 PROGRAMME AT A GLANCE WEDNESDAY 21 JUNE 2017 Hall 5a Hall 3a Hall 3b Hall 3c Hall 3g Room 101 Room 103a Room 208 Room 102 Room 103b 08:00 P :30 PL 7 Skin as a gateway to allergy 09:00 09:30 D, P, CA, PC 10:00 SYM 46 Uncontrolled asthma P.112 P.112 P.112 P.113 P.113 P.113 P.113 P.114 P :30 SYM 47 SYM 48 SYM 49 OAS 33 WS 10 OAS 34 LB OAS 5 Contact Epithelial Food allergy Management The interplay Anaphylaxis Allergen Immunotherapy dermatitis: An barrier in from a of drug allergy between update allergic different angle infections and - mechanisms 11:00 sensitisation the immune and vaccines and disease system in rhinosinusitis 11:30 A, P, PC D, P I, AH, D, P FA, AH, CA SYM 50 Integrating Component Resolved Diagnosis and Basophil testing in allergy diagnosis DI, CA, P DA ENT, CA, P I, FA, DA, CA P.114 Closing Ceremony 12:30 SESSION GUIDE TOPIC TRACKS OAS PL SYM Oral Abstract Session Plenary Symposium Symposium A Asthma AH Allied Health BA Basic Allergology BI Biologicals CA Clinical Allergology CI Clinical Immunology D Dermatology DA Drug Allergy DI Allergy Diagnosis ENT Ear, Nose, Throat FA Food Allergy I Immunology IT Immunotherapy OA Ocular Allergy P Pediatrics PC Allergy management in Primary Care IT 12:00 13:00 VIRTUAL CONGRESS HUB WEDNESDAY You won t miss a thing, thanks to EAACI s bigger and better virtual hubs. This year there are two, both open from June. - Exhibition Hall 9:00-17:30 - By Hall 5, 1st floor 8:30-19:30 EAACI Virtual Hubs } View webcasts of sessions you were not able to join } Search for abstracts and e-posters } Rate or comment on posters and webcasts } Search the Congress programme by topic or key words 111

112 WEDNESDAY 21 JUNE 2017 SOME SESSIONS FILL UP QUICKLY. ARRIVE EARLY TO GUARANTEE YOUR ENTRY. IF YOU HAVE MISSED A SESSION, YOU CAN CATCH UP ON IT AT THE VIRTUAL CONGRESS HUB IN THE EXHIBITION HALL. PROGRAMME IS STILL SUBJECT TO CHANGE. PLEASE REFER TO THE CONGRESS APP FOR LATEST UPDATE. PLENARY SYMPOSIUM (PL 7) 08:30-10:00 Skin as a gateway to allergy Hall 5a Chairs: Antonella Muraro, Italy Thomas Werfel, Germany Skin as the first step in allergen sensitisation? Donald Leung, United States New epidemics in contact dermatitis Jonathan White, United Kingdom Skin symptoms heralding anaphylaxis Carsten Bindslev-Jensen, Denmark SYMPOSIUM (SYM 46) 10:30-12:00 Uncontrolled asthma Hall 3a Chair: Vibeke Backer, Denmark OTE The role of biomarkers Hae-Sim Park, South Korea Challenging existing guidelines Guy Brusselle, Belgium WEDNESDAY The role of primary care Dermot Ryan, United Kingdom SYMPOSIUM (SYM 47) 10:30-12:00 Contact dermatitis: An update Hall 3b Chair: Jonathan White, United Kingdom OTE Clinical features indicating contact dermatitis Margarida Goncalo, Portugal Diagnosis of contact dermatitis: Pitfalls and tricks Radoslaw Spiewak, Poland Occupational allergic contact dermatitis: Epidemiology and main causes Maria Pesonen, Finland SYMPOSIUM (SYM 48) 10:30-12:00 Epithelial barrier in allergic sensitisation and disease Hall 3c Chairs: Gideon Lack, United Kingdom Donald Leung, United States OTE Barrier dysfunction in chronic allergic airways diseases Peter Hellings, Belgium Epidermal integrity in the pathogenesis of inflammatory skin disease Thomas Werfel, Germany Intestinal epithelial barrier function in IgE mediated disease Eva Untersmayr, Austria 112

113 WEDNESDAY 21 JUNE 2017 SYMPOSIUM (SYM 49) 10:30-12:00 Food allergy from a different angle Hall 3g Chair: Maria Montserrat Fernandez-Rivas, Spain OTE Regulatory T cells in the intestine Caspar Ohnmacht, Germany Allergic sensitisation to food through non-gastrointestinal routes Karine Patient, France The role of the mucosa in severe pollen associated food allergy Domingo Barber, Spain SYMPOSIUM (SYM 50) 10:30-12:00 Integrating Component Resolved Diagnosis and Basophil testing in allergy diagnosis Room 101 Chairs: Jörg Kleine-Tebbe, Germany Markus Ollert, Luxembourg OTE Component Resolved Diagnosis in the clinical workup of patients Wolfgang Hemmer, Austria Between first line tests and provocation: Basophil testing in drug and occupational allergy Hans-Jürgen Hoffmann, Denmark Does Basophil sensitivity distinguish benign sensitisation from severe allergy? Edward Knol, The Netherlands WORKSHOP (WS 10) 10:30-12:00 Arrive early to guarantee your entry, limited spaces. The interplay between infections and the immune system in rhinosinusitis Room 208 Chairs: Philippe Gevaert, Belgium Bitter taste in CRS: Can you feel it? Robert Schleimer, United States Noam A Cohen, United States Viruses, bacteria and fungi: Who to blame? Claus Bachert, Belgium WEDNESDAY What is a good microbiome? Martin Depner, Germany ORAL ABSTRACT SESSION (OAS 33) 10:30-12:00 Management of drug allergy Chair: Maria J. Torres, Spain Session roadmap: Maria J. Torres, Spain 0157 NSAIDs hypersensitivity reactions in children Natalia Blanca-López, Infanta Leonor University Hospital, Spain 0158 Demonstration of a specific sensitization in children with amoxicillin clavulanic acid-induced cutaneous adverse reactions within infectious mononucleosis Francesca Mori, Allergy Unit, Department of Pediatric Medicine, Anna Meyer Children s University Hospital, Italy Room 103a 0159 Vaccine allergy is extremely rare: a decade of experience from two large UK allergy centres Annette Wagner, Department of Allergy, Cambridge University Hospital, Cambridge, UK, United Kingdom 0160 Fixed drug eruptions: Report of 8 clinical cases João Marcelino, Immunoallergology Department, Santa Maria Hospital, Centro Hospitalar Lisboa Norte, Lisboa, Portugal, Portugal 0161 Carbonic anhydrase inhibitors-induced severe cutaneous adverse reactions: analysis of Korean SCAR registry database Sujeong Kim, Department of Internal Medicine, Kyungpook National University School of Medicine, South Korea 113

114 WEDNESDAY 21 JUNE A rare case of injection site reaction induced by icatibant and the skin test positivity Semra Demir, Istanbul University, Istanbul Faculty of Medicine, Adult Allergy Clinic, Turkey ORAL ABSTRACT SESSION (OAS 34) 10:30-12:00 Anaphylaxis Room 102 Chair: Victoria Cardona, Spain 0163 European Academy of Allergy and Clinical Immunology (EAACI) Anaphylaxis Survey (AXIS) 2016: The reality of anaphylaxis management Magnus Wickman, Karolinska Institute, Sweden 0164 Significant improvement in diagnosing anaphylaxis over time: A major factor compounding time-trend data? Kristina Rueter, University of Western Australia, Australia 0165 Exploring the mast cell compartment in patients with idiopathic anaphylaxis Melody C Carter, National Institutes of Health, United States 0166 TWEAK/Fn14 axis mediates histamine and PAF-induced subcutaneous vascular leakage and anaphylactic shock Nerea Mendez-Barbero, IIS- Fundación Jiménez Díaz, Spain 0167 Identification of an unknown mastocytosis in patients with severe anaphylaxis Sabine Dölle, Charité - Universitätsmedizin Berlin, Dpt. of Dermatology and Allergology, Allergy-Center-Charité, Germany 0168 The body mass index is an indicator of advanced systemic mastocytosis: preliminary results from a registry project of the European Competence Network on Mastocytosis (ECNM) registry Aleksandra Górska, Medical University of Gdansk Dep of Allergology, Poland LATE BREAKING ORAL ABSTRACT SESSION (LB OAS 5) 10:30-12:00 Allergen Immunotherapy - mechanisms and vaccines Room 103b WEDNESDAY 1443 Short course treatment of subcutaneous peptide hydrolysate from lolium perenne (LPP) suppresses basophil responses and induces igg-associated blocking antibodies: a RDPCT Mohamed H Shamji, Allergy and Clinical Immunology, Imperial College London, United Kingdom 1444 Der p 1-specific B cells in immune tolerance during 2-year house dust mite-specific immunotherapy Tadech Boonpiyathad, Swiss Institute of Allergy and Asthma Research, Switzerland 1445 Development and characterization of a ragweed allergy vaccine based on the peptide carrier principle Frank Stolz, Biomay AG, Austria 1446 Vitamin D treatment enhances anti-inflammatory and anti-th2 pathways in allergic individuals but not in healthy controls Esther De Jong, Dept. of Experimental Immunology, Academic Medical Center, University of Amsterdam, The Netherlands 1447 Sublingual immunotherapy with recombinant Mal d 1 improves birch pollen-associated apple allergy Tamar Kinaciyan, Medical University of Vienna, Austria 1448 Intralymphatic immunotherapy (ILIT) of insect bite hypersensitivity (IBH) in horses with recombinant fusion proteins Horst Rose, Boehringer-Ingelheim Animal Health GmbH, Germany CLOSING CEREMONY 12:15-13:15 Closing Ceremony Hall 5a Full abstract author lists are available on the official Congress website.

115 NOTES WEDNESDAY 115

116 WEDNESDAY 21 JUNE 2017 EASY EAACI 2017 Your live audio streaming channel Connect to WiFi Download the Interactio app Open the app and enter code: eaaci Plug in your headphones Choose your poster session and... Enjoy undisturbed audio of the presentations With Interactio, you have the perfect tool allowing you to hear all live poster presentations (TPS) in an acoustically clear and hassle-free way. Please kindly note: To be able to use the app and all functions, your smartphone must be connected to the internet. Therefore, free WiFi will be provided by EAACI to all delegates, and we encourage you to download the app prior to the poster sessions taking place during the lunch break. If you need assistance with the app, please ask our service staff at the poster area who will be happy to help you

117 POSTERS 18 JUNE 2017, 12:00-13:30 SUNDAY, 18 JUNE 2017 Thematic Poster Session (TPS 01) Animal studies in asthma Poster Exhibition Chair: Ellen Tufvesson, Sweden 0590 Effect of costimulatory signal blockade on T cell responsiveness to glucocorticoid in vitro and in vivo Akio Mori, National Hospital Organization, Sagamihara National Hospital, Clinical Research Center, Japan 0591 Regulation of allergic airway inflammation by adoptive transfer of IL -10-producing CD4+ T cells Masaya Matsuda, Setsunan University, Japan 0592 Reduced susceptibility to allergic airways disease in BALB/C offspring following maternal therapeutic immunomodulator (OM85) treatment during gestation. Kyle T Mincham, Telethon Kids Institute, Australia 0593 Inhibiting activation of complement c5 attenuates airway hyperresponsiveness and allergic lung inflammation in a house dust mite induced model Jack Yang, Academic Medical Center, The Netherlands 0594 Obesity promotes lung fibrosis through TGF-ß signaling in mice Misuk Yang, Department of Internal Medicine, Institute of allergy, Yonsei University College of Medicine, South Korea 0595 Evaluation of a murine allergic asthma model to study immunotherapy with purified Der p 1 and der p 2 Leonie Sara Van Rijt, Dept. Experimental Immunology, Academic Medical Center, The Netherlands 0596 Exacerbation of allergic responses including respiratory inflammation in Derp-induced allergic march in mice Kyu-Tae Jeong, Division of Allergy and Chronic Respiratory Diseases, Center for Biomedical Sciences, Korea National Institute of Health, Korea Center for Disease Control and Prevention, South Korea Thematic Poster Session (TPS 02) Asthma, education and epidemiology Chairs: Tomás Chivato, Spain Matteo Bonini, Italy 0604 What do patients with obstructive lung disease prefer about social media? a latinamerican multicenter study. Juan Carlos Calderon, Universidad Espíritu Santo, Ecuador 0605 Corticosteroid phobia among parents of asthmatic children Deniz Ozceker, Istanbul Medical Faculty, Turkey 0597 Additional effect of clopidogrel to montelukast is intervaldependent Hoang Kim Tu Trinh, Ajou University School of Medicine, South Korea 0598 A specific combined n-3 and n-6 long-chain fatty acid supplementation exhibits anti-inflammatory effects in allergic asthma bronchiale Daniela Fussbroich, Department of Food Technology, University of Applied Science, Germany 0599 Respiratory epithelial CD93 expression is decreased by pulmonary allergic inflammation in murine model of asthma Eun-Yi Oh, Department of Internal Medicine, Institute of allergy, Yonsei University College of Medicine, South Korea 0600 Cystatin from the nematode ascaris lumbricoides reduces inflammation in a mouse model of allergic asthma Sandra Coronado, Instituto de Investigaciones Inmunologicas, Universidad de Cartagena, Colombia 0601 The effects of montelukast and zileuton on bronchial hyperresponsiveness, airway inflammation and airway smooth muscle remodeling. Marina Alexandrovna Syrczova, Institut of Experimental Medicine, Russia 0602 A drosophila smoking model an emerging model for transgenerational studies Karolina-Theresa Neumann, Forschungszentrum Borstel, Germany 0603 Experimental Model Of Neutrophilic Allergic Asthma Alexander Babakhin, NRC - Institute of Immunology, Russia Poster Exhibition 0608 Higher mortality in adult-onset asthma: A 15 year follow-up of a population-based matched cohort Sanna Toppila-Salmi, Haartman Institute, Medicum, University of Helsinki, Finland 0609 Synchronization of seasonal rhino- and influenza-virus epidemic and asthma exacerbation across all age groups Jong Ouk Kim, CHA University, South Korea POSTERS 0606 Adaptation of education programmes for elderly patients with asthma Natalia Grigorievna Astafieva, Saratov State Medical University, Russia, Department of Clinical Immunology and Allergology, Russia 0607 Assessment of level of knowledge about asthma by parents / caregivers of children with asthma, elementary school teachers and university students in Uruguaiana RS, Brazil. Marilyn Urrutia-Pereira, Federal University of Pampa (UNIPAMPA), Brazil 0610 Weather type influences the harmful effect of air pollution on asthma symptoms Young-Min Kim, Environmental Health Center for Atopic Diseases, Samsung Medical Center; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea 0611 Endogenous and exogenous sex steroid hormones and asthma and allergy in women: a systematic review and metaanalysis Ulugbek B Nurmatov, Cardiff University, United Kingdom Full abstract author lists are available on the official Congress website

118 POSTERS 18 JUNE 2017, 12:00-13: Specific and generic questionnaires for the assessment of health related quality of life in adult asthmatics Aikaterini Brinia, National and Kapodistrian University of Athens, Greece 0613 Prevalence of metabolic syndrome in patients with bronchial asthma Jamol Uzokov, Republican specialized scientific-practical medical center of therapy and medical rehabilitation, Uzbekistan 0614 Study of age of asthma symptom onset as a potential predictor of disease development and progression. Olga Titova, Research Institute of Pulmonology, First St- Petersburg Pavlov State Medical University, Russia 0615 Non-atopic severe asthma is it really always non-atopic? The IDENTIFY project Jens Schreiber, University Hospital Magdeburg, Germany 0616 The challenges of living with severe asthma in Europe Paraskevi Katsaounou, Respiratory Medicine National and Kapodistrian, University of Athens, ERS fellow at Novartis, Greece 0617 Asthma in community settings - What pharmacists can offer? Mohammad Riyad Al-Dqour, Hikaya Center for Civil Society Development, Jordan 0618 Beta 2 agonists and doping Olga Lourenço, CICS - UBI - Health Sciences Research Centre - University of Beira Interior, Portugal Thematic Poster Session (TPS 03) Aerobiology: aeroallergens and their clinical impact Poster Exhibition POSTERS Chairs: Carmen Galán, Spain Jordina Belmonte, Spain 0619 Molecular characterization, gene expression profile and histopathology of fungal spore causing allergies in southwestern Nigeria Adeyinka Odebode, University of Lagos, Nigeria 0620 Q. rotundifolia and p. hybrida pollen extracts induced basophil degranulation: study using a cell line expressing human FcERI Celia Antunes, ICT Institute of Earth Sciences, IIFA & Dep. Chemistry, School of Sciences and Technology, University of Evora, Portugal 0621 Effect of airborne formaldehydeon skin barrier in a mouse model Minji Kim, Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea 0622 Distribution of aeroallergens on skin prick tests of atopic children living in akdeniz area Aysen Bingol, Akdeniz University Pediatric Allergy Immunology Pulmonology Department, Turkey 0623 Sensitization patterns to the common pollens in the city of Manila, Philippines Cecil Chua Wong, University of Santo Tomas Hospital, Philippines 0624 Aeropolinologic screening in patients with pollinosis. Revaz Sepiashvili, RUDN University, Russia 0625 Common aeroallergens and food allergens seen among allergic children in the united arab emirates Hanan Al Sharif, Sharjah University Hospital, United Arab Emirates 0626 Sensitisation and allergy patterns to inhalant and food allergens in a population from the mediterranean area Raquel Jurado-Escobar, Research Laboratory, IBIMA, Regional University Hospital of Malaga, UMA, Spain 0627 A search for novel allergens from penicillium oxalicum, a dominant airborne fungal spore from West Bengal, India Partha Karak, Visva Bharati, India 0628 Control of Fel d 1 levels in a cat allergen exposure chamber Suzanne Kelly, Red Maple Trials, Canada 0629 Allergic keratoconjunctivitis treatment: experience with omalizumab Amyra Ali Azamar Jacome, Instituto Nacional de Pediatría, Mexico Thematic Poster Session (TPS 04) Allergy epidemiology Poster Exhibition Chair: Denis Caillaud, France 0630 Canine sensitization in Fel d 1 allergic patients Natalia Ewa Ukleja-Sokolowska, Department and Clinic of Allergology, Clinical Immunology and Internal Diseases, L. Rydygier Collegium Medicum in Bydgoszcz, NCU, Poland 0631 Comparison of the level of six indoor allergens in homes of asthmatic and non-asthmatic in Birjand City, Iran. Shaghayegh Sadat Nourani Hassan Kiadeh, Asthma, Allergy & Immunology Reseaech Center of Birjand University of Medical Sciences, Iran 0632 Clinical impact of mosquito aedes aegypti in allergic respiratory diseases. Jorge Sánchez, Group of Experimental and Clinical Allergy, IPS Universitaria, University of Antioquia. Medellín, Colombia 0633 Prevalence of low diamine oxidase in patients with seasonal allergic rhinitis and cross food allergy Olha Naumova, Institute of Otolaryngology of National Academy of Medical Sciences of Ukraine, Ukraine Full abstract author lists are available on the official Congress website.

119 POSTERS 18 JUNE 2017, 12:00-13: Overweight and obesity in school-age and adolescence are associated with airway obstruction results from a population-based cohort study Sandra Ekström, Institute of Environmental Medicine, Karolinska Institutet, Sweden 0635 Associations between serum carotenoid and tocopherol concentrations and risk of asthma in childhood: a nested case-control study in Finland Niina Hamalainen, University of Tampere, Finland 0636 Allergic diseases and vitamin D Derya Unal, Yedikule chest surgeon and chest diseases education research hospital, Turkey 0637 Report of pilot study of prevalence of asthma, allergic rhinoconjunctivitis and atopic dermatitis in the pediatric age Cesar Fireth Pozo, Hospital Infantil de Mexico Federico Gomez, Mexico 0638 Rural area of the Natural Park Lonjsko Polje, Croatia - prevalence of allergic disease symptoms in young adolescents Iva Topalušic, Children s Hospital Zagreb, Croatia 0639 Prevalence of sensitization to aeroallergens in preschool children with symptoms of atopic disease Milan Tosic, Clinical centar, Serbia 0640 Overview of allergic rhinitis incidence and treatment in Slovak Republic in 2015: results from nationwide prospective study. Peter Pruzinec, Dept. of Clinical Immunology and Allergology, University Hospital Bratislava, Slovakia 0641 Do pharmacy customers make good choices when they manage their allergic rhinitis? Rachel Sze Bing Tan, Woolcock Institute of Medical Research The University of Sydney, Australia 0642 Patient perspectives with regards to how they measure allergic rhinitis severity and allergic rhinitis control. Biljana Cvetkovski, Woolcock Institute of Medical Research, The University of Sydney, Australia 0643 Calcium preparations do not inhibit allergic reaction - A randomized controlled trial Klaudia Matysiak, Department of Paediatric Pneumology and Allergy The Medical University of Warsaw, Poland 0644 Comparison of the prevalence of allergic diseases and risk factors of asthma development in urban and rural Pomeranian region. Marlena Magdalena Sztormowska, Medical University of Gdansk, Poland Thematic Poster Session (TPS 05) Diagnosis and management of rhinitis Poster Exhibition Chairs: Sanna Toppila-Salmi, Finland Elina M Toskala, United States 0645 Assessment of leukotriene E4 in exhaled breath condensate as a marker of inflammation in allergic rhinitis children Yong Mean Park, Department of Pedicatircs, Konkuk University Medical Center, South Korea 0646 A model proposal for allergic rhinitis studies: Isolated sensitivity to juniper pollen Bülent Topuz, Pamukkale University, School of Medicine, Turkey 0647 Real life effectiveness of mp-azeflu * in persistent allergic rhinitis, assessed by visual analogue scale and endoscopy: data from ireland Ranbir Kaulsay, The Clontarf Allergy Clinic, Ireland 0648 Review of the efficacy and safety of MP-AzeFlu * in children with allergic rhinitis William Berger, Allergy & Asthma Associates, United States 0651 Adaptation and validation of the rhinitis control assessment test (RCAT) for children between six and eleven years of age (RCAT kids) Carolina Rodrigues Boarini, Federal University of São Paulo, Brazil 0652 Usefulness of electronic nose breath analyzer in patients with persistent rhinitis Teresa Garriga-Baraut, Asthma and Allergy Unit, Pediatric Department, Hospital Universitari Vall d Hebron, Spain 0653 Mp-AzeFlu * improves sleep quality in patients with persistent allergic rhinitis: data from Austria, Ireland and Sweden Par Stjarne, Karolinska Institute, Sweden 0654 Real life effectives of MP-AzeFlu * in persistent allergic rhinitis, assessed by visual analogue scale: data from Austria Katharina Marth, Karl Landsteiner Institut fur Experimentelle und Klinische Pneumologie, Austria POSTERS 0649 The evaluation of life quality changes and the analysis of influencing factors before and after the treatment of adult allergic rhinitis patients Cuida Meng, China-Japan Union Hospital of Jilin University, China 0650 To study the value of patient education in treatment of allergic rhinitis Cuida Meng, China-Japan Union Hospital of Jilin University, China 0655 Real life effectiveness of MP-AzeFlu * in persistent allergic rhinitis, assessed by visual analogue scale: data from sweden Par Stjarne, Karolinska Institute, Sweden 0656 Survey on the clinical characteristics of paediatric allergic rhinitis Jichao Sha, China-Japan Union Hospital of Jilin University, China 119

120 POSTERS 18 JUNE 2017, 12:00-13: Children acute rhinosinusitis and intermittent allergic rhinitis Felicia Manole, Faculty of Medecine, Romania 0658 A herbal medicine might be effective for the chronic rhinitis patients Yasuhiro Suzuki, Tokyo Medical and Dental University, Japan Thematic Poster Session (TPS 06) Management of asthma Poster Exhibition POSTERS Chairs: Matea Deliu, United Kingdom Florin Dan Popescu, Romania 0659 Tiotropium add-on therapy improves lung function in children and adolescents with moderate and severe symptomatic asthma, independent of markers of allergic status Eckard Hamelmann, Evangelisches Krankenhaus Bielefeld, and Allergy Center of the Ruhr University, Germany 0660 Efficacy of mepolizumab in patients with severe eosinophilic asthma who had previously received omalizumab treatment Eric S Bradford, Respiratory Therapeutic Area, GSK, United States 0661 Statin use is associated with decreased asthma-related emergency department visits and hospital admissions Hui-Ju Tsai, National Health Research Institutes, Taiwan 0662 Tiotropium add-on therapy has a safety profile comparable with that of placebo in children and adolescents with symptomatic asthma Christian Vogelberg, University Hospital Carl Gustav Carus, Technical University of Dresden, Germany 0663 Effect of omalizumab on asthma control, exacerbation rate and quality of life in Italian patients with severe allergic asthma: results from the longitudinal phase of the proxima study Cristiano Caruso, Allergy Unit- Fondazione Policlinico Gemelli- Presidio Columbus, Italy 0664 Control of asthma, adherence to inhaled therapy and usefulness of the test of adherence to inhalers (TAI). results of the ascona study Paula Ribo, Pneumology and Allergy Dpt. Hospital Clinic. IDIBAPS. CIBERES, Spain 0665 Omalizumab in severe asthmatic patients: discontinuation effects Luis Amaral, Serviço de Imunoalergologia, Centro Hospitalar de São João E.P.E., Portugal 0666 Wellbeing of older adults with asthma Skaiste Linceviciute, University of Portsmouth, School of Health Sciences and Social Work, United Kingdom 0667 Response to omalizumab in urticaria & asthma; a life-time together? A. Fusun Kalpaklioglu, Kirikkale University Faculty of Medicine,Department of Immunology and Allergy Diseases, Turkey 0668 Ease of use of inhalers and its impact on treatment adherence and control of asthma. an observational study. Paula Ribo, Pneumology and Allergy Dpt. Hospital Clinic, IDIBAPS, CIBERES, Spain 0669 Impact of asthmatic patient satisfaction with the inhaler upon adherence, disease control and quality of life. Results of the ascona study Antonio Valero, Pneumology and Allergy Dpt, Hospital Clinic, IDIBAPS,CIBERES, Spain 0670 Mobile phone applications in asthma self-management: a systematic review Marzieh Heidarzadeh Arani, Pediatric Department, Faculty of Medicine Kashan University of Medical Sciences, Iran 0671 Budesonide easyhaler : dose consistency under simulated real-life conditions and low inspiratory flow rates Paula Rytilä, Orion Corporation Orion Pharma, Finland 0672 Under-utilization of spirometry and mis-diagnosis of lower airway obstructive diseases (asthma and COPD) in primary setting Giuseppe Picardi, University of Catania - Respiratory Medicine and Allergology, Italy 0673 Two components of patient adherence in the treatment of asthma: regular use and correct inhaler technique Zeynep Celebi Sozener, Ankara University School of Medicine Department of Chest Diseases Division of Allergy and Immunology, Turkey 0674 Assessment of clinical efficacy and impact of quality of life in patients with severe asthma treated with omalizumab Rita Aguiar, Immunoallergology Department. Centro Hospitalar Lisboa Norte-Hospital de Santa Maria, Portugal 0675 Does oil supplementation with omega - 3 -fatty acids protect for exercise induced asthma? A placebo controlled trial Stefan Zielen, Department for Children and Adolescents, Division of Allergology, Pulmonology and Cystic fibrosis, Goethe University Hospital, Germany 0676 Effectiveness and safety of bronchial thermoplasty for severe asthma in daily clinical practice Luis Puente-Maestu, Hospital Universitario Gregorio Marañón, Servicio de Neumolgía, Facultad de Medicina de la Universidad Complutense de Madrid, Spain Full abstract author lists are available on the official Congress website.

121 POSTERS 18 JUNE 2017, 12:00-13:30 Thematic Poster Session (TPS 07) Pediatric respiratory allergy Poster Exhibition Chair: Susanne Halken, Denmark 0677 Risk factors of overweight and obesity in children with allergy Eliza Wasilewska, Medical Universitety of Gdansk, Allergology Department, Poland 0678 Cost of asthma treatment in children in Poland Anna Bodajko-Grochowska, Dept. of Paediatric Pneumonology and Rheumatology, Medical University, Poland 0679 Serum vitamin d and IL-31 levels in children with allergic or nonallergic rhinitis Hye Lim Jung, Sungkyunkwan University School of Medicine, South Korea 0680 Between the questionnaire and cotinine level for studying exposure to tobacco smoke among allergy and healthy children Woo Kyung Kim, Department of Pediatrics, South Korea 0681 Environmental and genetic determinants for early-life wheezing: findings from a birth cohort in Hong Kong Agnes Sze-Yin Leung, Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong SAR 0682 Hygiene hypothesis in childhood asthma Tara Ristevska, Faculty of Medicine, Macedonia, Former Yugoslav Republic of 0683 Residential greenness and allergic respiratory disease in children and adolescents: a systematic review and metaanalysis Katrina Anne Lambert, School of Psychology and Public Health, La Trobe University, Australia 0684 Bronchial hyperresponsiveness phenotypes can be modified by atopy, air pollution, overweight and early-life respiratory infections Ji-Won Kwon, Seoul National University Bundang Hospital, South Korea 0685 Associations of urine phthalate level with small airway dysfunction and bronchial hyperresponsiveness in 6 year-old children Mi-Ae Kim, Department of Pulmonology, Allergy and Critical Care Medicine, CHA Bundang Medical Center, CHA University, South Korea 0686 Peak expiratory flow among healthy children in China Wujun Jiang, Children s Hospital of Soochow University, China 0687 Evaluation of reversibility with impulse oscillometry in preschool children with recurrent upper and lower respiratory symptoms Hikmet Tekin Nacaroglu, Bagcilar Training and Research Hospital, Pediatric Allergy and Immunology, Turkey 0688 Elevated exhaled nitric oxide levels in adolescents are related to new-onset allergic symptoms to cat within four years. Pia Kalm-Stephens, Uppsala University, Sweden 0689 Nasal cellulose powder in children with allergic rhinitis, a randomized, double-blind, placebo-controlled trial Natchanun Klangkalya, Ramathibodi Hospital, Mahidol University, Thailand Thematic Poster Session (TPS 08) Advances in molecular allergy Poster Exhibition Chair: Elide Pastorello, Italy 0690 IgE response to Der p 1 and Der p 2 in Portuguese house dust mite allergic patients Sofia Martins Farinha, Centro Hospitalar de Setúbal, Portugal 0694 The usefulness of molecular based allergy diagnostics in a secondary pediatric referral center. Ole D. Wolthers, Asthma and Allergy Clinic, Children s Clinic Randers, Denmark POSTERS 0691 Specific IgE to Der p 1 and Der p 2, do they explain IgE response to dermatophagoides pteronyssinus? Sofia Martins Farinha, Centro Hospitalar de Setúbal, Portugal 0692 Elevated level of IgE specific to can f 2 is related to dyspnea in patients with pet allergies Natalia Ewa Ukleja-Sokolowska, Department and Clinic of Allergology, Clinical Immunology and Internal Diseases, L. Rydygier Collegium Medicum in Bydgoszcz, NCU, Poland 0693 Increased diagnostic accuracy by using allergen component tests in hazelnut allergy: a systematic literature review and meta-analysis. Malin Berthold, Thermo Fisher Scientific - ImmunoDiagnostics, Sweden 0695 The molecular allergen pattern to asthma and rhinitis in a cross sectional study among adolescents in southern Sweden Therese Sterner, Dep of clinical sciences, Faculty of Medicine, Lund University. Dep of Dermatology, Skane University Hospital, Sweden 0696 Combination of allergen component microarray and urea buffer allows the discrimination between specific ige of high or low functional affinities Pol André Apoil, Laboratoire d Immunologie, C.H.U. de Toulouse, France 0697 High fidelity of ISAC112 microarray for first line screening of type i allergy: results from a clinical study. Erika Jensen-Jarolim, Dept. of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University Vienna, Austria 121

122 POSTERS 18 JUNE 2017, 12:00-13: The first allergen components profile of five main food allergens in 492 atopic children: an important absence of major allergen components. Lukasz Blazowski, Allergy and Pulmonary Medicine Department, Poland 0699 Component resolved diagnosis for phleum pratense in a multinational multicenter clinical trial of a depigmented polymerized phleum pratense extract. Jaime Sánchez-López, Laboratorios LETI, Spain 0700 IgE response to grass pollen-specific components in a population of the Mediterranean area Vincenzo Patella, UO ALLERGY, ASL SALERNO and Medical School, University of Naples Federico II, Italy Thematic Poster Session (TPS 09) Advances in skin testing and characterisation of novel allergens Poster Exhibition POSTERS Chairs: Ralph Mösges, Germany Hans-Jürgen Hoffmann, Denmark 0701 Effects of acute stress on the reliability of skin prick testing and mediator release: clinical study in healthy and allergic volunteers using the trier social stress test Christina Lisa Pranger, Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Austria 0702 Single or multiple devices for allergy skin testing in children? Herberto Jose Chong Neto, Pediatric Allergy and Immunology Division-Federal University of Parana, Brazil 0703 The role of microneedle patch test in the diagnosis of atopic dermatitis Chang Ook Park, Yonsei University College of Medicine, South Korea 0704 Comparison of commercial skin prick test reagents using in vivo and in vitro methods Jung-Won Park, Division of Allergy and Immunology, South Korea 0705 The optimal conditions for the long-term storage of the extracts of sawtooth oak, Japanese hop, ragweed and mugwort pollens Ji Eun Yuk, Department of Internal Medicine Institute of Allergy Yonsei University College of Medicine, South Korea 0706 Specific IgE to propolis extracts among pollen allergic patients Youcef Shahali, Razi Vaccine and Serum Research Institute, Iran 0707 Mono-sensitization to only one allergen component is rare in canine and feline allergic patients Natalia Ewa Ukleja-Sokolowska, Department and Clinic of Allergology, Clinical Immunology and Internal Diseases, L. Rydygier Collegium Medicum in Bydgoszcz, NCU, Poland 0708 Ragweed pollen allergy - patterns and cross-reactivity Carmen Panaitescu, Victor Babes University of Medicine and Pharmacy Timisoara, Romania 0709 Study of results of modified skin prick test [MSPT] with 140 allergens performed in single sitting in cases of severe persistent allergic rhinitis [SPAR] in Central India. Subir Jain, ENT Centre, India 0710 Manufacturing of guideline-conform human sera pools for assessment of ige reactivity Bernd Laffert, Allergopharma GmbH & Co. KG, Germany Thematic Poster Session (TPS 10) Atopic dermatitis Chair: Radoslaw Spiewak, Poland 0711 Staphylococcus spp. susceptibility to antimicrobial agents in atopic dermatitis: current prevalence of methicillinresistant staphylococcus aureus and methicillin-resistant staphylococcus epidermidis. Katerina Neskorodova, First Moscow State Medical University, Russia 0712 Assessment of IL-31 level and disease severity in children with atopic dermatitis Deniz Ozceker, Istanbul Medical Faculty, Turkey 0713 Prick to prick skin test improved clinical outcome of atopic dermatitis in infants Guanghui Liu, Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China Poster Exhibition 0714 The role of staphylococcus spp. in clinical course of atopic dermatitis Katerina Neskorodova, First Moscow State Medical University, Russia 0715 Mold exposure during fetal periods is associated with the development of atopic dermatitis in infants through allergic inflammation Eun Lee, Department of Pediatrics, Chonnam National University Hospital, South Korea 0716 Water-soluble fullerene C60 stimulates filaggrin expression Elena Bashkatova, NRC Institute of Immunology FMBA, Russia 0717 Oral immunosuppresive treatment of severe atopic dermatitis. Magdalena Czarnecka-Operacz, Poznan University of Medical Sciences, Department of Dermatology, Poland Full abstract author lists are available on the official Congress website.

123 POSTERS 18 JUNE 2017, 12:00-13: Atopic dermatitis and probiotics: a real life experience Manuel Jorge Rial Prado, Allergy and Clinical Immunology Department, University Hospital Complex A Coruña, Spain 0719 Patients with atopic dermatitis and allergic rhinitis treated with slit for house dust mite Barbara Kecelj, Remeda, medical centre Domžale, Slovenia 0720 Is it possible to predict the development of infectious complications in specific immunotherapy in children with atopic dermatitis? Tatiana Slavyanskaya, RUDN University, Russia 0721 Skin-tropic immune responses of house dust mite allergens in atopic dermatitis and allergic march Jungsoo Lee, Yonsei University College of Medicine, South Korea 0722 Polymorphism of ttlr2 and TLR4 cell receptors and cytokine levels in patients with atopic dermatitis Rustem Fassakhov, Kazan Federal University, Russia Thematic Poster Session (TPS 11) Allergy and immune-related disorders Poster Exhibition Chairs: Paula Kauppi, Finland Erik Melén, Sweden 0723 Altered mast cell reactivity in patients with mastocytosis Theo Gulen, Department of Respiratory Medicine and Allergy, Karolinska University Hospital Huddinge; and Mastocytosis Center Karolinska, Karolinska University Hospital and Karolinska Institutet, Sweden 0724 Aeroallergen sensitization and irritable bowel syndrome Andreea Ioana Popescu, Life-Med Clinic, Romania 0725 Can plane tree be considered a marker of polisensitization to pollens? Joana Cosme, Immunoallergology Department, Hospital de Santa Maria Northern Lisbon Hospital Center, Portugal 0726 Allergooncology: the canine IgE antibody can225ige-? triggers strong and specific effector-cell mediated cytotoxicity against EGFR+ tumor cells. Judit Fazekas, Comparative Medicine, The interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Austria 0727 Chronic eosinophilic pneumonia and bronchiolocentric interstitial pneumonia associated with angioimmunoblastic T-cell lymphoma Seung Eun Lee, Pusan National University Yangsan Hospital, South Korea 0728 Low molecular-weight heparins could be useful in selected cases of chronic urticaria Corina Ureche, University of Medicine and Pharmacy, Romania 0729 Bird fancier s lung: the importance of an early suspicion and a detailed medical interview Gian Marco Chiarella-Privette, Hospital Infanta Cristina, Spain 0730 Unusual cause of throat swelling in the allergy clinic. Magdalena Dziadzio, UCL, United Kingdom 0731 Is mastocytosis really rare disease? 3 case experience Betül Ayse Sin, Ankara University, School of Medicine, Department of Pulmonary Diseases, Division of Allery and Immunology, Turkey 0732 Acquired angioedema a link to immunologic dysregulation Rosa-Anita Fernandes, Allergy and Clinical Immunology Department, Coimbra University Hospital Center, Coimbra, Portugal, Portugal 0733 C1 inhibitor concentrate - Impact of consumption Tatiana Lourenço, Immunoallergology Department, Santa Maria Hospital, Centro Hospitalar Lisboa Norte, Portugal 0734 Off-label subcutaneous use of 1500 ie c1-inh A new approach for prophylaxis in hae? Jens Greve, Department of Otorhinolaryngology, Head and Neck Surgery, Ulm University Medical Center, Germany 0735 Gender influence on hereditary angioedema with C1-inhibitor deficiency Juliana Fóes Bianchini Garcia, University of São Paulo, Brazil 0736 Icatibant: only in the treatment of hereditary angioedema attacks? Mara Fernandes, Immunoallergology Department, Hospital de Santa Maria (HSM), Centro Hospitalar Lisboa Norte EPE; Immunoallergology Unit, Hospital Dr. Nélio Mendonça, SESARAM, EPE, Funchal, Portugal 0737 Is isolated angioedema in the perioperative setting a symptom of allergy? a retrospective single-centre study. Birgitte Louise Bech Melchiors, Danish Anaesthesia Allergy Centre (DAAC), Allergy Clinic, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Denmark 0738 Uvular edema in the emergency department Ines Torrado Español, Allergy Department HGUGM, Spain POSTERS 123

124 POSTERS 18 JUNE 2017, 12:00-13:30 Thematic Poster Session (TPS 12) Drug allergy: Clinical aspects Poster Exhibition Chairs: Werner Aberer, Austria Ingrid Terreehorst, The Netherlands 0739 Oral desensitization to lenalidomida Estefanía Moreno Mata, Hospital La Mancha Centro, Spain 0740 Exanthematic reaction to methocarbamol Maria Valle Campanón-Toro, University Of Salamanca, Spain 0741 Stevens-Johnson syndrome without mucosal lesions: report of a rare entity Maria Tsami, Department of Allergy, Sotiria General Hospital, Greece 0742 Clinical characteristics and predictors of non-steroidal antiinflammatory drug (NSAID) hypersensitivity in Thailand Porntip Intapiboon, Division of Allergy, Immunology and Rheumatology, Department of Medicine, Ramathibodi hospital, Mahidol University, Thailand 0743 Individuals monosensitized to acetaminophen Ignacio García Nuñez, Hospital Quirón, Spain 0744 Nail toxicity induced by liposomal doxorubicin:a singleinstitution, retrospective case series. Mario Vaccaro, Department of Clinical and Experimental Medicine, Dermatology, University of Messina, Italy 0745 Anaphylactic reaction induced by diclofenac Gabriel Antonio Colamarco, Hospital Clínico Universitario de Valencia, Spain 0746 Iodide mumps: report of two cases Karen Lozano, Allergy department Hospital Universitario 12 de Octubre, Spain 0747 New syndrome caused by angiotensin inhibitors Ana Margarita Montoro De Francisco, Hospital Central de la Defensa, IMIDEF, Spain 0748 Kounis syndrome caused by amoxicillin Gabriele Cortellini, Rimini Hospital, Italy 0749 Potential adverse and allergic reaction from topical complementary and alternative medicine (CAM) H. C. George Wong, University of British Columbia, Canada 0750 DRESS syndrome induced by methotrexate Timothy John Watts, Guy s Hospital, United Kingdom 0751 Reccurent drug eruption and reccurent fever in a pediatric case Pinar Gokmirza Ozdemir, Trakya University Medical Faculty, Turkey 0752 Anaphylaxis and severe immune haemolytic anaemia developed in the course of desensitisation with a carboplatin: a case report Diana Perez-Alzate, Hospital Universitario Infanta Leonor, Spain 0753 Allergy to mitomycin C Ana Maria Burgos Montero, hospital, Spain 0754 Profile of a population of 69 patients allergic to NSAIDs Darío Antolín-Amérigo, ESI-Alergia. Hospital Universitario Príncipe de Asturias. Departamento de medicina y especialidades médicas. Universidad de Alcalá, Spain 0755 Delayed hypersensitivity reaction to epoetin beta: a case report. Macarena Piñero-Saavedra, Algarve Hospital Complex, Portugal 0756 A patient worsening with acute COPD exacerbation treatment Insu Yilmaz, Erciyes University School of Medicine, Division of Allergy and Clinical Immunology, Turkey POSTERS Thematic Poster Session (TPS 13) Anaphylaxis from childhood to adulthood Poster Exhibition 0757 Prevalence of anaphylaxis among children 3 to 18 years of 0763 Immunologic evaluation of perilla seed-induced allergic age in Kuwait reactions Abdal Jabbar Farhan, New Mowasat Hospital, Kuwait Cheol-Woo Kim, Inha Universtiy School of Medicine, South Korea 0758 Anaphylaxis in children- our experience Iva Topalušic, Children s Hospital Zagreb, Croatia 0764 Anaphylaxis to pumpkin seed Catharina Chatain, Department of Dermatology, Allergology 0759 Cold-induced anaphylaxis in pediatric age: an imminent fatal and Photobiology, France risk Filipe Benito-Garcia, Immunoallergy Department, CUF 0765 Beer: un uncommon cause of anaphylaxis Descobertas Hospital, Portugal Joana Pita, Allergy and Clinical Immunology, Coimbra Universitary Hospital, Portugal 0760 Anaphylaxis by PR10 at pediatric age Elena Bradatan, Centre Hospitalier Régional, Belgium 0766 Fdeia - which allergen to blame? Joana Pita, Allergy and Clinical Immunology, Coimbra 0761 Mite anaphylaxis, flour and drug hypersensitivity, a Universitary Hospital, Portugal distinctive clinical phenotype in teenagers Elena Mederos, Hospital Universitario 12 de Octubre, Spain 0767 Fish anaphylaxis and anisakis simplex: a reason you don t have to forget 0762 Anaphylaxis from ingestion of mites: oral mite anaphylaxis Ignacio Garcia-Nunez, Hospital Quironsalud Campo de Evangelia Chytiroglou, Attikon University Hospital, Greece Gibraltar, Spain Full abstract author lists are available on the official Congress website.

125 POSTERS 18 JUNE 2017, 12:00-13: Specific allergic responses to ectoparasites: the alpha-gal model Matteo Ferrando, Allergy & Respiratory Diseases, DIMI Dept of Internal Medicine, University of Genoa, IRCCS AOU San Martino-IST, Italy 0769 An interesting case: latex allergy in healthcare personnel with a history of anaphylactic shock Cihan Örçen, Süreyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital,Training Clinic of Adult Immunology and Allergy Diseases, Turkey 0770 Anaphylaxis secondary to progesterone hypersensitivity successfully treated with omalizumab Rossella Intravaia, University of Catania - Respiratory Medicine and Allergology, Italy 0771 Anaphylactic shock to bilastine Yann Coattrenec, University Hospital and Medical Faculty, Switzerland 0772 Anaphylaxis caused by a natural microenema Aida Gomez Cardeñosa, Fundación Jiménez Díaz, Spain 0773 Anaphylaxis due to citalopram Moreno-Fernandez Antonio, Virgen de la Luz Hospital, Spain Thematic Poster Session (TPS 14) Food allergy and molecular diagnosis Poster Exhibition Chair: Domingo Barber, Spain 0774 Study of a LTP syndrome in a Mediterranean area using microarray. Maria Basagaña, Hospital Universitari Germans Trias i Pujol, Spain 0775 How immunoblotting and mass spectrometry can help to diagnose kiwi fruit allergy. Justine Courtois, CRIG, Belgium 0782 Prevalence of salmon roe allergy patients who also show allergic symptoms due to ingestion of other fish roe Kaoru Okamoto, Fujita Health University, Japan 0783 Analysis of IgA levels in patients with a diagnosis of cow s milk protein allergy Ilknur Kulhas Celik, Ankara Children s Hematology Oncology Training and Research Hospital, Department of Pediatric Allergy and Immunology, Turkey 0776 Identification of the IgE-binding protein pommaclein, Pun g 7, in pomegranate fruit Claudia Alessandri, CAAM - Centri Associati di Allergologia Molecolare, Italy 0777 Diagnosis of peanut, tree nuts and sesame seed allergies: utility of skin prick tests and component resolved diagnosis Jean-Christoph Caubet Caubet, Geneva University Hospitals, Switzerland 0778 Peanut allergen protein extraction from foods for immunoassay quantification Max Bermingham, Indoor Biotechnologies, United Kingdom 0779 Quantification of peanut allergen absorption using autologous serum in a human model of passive cutaneous anaphylaxis Anja Pahlow Mose, Odense Research Centre for Anaphylaxis (ORCA), Department of Dermatology and Allergy Centre, Odense University Hospital, Denmark 0780 Patients allergic to fish: Clinical and immunological characterization of sensitization profile in the last decade Sara Carvalho, Immunoallergology Universitary Department, Hospital Santa Maria, Lisbon Academic Medical Center, CHLN, Portugal 0784 What makes an allergen an allergen? the sensitization capacity to the paradigmatic lipocalin allergen bos d 5 critically depends on its ligand loading state in BALB/c mice. Sheriene Moussa Afify, Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria AND Laboratory Medicine and Immunology Department, Faculty of Medicine, Menoufia University, Egypt 0785 Sensitization to alpha gal and to hymenoptera venom: the possible role of excessive alcohol consumption Catharina Chatain, Department of Dermatology, Allergology and Photobiology, France 0786 Prevalence of red meat allergy in rural mountainous area of Japan: Shimane CoHRE study Hiroyuki Niihara, Shimane University, Japan 0787 Galactose alpha-galactose allergy María Del Pilar Cuesta Apausa, Hospital Universitario de GC Dr Negrín, Spain 0788 Adult red meat allergy: Our clinical experience Fevzi Demirel, Gülhane Training and Research Hospital, Division of Immunology and Allergic Diseases, Turkey POSTERS 0781 Contribution of recombinant parvalbumin Gad c 1 in diagnosis and prognosis of fish allergy Sara Carvalho, Immunoallergology Universitary Department, Hospital Santa Maria, Lisbon Academic Medical Center, CHLN, Portugal 0789 Evaluation of a hypoallergenic wheat line 1BS-18 lacking omega-5 gliadin Kunie Kohno, Shimane University, Japan 0790 Allergens involved in wheat food allergy with sensitization through different routes: cutaneous or digestive. María Andreína Marques, Hospital La Paz, Spain 125

126 POSTERS 18 JUNE 2017, 12:00-13:30 Thematic Poster Session (TPS 15) Immune responses in allergy and asthma Poster Exhibition Chairs: Nanna Fyhrquist, Sweden Nonhlanhla Lunjani, South Africa 0791 The immunomodulatory effects of farm dust and urban air particulate matter: a pilot study Maria-Viola Martikainen, Department of Environmental and Biological Sciences, University of Eastern Finland, Finland 0792 Circulating erythrocytes decrease and neutrophils increase upon airway allergen challenge in house dust mite allergic rhinitis subjects independent of sublingual immunotherapy Galateja Jordakieva, Institute of Occupational Medicine, Medical University of Vienna, Austria 0793 immunomodulatory effects of autologous total IgG in patients with atopic dermatitis Dong-Ho Nahm, Ajou University School of Medicine, South Korea 0794 Aqueous fullerene C60 dispersion reduces the risk of lethal anaphylactic hypersensitivity in mice Nadezhda Nikolaevna Shershakova, NRC Institute of Immunology FMBA of Russia, Russia 0795 Olfactory epithelium-derived mesenchymal stem cells impact antigen-presenting cells when co-cultured ex vivo A Hancharou, Republican Research and Practical Center for Epidemiology and Microbiology, Belarus 0796 Cow s milk and rice fermented with L. paracasei CBA L74 modulate gut microbiota in children Rita Nocerino, University of Naples Federico II, Italy 0797 IgE and IgG production to innocuous and live allergens. Anna Sergeevna Dolgova, Central Research Institute of Epidemiology, Federal Service on Consumers Rights Protection and Human Well-Being Surveillance, Russia 0798 Effect of shallot extract (allium hirtifolium) on splenic lymphocytes: in vitro and in vivo evaluations Somayeh Shamlou, Department of Immunology, School of medicine, Kermanshah University of medical Sciences, Iran 0799 Role placenta in programming of newborn s allergic phenotype. Olga Vladimirovna Il chukova, 1Physiology and Pathology of Newborn, Neonatology. 2Department of Pathomorphology. FSBI The Research Institute of Obstetrics and Gynecology and Reproductology named D. O. Ott, Russia 0800 Dose dependent anti-proliferative effect of an organophosphate pesticide on proliferation in an in vitro Th2-induced model Carine Delayre-Orthez, Institut Polytechnique UniLaSalle, Nutrition and Health Department, EGEAL Unit, France 0801 A new combination of probiotics and prebiotics attenuates symptoms in a mouse food allergy model Carine Delayre-Orthez, Institut Polytechnique UniLaSalle, EGEAL, France 0802 Effects of titanium dioxide nanoparticles on food allergy development Natalia Aliakhnovich, Vitebsk State Medical University, Belarus Thematic Poster Session (TPS 16) Immune responses in inflammation Poster Exhibition POSTERS Chairs: Tuomas Jartti, Finland Remo Frei, Switzerland 0803 Changes in subpopulations of peripheral blood monocytes in patients with acute versus chronic oral lichen planus A Kurchenko, Bogomolets National Medical University, Ukraine 0804 Interrelations of depression, cytokines in semen and chronic pain syndrome in patients with chronic abacterial prostatitis G Drannik, Institute of Urology AMSci, Ukraine 0805 Identifying genetic hypomethylation and upregulation of tolllike receptors in Kawasaki disease Ho-Chang Kuo, Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Taiwan 0806 Immune status and the susceptibility to alcohol hangover Aurora Van De Loo, Utrecht University, The Netherlands 0807 Changes over time in saliva cytokine concentrations the day following heavy alcohol consumption Aurora Van De Loo, Utrecht University, The Netherlands Thematic Poster Session (TPS 17) Immunotherapy - Improving the evidence base Poster Exhibition Chair: Constantinos Pitsios, Cyprus 0808 A cost-effectiveness study on the grass pollen tablets for seasonal rhinitis Valentina Natoli, Stallergenes Italia srl, Italy 0809 Nasal provocation test with house dust mite allergens as the final step of allergic rhinitis child evaluation before allergenspecific immunotherapy Olga V. Trusova, St-Petersburg State Pediatric Medical University, Russia 0810 Assessment of cat subcutaneous immunotherapy in allergy unit of hospital Universitario Fundacion Alcorcon (Madrid, Spain) Ana Gonzalez-Moreno, Hospital Universitario Fundacion Alcorcon, Spain 0811 Assessment of dog subcutaneous immunotherapy, in allergy unit of hospital Universitario Fundación Alcorcón (Madrid, Spain) Wendy Vargas Porras, Hospital Universitario Fundación Alcorcón, Spain Full abstract author lists are available on the official Congress website.

127 POSTERS 18 JUNE 2017, 12:00-13: Early efficacy onset, already prior to the start of the birch pollen season, after sublingual immunotherapy with a liquid birch pollen extract Pieter Jan De Kam, HAL Allergy BV, Clinical Development & Pharmacovigilance department, The Netherlands 0813 Sublingual immunotherapy with a liquid birch pollen extract is similarly effective in birch pollen allergic patients with high sensitization profile compared to patients with low sensitization profile Pieter Jan De Kam, HAL Allergy BV, Clinical Development & Pharmacovigilance department, The Netherlands 0814 Effectiveness and tolerability of sublingual allergen immunotherapy (ait) with or without titration in routine medical practice in house dust mites allergic patients. Jaswinder Singh, Institute for Medical Statistics, Informatics and Epidemiology, Faculty of Medicine, University of Cologne, Germany 0815 Comparison of house dust mite sublingual immunotherapy in monosensitized and polysensitized patients with allergic rhinitis Yang Park, Wonkwang University Sanbon Hospital, Pediatrics, South Korea 0816 Safety and tolerability of a subcutaneous vaccine (SCIT) with native extract of parietaria judaica. Ernesto Enrique Miranda, Hospital Sagunto, Spain 0817 Preliminary results of a tolerability study of SCIT with native depot Olea europaea pollen extract. María Angela Gonzalo-Garijo, Hospital Universitario Infanta Cristina. Allergology Service, Spain 0818 Title: a prospective open multi-centre non-interventional study to assess the tolerability, the safety profile and the adherence of different up-dosing schemes for a sublingual immunotherapy treatment Nils Yannick Breitrueck, Institute for Medical Statistics, Informatics and Epidemiology, Faculty of Medicine, University of Cologne, Germany 0819 Allergenicity and immunogenicity of chemically modified ragweed pollen extract Alexander Alexandrovich Babakhin, National Research Center - Institute of Immunology, FMBA of Russia, Russia 0820 Oral immunotherapy in severe milk allergy in adults results Jarkko Mäntylä, HUH, Helsinki University Hospital, Finland 0821 Sublingual immunotherapy in polysensitized patients with seasonal allergic rhinitis and SCUAD phenotype Rajica Stosovic, Clinic of Allergology and Immunology, Clinical Center of Serbia, Belgrade, Serbia 0822 Control of allergic rhinitis after one year of sublingual immunotherapy with 5 grasses/4 cereals extract Plamena Ivanova Novakova, Medical University Sofia, Bulgaria 0823 Allergen specific IgE-modulating effect of sublingual immunotherapy in mono- and poly-sensitized patients L Titov, Republican Scientific and Practical Center for Epidemiology and Microbiology, Belarus 0824 Study of efficacy of sublingual immunotherapy (SLIT) in cases severe persistent allergic rhinitis. Subir Jain, ENT Centre, India 0825 The effectiveness of ASIT under the pollinosis with concomitant immune deficiency Ella Vitalievna Churyukina, Rostov on Don Medical University, Russia 0826 Tolerance of a high-dose allergoid subcutaneous immunotherapy treatment in children Andreu Penas-Aguilera, Hospital Universitari Josep Trueta, Spain Thematic Poster Session (TPS 18) Infection and allergy Poster Exhibition POSTERS Chair: Sylwia Smolinska, Poland 0827 Salidroside attenuates lipopolysaccharide induced inflammatory response in rat alveolar macrophages though inhibiting NF-KB activation Xiaolan Hu, Zhejiang University, China 0828 Comparison of clinical severity between single and co-infections in respiratory syncytial virus (RSV) and influenza virus Jin-Sung Park, Inje university, Sanggye Paik hospital, South Korea 0829 A case of Toxocara infection as manifesting itself recurrent bronchitis Rosanna Qualizza, ASST Nord Milano, Italy 0830 An in vitro model of fully differentiated human nasal epithelial cells revealed the transcriptomic signatures of the nasal epithelium following human influenza H3N2 infection Yan Yan, National University of Singapore, Singapore 0831 The role of viruses in post-bronchiolitis wheezing/asthma development a systematic review and meta-analysis Heidi Makrinioti, Imperial Healthcare NHS Trust, United Kingdom 0832 Induced interferon lambda 1 helps bacterial clearance in persistent mucosal inflammation during staphylococcus aureus infection Feng Lan, Upper Airways Research Laboratory, ENT Department, Ghent University; Beijing Institute of Otolaryngology, Department of Otolaryngology Head and Neck Surgery, Capital Medical University, Beijing, China, Belgium 0833 Growth factors play major role in maturation process of airway epithelium in presence of atopy Styliani Taka Taka, 1National and Kapodistrian University of Athens, 2nd Pediatric Clinic, Athens, Greece 127

128 POSTERS 18 JUNE 2017, 12:00-13: Allergic fungal rhinosinusitis: our experience in the last two decades María Andreína Marques-Mejías, Allergy department, University Hospital La Paz. Hospital La Paz Institute for Health Research (IdiPaz), Spain 0835 Ascaris lumbricoides induces, both, reduction and increase of asthma symptoms in a rural community Josefina Zakzuk, Institute for Immunological Research. University of Cartagena, Colombia 0836 Decline in serum cytidine deaminase activity in patients with Hepatitis C infection L Titov, Republican Scientific and Practical Center for Epidemiology and Microbiology, Belarus 0838 ROS-dependent inhibition of phosphatases is involved in disruption of tight junctions of human nasal epithelial cells induced by rhinovirus Seon Tae Kim, Dept. of Otolaryngology, Gachon University Gil Medical Center, South Korea 0839 Hyperbaric oxygen therapy of olfactory dysfunction following viral infection of the upper respiratory tract Na Cui, China-Japan Unite Hospital of Jilin University, China 0841 The living environment shapes intestinal microbial communities and immune responses in a mouse model Noora Ottman, Institute of Environmental Medicine, Karolinska Institutet, Sweden 0837 Molecular epidemiological analysis on the human rhinovirus infections among hospitalized children in Hong Kong Hai Chao Wang, Department of Paediatrics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR Thematic Poster Session (TPS 19) Clinical presentation and management of anaphylaxis Poster Exhibition POSTERS Chair: Alberto Alvarez-Perea, Spain 0842 Patterns of anaphylaxis after diagnostic work-up: a followup study of 226 patients with suspected anaphylaxis at the emergency care setting. Athamaica Ruiz Oropeza, Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Denmark 0843 Characteristics of patients with anaphylaxis presenting to the emergency department Anamarija Sutic, Division of Clinical Immunology, Allergology and Rheumatology, Department of Internal Medicine, University of Zagreb School of Medicine, University Hospital Dubrava, Croatia 0844 Different clinical features of anaphylaxis according to the cause Min-Hye Kim, Ewha Womans University School of Medicine, South Korea 0849 Exercise induced anaphylaxis: does it occur only with food? Ayse Baccioglu, Kirikkale University Faculty of Medicine Department of Allergic Diseases, Turkey 0850 Rhabdomyolysis in the context of food-dependent exercise induced anaphylaxis Miriam Sobrino, Complejo Asistencial Universitario de Salamanca, Spain 0851 Cofactors of anaphylaxis Corina Veronica Marton, County hospital, Romania 0852 Allergic reactions induced by cofactors in patients sensitised to lipid transfer protein Mercedes Ramirez Hernandez, University Hospital Complex of Cartagena, Spain 0853 Metabolomic analysis in anaphylactic reactions.* Carolina Perales Chorda, Hospital Universitario y Politécnico La Fe, Spain 0845 Anaphylaxis in a food allergy outpatient department one year case series Rosa-Anita Fernandes, Allergy and Clinical Immunology Department, Coimbra University Hospital, Portugal 0846 Perioperative anaphylaxis in a single tertiary hospital Gyu Young Hur, Korea University College of Medicine, South Korea 0847 Level of knowledge about food allergy and anaphylaxis of parents / caregivers, elementary school teachers and university students in Uruguaiana, RS, Brazil. Marilyn Urrutia-Pereira, Federal University of Pampa (UNIPAMPA), Brazil 0848 Declarative knowledge about anaphylaxis of primary care interns in France Sébastien Lefevre, Unit of Allergy - CHR Metz-Thionville, France 0854 Use of adrenaline auto-injectors in patients at a British tertiary paediatric allergy clinic Lizanne Noronha, St Thomas Hospital, United Kingdom 0855 Use assessment of adrenaline autoinjectors among adults Ebru Özdemir, Hacettepe University School of Medicine, Department of Chest Diseases, Division of Allergy and Immunology, Turkey 0856 Adrenaline auto-injector needle length: a real concern or a red herring? Phil Lieberman, University of Tennessee, United States 0857 Anaphylaxis management in the emergency department of a tertiary hospital in the Philippines Michelle Baldorado De Vera, The Medical City and Ateneo School of Medicine and Public Health, Philippines Full abstract author lists are available on the official Congress website.

129 POSTERS 18 JUNE 2017, 12:00-13: Omalizumab for idiopathic anaphylaxis a case series Mitja Kosnik, University Clinic of respiratory and Allergic Diseases, Slovenia 0859 Is there anything else than omalizumab allergy? Soledad Sanchez Sanchez, Complejo Hospitalario Universitario A Coruña, Spain 0860 Use of omalizumab for the prevention of intraoperative anaphylaxis due to ethylene oxide sensitization in a patient with concomitant latex allergy Chiara Tontini, Postgraduate School of Allergy and Clinical Immunology, Università Politecnica delle Marche, Italy Late Breaking Thematic Poster Session (LB TPS 1) Allergen immunotherapy: From vaccines to efficacy and safety Poster Exhibition 1517 The effect of azoximer bromide in treatment irritable bowel syndrome Mohammad Reza Sheikh Sajjadieh, Nobel Medical Laboratory, Iran 1518 Sublingual immunotherapy in treatment of perennial allergic rhinitis with or without allergic asthma Michael Rudenko, London Allergy & Immunology Centre, United Kingdom 1519 Real life study on the therapeutic criteria and adverse events in the course of sublingual allergen immunotherapy in 150 patients with allergic rhinitis and asthma George Christoff Christoff, Medical University Sofia, Faculty of Public Health, Bulgaria 1520 A novel H4R-based epitope vaccine screening by phage display peptide library change the unbalance of the Th1 /Th2 in an allergic rhinitis model Lin Li, China-Japan Union Hospital of Jilin University, China 1521 Preseasonal grass pollen SLIT in at risk individuals confers protection from epidemic thunderstorm asthma Robyn E O Hehir, Allergy, Immunology & Respiratory Medicine, Monash University and Alfred Health, Australia 1522 Clinical research on the sublingual immunotherapy in mitesensitized patients with allergic rhinitis Yong Li, Hangzhou First People S Hospital, China 1523 Intra-seasonal initiation of the SQ-standardised grass sublingual tablet is well tolerated when applied by allergy specialists and allergologically experienced general practitioners Hendrik Wolf, ALK-Abelló Arzneimittel GmbH, Clinical Development, Germany 1524 Actions of improvement in the follow-up of patients subject to treatment with specific immunotherapy in the allergology consulting room of the Hospital Comarcal Noroeste (Caravaca de la Cruz, Spain) Margarita Tomás Pérez, Hospital Sanitas La Moraleja, Spain 1525 Patient s perceptions of using two types of sublingual immunotherapy Roisin Fitzsimons, Guys and St Thomas NHS, United Kingdom 1528 Treatment with a 300 index of reactivity (IR) 5 grass pollen tablet is associated with long-term relief of allergic rhinitis: a retrospective real-life dataset subgroup analysis Ulrich Wahn, Department for Pediatric Pneumology and Immunology, Germany 1529 Comparison of immunogenicity of the recombinant B cell epitope-based grass pollen vaccine BM32 with allergen extract-based scit Milena Weber, Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria;, Austria 1530 Formulation development of a new hypoallergen birch pollen vaccine and its physico chemical validation by ich conform quality control assays for a first in man clinical trial Julia Hess, Biomay AG, Austria 1531 Effect of immunotherapy with total body bacterial extract inactivated in the prevention of infections in upper airways in patients with partial IgA deficiency Fernando Monteiro Aarestrup, Clinic of allergy and clinical immunology of Terezinha de Jesus Hospital, Faculty of Medical Sciences and Health (SUPREMA), Brazil 1532 Influence of combined allergen-specific immunotherapy on immune status of patients with pollinosis with sensitization to the pollen and domestic allergens Sofiia Biletska, Department of Family Medicine of FPE of State Establishment «Dnipropetrovs k Medical Academy of Health Ministry of Ukraine», City allergology center, Ukraine 1533 A retrospective, real world database analysis to assess the long-term relief in allergic rhinitis and the impact on asthma of a treatment course with grass pollen sublingual tablets: Methodology Ulrich Wahn, Department for Pediatric Pneumology and Immunology, Charité Medical University, Germany 1534 A treatment with 300 index of reactivity (IR) 5-grass pollen tablet is associated with a reduction of asthma onset and a reduction of its progression Philippe Devillier, UPRES EA 220, Hospital Foch, University Versailles Saint Quentin, France POSTERS 1527 Development of an elisa-based surrogate assay for measuring blocking IgG induced by ait Raffaela Campana, Medical University of Vienna, Austria 129

130 POSTERS 18 JUNE 2017, 12:00-13: Quantitative measurement of allergen-specific IgG1 and IgG4 during immunotherapy with the recombinant B cell epitopebased grass pollen allergy vaccine BM32 Margarete Focke-Tejkl, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria Late Breaking Thematic Poster Session (LB TPS 2) Food allergy in children: From epidemiology to management Poster Exhibition POSTERS 1536 Allergen safe food in the roadside small restaurants in 11 cities across Europe, Thailand & India - Differences in practice, perception & legislation: An observational study Tushar Banerjee, County Durham & Darlington NHS Foundation Trust, United Kingdom 1537 Anaphylaxis to food in children up to 3 years Julia Gawryjolek, Department of Pediatrics, Allergology and Gastroenterology, Nicolaus Copernicus University, Ludwik Rydygier Collegium Medicum, Poland 1538 Anaphylaxis induced by tree nuts in preschool age children João Azevedo, CUF Descobertas Hospital, Portugal 1539 Single dose food challenge with milk significantly accelerates tolerance acquisition in milk allergic infants Darren Buckley, University College Cork, Ireland 1540 Novel smartphone based interactive system to prevent food allergy in school Min-Gyu Kang, Chung-Buk National University Hospital, South Korea 1541 The prevalence and characteristics of oral allergy syndrome in japanese children from a nation-wide survey Mari Sasaki, Tokyo Metropolitan Children s Medical Center, Japan 1542 Walnuts allergy in children as primary and secondary allergy Adnan Bajraktarevic, Public Health Institution of Health Center Sarajevo Pediatrics department, Bosnia and Herzegovina 1543 Comparison of the prevalence and characteristics of food allergy in children between urban and rural areas in beijing Chuanhe Liu, Capital Institute of Pediatrics, China 1544 Food allergy profile and its influencing factors in children from schools in Hortaleza District, Madrid Martha Cabrera, Servicio de Alergia. Hospital Los Madroños. Brunete, Spain 1545 Diagnostic algorithm for gluten intolerance in children V A Revyakina, Federal Research Centre of Nutrition, Biotechnology and Food Safety, Russia 1546 Implementation of EAACI Food Allergy Guidelines 2014 and National Russian Recommendations 2015 in 36 cities of Russian federation Tatiana E Lavrova, Nutricia LLC, Russia 1547 Goat s milk allergy in children under specific oral tolerance induction protocol for cow s milk allergy Vasiliki Zisaki, 2nd Pediatric Clinic, University of Athens, Allergy Unit, Children Hospital P&A Kyriakou, Greece 1548 Allergy to cow s milk associated with allergic dermatitis and chronic diarrhea Maria Alul, Centro de Inmunologia Pediatrica Asma y Alergia, Argentina 1549 Food intolerance and food allergy in children in lviv region (ukraine) Oksana Matsyura, Danylo Halytsky Lviv National Medical University, Ukraine 1550 Severe brazil nut anaphylaxis in a 3 year-old boy Olaya Alvarez García, Allergy Dept., Hospital Clínico San Carlos, IdISSC, Spain 1551 Tolerance to hazelnut cocoa spread in hazelnut allergic children Georgia Christopoulou, 2nd Pediatric Clinic, University of Athens, Allergy Unit, Children Hospital P&A Kyriakou, Greece 1552 The nutcracker study: specific IgE to Ara H 2 as part of a 2-step model for the diagnosis of peanut allergic in egg allergic children. Deborah Marriage, Bristol Royal Hospital for Children, United Kingdom 1553 Health-related quality of life of food allergic chidren compared to general population and other diseases in southwestern europe Lisa Giovannini-Chami, Hôpitaux pédiatriques de Nice CHU- Lenval, France 1554 A complex diagnosis for a complex evolution Ana Isabel Igreja, Pediatric Department of Centro Hospitalar de Trás-os-Montes e Alto Douro, Portugal Full abstract author lists are available on the official Congress website.

131 POSTERS 18 JUNE 2017, 12:00-13:30 Late Breaking Thematic Poster Session (LB TPS 3) Anaphylaxis, venom and drugs Poster Exhibition 1555 A case study: the effect of massive honeybees attack on various body parameters atopic girl including allergy Mohemid M Al-Jebouri, College of Medicine,University of Tikrit, Iraq 1556 Specific IgE sensitization to honey bee venom and autoinjector adrenaline prescriptions for japanese beekeepers Masamitsu Tatewaki, Dokkyo Medical University Koshigaya Hospital, Japan 1564 Basophil activation test is a useful ancillary test in perioperative anaphylaxis Nagesh Chowdahalli Nanjappa, The Queen Elizabeth Hospital, Australia 1565 Severe allergic reaction triggered by colic pain releiver medication in a newborn Azize Pinar Metbulut, Near East University Hospital, Department of Pediatrics, Cyprus 1557 Anaphylaxis in the Greek pediatric population Ioanna Manolaraki, Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University, Greece 1558 Severe abdominal pain in anaphylaxis Olaya Alvarez García, Allergy Dept., Hospital Clínico San Carlos, IdISSC, Spain 1559 Anaphylaxis IgE mediated to iodinated contrast agents with tolerance A iodixanol Dorimar Cristina Brugaletta Matheus, Hospital Universitario de Torrevieja, Spain 1560 Limited clinical utility of a panel of routine honeybee venom components Martina Vachová, Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Czech Republic 1561 Clinical characteristics of anaphylaxis by honeybee venom in north china Kai Guan, Allergy Department of Peking Union Medical College Hospital, China 1562 Hymenoptera venom imunotherapy in a pediatric group Ana Castro Neves, Immunoallergology Department, Dona Estefânia Hospital, Centro Hospitalar Lisboa Central, Portugal 1563 Tryptase behaviour during venom immunotherapy associates with the risk of adverse reactions Arantza Vega Castro, Hospital Universitario de Guadalajara, Spain 1566 Cefixime induced fixed drug eruption in an adolescent Ilknur Kulhas Celik, Ankara Children s Hematology Oncology Training and Research Hospital, Department of Pediatric Allergy and Immunology, Turkey 1567 Successful desensitization in a patient with hypersensitivity reaction to laronidase Insu Yilmaz, Erciyes University School of Medicine, Department of Chest Diseases, Division of Immunology and Allergy, Turkey 1568 Challenge is needed to obtain accurate diagnosis in allergic reactions to low-molecular-weight heparins Inmaculada M Sánchez-Guerrero, Hospital Clínico Universitario Virgen de la Arrixaca, Spain 1569 A rare case of angioedema to different antihypertonic drug classes due to possible hypersensitivity to drug additives Claudia Lang, Department of Dermatology, University Hospital Zurich, Switzerland 1570 A new penicillin allergy diagnosis in pregnancy at Groote Schuur Hospital, Cape Town, South Africa: Could this be a hormonal phenotype? Tshegofatso Mabelane, University of Cape Town, South Africa 1571 Unusual presentation of amoxicillin hypersensitivity: a case report Macarena Pinero-Saavedra, Centro Hospitalar do Algarve, Portugal 1572 The efficiency of venom immunotherapy and its positive correlation on pollen allergy Leonora Hana Lleshi, Allergology & Immunology, Kosovo POSTERS 131

132 POSTERS 19 JUNE 2017, 12:15-13:45 MONDAY, 19 JUNE, 2017 Thematic Poster Session (TPS 20) Immunotherapy - Efficacy, safety and individualised therapy Poster Exhibition Chairs: Gunter Sturm, Austria Constantinos Pitsios, Cyprus 0861 Relevant patient benefit of 5-grass pollen tablet allergen immunotherapy (AIT) in grass-pollen allergic adults, adolescents and children with different clinical profiles Meike Hadler, Stallergenes GmbH, Germany 0862 Efficacy of allergen specific immunotherapy in children with pollen-food allergy syndrome and different IgE profiles to recombinant component-resolved allergens (preliminary results). Oxana A Ereshko, Scientific Centre of Children Health, Russia 0863 Short course specific immunotherapy for seasonal allergic rhinoconjunctivitis and its impact on quality of life Claire Corps, St James s University Hospital, United Kingdom 0864 Tolerability of concentrated extract of house dust mite carbamylated allergoid delivered at high frequency to allergic patients in a period of six months. Gino Scalone, Unità Operativa di Fisiopatologia e Allergologia Respiratoria, Casa della Salute - Chiaravalle Centrale (CZ)., Italy 0865 Effect of immunotherapy with a subcutaneous polymerised mites extract on degranulation of basophils. Esther Bartoll, Paediatric Service. La Fe Hospital, Spain 0866 Effectiveness of slit for birch and house dust mite in patients with allergic rhinitis Mojca Kecelj, Remeda, medical centre, Slovenia 0869 Analysis of sensitization profile to airborne allergens of ukrainian children and efficiency of slit to the most common allergens in the atopic dermatitis treatment. Tetiana Umanets, Institute of Pediatrics, Obstetrics and Gynecology of NAMS, Ukraine 0870 The analysis of safety and effectiveness of allergen immunotherapy for hymenoptera venom allergy Karol Kempinski, Department of Allergology at Medical University of Gdansk, Poland 0871 Efficacy of the subcutaneous immunotherapy performed in a woman with a whole body extract of pseudomyrmex ant, in Argentine Raquel M Rodriguez, Hospital de Clínicas, Argentina 0872 Time to achieving maintenance dose of allergoid preparation of dermatophagoides pteronissimus in specific subcutaneous immunotherapy of asthmatic subjects Besim Prnjavorac, General Hospital Tešanj, Bosnia and Herzegovina 0873 Allergen immunotherapy in a patient with eosinophilic granulomatosis with polyangitis and allergic rhinitis Yasmin Hamzavi Abedi, Hofstra Northwell School of Medicine, Division of Allergy and Immunology, United States 0874 Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: A meta-analysis Hussien Ahmed, Faculty of Medicine, Zagazig University, Egypt POSTERS 0867 Routine clinical management of children and adolescents with house dust mite allergy in france Isabelle Bossé, Private practice, France 0868 Non-allergic rhinitis: new adjuvant treatment with probiotic formulation Fabio Guagnini, Medical and Scientific Department, Allergy Therapeutics Italia, Italy 0875 Bacillus Calmette Guérin immunotherapy enhances cellular immunity against human papillomavirus infection Evelina Vetskova, National Center of Infectious and Parasitic Diseases, Bulgaria 0876 Effects of ß glucan on natural killer cells and their subpopulations in patients after cancer treatment Jitka Pohorská, Institute of Public Health, Centre of Immunology and Microbiology, Czech Republic Thematic Poster Session (TPS 21) Asthma mechanisms Poster Exhibition 0877 The anti-inflammatory effects of pentaherbs formula on ovalbumin-induced asthmatic mice model Sin Man Tsang, Institute of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong SAR 0878 The level of adipokines at patients of young age with bronchial asthma Irina Vladimirovna Demko, KrasGMU, Russia 0879 Flow cytometry analysis of surface molecule expression on in vitro differentiated human macrophages Igor P. Shilovskiy, National Research Center - Institute of Immunology, FMBA of Russia, Russia 0880 Effect of IgE sensitization to apergillus fumigatus on eosinophilic airway inflammation and bronchial hyperresponsiveness in adult atopic asthma Michiyoshi Imaoka, Fukuoka National Hospital, Japan 0881 Activation of eosinophils interacting with bronchial epithelial cells by antimicrobial peptide LL-37 in allergic asthma Chun Kwok Wong, Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong SAR 0882 The prevalence of seasonal asthma and rhinitis in mite allergic patients Rana S. Isik, Yedikule Chest Diseases and Surgery Education and Research Hospital, Turkey Full abstract author lists are available on the official Congress website.

133 POSTERS 19 JUNE 2017, 12:15-13: Disturbed balance of treg cell subpopulations in late-onset elderly asthma Sung-Yoon Kang, Department of Internal Medicine, Seoul National University College of Medicine, South Korea 0884 Exercise-induced dyspnoea: results of a standardized exercise challenge in a cold chamber Melanie Dreßler, Department for Children and Adolescents, Division of Allergology, Pulmonology and Cystic fibrosis, Goethe University Hospital, Germany 0885 Cadherin-related family member 3 expression in alveolar type II epithelial cells and primary human nasopharyngeal epithelial cells upon exposure to asthma-related stimuli Ting Fan Leung, Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong SAR 0886 To study the role of t regulatory cells in developing asthma in a birth cohort of babies with family history of allergies Gurjit Kaur, Postgraduate Institute of Medical Education and Research, India 0887 The role of eosinophils and matrix metalloproteinases-2 in airway remodeling Yu Kuwabara, Allergy Center,Mie National Hospital, Japan 0888 Recurrent wheezing 36 months after the first episode of bronchiolitis in infancy: the viral link Heidi Makrinioti Makrinioti, imperial healthcare nhs trust, United Kingdom 0889 Serum leptin and adiponectin levels correlate with mast cell activation during exercise-induced bronchospasm in asthmatic children Jae-Won Oh, Hanyang.ac.kr, South Korea 0890 Fixed airflow obstruction in patients with asthma Galina Raisovna Sergeeva, North-Western State Medical University named after I.I.Mechnikov, Russia 0891 Modulating factors of cortisol response to an exercise challenge Diana Silva, Basic and Clinical Immunology, Department of Pathology, Faculty of Medicine, University of Porto & Serviço de Imunoalergologia, Centro Hospitalar de São João E.P.E., Portugal 0892 Exercise induced asthma: when the disease is not an excuse Alexandra Rodrigues, Hospital Dr. Nélio Mendonça, Portugal Thematic Poster Session (TPS 22) Nutritional and psycho-social issues in food allergy Poster Exhibition Chairs: Kate Grimshaw, United Kingdom Inger Kull, Sweden 0893 Effects of allergenic food diversity and avoidance on the risk of ige sensitization in the first year of life Jing-Long Huang, Department of Pediatrics, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taiwan 0894 IgE sensitization to food allergens and food allergy manifestation in children following different vegetarian diets (first results) Dmitry Yasakov, Federal State Autonomous Institution, Russia 0895 Excessive food elimination by pediatricians in food allergic infants and their mothers Betul Buyuktiryaki, Ankara Children s Hematology Oncology Education and Research Hospital, Pediatric Allergy and Immunology, Turkey 0896 The role of a dietitian in the management of wheatdependent exercise-induced anaphylaxis Iason Thomas, Department of Allergy, Guy s and St Thomas NHS Foundation Trust, United Kingdom 0897 Allergy service dietetic support and food challenge testing: variation in practice Emily Carne, University Hospital of Wales, United Kingdom 0898 Nutritional status and growth in children with food allergies Elena Rodriguez Martin, Allergy Department, Hospital Don Benito-Villanueva, Spain 0900 Treatment of SNAS only with diet or with diet + tionickel: evaluation of the blinded challenge at T0 (start) and after 36 months of therapy Maria Assunta Boscolo, S.L.Mandic Hospital Merate (LC) Italy, Italy 0901 The effects of individualized nutrition intervention on the disease severity and nutrition status in the children with atopic dermatitis and food allergy Jae Ho Lee, 1Department of Pediatrics, College of Medicine, Chungnam National University, South Korea 0902 Living healthily with food allergy Debbi Stockhammer, Charles Sturt University, Australia 0903 Application of management of food allergy guideline into day-by-day practice of paediatricians in Russia Svetlana Makarova, Federal State Autonomous Institute Scientific Center of Children s Health The Ministry of Health of the Russian Federation, Russia 0904 Teaching teachers: development of an educational strategy to improve school teachers knowledge on food allergy and anaphylaxis. Paloma Poza-Guedes, Servicio de Alergia, Hospital del Tórax, HUNSC, Spain 0905 Turkish validation and reliability of food allergy quality of life questionnaire-parent form Ebru Arik Yilmaz, Hacettepe University School of Medicine, Department of Pediatric Allergy, Turkey POSTERS 0899 Longitudinal study shows improved nutrient intakes and growth with an amino acid formula for children 1y with cow s milk allergy and related conditions Katy Sorensen, Nutricia, United Kingdom 0906 Effect of dietary elimination on psychosocial functioning status in breastfeeding mothers of infants with food allergy Cansin Sackesen, Koc University School of Medicine, Pediatric Allergy, Turkey 133

134 POSTERS 19 JUNE 2017, 12:15-13: Pre-service teachers perception of allergic students quality of life Tina Vesel, University Medical Center, University Children s Hospital, Department of Allergology, Rheumatology and Clinical Immunology, Slovenia 0908 Impact of suspected food allergy on parental anxiety Burcin Beken, Trakya University Medical Faculty, Department of Pediatric Allergy and Immunology, Turkey 0910 Social media and food allergy in children Alberto Alvarez-Perea, Hospital Materno Infantil Gregorio Marañón, Spain 0911 Internet use and attitudes of the parents of children with food allergy Ilknur Kulhas Celik, Ankara Children s Hematology Oncology Training and Research Hospital, Department of Pediatric Allergy and Immunology, Turkey 0909 Understanding why young people with severe allergies join support groups. Lauren Aimee Sommereux, Brighton & Sussex Medical School, United Kingdom Thematic Poster Session (TPS 23) Pediatric food allergy Poster Exhibition POSTERS Chair: Anna Pelkonen, Finland 0912 Immunophenotypes of cow s milk protein allergy: new approach in predicting the development of tolerance Maria Petrovskaya, Federal State Autonomous Institution, Russia 0913 Opportunities for primary prevention of food allergy in infants by the introduction of hypoallergenic commercially produced complementary foods Tatiana E. Borovik, Scientific Center of Children s Health, Russia 0914 The dark side of The poppaea S soap Matteo Martini, Allergy Unit, Department of Internal Medicine, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Italy 0915 A new strategy for diagnosing egg allergy in children with cow milk allergy Francisco Javier Ruano, Hospital Universitario Infanta Leonor, Spain 0916 Cow s milk-related symptom score (CoMiSS) as a screening tool for cow s milk allergy in children aged 0-24 months- a cross sectional longitudinal study in india. Rajniti Prasad, Institute of medical sciences, India 0917 Mirnome analysis highlights a specific cow s milk allergyrelated epigenetic signature Lorella Paparo, University of Naples Federico II, Italy 0918 Food allergy diagnosis: in vitro method for measurement of basophil activation and/or degranulation in children with food allergies Jelena Živkovic, Children s Hospital Srebrnjak, Croatia 0921 Cow s milk protein allergy a retrospective study in a pediatric clinic from Nord-East of Romania Dana-Teodora Anton-Paduraru, Romania 0922 Multiple food FPIES : An unusual, severe phenotype Hamed Al-Shammari, St Thomas Hospital, United Kingdom 0923 Clinical and feeding behaviour assessment of egg oral immunotherapy treated children after 7 years of follow up Gian Marco Chiarella-Privette, Allergy Department. Hospital Infantil Universitario Niño Jesús, Spain 0924 Tropomyosin from vertebrates as an allergen case report Sara Peixoto, Pediatric Department of Centro Hospitalar de Trás-os-Montes e Alto Douro (CHTMAD), Portugal 0925 Allergy to goat and sheep whey proteins without allergy to cow s milk. Remedios Cárdenas, H.U. Guadalajara, Spain 0926 Allergic reaction to whey protein powder in infancy Peter Korošec, University Clinic of Respiratory and Allergic Diseases Golnik, Slovenia 0927 Case report: allergy to donkey s milk Martine Morisset, Immunology Allergology Unit, Centre Hospitalier, Luxembourg 0928 Anaphylactic reactions to novel foods: Case report of a child with severe crocodile meat allergy Natalia Ballardini, Karolinska Institutet, Sweden 0929 Ig-e mediated severe cow s milk allergy and salmonella carrier in a child with good weight gain Irina Veronica Costache, Faculty of Medicine, Romania 0919 Multiple food allergy unexpected culprits Cristina Ornelas, Imunoallergology Department, Centro Hospitalar Lisboa Norte, Hospital Santa Maria, Portugal 0920 Food allergy in preschools in Japan : survey of 1152 facilities in chiba prefecture Izumi Kato, Department of Pediatrics, Chiba Municipal Hospital, Japan 0930 Watery Diarrhea Hypkalemia Achlorhydria (WDHA) syndrome may mimic celiac disease or allergic gastroenteritis K Lishchuk-Yakymovych, Danylo Halytskyi Lviv national medical university, Lviv regional clinical diagnostic center, Ukraine Full abstract author lists are available on the official Congress website.

135 POSTERS 19 JUNE 2017, 12:15-13:45 Thematic Poster Session (TPS 24) Cellular diagnostics and IgE test development Poster Exhibition Chair: Wolfgang Hemmer, Austria 0931 Basophil testing contributes to the diagnosis of drug allergy in an allergy center Hans Jürgen Hoffmann, Aarhus University, Denmark 0932 Lymphocyte activation test, an emerging tool in the diagnosis of drug allergy. Lourdes González-Cavero, Hospital Universitario La Paz, Spain 0933 Toward fully leveraging the capabilities of basophil activation test in clinical research through workflow simplification and standardization Rihane Arif, Beckman Coulter Immunotech, France 0934 Granzyme b enzyme-linked immunospot assay in diagnosis of Stevens-Johnson syndrome induced by allopurinol Grzegorz Porebski, Jagiellonian University, Department of Clinical and Environmental Allergology, Poland 0935 Elevated DAO in patients with histamine intolerance Tihomir B. Mustakov, Clinic of Allergy & Asthma, Medical University Sofia, Bulgaria, Bulgaria 0936 Passive sensitization by transfusion with solvent-detergent treated pooled plasma in patients undergoing cardiothoracic surgery Kari Eilidh Mikkelsen, Haukeland University Hospital, Norway 0937 Testing for allergy to common and rare metals in patients with intolerance to implanted metallic devices Radoslaw Spiewak, Department of Experimental Dermatology and Cosmetology, Jagiellonian University Medical College, Poland 0938 Analysis of ICD-10 diagnosis codes of patients with hypereosinophilia Ilknur Kulhas Celik, Ankara Children s Hematology Oncology Training and Research Hospital, Department of Pediatric Allergy and Immunology, Turkey 0939 Determination of reference values for IgG antibodies against typical antigens of hypersensitivity pneumonitis current data of a German multicentre study Monika Raulf, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Germany 0940 Correlations between pollen exposure, pollen sensitization and patent pollen allergy Denis Charpin, Aix Marseille universités, France 0941 Measurement of 181 atopy cases allergic state of dust mites and fractional exhaled nitric oxide (FeNO) and serum IgE Yinshi Guo, Renji Hospital, China 0942 Fractional exhaled nitric oxide in elementary school children: a candidate predictor for atopy? Doo Hee Han, Seoul National University Hospital, South Korea 0943 Do we appropriately do allergy testing in primary care? Jurgita Janukonyte, Central Jutland Hospital, Denmark 0944 Use of high technologies in clinical laboratory diagnostics of a seasonal allergic rhinitis. Olga Petrovna Ukhanova, Stavropol regional medical university, Russia 0945 Establishment of Artificial Human Sera (ARTHUS) based on Chimeras of FcγRI and Human Immunoglobulin G4 (IgG4) Domains Nadine Offermann, Dr. Fooke Laboratorien GmbH, Germany Thematic Poster Session (TPS 25) Component resolved Diagnosis Chairs: Victoria Cardona, Spain Alex Straumann, Switzerland 0946 Phylogenetic relationship according allergen sensitization pattern between 10 mites in a tropical area. Andres Sánchez, Corporation University, Rafael Nuñez., Colombia 0947 Serum ige reactivity to major dermatophagoides pteronyssinus allergens in house dust mite allergic patients from northeast poland. Krzysztof Kowal, Medical University of Bialystok, Poland 0948 Regional differences in the prevalence of sensitization to lipid transfer proteins and severity of allergy symptoms in Italy: results of a multicenter study Maria Teresa Liuzzo, University of Catania - Respiratory Medicine and Allergology, Italy Poster Exhibition 0949 A comparison of IgE- and IgG-immunoreactive properties of protoplasmic proteins derived from different strains of lactobacillus genus. Anna Szyc, Institute of Animal Reproduction and Food Research of PAS, Olsztyn, Poland, Poland 0950 The first European allergen components profile of six main inhalant allergens in 492 atopic children. An important absence of major allergen components. Lukasz Blazowski, Allergy and Pulmonary Medicine Department, National Research Institute for Tuberculosis and Lung Diseases - Rabka Branch, Poland 0951 Assessment of allergen specific IgE to pollen allergens in allergic patients from Central Ukraine V Rodinkova, Vinnitsa National Pirogov Memorial Medical University, Ukraine POSTERS 135

136 POSTERS 19 JUNE 2017, 12:15-13: Skin prick test reactivity to eighty different allergens among medical students in Birjand, Iran. Mohammad Fereidouni, Asthma, Allergy & Immunology Research Center, Birjand University of Medical Sciences, Iran 0953 Five-years follow-up in Italian children with seasonal allergic rhinitis: preliminary data Francesca Cipriani, Pediatric Unit, Department of Medical and Surgical Sciences, University of Bologna, Italy 0954 A cross-sectional observational study on allergen-specific IgE positivity among allergic patients in a southeast coastal versus a southwest inland region of China Wenting Luo, State Key Laboratory of Respiratory Disease; National Clinical Research Center of Respiratory Disease; Guangzhou Institute of Respiratory Disease; First Affiliated Hospital of Guangzhou Medical University, China 0955 The use of LTP s sensitization profile and protein alignment tools in food allergy management Ramon Lopez-Salgueiro, Hospital Universitario La Fe, Spain 0956 Rhi o 1 and its hypoallergenic version for immunotherapy against fungal allergy Gaurab Sircar, Bose Institute, India 0957 Different profiles of sensitization to phleum pratense: Association to response to nasal provocation test Ifigeneia Sfika, Pediatric Department and Allergy Unit Sandro Pertini Hospital, Italy 0958 The concordance between component tests and clinical history in british adults with suspected pollen-food syndrome (PFS) to peanut and hazelnut Sarah C Beck, Heart of England NHS Foundations Trust, United Kingdom Thematic Poster Session (TPS 26) Early life factors in the development of allergic disease Poster Exhibition POSTERS Chair: George Konstantinou, Greece 0959 Maternal effects on development of childhood allergic sensitization and associated diseases Ann-Marie Malby Schoos, Copenhagen Prospective Studies on Asthma in Childhood, Denmark 0960 Prenatal maternal psychosocial stress and offspring asthma and allergy risk: a systematic review and meta-analysis Audrey Dunn Galvin, University College Cork, Ireland 0961 Relation of maternal dietary and probiotic intervention during pregnancy to the risk of atopic eczema and asthma in the offspring by the 4 years of age Kirsi Laitinen, Institute of Biomedicine, University of Turku, Finland 0962 Early probiotic prophylaxis reduces allergic symptoms in 13- year follow-up Sampo Kallio, The Hospital for Children and Adolescents, Helsinki University Central Hospital, Finland 0963 Timing of solid food introduction and atopic dermatitis Corina Veronica Marton, County Hospital, Romania 0964 Associations between early infant feeding with soy formula and allergic disease in adulthood Charlotta Flodström, Department of Clinical Science and Education, Karolinska Institutet, and Sachs Children and Youth Hospital, Stockholm South General Hospital, Sweden 0965 Differences between parentally-reported and general practitioner diagnosed eczema Toshinori Nakamura, Department of Paediatrics, Imperial College London, United Kingdom 0966 The impacts of environmental factors on the changes in individual prevalence of atopic diseases in elementary school students in ulsan, korea: a cohort study Jiho Lee, Ulsan University Hospital, University of Ulsan College of Medicine, South Korea 0967 Risk factors associated with eczema throughout childhood Toshinori Nakamura, Department of Paediatrics, Imperial College London, United Kingdom 0968 The lipocalin beta-lactoglobulin accumulates in stable dust: potential implications for the allergy- and asthma-protective effect Isabella Pali-Schöll, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Austria 0969 Influence of mode of delivery on asthma, fractional exhaled nitric oxide and total serum IgE in a cohort of children aged 6 years Chi-Yen Hung, Department of Pediatrics, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taiwan 0970 Breastfeeding in relation to allergic diseases and total serum IgE at 6 years of age in Taiwanese children: A birth cohort study Chun-Hui Chu, Department of Pediatrics, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taiwan 0971 Antenatal dexamethazone exposure in preterm infants and allergic diseases in later childhood. Iuliia Kyslova, Vinnytsia National Medical University, Ukraine 0972 Prenatal and perinatal risk factors for childhood asthma and asthma-like symptoms Emilija Vlashki, Department of Pulmonology and Allergology, University Children s Clinic, Macedonia, Former Yugoslav Republic of 0973 Birth order and pediatric allergic diseases: A nationwide longitudinal survey in Japan Tomonobu Kikkawa, Department of Pediatrics, Okayama University, Japan Full abstract author lists are available on the official Congress website.

137 POSTERS 19 JUNE 2017, 12:15-13: PREGRALL: A multicenter vlinical trial to assess the efficacy of antenatal maternal supplementation with GOS/inulin prebiotics on atopic dermatitis prevalence in high-risk oneyear-old children. Marie Bodinier, INRA, UR 1268 BIA, France Thematic Poster Session (TPS 27) Asthma: Diagnosis and management Poster Exhibition Chairs: Jussi Karjalainen, Finland Silvia Sanchez-Garcia, Spain 0975 Omalizumab for severe asthma in clinical practice Arja Viinanen, Turku University Hospital, Finland 0976 The impact of long-term targeted therapy with omalizumab (more than 2 years) on the asthma control according to the registry of children with uncontrolled severe persistent asthma (Russian experience) Elena Vishneva, Scientific Center of Children s Health, Russia 0977 The dynamics of disease control in children with uncontrolled severe persistent asthma receiving omalizumab (based on pediatric registry) Elena Vishneva, Scientific Center of Children s Health, Russia 0978 Chest high-resolution computed tomography: Clinical utility in a severe asthma unit Cinthia Aracelis De La Cruz Martinez, Hospital Universitario 12 de octubre i+12, Spain 0979 The effects of saline nasal irrigation on allergic rhinitis and asthma in children Ji Young Lee, 1 Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 2 Environmental Health Center for Atopic Diseases, Samsung Medical Center, South Korea 0980 Impulse oscillometry (IOS) may be helpful in the diagnosis of asthma Johannes Martin Schmid, Department of Respiratory Medicine and Allergy, Aarhus University Hospital, Denmark 0981 Neuropsychiatric side effects induced by montelukast in children Zafer Arslan, Pediatric allergy and immunology department, TOBB ETU School of Medicine, Turkey 0982 The results of long-term dynamic monitoring of children with uncontrolled severe persistent asthma, receiving omalizumab. Elena Vishneva, Scientific Center of Children s Health, Russia 0983 Changing spectrum and causes for chronic cough in children Haralappa Paramesh Haralappa, Lakeside Center for Health Promotion, India 0984 Extracorporeal membrane oxygenation as emergency treatment for patients with near-fatal status asthmaticus Seung Eun Lee, Pusan National University Yangsan Hospital, South Korea 0985 Biological agents in severe asthma. Blood eosinophils: les joues sont fait? Anna Radice, Department of Experimental and Clinical Medicine, Unit of Internal Medicine Careggi, University of Florence, Italy 0986 Graves-Basedow disease in an asthmatic woman. Ignacio García Nuñez, Hospital Quirón, Spain 0987 Anti-IgE therapy in asthma: the western Romanian experience Carmen Panaitescu, University of Medicine and Pharmacy Victor Babes, Romania 0988 Not a difficult asthma but an easy patient solution: flowvolume curve Metin Keren, Sureyyapasa Gogus Hastaliklari ve Gogus Cerrahisi EAH, Immunology and Allergy department, Turkey 0989 Dynamics of cytokines in exhaled breath condensate and serum in patients with bronchial asthma under the influence of l-arginine Sayyora Bazarova, Center of therapy, Uzbekistan 0990 Omalizumab safety in 91 asthmatic patients given 10,472 injections up to 9 years. Danilo Di Bona, School and Chair of Allergology and Clinical Immunology, University of Bari Aldo Moro, Italy, Italy 0991 Evaluation of quality of life and prognostic scales in patients with chronic obstructive pulmonary disease Galina Ignatova, South Ural State Medical University, Russia 0992 Bronchial methacholine challenge in children Irena Ivkovic-Jurekovic, Children s Hospital Zagreb; Faculty of Medicine, University of Osijek, Croatia POSTERS 137

138 POSTERS 19 JUNE 2017, 12:15-13:45 Thematic Poster Session (TPS 28) Pediatric skin and drug allergy and varia Poster Exhibition POSTERS Chair: Flora B. de Waard-van der Spek, The Netherlands 0993 Chemiluminescent immunoassay and LC/MS-MS methodology for the determination of vitamin D status in infants at high risk for developing allergic diseases: Is there any analytical bias? Kristina Rueter, University of Western Australia, Australia 0994 Sensitized pediatric patients show lower vitamin D levels Davide Paolo Caimmi, CHRU de Montpellier, Allergy Unit and Cystic Fibrosis center, France 0995 The relation of gender to prevalence, severity and comorbidity of childhood allergic diseases in a cohort study in Taiwan Yu-Tung Lan, Department of Pediatrics, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taiwan 0996 Sensitization profiles in children and adults newly referred to a university hospital Olga Lourenço, CICS - UBI - Health Sciences Research Centre, University of Beira Interior, Portugal 0997 Aeroallergen and foodallergen sensitization in young Korean children presenting urticaria symptoms and association with vitamin D status and urticaria Jungwon Yoon, Myongji Hospital, Seonam University school of medicine, South Korea 0998 Ecthyma gangrenosum and agranulocytosis in a previously healthy child. Joon Soo Park, Soonchunhyang University Cheonan Hospital, South Korea 0999 Angioedema in women of three generations: A form of hereditary angioedema type iii Artur Bonito Vítor, Unidade de Alergologia e Imunodeficiências primárias do Hospital Pediátrico Integrado do Centro Hospitalar São João-Porto, Portugal 1000 Hypersensitivity to antibiotics in children in Vilnius University Hospital Neringa Stirbiene, Vilnius University Faculty of Medicine, Children Hospital Affiliate of Vilnius University Hospital Santariškiu klinikos, Pediatrics Centre, Lithuania 1001 Delayed hypersensitivity reactions to beta-lactams in children: challenging diagnostic Joana Cosme, Immunoallergology Department, Hospital de Santa Maria Northern Lisbon Hospital Center, Portugal 1002 Sensitization to tiurans in a pediatric patient Sara Carvalho, Immunoallergology Universitary Department, Hospital Santa Maria, Lisbon Academic Medical Center, CHLN, Portugal 1003 Guidance and preparation initiatives for participants in clinical research on pediatric allergies Hiromi Uehara, Department of Pediatrics, Fukuyama City Hospital, Japan 1004 Lithuanian allergic patient s family s experience map Kotryna Linauskiene, Vilnius University Hospital, Santariskiu Klinikos, Center of Pulmonology and Allergology, Lithuania 1005 A nursing protocol of assistance in a pediatric daily hospital of allergy Montserrat López Onieva, Hospital Infanta Leonor, Spain 1006 Outcomes of ß-lactam drug allergy challenges: A retrospective audit in a tertiary children s allergy service Julie Pentland, Great North Children s Hospital, United Kingdom 1007 Sensitization to contac allergens in a pediatric population Ana Castro Neves, Immunoallergology Department, Dona Estefânia Hospital, Centro Hospitalar Lisboa Central, Portugal 1008 Use of social media for information needs in families of children with allergies James Gardner, Great North Children s Hospital, United Kingdom Thematic Poster Session (TPS 29) Aerobiology exposures Poster Exhibition Chairs: Isabella Annesi-Maesano, France Michel Thibaudon, France 1009 Validation of a novel sampling technology for airborne allergens Iin low income urban homes Julian Gordon, Inspirotec Inc, United States 1010 Effect of meteorological parameters on pollen concentration in the city of Athens Paraskevi Katsaounou, National and Kapodistrian University of Athens, Greece 1011 Allergenic importance of alstonia pollen: a common respiratory sensitizer of Eastern India Moumita Bhowmik, Bose Institute, India 1012 Monitoring of plant aeroallergens in batumi, second largest city of Georgia Tamar Abramidze, Center for Allergy & Immunology Research, Georgia 1013 Case study France: analysis of plant occupation of public green spaces Michel Thibaudon, RNSA, France 1014 City arboreal pollen rain is a mix of local and migrating pollen in Vinnytsia, Ukraine V Rodinkova, Vinnytsya National Pirogov Memorial Medical University, Ukraine Full abstract author lists are available on the official Congress website.

139 POSTERS 19 JUNE 2017, 12:15-13: Exposure to bioaerosols during fish processing on board fishing trawlers Lisbeth Aasmoe, University Hospital of North Norway, Department of Occupational and Environmental Medicine, Norway 1016 Allergic diseases and impacts of climate changes in children Darejan Khachapuridze, NIAACI, Georgia 1017 Polcalcin sensitization in a sample of patients with respiratory allergy in Barcelona (Spain). Cynthia Giovanna Araujo Sánchez Giovanna, Allergy Unit. Pneumology Deparment. Hospital Clinic., Spain 1018 Environmental tobacco smoke exposure and childhood asthma Is it a trigger or risk factor or both? Valentina Cvejoska Colakovska, University Children s Clinic, Department of Pulmonology and Allergology, Macedonia, Former Yugoslav Republic of 1019 Efficacy of air cleaners for the removal of house dust mites and dog allergens Jinyoung Choi, Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, South Korea 1020 Study on the correlation of airborne pollen and anti-allergic eye drops consumption in Beijing urban area. Xiaoyan Wang, allergy department of beijing shijitan hospital, China Thematic Poster Session (TPS 30) Hereditary angioedema and mast cell disorders Poster Exhibition Chair: Bettina Margrethe Jensen, Denmark 1021 Hereditary angioedema experience in a Belgian reference centre. Athina L. Van Gasse, University of Antwerp, Belgium 1022 Genetic study of hereditary angioedema type II in two siblings in Iran Susan Nabilou, Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Iran 1027 A unique presentation of pulmonary disease in advanced systemic mastocytosis, proven by the presence of mast cells in broncheoalveolar lavage. Maud Hermans, Erasmus MC, The Netherlands 1028 Genotype has impact on complement proteins in patients with hereditary angioedema Nihal Mete Mete Gokmen, Ege University Medical Faculty, Turkey 1023 Hereditary angioedema in two sisters due to parental mosaïcism Athina L. Van Gasse, University of Antwerp, Belgium 1024 The impact of the introduction of icatibant on A&E attendance, hospital admissions and acute treatment episodes in patients with hereditary angioedema Sarah Denman, The Leeds Teaching Hospitals NHS Trust, United Kingdom 1025 Identifying early HAE attack signs and symptoms: A UK nurse consensus John Dempster, Barts Health NHS Trust, United Kingdom 1026 Routine abdominal ultrasonography has limited value in the care for patients with systemic mastocytosis. Maud Hermans, Erasmus MC, The Netherlands 1029 BCX7353, a once-daily oral kallikrein inhibitor, is effective and safe in the prophylaxis of acute attacks in patients with hereditary angioedema: Attack-level analysis of the APeX-1 study Emel Aygören, Department for Children and Adolescents, University Hospital, Germany 1030 Health related quality of life in hereditary angioedema patients Nihal Mete Gokmen, Ege University Medical Faculty, Turkey 1031 Specialty in hereditary angioedema patients from china mainland Yu Xiang Zhi, Peking Union Medical College Hospital, China 1032 Just syncope... are you sure? Paloma Jaqueti, Hospital Clínico San Carlos, Spain POSTERS 1033 Hereditary angioedema in Neiva, Colombia Jairo Antonio Rodriguez, Universidad Surcolombiana, Colombia Thematic Poster Session (TPS 31) Immune deficiency Chairs: Isabella Quinti, Italy Anna Sediva, Czech Republic 1034 New aspects of the pathogenesis of respiratory diseases in frequently ill children Maleyka Knyaz Karimova, Azerbaijan Medical University, Azerbaijan Poster Exhibition 1035 Is lymphopenia overlooked in pediatric clinics? Ilknur Kulhas Celik, Ankara Children s Hematology Oncology Training and Research Hospital, Department of Pediatric Allergy and Immunology, Turkey 1036 Enteritis in a child with severe combined immunodeficiency (SCID) Marta Martins Batista, Hospital de São Bernardo, Portugal 139

140 POSTERS 19 JUNE 2017, 12:15-13: Clinical features and effectiveness of intravenous immunoglobulins in patients with primary antibody production deficiencies in the middle urals Evgeny Beltyukov, Ural State Medical University, Russia 1038 Our experience with primary immunodeficiency patients started on subcutaneous immunoglobulin treatment at gaziantep university s pediatric allergy immunology clinic: Preliminary data Sevgi Bilgic Eltan, Gaziantep University Pediatric Allergy and Immunology, Turkey 1039 Hyper-ige syndrome: A case report Marta Martins Batista, Hospital São Bernardo, Portugal 1040 Autosomal dominant and recessive hyper IgE syndrome in Turkish children: a single centre experience Neslihan Edeer Karaca, Ege University Faculty of Medicine, Department Of Pediatrics, Division of Pediatric Allergy and Immunology, Turkey 1042 Deficiency of glucose 6 phosphatase: the importance of screening for primary immunodeficiency (PI) Marta Martins Batista, Hospital de São Bernardo, Portugal 1043 Optimal response to canakinumab in a patient with chronic recurrent multifocal osteomyelitis Ines Torrado Español, Pediatric Immunology and Allergy Department HGUGM, Spain 1044 Immune deficiency and wegener s granulomatosis: A rare coexistence Fevzi Demirel, Gülhane Training and Research Hospital, Division of Immunology and Allergic Diseases, Turkey 1045 Tolerance of rapid intravenous immunoglobulin (IVIG) infusion Sanny K Chan, Division of Allergy and Immunology and the Immunodeficiency Diagnosis and Treatment Program, National Jewish Health, United States 1041 DOCK2 deficiency in one Iranian patient Zahra Alizadeh, Immunology, Asthma & Allergy Research Institute, Tehran University of Medical Sciences, Iran Thematic Poster Session (TPS 32) Hereditary angioedema Poster Exhibition POSTERS 1046 C1-inh-hae: the relationship between parents and children s emotional status, children s disease activity and health related quality of life Aharon Kessel, Bnai Zion Medical Center, Israel 1047 Safety of diverse treatment modalities in pediatric patients with hereditary angioedema Henriette Farkas, Hungarian Angioedema Center,3rd Department of Internal Medicine, Semmelweis University, Hungary 1048 Hereditary angioedema in Slovakia results from national pilot study Milos Jesenak, Center for Hereditary Angioedema, Dpt. of Paediatrics JFM CU, Slovakia 1049 Hereditary angioedema: analysis of 287 attacks treated with C1 esterase inhibitor in the French cohort cobra Francois Allaert, Hospital, France 1050 Elderly vs younger patients (pts) with hereditary angioedema type I/II: safety analysis from the icatibant outcomes survey Hilary J. Longhurst, Department of Immunology, Barts Health NHS Trust, United Kingdom 1051 Presence and family distribution of SERPING1 mutations in macedonian HAE type I patients Vesna Grivcheva-Panovska, PHI University Clinic of Dermatology, School of Medicine, University St. Cyril and Methodius, Macedonia, Former Yugoslav Republic of 1052 The international registry for angioedema without wheals Francesca Perego, Dept. Biomedical and Clinical Sciences Luigi Sacco; ASST Fatebenefratelli-Sacco, Milano, Italy 1053 A novel prophylaxis in hereditary angioedema with C1- inhibitor deficiency: administration of C1-inhibitor during erythema marginatum Kinga Viktória Kohalmi, Hungarian Angioedema Centre, 3rd Department of Internal Medicine, Semmelweis University, Hungary 1054 The goal of prophylaxis against hereditary angioedema attacks is no attacks: A summary of findings for approved and investigational products Emel Aygören-Pürsün, Department for Children and Adolescents, Angioedema Centre, University Hospital Frankfurt, Goethe University, Germany 1055 Approaches to estimate plasma kallikrein inhibition levels required for attack prophylaxis in hereditary angioedema Daniel J Sexton, Shire, United States 1056 Novel high-resolution follow-up of the coagulation and fibrinolytic parameters in a single angioedematous attack of a C1-INH-HAE patient Nora Veszeli, Hungarian Angioedema Centre, 3rd Department of Internal Medicine, Semmelweis University, Hungary 1057 Prevention of Hereditary Angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: Effects on severity and attack location Michael Tarzi, Brighton and Sussex Medical School, United Kingdom 1058 Real-world outcomes in C1 inhibitor hereditary angioedema: experience from the icatibant outcome survey in Spain Mar Guilarte, Allergy Section, Medicine Department, Hospital Universitari Vall d Hebron, Universitat Autònoma de Barcelona, Spain Full abstract author lists are available on the official Congress website.

141 POSTERS 19 JUNE 2017, 12:15-13: A phase 3 open-label extension study of the efficacy and safety of lanadelumab for the prevention of angioedema attacks in patients with hereditary angioedema: trial design Marc Riedl, University of California San Diego School of Medicine, United States Thematic Poster Session (TPS 33) Management of atopic dermatitis and other skin diseases Poster Exhibition Chair: Tilo Biedermann, Germany 1060 Cyclosporine in the management of patients with refractory severe atopic dermatitis to conventional treatment Cesar Fireth Pozo, Hospital Infantil de Mexico Federico Gomez, Mexico 1061 Antroquinonol inhibit keratinocyte apoptosis and attenuate skin epithelial cell inflammation in mice model of atopic dermatitis Hui Fang Kao, National Tainan Junior College of Nursing, Taiwan 1062 Seminal plasma hypersensitivity in female atopic dermatitis patients Valentina Laghai, University Hospital Bonn, Germany 1063 The beneficial effects of an insect protein based elimination diet on clinical signs of food allergy in dogs Teresa Manon Sophie Alice Böhm, Small Animal Medicine Clinics, LMU Munich, Germany 1064 Successful treatment with mepolizumab in a patient with refractory wells syndrome Dorothea Terhorst, Dept. of Dermatology, Charité - Universitätsmedizin Berlin, Germany 1065 Adult Henoch-Schönlein Purpura: Clinical and histopathological predictors of systemic disease and profound renal disease Hong Liang Tey, National Skin Centre, Singapore 1066 Malassezia spp and candida albicans allergic sensitization are associated with increased severity of atopic dermatitis Cristina Lopes, Serviço e Laboratório de Imunologia, Faculdade de Medicina, Universidade do Porto; 2.Unidade de Imunoalergologia, Hospital Pedro Hispano, ULS Matosinhos, Portugal 1067 The effects of a homeopathic combined preparation on clinical signs of atopic dermatitis Teresa Manon Sophie Alice Böhm, Small Animal Medicine Clinics, LMU Munich, Germany 1068 Current management of moderate-to-severe atopic dermatitis: a survey of physicians in Korea Hyeyung Yum, Seoul Medical Center, South Korea 1069 Burden of illness in atopic dermatitis (AD) patients by selfreported severity: Analysis of national health and wellness survey data from France, Germany, Italy, Spain, and the UK Laurent Eckert, Sanofi, France 1070 The effect of dupilumab on the pharmacokinetics of cytochrome P450 substrates in adult patients with moderateto-severe atopic dermatitis: an open label phase 1 trial John D. Davis, Regeneron Pharmaceuticals, Inc., United States 1071 Unraveling a case of junctional epidermolysis bullosa in a newborn: Tragic coincidence of a novel mutation of the ITGA6 gene and trisomic rescue Annika N. Jensen, Department of Dermatology and Allergology, Cantonal Hospital St. Gallen, Switzerland 1072 IL-17A-producing ILC3 is increased in HDM-induced AD mice model Kyu Han Kim, 1Department of Biomedical Sciences, Seoul National University Graduate School, 2Department of Dermatology, Seoul National University College of Medicine, 3Institute of Human environmental Interface Biology, Medical Research Center, Seoul National University, South Korea POSTERS Thematic Poster Session (TPS 34) Urticaria and angioedema management Poster Exhibition Chair: Marta Ferrer, Spain 1073 Management of chronic refractory urticaria Madona Devidze, Center of Allergy and Immunology, Georgia 1074 Treatment of patients with chronic urticaria in Europe: findings from visit 1 of the worldwide prospective observational aware study Marcus Maurer, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité Universitätsmedizin Berlin, Germany 1075 Aware-amac: first results from a large non-interventional study on the management and clinical impacts of chronic urticaria in patient refractory to h1-antihistamines in Asia, Middle-East and Africa Chia-Yu Chu, National Taiwan University Hospital, Taiwan 1076 Patient characteristics and associated conditions to define treatment responses in chronic spontaneous urticaria: a study evaluating treatment responses by urticaria control test Emek Kocatürk, Okmeydani Training and Research Hospital Department of Dermatology, Turkey 1077 Mean wheal diameter and presence of angioedema in chronic spontaneous urticaria linked to values of D-dimer, CRP, ESR and disease duration Pavel Kolkhir, I.M.Sechenov First Moscow State Medical University, Russia 141

142 POSTERS 19 JUNE 2017, 12:15-13: Acquired angioedema in a patient with adrenal insufficiency and marginal zone lymphoma: A challenging diagnosis and management Alice Corsi, SOD Immunologia Clinica, Università Politecnica delle Marche, Italy 1079 Localized heat urticaria: a report of 2 cases Jesús Macías Iglesias, Hospital Universitario Fundación Alcorcón, Spain 1080 Population-based age-adjusted incidence and prevalence of chronic urticaria in a united states locale Daniel E Maddox, Mayo Clinic, United States 1081 Clinical presentation, classification and approach to angioedema in an emergency department: four years retrospective study Leonor Rosário Carneiro-Leão, Serviço de Imunoalergologia, Centro Hospitalar de São João E.P.E., Portugal 1082 Synergistically expressed tissue factors on vascular endothelial cells by histamine and LPS trigger the extrinsic coagulation pathway followed by inter-cell gap formation Yuhki Yanase, Hiroshima University, Japan 1083 Major basophil chemotactic factor CCL2 is increased in chronic urticaria patients and correlates with basopenia Ana Koren, University Clinic of Respiratory and Allergic Diseases Golnik, Slovenia 1084 Becoming chronic urticaria remission after the first injection of omalizumab Marina Peredelskaya, State Hospital 52, Russia 1085 Chronic urticaria difficult to treat Corina Porr, County Clinical Hospital, Romania Thematic Poster Session (TPS 35) Immunodeficiency Chair: Jiri Litzman, Czech Republic 1086 Immunological deficits in children with recurrent pneumonia Lucija Zenic, Children s Hospital Srebrnjak, Croatia 1087 Clinical phenotypes associated with common variable immunodeficiency (CVID) Veronica Pedini, Clinical Medicine, Polytechnic University of Marche and Ospedali Riuniti, Italy Poster Exhibition 1094 A report of two new mutations in RAG1 and ADA genes in severe combined immunodeficiency disease Leila Shakerian, Immunology, Asthma and Allergy Research Institute, Iran 1095 Situation of care for patients with systemic autoinflammatory diseases - results of an expert survey Karoline Krause, Charité-Universitätsmedizin Berlin, Germany POSTERS % subcutaneous immunoglobulin (20%SCIg): long-term evaluation in a population of adult patients with CVID Veronica Pedini, Clinical Medicine, Polytechnic University of Marche and Ospedali Riuniti, Italy 1089 Phenotypic profile of IgA (SIGAD) in Paraguay, corresponding record deficit to 4 years of follow-up and subsequent related illnesses. Carmen Carolina Fernandez, INMUNE, Paraguay 1090 Cytomegalovirus infection in a patient with leukocyte adhesion deficiency type 1 Sara Harsini, Research Center for Immunodeficiencies, Children s Medical Center, Tehran University of Medical Sciences, Iran 1091 Hereditary angioedema laryngeal attacks: Report from the Czech national registry Roman Hakl, Department of Clinical Immunology and Allergology, St.Anne s University Hospital in Brno, Masaryk University, Czech Republic 1092 Severe congenital neutropenia: two case reports and literature review in Vietnamese patients Le Nguyen-Ngoc-Quynh, National Children s Hospital, Viet Nam 1093 Diagnosis of duncan s syndrome in patients with hemophagocytic lymphohistiocytosis Diego Gutiérrez Fernández, UGC Neumología-Alergia. Hospital Universitario Puerta del Mar, Spain 1096 Nutritional and bone mineral density state in patients with primary immunodeficiencies Bianca Laura Cinicola, Service of Pediatric Immunology and Allergology (SIAP), Department of Pediatrics, Sapienza, University of Rome, Italy 1097 Adenosine deaminase severe combined immunodeficiency (ADA-SCID): Profile of efficacy and safety in long-term pegada replacement therapy Lucia Leonardi, Sapienza Università, Policlinico Umberto I, Italy 1098 Use of subcutaneous immunoglobulin in immune deficiencies Abdülkadir Koçak, osmangazi university medical school, Turkey 1099 Efficacy Of Intravenous Cyclophosphamide Therapy For Adult-Onset Immunodeficiency Disease Associated With Interferon-Gamma Autoantibodies Wannada Laisuan, Division of Allergy Immunology and Rheumatology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Thailand 1100 Gain-of-function mutations in signal transducer and activator of transcription 1 (STAT1): a case with chronic mucocutaneous candidiasis mimicking combined immunodeficiency Sanem Eren Akarcan, Ege University Medical Faculty, Pediatric Immunology Department, Turkey 1101 A homozygous missense mutation in adenylate kinase 2 presented with hypogammaglobinemia and absence of agranulopoiesis Murad Habazi, King Fahad Medical City, Saudi Arabia Full abstract author lists are available on the official Congress website.

143 POSTERS 19 JUNE 2017, 12:15-13: Combined immunodeficiency and selective CD8+ lymphopenia having a novel mutation in LCK gene Murad Habazi, King Fahad Medical City, Saudi Arabia 1103 Neutrophil-specific granule deficiency with novel nonsense mutation in CEBPE gene got atypical mycobacterial infection Murad Habazi, King Fahad Medical City, Saudi Arabia Thematic Poster Session (TPS 36) Lessons from society and patients Poster Exhibition Chairs: Alexander Salava, Finland Silvi Plado, Estonia 1104 The association between perceived immune status, general health, and well-being Livia Wilod Versprille, Utrecht University, The Netherlands 1105 Twitter use during the Spanish allergy and clinical immunology society annual meetings ( ) Alberto Alvarez-Perea, Hospital Materno Infantil Gregorio Marañón, Spain 1106 Online microblogging providing information dissemination of anticolinergic therapy in asthma Florin Dan Popescu, Carol Davila University of Medicine and Pharmacy Department of Allergology, Romania 1107 Tools in the diagnosis of allergy to dogs and/or cats. recommendations of the quasar group. pet-all project. Ignacio Dávila, University Hospital, Spain 1108 Similarities and differences between dog and cat allergy. The quasar group. pet-all project Javier Domínguez-Ortega, Hospital Universitario La Paz, Spain 1109 Allergy on the internet: is it a complement or a substitute to the physician? Laura Victoria Carpio-Escalona, Hospital Universitario Ramón y Cajal, Spain 1110 Allergodermia and other related obsolete terms improperly used for various skin disorders Florin Dan Popescu, Carol Davila University of Medicine and Pharmacy Department of Allergology, Romania 1111 Not every syncope is allergy - false labelling of patients as drug hypersensitive Joana Cosme, Immunoallergology Department, Hospital de Santa Maria Northern Lisbon Hospital Center, Portugal 1112 Allergy to chlorhexidine in a child Figueroa-Zorrilla Carolina, UAD-S5 SUMMA, Spain 1113 Protective and anti-inflammatory effect of resveratrol in right ventricle failure Andras Laszlo Soti, Department of Biochemistry and Medical Chemistry, Medical Faculty, University of Pécs, Hungary 1114 Sisters but not twins Diego Bagnasco, Allergy & Respiratory Diseases, DIMI Dept of Internal Medicine, University of Genoa, IRCCS AOU San Martino-IST, Genoa, Italy., Italy 1115 Implementation of latex allergy clinical care pathways in Ghent University Hospital (Belgium) Patricia Oosterlinck, Ghent University hospital, Belgium 1116 Psychological distress and mood in young Dutch women with reduced perceived immune functioning Babette Arts, Utrecht University, The Netherlands 1117 Reduced perceived immune functioning and sleep Livia Wilod Versprille, Utrecht University, The Netherlands 1118 Irritable bowel syndrome, perceived immune functioning and general health perception Stephanie Balikji, Utrecht University, The Netherlands 1119 What are the key influencers on patient s decisions about their allergic rhinitis management? Biljana Cvetkovski, Woolcock Institute of Medical Research, The University of Sydney, Australia POSTERS Thematic Poster Session (TPS 37) Management of drug allergy Poster Exhibition Chairs: Gulfem Celik, Turkey Luciana Tanno, Brazil 1120 Rapid desensitization for hypersensitivity reactions to chemotherapeutic drugs; a case series Delara Babaie, Shahid Beheshti University of Medical Sciences, Iran 1121 Dabrafenib: a safe alternative in two patients with vemurafenib-induced dress Olga Luengo, Hospital Vall d Hebron, Spain 1122 Desensitization to rituximab: results of a case series from a tertiary referral centre. Marianna Tziotou, Department of Allergy, Sotiria General Hospital, Greece 1123 Desensitization to temozolomide, experience in a tertiary allergy unit Diego Blanco Garcia-Granero, Hospital 12 Octubre, Spain 1124 Negative predictive value of typing safe iodinated contrast medium Krzysztof Specjalski, Medical University of Gdansk, Poland 1125 Program for optimizing the use of antibiotics (proa) and betalactam hypersensitivity. a prospective analysis. Dolores Guerra-Vilaplana, Ramón y Cajal University Hospital, Spain 1126 Successful desensitization to cyanocobalamin using an ultra-rush protocol Magna Correia, Immunoallergy Department, CUF Descobertas Hospital, Lisbon, Portugal, Portugal 143

144 POSTERS 19 JUNE 2017, 12:15-13: Desensitization to irinotecan. A case report. Ana Gonzalez-Moreno, Hospital Universitario Fundacion Alcorcon, Spain 1128 Effectiveness and safety of a readministration protocol in patients with immediate type hypersensitivity reactions due to anti-tuberculosis drugs Ferda Öner Erkekol, Ataturk Chest Disease and Thoracic Surgery Education and Research Hospital, Immunology and Allergy Clinics, Turkey 1129 Successful desensitization to intravenous immunoglobulin: report of two cases Maria Tsami, Department of Allergy, Sotiria General Hospital, Greece 1130 Chronic pruritus caused by intravenous levothyroxine sodium treated with off-label omalizumab Marta Seoane-Rodriguez, Hospital Universitario Infanta Elena, Spain 1131 Anaphylaxis during reevaluation with skin testing for amoxicillin allergy. Maria Tsami, Department of Allergy, Sotiria General Hospital, Greece 1132 Immediate type hipersensitivity to low molecular weight heparin (enoxaparin) Arturo Velasco Arregui, Araba University Hospital, Spain 1133 Slow aspirin desensitization in a patient with aspirin exacerbated respiratory disease Muge Olgac, Istanbul University, Istanbul Medical Faculty, Internal Medicine Department, Division of Immunology and Allergy Diseases, Turkey hour successful desensitisation protocol to intravenous immunoglobulin (IVIG) in a case of common variable immune deficiency (CVID) with severe panhypogammaglobulinemia Ileana Maria Ghiordanescu, Elias University Emergency Hospital, Romania 1135 Aspirin desensitization in a patient with chronic Eosinophilicpneumonia: After unsuccessful desensitization 5-year follow-up Oznur Abadoglu, -, Turkey 1136 A case of gancyclovir desensitization Ezgi Ulusoy, Ege University Faculty of Medicine Department of Pediatrics, Divison of Pediatric Allergy and Immunology, Turkey 1137 Amoxicillin-clavulanic acid desensitization: clinical report and schedule employed Ignacio Garcia-Nunez, Hospital Quirónsalud Campo de Gibraltar, Spain 1138 A desensitization case of recombinat factor VIIa Ezgi Ulusoy, Ege University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Allergy and Immunology, Turkey Thematic Poster Session (TPS 38) New problems in occupational allergy Poster Exhibition POSTERS Chair: Gianna Moscato, Italy 1139 Contact dermatitis among workers exposed to ferronickel alloys Saso Stoleski, Institute for Occupational Health of R. Macedonia, WHO Collaborating Center and GA2LEN Collaborating Center, Skopje, R. Macedonia, Macedonia, Former Yugoslav Republic of 1140 Questionnaire-based evaluation of occupational hand eczema among health-care providers in hospitals and outpatient clinics in Romania Anca E. Chiriac, University of Medicine and Pharmacy, Romania 1141 Occupational exposure to ionizing radiation in a hospital context. Isabel Rezende, Immunoallergology Service, Centro Hospitalar do Porto, Portugal 1142 Occupational respiratory diseases in mosque workers Ayse Baccioglu, Kirikkale University Faculty of Medicine, Division of Immunology and Allergic Diseases, Turkey 1143 Occupational exposure and co-occurrence of work-related skin and respiratory allergic disorder in a washer-up: a case report Jordan Minov, Institute for Occupational Health of R. Macedonia, Skopje WHO Collaborating Center and GA2LEN Collaborating Center, Macedonia, Former Yugoslav Republic of 1144 Occupational rhinitis caused by green coffee beans in coffee roastery worker Soile Jungewelter, Finnish Institution of Occupational Health, Finland 1145 Occupational rhinitis due to locust bean gum María Vázquez De La Torre Gaspar, Hospital Universitario Infanta Leonor, Spain 1146 Occupational asthma due to carmine (E120) inhalation in a candy factory worker Nicola Giangrande, Infanta Cristina University Hospital. Allergology Department, Spain 1147 Occupational rhinitis caused by guar gum Maria Jose Castillo, Hospital de Terrassa, Spain 1148 Occupational allergic contact urticaria due to aerosolized peach (prunus persica) lipid transfer protein Krasimira Baynova, University Hospital Virgen del Rocío, Spain 1149 Allergic pathology - employed in confectionery and bakery persons Svetlan Dermendzhiev, Medical University of Plovdiv, Department of Occupational Diseases Toxicology and Allergy, Bulgaria 1150 Food allergy in workers sensitized to peach leaves María Ángeles Gonzalo-Garijo, Infanta Cristina University Hospital. Allergology Department, Spain Full abstract author lists are available on the official Congress website.

145 POSTERS 19 JUNE 2017, 12:15-13: Soybean allergy in relation to the presence of soy at the riverbank of the tajo river Alice Ferreira, Unidade de Imunoalergologia Hospital das Forças Armadas, Portugal 1152 Occupational asthma to the mussel anenome, actinia equina Jonathan Kilimajer, Clínica Subiza, Spain 1153 Ocupational asthma caused by poppy seeds (papaver somniferum) Jonathan Kilimajer, Clìnica Subiza, Spain Late Breaking Thematic Poster Session (LB TPS 4) Dermatitis and other skin conditions Poster Exhibition 1573 Oral H1 antihistamines as add-on therapy to topical treatment for eczema: A cochrane systematic review Christian J Apfelbacher, Medical Sociology, Institute of Epidemiology and Preventive Medicine, University of Regensburg, Germany 1574 Neutrophil-lymphocyte ratio in pediatric atopic dermatitis patients Sehra Birgül Batmaz, Tokat State Hospital, Turkey 1575 Investigation of immune-regulatory effects of mageumsan hot spring via protein microarray in vitro Hyun Jee Kim, Department of Dermatology, Uijeongbu St.Mary s Hospital, South Korea 1576 Association of single-nucleotide polymorphisms of the MBL 2 with atopic dermatitis in korean patients Hyun Jee Kim, Department of Dermatology, Uijeongbu St.Mary s Hospital, South Korea 1577 Atopic dermatitis as a risk factor to chronic urticaria in children: new insights in atopic march? Nikolaos Aggelis Kitsioulis, National and Kapodistrian University of Athens, Greece 1581 Does adiponectin play a role in the pathogenesis of chronic spontaneous urticaria? Zenon Brzoza, Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia, Poland 1582 Fermented food matrix: A new therapeutic approach in atopic dermatitis? Enza D Auria, Pediatric Department, V. Buzzi Children s Hospital, University of Milan, Italy 1583 Evaluation of natural products extracted from copaiba, native tree of Brazil, in the treatment of experimental atopic dermatitis in mice Fernando Monteiro Aarestrup, Federal University of Juiz de Fora, Brazil 1584 Solar urticaria augmented with cold Jia Li Liau, University Hospital of South Manchester, United Kingdom 1585 Two cases of acute generalized exanthematous pustulosis induced by Rhus Hee Joon Yu, Department of Dermatology, Hanyang University Guri Hospital, South Korea 1578 Evaluation of the IL-1 R and IL-1RA gene polymorphism in chronic spontaneous urticaria Marzieh Tavakol, Department of Allergy and Clinical Immunology, Shahid Bahonar Hospital, Alborz University of Medical Sciences, Iran 1579 Hypersensitivity to natural rubber latex gloves among Albanian dental students: The role of exposure duration Ervin Mingomataj, Mother Theresa School of Medicine, Albania 1586 Epidermolysis bullosa in newborn: A case report Kristina Amosova, Children s Clinical University Hospital, Riga Stradins University, Latvia 1586 A Moving towards endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis DirkJan Hijnen, Department of Dermatology and Allergology, University Medical Center, The Netherlands POSTERS 1580 TNFalpha polymorphisms in the pathogenesis of chronic spontaneous urticaria. Zenon Brzoza, Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia, Poland Late Breaking Thematic Poster Session (LB TPS 5) Rhinitis, Rhinosinusitis and Conjunctivitis Poster Exhibition 1587 Interaction between allergic and neurogenic response to allergen, histamine and hypertonic saline after specific and non specific nasal provocation in subjects with seasonal allergic rhinitis Livije Kalogjera, Endo Lab, University Hospital Centre, Croatia 1588 MP29-02 treatment reduces cold dry air-induced nasal mediators and nasal hyperreactivity in patients with house dust mite allergic rhinitis Inge Kortekaas Krohn, Laboratory of Clinical Immunology, Dpt. Microbiology & Immunology, University of Leuven, Belgium 1589 Impact of serum 25-hydroxyvitamin D3 levels deficiency upon the symptoms and anxiety of allergic rhinitis Na Cui, China-Japan Unite Hospital of Jilin University, China 1590 Fluticasone propionate and mometasone furoate are equally effective in restoring epithelial barrier defects in allergic rhinitis. Maria Doulaptsi, Laboratory of Clinical Immunology, Catholic University Leuven, Belgium 145

146 POSTERS 19 JUNE 2017, 12:15-13: Saline could improve the quality of life In the pregancy rhinitis Lin Li, China-Japan Union Hospital of Jilin University, China 1592 The clinical characters of the allergic rhinitis in North China for 5 years Lin Li, China-Japan Union Hospital of Jilin University, China 1593 Rhinologic disease is a burden for a patient Maija Ylitalo-Heikkilä, Department of Otorhinolaryngology Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Finland 1594 Serum 25-hydroxyvitamin D levels are inversely associated with blood eosinophil count in patients with persistent allergic rhinitis Lei Cheng, The First Affiliated Hospital, Nanjing Medical University, China 1595 Role of allergy in the management of patients subjected to adenoid hypertrophy and otitis media with effusion Alireza Shafiei Esfidvajani, Tehran University of Medical Sciences, Iran 1597 Differential response of primary nasal epithelial cells vs. calu- 3 cells to exogenous stimuli. Katleen Martens, Laboratory of Clinical Immunology, Catholic University Leuven, Leuven, Belgium 1598 Effect of dexamethasone induced autophagy on senescence in nasal epithelial cells of allergic rhinitis Na Cui, China-Japan Unite Hospital of Jilin University, China 1599 Administration of liposomal eye spray versus antihistamine eye drops in patients with allergen-induced conjunctivitis - A comparison between different mechanisms of action Anne-Nele Grzella, Institute for Medical Statistics, Informatics and Epidemiology, Faculty of Medicine, University of Cologne, Germany 1601 Chronic rhinosinusitis associated with alpha 1 antitrypsin deficiency. Magdalena Dziadzio, UCLH, United Kingdom 1603 Atopy associated keratoconus: A case report Adi Surya Komala, University of Indonesia, Indonesia 1596 Ph alteration of paranasal sinus mucosa Felicia Manole, Faculty of Medicine Oradea, Romania Late Breaking Thematic Poster Session (LB TPS 6) Food allergy: Mechanisms, diagnosis and management Poster Exhibition POSTERS 1604 Dermatitis caused by ingestion of chia seeds. Ana Entrala, Allergy Department, Hospital La Paz, Spain 1605 Wheat allergy: Beyond the diagnostic suspicion Alba García-Moral, Hospital Clínic, Spain 1606 Contribution of conformational and linear ige epitopes to ara h 2-specific ige-binding Angelika Tscheppe, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria 1607 Molecular diagnosis of peanut allergy. Adam Wawrzenczyk, The Nicolaus Copernicus University in Torun, Allergology, Clinical Immunology and Internal Medicine in Bydgoszcz, Poland 1608 Immunotherapy in food allergy: can it change the course of the disease? Anna Giulia Ricci, Catholic University, Italy 1609 Basophil-derived interleukin-4 promotes epicutaneous antigen sensitization concomitant with the development of food allergy Maryam Hussain, University of Bern, Switzerland 1610 Biomarkers associated to patients with a severe allergic phenotype using metabolomics David Obeso, San Pablo Ceu University, Spain 1611 Alpha-gal epitope on protein surface affects uptake and degradation in immature monocyte-derived dendritic cells Maja Krstic, Center of Excellence in Molecular Food Sciences, Faculty of Chemistry, University of Belgrade, Serbia 1612 Conducting an oral food challenge with fresh fruit: A guide for clinicians Angela Palladino, Food Allergy Referral Centre, Veneto Region, University Hospital of Padua, Department of Women and Child Health, Italy 1613 Evaluation of the primary sensitizer in galactooligosaccharide (GOS) allergy Gaik Chin Yap, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 1614 Anaphylaxis by a hidden allergen - A diagnostic challenge Ana Montoro Ferrer, HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON, Spain 1615 Peanut allergens ara H 1 and ara H 2 and peanut lipids impact on the barrier function of human airway epithelial cells Chiara Palladino, Department of Pathophysiology and Allergy Research, Medical University of Vienna, Austria 1616 Pru p 7 is a major allergen and a severity marker in peach allergic patients from Southern France Caroline Klingebiel, Laboratoire Montgrand, LBM Multisite SELDAIX-BIOPLUS, France 1617 Allergen declaration in non-prepacked food: The current European state and the unmet needs Daniela Prozorovscaia, Bern University of Applied Sciences, Switzerland Full abstract author lists are available on the official Congress website.

147 POSTERS 19 JUNE 2017, 12:15-13: How useful is serum tryptase measurement during food allergic reactions: A prospective study of 52 peanut allergic adults Shelley Dua, University of Cambridge, United Kingdom 1619 How often a low risk allergy patient with a single food allergy should be followed up in clinic? Reviewing current practice on follow up appointments in allergy outpatient department Victoria Holdstock, University of Glasgow, United Kingdom 1620 Anaphylaxis due to avocado with different sensitization pattern Rosialzira Natasha Vera Berrios, Allergy Department. IIS- Fundación Jiménez Díaz, Spain 1621 Anaphylaxis caused by linseed as a hidden food allergen Rosialzira Natasha Vera Berrios, Allergy Department. IIS- Fundación Jimenez Díaz, Spain 1622 An unusual case of positive SIgE to galactose -Alpha 1,3 galactose from south italy Carina G. Uasuf, Allergy Diseases Center Prof G. Bonsignore, Institute of Biomedicine and Molecular Immunology A. Monroy (IBIM) - National Research Council (CNR), Palermo, Italy., Italy EAACI GLOBAL ATLASES Available ON & OFFLINE Also available in Greek Also available in Chinese, Greek and Spanish POSTERS Global atlas of asthma Published by the European Academy of Allergy and Clinical Immunology Global atlas of allergy Published by the European Academy of Allergy and Clinical Immunology GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS Published by the European Academy of Allergy and Clinical Immunology All EAACI Atlases are available to download at

148 POSTERS 20 JUNE 2017, 12:00-13:30 TUESDAY, 20 JUNE, 2017 Thematic Poster Session (TPS 39) Asthma epidemiology Poster Exhibition Chair: Mariana Couto, Portugal 1154 Impact of omalizumab on healthcare utilization among patients with uncontrolled allergic asthma followed in canadian clinical settings. Jean-Louis Stril, Novartis Pharmaceuticals Canada Inc., Canada 1155 Non-utilization of medical rehabilitation before the occurrence of early retirement due to asthma bronchiale in Germany prevalence and sociodemographic correlates. Maria Weyermann, Niederrhein University of Applied Sciences, Germany 1163 Prevalence change of asthma and allergic diseases by using claim data from national health insurance service in Korea: Dae Hyun Lim, Department of Pediatrics, and Environmental health center for Allergic Disease, Inha University Hospital,, South Korea 1164 Prevalence of asthma in patients with psoriasis Anca E. Chiriac, University of Medicine and Pharmacy, Romania 1165 Severe asthma profile in Madrid, Spain Elisa Haroun Díaz, Hospital Universitario Infanta Leonor, Spain POSTERS 1156 Costs of exacerbations in asthma in a French tropical island (Reunion Island). Bashir Omarjee, Consultation des Pathologies Respiratoires, de l Allergie et du Sommeil, Reunion 1157 Correlation between the age of onset of asthma and the severity of asthma in elderly patients Susana Norma De Barayazarra, Hospital San Roque, Argentina 1158 Level of control of patients with severe asthma at a tertiary hospital. Silvia Toldra, Dr Peset University Hospital, Spain 1159 Older adults with asthma: characteristics and outcomes of long-standing versus late-onset asthma Yavuz Havlucu, Celal Bayar University Faculty of Medicine Department of Chest Disease, Turkey 1160 Variability in assessment of severe asthma at a tertiary hospital Silvia Toldra, Dr Peset University Hospital, Spain 1161 Prevalence and seasonal variation of airway hyperresponsiveness in asthmatic children in Taiwan Shu-Jung Huang, Chang Gung Memorial Hospital, Taiwan 1162 Relation between atopy and positive bronchoprovocative methacholine challenge testing (BPT) in suspected asthma patients Nataša Karamarkovic Lazarušic, Outpatient Centre for Respiratory Diseases, Zagreb, Outpatient Centre for Respiratory Diseases, Croatia 1166 Body mass index and risk of asthma and asthma-like symptoms in childhood Emilija Vlashki, Department of Pulmonology and Allergology, University Children s Clinic, Macedonia, Former Yugoslav Republic of 1167 The frequency of wheezing and airway resistance in preterm preschool children Sait Karaman, Behcet uz children hospital, Turkey 1168 Birth decade affects the sensitization pattern and asthmarisk in Finnish adult population Annika Luukkainen, Haartman Institute, University of Helsinki and Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Finland 1169 Allergy in children Darejan Khachapuridze, National Institute of Allergy, Asthma and Clinical Immunology, Georgia 1170 Are there seasonal differences in the prevalence of exerciseinduced bronchoconstriction using the 6-minute free-running test? - a cross-sectional study in 4- to 6-year-old Japanese children Miwa Shinohara, Department of Pediatrics, Ehime University Hospital, Japan 1171 The impact of swimming pool attendance on schoolchildren allergic and respiratory inflammation João Cavaleiro Rufo, Faculty of Medicine of the University of Porto & S. João Hospital Centre, Portugal 1172 Is there a link between exercise-induced bronchospasm and gastroesophageal reflux in asthmatic children? Urszula Jedynak-Wasowicz, Department of Pediatrics, Jagiellonian University Medical College, Poland Thematic Poster Session (TPS 40) Rhinitis and rhinosinusitis Poster Exhibition Chair: Martin Wagenmann, Germany 1173 Profile of patients with persistent allergic rhinitis prescribed MP-AzeFlu * in routine clinical practice in the austria Katharina Marth, Karl Landsteiner Institut fur Experimentelle und Klinische Pneumologie, Austria 1174 Profile of patients with uncontrolled allergic rhinitis prescribed mp-azeflu * in routine UK clinical practice Glenis Scadding, Royal National Throat Nose & Ear Hospital, United Kingdom Full abstract author lists are available on the official Congress website.

149 POSTERS 20 JUNE 2017, 12:00-13: Work productivity in rhinitis using cell phones: The MASK study Jean Bousquet, MACVIA-LR EIP on AHA Reference Site, France 1176 Profile of patients with persistent allergic rhinitis prescribed mp-azeflu * in routine clinical practice in the ireland Ranbir Kaulsay, The Clontarf Allergy Clinic, Ireland 1177 Profile of patients with persistent allergic rhinitis prescribed MP-AzeFlu * in routine clinical practice in the sweden Par Stjarne, Karolinska Institute, Sweden 1178 Burden of allergic rhinitis: Australia vs UK Glenis Scadding, Royal National Throat Nose & Ear Hospital, United Kingdom 1179 Characterization of Australian allergic rhinitis patients: Results from a patient survey Pete Smith, Griffith University, Australia 1180 State of allergic rhinitis control and impact on asthma in australia: Results from a patient survey David Price, Observational & Pragmatic Research Institute Pte Ltd, Singapore 1181 Mp-AzeFlu* has superior effect on the transactivation of anti-inflammatory genes than fluticasone proprionate and azelastine alone in nasal mucosa and polyp fibroblasts. Laura Pujols, IDIBAPS & CIBERES, Spain 1182 Ameliorative potential of herbal medicines and their chemical constituents in allergic rhinitis via modulation of calcium and chloride ion channels Yu Ran Nam, Department of Physiology, Dongguk University College of Medicine, South Korea 1183 Autonomic function in adults with allergic rhinitis and its association with disease severity and duration. Younghee Yun, Kyung Hee University Hospital at Gangdong, South Korea 1184 Is anti-ige treatment effective on nasal polyposis in aerd? Müge Olgaç, Istanbul University, Istanbul Medical Faculty,Internal Medicine Department, Division of Immunology and Allergy Diseases Department, Turkey 1185 Chronic rhinosinusitis with unilateral nasal polyps in Chinese patients - clinical and histopathological characteristics Zhuo Chen, Department of Otolaryngology Head & Neck Surgery, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China 1186 Th17 inflammation may be associated with refractoriness of non-eosinophilic nasal polyps Hun-Jong Dhong, Sungkyunkwan University School of Medicine, South Korea 1187 To explor the incidence of chronic sinusitis and analysis of related factors in Northease China. Jun Zheng, China-Japan Union Hospital of Jilin University, China 1188 Histopathologic study of the mucosa tissue remodeling and the bone in chronic rhinosinusitis Jun Zheng, China-Japan Union Hospital of Jilin University, China 1189 Suppression of neuropeptide production by quercetin in allergic rhinitis model rats Atsuko Furuta, Department of Otorhinolaryngology, School of Medicine, Showa University, Japan 1190 Knowledge of rhinitis: Educational intervention on first contact physicians Cesar Fireth Pozo, Hospital Infantil de Mexico Federico Gomez, Mexico Thematic Poster Session (TPS 41) Biomarkers in asthma Chairs: Helena Pite, Portugal Sven-Erik Dahlén, Sweden 1191 A novel automated immunoassay for measurement of eosinophil derived neurotoxin in serum and urine Magnus Molin, Thermo Fisher Scientific, Sweden 1192 Increased sputum thymus and activation-regulated chemokine levels in children with asthma, not with eosinophilic bronchitis Min Jung Kim, Yonsei University College of Medicine, South Korea 1193 A study of relationships between the regulatory T cells and asthma Yan Hua Xu, Department of Allergy & Immunology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China 1194 Serum periostin level and exhaled nitric oxide in children with asthma Hasibe Artac, Selcuk University Medical Faculty, Turkey Poster Exhibition 1195 Usefulness of exhaled nitric oxide to predict airway hyperresponsiveness in adults with asthmatic symptoms Byung Jae Lee, Sungkyunkwan University School of Medicine, Samsung Medical Center, South Korea 1196 Fractional exhaled nitric oxide (FeNO) in the screening and diagnosis work-up of occupational asthma Isabel Coman, Hopital du Sacré-Coeur de Montréal, Canada 1197 Variable inflammatory responses in the airways of patients with aspirin-exacerbated respiratory disease Grazyna Bochenek, II Chair of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Poland 1198 Eosinophilic cationic protein (ECP) in the clinical work-up of chronic cough. Davide P Caimmi, CHRU de Montpellier, Allergy Unit and Cystic Fibrosis center, France POSTERS 149

150 POSTERS 20 JUNE 2017, 12:00-13: Simultaneously elevated exhaled nitric oxide and blood eosinophils in children with atopic asthma Doina Anca Plesca, Dr.Victor Gomoiu children hospital Bucharest, Romania, University of Medicine and Pharmacy Carol Davila Bucharest, Romania 1200 Increased frequency of CD56- CD16+/- NK cells in exacerbated asthma respiratory disease - A suggestive role as biomarker Juan Raymundo Velazquez, Instituto Nacional de Enfermedades Respiratorias, Mexico Thematic Poster Session (TPS 42) A new multiplex test for specific IgE Poster Exhibition POSTERS Chairs: Paolo Matricardi, Germany Chrysanthi Skevaki, Germany 1201 Multiplex IgE diagnostic test: IgE sensitization to furry animal dissected by allergenic molecules and extracts Adriano Mari, CAAM - Centri Associati di Allergologia Molecolare, Italy 1202 Multiplex IgE diagnostic test: house dust mite sensitization dissected using six allergenic molecule groups Adriano Mari, CAAM - Centri Associati di Allergologia Molecolare, Italy 1203 Multiplex IgE diagnostic test: the broad view on IgE reactivity to seeds, legumes, nuts, and cereals Adriano Mari, CAAM - Centri Associati di Allergologia Molecolare, Italy 1204 A digital reporting system an exclusive online free tool for allergy test visualization dedicated to patients and accessible by allergists Adriano Mari, CAAM - Centri Associati di Allergologia Molecolare, Italy 1205 Multiplex IgE diagnostic test: the most comprehensive view on IgE sensitization to vegetables, fruits and seeds due to lipid transfer proteins Adriano Mari, CAAM - Centri Associati di Allergologia Molecolare, Italy 1206 Multiplex method for IgE determination: a report of six severe peach allergic patients from Southern France Joana Vitte, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, La Conception Hospital, Immunology Laboratory, France 1207 Multiplex IgE diagnostic test performances compared to singleplex Adriano Mari, CAAM - Centri Associati di Allergologia Molecolare, Italy 1208 Evaluation of a multiplexed biochip (friendly allergen nanobead array) in different clinical contexts Pascale Nicaise Roland, Immunology Department-Hôpital Bichat, France 1209 Comparing IgE reactivity distribution between Iranian and Italian allergic patients using a multiplex IgE diagnostic test Raheleh Shokouhi Shoormasti, Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Iran 1210 A multiplex diagnostic test: exploring IgE sensitization to tropomyosins and related sea foods and arthropods Adriano Mari, CAAM - Centri Associati di Allergologia Molecolare, Italy 1211 FABER IgE diagnostic test: a useful help in understanding IgE sensitization to fishes Adriano Mari, CAAM - Centri Associati di Allergologia Molecolare, Italy 1212 Faber IgE test: A standard multiplex diagnostic tool to explore allergic sensitization across Northern, Central and Southern areas in Italy Adriano Mari, CAAM - Centri Associati di Allergologia Molecolare, Italy Thematic Poster Session (TPS 43) Respiratory pediatric allergy Poster Exhibition Chairs: Olympia Tsilochristou, United Kingdom Antonio Nieto Garcia, Spain 1213 Identification of pediatric asthma phenotypes in daily practice Hannah M Kansen, Department of Pediatric Pulmonology and Allergology, Wilhelmina Children s Hospital, University Medical Center, The Netherlands 1214 Clinical state during last one year treatment and examination before remission about asthmatic children in long-term remission cases Tomio Kondo, Hirano General Hospital, Japan 1215 Airway diseases education and expertise (ADEX) in pediatrics: The success so far in India K Nagaraju, Saveetha Medical College and Hospital, India 1217 Childhood asthma analysis from the Korea national health insurance claims database Yoon Hee Kim, Gangnam Severance Hospital, South Korea 1218 Pre-clinical diagnosis of formation of asthma in children with allergic rhinitis Tahira Panahova, Azerbaijan Medical University, Azerbaijan 1219 Acute respiratory failure in pediatric patients with bronchiolitis: series of 2 years in a pediatric intensive care unit (PICU) Marta Martins Batista, Hospital São Bernardo, Portugal 1220 Pediatric Asthma E-care: a smart tool for improving asthma controlled in children Wasu Kamchaisatian, Samitivej Children s Hospital, Bangkok Hospital Group, BDMS, Thailand Full abstract author lists are available on the official Congress website.

151 POSTERS 20 JUNE 2017, 12:00-13: Allergic bronchopulmonary aspergillosis misdiagnosed as recurrent pneumonia in a child: a case report Nan Nan Jiang, Allergy Department,Beijing Children s Hospital, China Thematic Poster Session (TPS 44) Functional genomics and proteomics Poster Exhibition Chair: Risto Renkonen, Finland 1222 Mite allergoid immunotherapy: allergome content and immunoreactivity defines effective platform for SCIT Sviatlana Starchenka, Allergy Therapeutics, United Kingdom 1223 Impact of bacteria bifidobacterium bifidum and bacterial components on gene expression of immune response cells L Titov, Republican Research-Practical Center for Epidemiology and Microbiology, Belarus 1224 Association between polymorphism in a tight junction gene CLDN10 and allergic rhinitis: a case-control study in Han Chinese Xu Zhang, Beijing Institute of Otolaryngology &Beijing TongRen Hospital, China 1225 IL-33 and its soluble receptor sst2 in lower airways of seasonal allergic rhinitis patients. Amaryllis Haccuria, Université Libre de Bruxelles, Belgium 1226 Evaluation of the seasonal and immunotherapy-related alterations in nasal epithelial transcriptome in subjects with birch pollen allergic rhinitis. Tanzeela Hanif, University of helsinki, Finland 1227 Polymorphisms in complement lectin pathway serine proteases genes are associated with ischemic stroke Gohar Tsakanova, Institute of Molecular Biology NAS RA, Armenia 1228 Association of polymorphic markers in the genes of cytokines with the development of pneumonia in newborns Oxana Anatolievna Svitich, Mechnikov Research Institute of Vaccines and Sera, Russia 1229 Interleukin-2 and interferon-gamma single nucleotide polymorphisms in iranian patients with chronic heart failure Sara Harsini, Molecular Immunology Research Center, Tehran University of Medical Sciences, Iran 1230 Identification of two novel CFTR mutations in iranian patients with cystic fibrosis Marzieh Mazinani, Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Iran 1231 Qmics and food allergy: From allergens to new forms of diagnosis and therapy Enza D Auria, Pediatric Department, V. Buzzi Children s Hospital, University of Milan, Italy Thematic Poster Session (TPS 45) Insect venom allergy Poster Exhibition Chairs: Betul Ayse Sin, Turkey Dario Antolin Amerigo, Spain 1232 Hymenoptera sting reactions in southern Italy forestry workers. Francesco Papia, Allergy and Clinical Immunology Unit, University of Messina, Italy 1233 Is the skin prick test sufficient to diagnose vespid venom allergy? Danijela Bokanovic, Department of Dermatology and Venereology, Medical University of Graz, Austria 1234 Inconsistency of the common diagnostic tests to identify the venom to be used for immunotherapy in patients with allergic reactions to vespa crabro Elisa Boni, Allergy Unit, Sant Anna Hospital, ASST Lariana, Italy 1235 History of large local reaction to hymenoptera stings: outcome of re-stings (preliminary data) Maurizio Severino, Allergy Unit, San Giovanni di Dio Hospital, Italy 1236 Is the severity of anaphylactic reaction influenced by the site of hymenoptera sting? Radoslaw Gawlik, Department of Internal Diseases, Allergology and Clinical Immunology. Medical University of Silesia, Poland 1237 The severity of hymenoptera sting reactions and the levels of recombinant sfse and the bat response Julij Šelb, University Clinic of Respiratory and Allergic Diseases Golnik, Slovenia 1238 Severity of sting-induced anaphylaxis in relation to the culprit insect sting: is european hornet (vespa crabro) a risk factor for life-threatening allergic reaction? Fedra Ciccarelli, Allergy Unit, Italy 1239 Prevalence of mastocytosis in hymenoptera venom allergic patients from ciudad real Teresa Alfaya, Hospital General Universitario de Ciudad Real, Spain 1240 Inpatient stinging with hymenoptera venom: experience in our service Estefanía Moreno Mata, Hospital Mancha Centro, Spain 1241 Protein identification in apis mellifera crude venom by a shotgun proteomics approach Barbara Pantera, Entomon sas, Italy 1242 Benefits of venom immunotherapy: how soon can they be expected Karmen Perko, University Clinic of Respiratory Diseases and Allergy, Slovenia 1243 The frequency of venom re-stings in field and protectiveness of venom immunotherapy : real life results Ceyda Tunakan Dalgiç, Ege University Medical Faculty,Department of Allergy and Clinical Immunology, Turkey POSTERS 151

152 POSTERS 20 JUNE 2017, 12:00-13: Allergy to vespa crabro venom: Venom Immunotherapy with vespula vs vespa crabro Elisa Meucci, Allergy Unit, S. Giovanni di Dio Hospital, Italy 1245 Comparison of bee and wasp venom allergic patients treated by venom immunotherapy Martina Vachová, Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Czech Republic 1246 Questionable benefit of the commercially available panel of bee venom components in the diagnosis of bee venom allergy Lisa Arzt, Department of Dermatology and Venerology, Medical University of Graz, Austria 1247 Maintenance specific immunotherapy for hymenoptera venom allergy: what to do if the allergenic extract is suddenly no longer available? Chiara Tontini, Postgraduate School of Allergy and Clinical Immunology, Università Politecnica delle Marche, Italy 1248 Omalizumab in prevention of anaphylaxis due to bee venom immunotherapy Joana Barradas Lopes, Centro Hospitalar Vila Nova de Gaia/ Espinho, Portugal 1249 Omalizumab in immunotherapy with hymenoptera venom Tatiana Lourenço, Immunoallergology Department, Hospital Santa Maria - Centro Hospitalar Lisboa Norte, Portugal 1250 Omalizumab as adjuvant treatment during venom immunotherapy in mast cell disorders Paula Vázquez-Revuelta, Hospital Universitario Ramón y Cajal, Spain 1251 Bee venom immunotherapy only tolerated with concurrent treatment with omalizumab. Silvia Toldra, Dr Peset University Hospital, Spain Thematic Poster Session (TPS 46) Contact dermatitis Poster Exhibition POSTERS Chair: Radoslaw Spiewak, Poland 1252 Allergic contact dermatitis from ophthalmic medications Osmo Kari, Helsinki University Skin and Allergy Hospital, Finland 1253 Our experience in allergic contact dermatitis: A map of allergens through the body Isabel Fernandez De Alba Porcel, Hospital Universitario de Burgos, Spain 1254 Clinicopathological analysis of pigmented contact dermatitis from henna in Korean patients Yu Ri Woo, Yeouido St. Mary s Hospital, South Korea 1255 Occupational contact dermatitis: to whom? Due to what?: our experience in 2015 Isabel Fernandez De Alba Porcel, Hospital Universitario de Burgos, Spain 1256 Utility of scratch test for allergic contact dermatitis caused by Dermabond Sébastien Lefevre, Unit of Allergy - CHR Metz-Thionville, France 1257 Contact urticaria due to phlebotonic drug Carolina Figueroa-Zorrilla, UAD-S5 SUMMA, Spain 1258 Allergic contact dermatitis to temporary black henna tattoo due to sensitization to paraphenyldiamine Emine Dibek Misirlioglu, Department of Pediatric Immunology and Allergy, Ankara Children s Hematology Oncology Training and Research Hospital, Turkey 1259 The skin as a mirror of the functionality of our immune system Luljeta Ahmetaj Ahmetaj, University Hospital Clinic, Albania 1260 A rare cause of contact dermatitis Corina Porr, County Clinical Hospital, Romania 1261 Nickle element distribution in skin tissue of mice nickelinduced allergic contact dermatitis Jin Lu Sun, Dept. of Allergy, Peking Union Medical College Hospital, China 1262 Allergic contact dermatitis to acrylates in manicurists Dimitrina Guleva, Medical University - Sofia, Bulgaria 1263 Allergic contact dermatitis in athlete adolescent: Mercaptobenzothiazole and mercapto mix Ilknur Bostanci, Healthy Science University, Dr Sami Ulus Maternity and Children Training & Research Hospital, Department of Pediatric Immunology and Allergy, Turkey 1264 Allergic Contact Hand Dermatitis With An Unexpected Route Of Sensitization. Case Report. Catalina Florea, Department of Dermatology Victor Babes Clinical Hospital, Romania Full abstract author lists are available on the official Congress website.

153 POSTERS 20 JUNE 2017, 12:00-13:30 Thematic Poster Session (TPS 47) Drug allergy: Clinical aspects and diagnosis Poster Exhibition Chairs: Mariana Castells, United States Cristobalina Mayorga, Spain 1265 Urticaria due to calcium dobesilate Antonio Moreno-Fernandez, Virgen de la Luz Hospital, Spain 1266 Is gadolinium a safe alternative to iodinated contrast agent allergy? Fevzi Demirel, Gülhane Training and Research Hospital, Division of Immunology and Allergic Diseases, Turkey 1267 Potentially life-threatening dress - syndrome in a 19 year old male patient. Mariam R. Movsisyan, Yerevan State Medical University, Armenia 1268 Nonimmediate reactions to amoxicillin in infectious mononucleosis: three case reports. María Ascensión Aranzabal, OSI Goierri-Alto Urola, Spain 1269 Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome and tuberculosis: case report Vittoria Montecchiani, Hospital Marques de Valdecilla, Spain 1270 acute hepatitis due to adverse drug reaction in two young patients Different mechanisms and clinical approach Polliana Mihaela Leru, Colentina Clinical Hospital, Romania 1271 Rituximab hypersensitivity reaction in a child with nephrotic syndrome: a case report Davide Paolo Caimmi, CHRU de Montpellier, Allergy Unit and Cystic Fibrosis center., France 1275 NSAIDs non chemically related induced urticaria Marina Labella, Virgen del Rocío University Hospital, Spain 1276 Immediate hypersensitivity to oral dimethyl fumarate (tecfidera ): A new desensitization protocol Danilo Di Bona, School and Chair of Allergology and Clinical Immunology, University of Bari Aldo Moro, Italy 1277 Usefulness of histamine and tryptase in allergic reaction during surgery Davide Paolo Caimmi, CHRU de Montpellier, Allergy Unit and Cystic Fibrosis center, France 1278 Baboon syndrome in relation to the intake of lysine carbocysteinate Leticia Maday Pedraza Escobar, Hospital Ramón y Cajal, Spain 1279 Severe ibuprofen hypersensitivity case report Filipa Lourenço Ribeiro, Centro Hospitalar do Algarve, Portugal 1280 Continuation of treatment with etanercept despite drug hypersensitivity Gintare Paulikaite, Vilnius University, Center of Pulmonology and Allergology, Vilnius University hospital Santariskiu klinikos, Lithuania 1281 Sonovue (sulfure hexafluoride), immediate hypersensitivity reaction in echocardiography Nicola Giangrande, Allergy Department, Infanta Cristina University Hospital, Spain 1272 Carbamazepine induced dress syndrome: A case report Ali Selcuk, Gülhane Education and Research Hospital, Division of Immunology and Allergic Diseases, Turkey 1273 Infusional fever cause by piperacillin-tazobactam and meropenen, report of a case. Diana Carolina Ochoa Gutiérrez, Hospital Universitario Ramón y Cajal, Spain 1274 Serum sickness-like reaction due to amoxicillin/clavulanic acid in two children Ilknur Kulhas Celik, Ankara Children s Hematology Oncology Training and Research Hospital, Department of Pediatric Allergy and Immunology, Turkey 1282 An unexpected anaphylaxis after an amoxicillin provocation test in support of the practice that two full doses of the drug are sufficient, even if a rash reaction only appeared after 8 days of treatment. Jaroslaw Gornicki, The Jan Bogdanowicz Children s Specialised Teaching Hospital/Allergy Department of Warsaw., Poland 1283 Dress syndrome caused by anti-tuberculosus drugs in a child Vladimir Tmusic, University Children s Hospital, Serbia POSTERS Thematic Poster Session (TPS 48) Drug allergy: Diagnosis Poster Exhibition Chair: Marek Kowalski, Poland 1284 Differential features between DRESS syndrome and angioimmunoblastic T cell lymphoma Young-Il Koh, Chonnam National University Medical School, South Korea 1285 Anaphylaxis tothiocolchicoside: two new cases Elisa Meucci, Allergy Unit, San Giovanni di Dio Hospital, Italy 1286 Anaphylactic reaction due to an excipient included in an injectable corticosteroid formulation Andrea Lissett Vera, Hospital Universitario de la Princesa; Instituto de Investigación Sanitaria Princesa, Spain 1287 Multiple allergic contact blepharitis due to azithromycin and tropicamide eye drops and povidone iodine solution. Teresa Aramburu, Allergy Unit. Virgen del Rocío University Hospital, Spain 1288 Concomitant immediate and delayed type hypersensitivity to amoxicillin in the same patient: two case reports Viviane Steiner-Monard, Allergology, University Hospital Basel, Switzerland 1289 Performance of the basophil activation test and skin test in a patient with sugammadex-induced anaphylaxis and his monozygotic twin brother Tomonori Takazawa, Intensive Care Unit, Gunma University Hospital, Japan 153

154 POSTERS 20 JUNE 2017, 12:00-13: Allergy to daptomycin Laura Zanon-Moreno, Hospital Clinico Universitario, Spain 1291 Evaluation of adverse drug reactions in children Mustafa Erkocoglu, Abant Izzet Baysal University Faculty of Medicine, Turkey 1292 Looking beyond the chemotherapy: A case of anaphylaxis to mesna Sébastien Lefevre, Unit of Allergy - CHR Metz-Thionville, France 1293 Functionality of specific IgE to penicillins investigated by passive cutaneous sensitization Line Kring Tannert, Odense Research Center for Anaphylaxis, Department of Dermatology and Allergy Center, Odense University Hospital, Denmark 1294 Buccal provocative test in saliva for determination of hypersensitivity to dental materials Lyudmila Leonidovna Lazarenko, North-Western State Medical University named after I.I. Mechnikov, Russia 1295 The phenotypes of patients with immediate drug specific hypersensitivity to nonsteroidal anti-inflammatory drugs Ana Luisa Moura, Coimbra Hospital and University Centre, Portugal 1296 An interesting case: antihistamine allergy in a case of multiple drug allergy Ismet Bulut, Sureyyapasa Gohus Hastaliklari ve Gogus Cerrahisi EAH, Immunology and Allergy department, Turkey 1297 Skin tests positivity in consecutive pediatric and adult patients referred to an outpatient department for preoperative allergy risk assessment Polina Shahid, Clinic of Allergy & Asthma, Medical University, Bulgaria 1298 Late reaction to clavulanic acid Tatiana Lourenço, Immunoallergology Department, Hospital Santa Maria - Centro Hospitalar Lisboa Norte, EPE, Portugal 1299 Ace inhibitor-associated angioedema Ethel Ibáñez, Hospital Universitari i Politècnic La Fe, Spain 1300 Anaphylaxis due to lysine clonixinate during hemodialysis - First case report of lysine clonixinate allergy Jorge Rojas, University of Chile. University of Chile Clinical Hospital., Chile 1301 Flare-up reaction of beta-lactam patch tests after administration of cephalosporins Laura Argiz, University Hospital La Princesa, Spain Thematic Poster Session (TPS 49) Hereditary angioedema Poster Exhibition POSTERS Chair: Henriette Farkas, Hungary 1302 The evaluation of the adherence to the prophylactic treatments in hereditary angioedema patients and the potential factors which may affect the adherence: a real life study Semra Demir, Istanbul University, Istanbul Faculty of Medicine, Adult Allergy Clinic, Turkey 1303 A clinical care program to evaluate and support individualized treatment in patients with hereditary angioedema (HAE-C1-INH) Inmaculada Martinez Saguer, Haemophilia Centre Rhine Main, Germany 1304 Blindness, tetraspasticity, and other signs of irreversible brain damage in hereditary angioedema Konrad Bork, Department of Dermatology, Johannes Gutenberg University, Germany 1305 The Turkish version of the angioedema quality of life questionnaire and angioedema activity score: cultural adaptation, assessment of reliability and validity Emek Kocatürk, Okmeydani Training and Research Hospital Department of Dermatology, Turkey 1306 Turkish patients perception about the C1 inhibitor concentrate in the treatment of the acute attacks of hereditary angioedema Semra Demir, Istanbul University, Istanbul Faculty of Medicine, Adult Allergy Clinic, Turkey 1307 Hereditary angioedema type I not supported by genetic testing Mehmet Hoxha, UHC Mother Theresa, Albania 1308 Angioedema attacks related to endometrial hyperplasia in a case of estrogen dependent FXII-hereditary angioedema Dasha Roa-Medellín, Allergy Department. Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón, Spain 1309 Off-label intramuscular prophylactic treatment with conestat alfa (4200 u / 20 ml) in HAE patient with difficult peripheral venous access Anna Valerieva, Medical University of Sofia, Bulgaria 1310 Angioedema by acquired c1inhibitory deficit case report Laura Zurbano, Hospital Universitario Marques de Valdecilla, Spain 1311 Design and rationale of the optima study: retreatment or step-up therapy with omalizumab in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) Gordon Sussman, Department of Medicine, University of Toronto, Canada 1312 Clinical and diagnostic relevance of basophil CD203c in chronic spontaneous urticaria Lobna Abdel Aziz El-Korashi, Zagazig University, Egypt 1313 Etiological reasons and prognosis of acute urticaria in children under 5 years of age Pinar Gür çetinkaya, Hacettepe University School of Medicine, Pediatric Allergy Department, Turkey Full abstract author lists are available on the official Congress website.

155 POSTERS 20 JUNE 2017, 12:00-13: Autologus serum skin test in chronic urticaria comparative study and procedure assessment Leonor Carneiro-Leão, Serviço de Imunoalergologia, Centro Hospitalar de São João, E.P.E., Portugal 1315 Angioedema related to angiotensin-converting-enzyme inhibitors: A case series Maria Bova, Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy Thematic Poster Session (TPS 50) Urticaria and angioedema Poster Exhibition Chairs: Marcus Maurer, Germany Antti Lauerma, Finland 1316 Economic and humanistic burden associated with angioedema in patients with chronic spontaneous/idiopathic urticaria Ana Giménez-Arnau, Hospital Del Mar. Parc De Salut Mar Universitat Autonoma Barcelona, Spain 1317 Effectiveness of omalizumab in a daily practice cohort of adults with chronic spontaneous urticaria Harmieke Van Os-Medendorp, University Medical Centre Utrecht, The Netherlands 1318 Omalizumab for severe chronic spontaneous urticaria (CSU)- real life experience of 251 patients Keren Mahlab-Guri, Israeli Chronic Urticaria study group., Israel 1319 Evaluation of the clinical utility of the spanish version of urticaria activity score and urticaria activity score-7 for chronic urticaria Antonio Valero, Hospital Clínic i Provincial de Barcelona, Spain 1320 Features of immune status of patients with autoimmune urticaria Ella Vitalievna Churyukina, Rostov state medical University, Russia 1321 Increased risk of chronic spontaneous urticaria in patients with autoimmune thyroid diseases: a nationwide populationbased study Yoon Seob Kim, Department of Dermatology, College of Medicine, The Catholic University of Korea, South Korea 1322 Positive CD63 basophil activation test is common in patients with chronic spontaneous urticaria and concomitant autoimmune thyroiditis and therefore may represent a good marker for immunoreactivity. Galina Balakirski, University Hospital of Aachen, Germany 1323 Chronic cold urticaria experience of an allergy department of north of Portugal Isabel Rosmaninho, Centro Hospitalar Vila Nova De Gaia, Portugal 1324 Omalizumab in chronic spontaneous urticaria and angioedema; lessons from an Irish cohort Vyanka Sahni, St. James s Hospital, Ireland 1325 Patient tailored omalizumab treatment in chronic urticaria our experiences Peter Kopac, University Clinic of Pulmonary and Allergic Diseases Golnik, Slovenia 1326 Treatment and retreatment with omalizumab in chronic spontenous urticaria: real life experience with twenty-five patients Insu Yilmaz, Erciyes University School of Medicine, Division of Allergy and Clinical Immunology, Turkey 1327 Successful prophylactic treatment of acquired angioedema with plasma derived C1-inhibitor Michaela Wiednig, Medical University of Dermatology Graz, Austria 1328 Characteristics of patients attending the allergy clinic for chronic spontaneous urticaria Ana Montoro-Ferrer, Hospital General Universitario Gregorio Marañón, Spain 1329 Diagnostic and therapeutic profiles of patients with chronic urticaria at a reference center Juliana Augusta Sella, Ribeirão Preto Medical School, University of São Paulo, Brazil 1330 Analysis of the efficacy and safety of omalizumab in treatment of idiopathic chronic urticaria in Vietnam Bui Van Khanh, BACH MAI HOSPITAL, Viet Nam 1331 Generalized pruritus as manifestation of primary biliary cirrhosis. Mehmet Hoxha, UHC, Albania POSTERS Thematic Poster Session (TPS 51) Immune response and mechanisms of allergy Poster Exhibition Chair: Harald Renz, Germany 1332 Pru p 3-epitope-based immunotherapy in murine model for the treatment of peach allergy Maria José Rodriguez, Research laboratory IBIMA-UMA, Spain 1333 Effects of subcutaneous immunotherapy (SCIT) on the numbers of IL-10-producing CD4+ T cells and IL-10- producing B cells in peripheral blood of pollinosis patients Takeshi Nabe, Setsunan University, Japan 1334 Dose-response of skin prick tests with native and glutaraldehyde-polymerised allergen extract of alternaria alternata. Miguel Casanovas, Inmunotek, S.L., Spain 1335 Prospective RT-PCR analysis of chosen genes expression in patients with hymenoptera venom allergy Karol Kempinski, Department of Allergology, Medical University of Gdansk, Poland 155

156 POSTERS 20 JUNE 2017, 12:00-13: Reducing allergic symptoms with oral immunotherapy supported by a non-digestible oligosaccharide supplemented diet in a peanut allergy mouse model. Laura Wagenaar, Department of Immunotoxicology, Institute for Risk Assessment Sciences, Faculty of Veterinary Medicine, Utrecht University, The Netherlands 1337 Bioavailability of hdm allergens in sublingual tablet allergy immunotherapy is highly dependent on formulation Katsuyo Ohashi-Doi, Torii Pharmaceutical Co. Ltd, Japan 1338 Antibody responses to sublingual treatment with recombinant bet v 1 and mal d 1 Gabriela Sánchez Acosta, Department of Pathophysiology and Allergy Research and Christian Doppler Laboratory for Immunomodulation, Austria 1339 Immunotherapy with depigmented-polymerized peanut extract. Mouse model of peanut allergy Philippe A Eigenmann, Adult&Child Allergy Unit. Geneva University Children s Hospital, Switzerland 1340 Delineation of T cell responses after COP immunotherapy in birch pollen allergic patients Pawel Gajdanowicz, Wroclaw Medical University, Poland 1341 Sublingual immunotherapy with 5-grass allergen suppresses the spilling of the airway inflammation to the lung periphery during the pollen season Tanya Zdravkova Kralimarkova, Medical University Sofia, Clinic of Allergy and Asthma, Bulgaria Thematic Poster Session (TPS 52) Miscellaneous Poster Exhibition POSTERS 1342 The horse allergen Equus caballus Equ C 4 in horse saliva Susanne Victor, Department of Medical Sciences, Sweden 1343 Particle size distribution of aluminium hydroxide adsorbed allergen preparation by laser diffraction. Rob Van Den Hout, HAL Allergy B.V., The Netherlands 1344 Circular dichroism as a valuable tool to characterise allergen products Niels Sinnige, HAL Allergy B.V., The Netherlands 1345 Development of an aluminium-based ragweed allergoid immunotherapy using quality-by-design Werner L. Vos, HAL Allergy B.V., Development Department, The Netherlands 1346 A metaanalysis on the role of leukotriene receptor antagonist in reducing the cardiovascular risk Malvina Hoxha, Catholic University Our Lady of Good Counsel, Department of Chemical, Toxicological and Pharmacological Evaluation of Drugs, Albania 1347 A sensitive, specific, and validated immunoassay for cat allergen, Fel d 4. Stephanie Filep, Indoor Biotechnologies, Inc., United States 1348 Strategy for quality and safety Aassessment of hydrolyzed whey-based infant formula Karen Knipping, Nutricia Research, The Netherlands 1349 Therapeutic measures in allergy to dogs and/or cats. recommendations of the quasar group. pet-all project Ana Navarro, Hospital El Tomillar, Spain 1351 Fel d 1 and fel d 4 allergen levels in fur, urine and saliva of domestic house cats. William Yang, Red Maple Trials, Canada 1352 Dog allergy to meat: is IDT and specific IgE of any usefulness? Luís Lourenço Martins, Institute of Mediterranean Agricultural and Environmental Science (ICAAM) & Department of Veterinary Medicine, School of Sciences and Technology, University of Évora, Portugal 1353 Publication trends of Allergy and Clinical and Translational Allergy journals: a MeSH term-based bibliometric analysis Bernardo Sousa-Pinto, CINTESIS - Center for Health Technology and Services Research, Faculty of Medicine, University of Porto, Portugal 1354 Behavioural and immunological effects of early life prebiotic and omega-3 poly-unsaturated fatty acid dietary supplementation in healthy mice Kirsten Szklany, Utrecht University, Utrecht Institute of Pharmaceutical Sciences, Pharmacology, The Netherlands 1355 Insect bite hypersensitivity (IBH) in horses: in silico selection of major culicoides allergens Horst Rose, Boehringer Ingelheim Animal Health GmbH, Germany 1356 Fibrous dysplasia: outcome of long time follow-up Ping Ye, Department of Otolaryngology, Qilu hospital, Shandong University; Key Laboratory of Otolaryngology, Chinese Ministry of Health, China 1350 Objective indicators substantiating the benefits of micronized methylcellulose use by sensitized subjects during the grass pollens season Diana Mitkova Hristova, Medical University Sofia, Clinic of Allergy and Asthma, Bulgaria 1357 Hypersensitivity pneumonitis after lung volume reduction with endobronchial valves in a patient with nickel contact allergy Claudia Lang, Department of Dermatology, University Hospital Zurich, Switzerland Full abstract author lists are available on the official Congress website.

157 POSTERS 20 JUNE 2017, 12:00-13:30 Thematic Poster Session (TPS 53) Risk factors and management of food allergy Poster Exhibition Chairs: Kirsten Beyer, Germany Montserrat Alvaro, Spain 1358 Peanut allergy in Chile: First clinical series of 10 Chilean cases Raquel E. Aguilera, Pontificia Universidad Católica de Chile, Chile 1359 Visual recognition of peanuts and tree nuts in 440 allergic children and their parents Anne-Christine Vilain, Service d Allergologie et d Education Thérapeutique, Groupement des Hôpitaux de l Institut Catholique de Lille, Hôpital Saint-Vincent de Paul, France 1359 A Early risk factors for sensitization to food allergens in children up to 3 years. Julia Gawryjolek, Department of Pediatrics, Allergology, and Gastroenterology, Nicolaus Copernicus University of Torun, Collegium Medicum in Bydgoszcz, Poland 1360 Effect of egg and folic acid supplement consumption by pregnant women on food allergies in their children Masako Abe, Oita University of nursing and health sciences, Japan 1361 Evaluation of L.RhamnosusGG heat-stability during formula preparation according to FAO/WHO recommendation Aitoro Rosita, University of Naples Federico II, Italy 1362 Baked egg challenges: A 6-year clinical experience from a large, paediatric allergy specialist centre in the UK. Mohammad Al-Enezi, St Thomas Hospital, United Kingdom 1366 Safety and tolerability of subcutaneous immunotherapy (SCIT) with a modified peanut extract in peanut-allergic adults, adolescents and children Edwin H. Kim, UNC School of Medicine, Allergy and Immunology, United States 1367 Oral inmunotherapy and follow-up in highly sensitized egg allergic children Margarita Acevedo, Paediatric allergy department, Hospital Materno-Infantil Gregorio Marañon, Spain 1368 Adverse reactions during oral food immunotherapy in patients allergic to cow s milk or egg proteins: our experience. Martina Indiveri, Allergy Department. Hospital Universitari Joan XXIII., Spain 1369 Current management and use of oral immunotherapy for peanut allergy across Western Europe Amr Radwan, Aimmune Therapeutics, United Kingdom 1370 Omalizumab combined with oral immunotherapy for the treatment of severe cow s milk allergy: Our 2-year-long experience Stefania Arasi, University of Messina, Italy 1371 An adult-onset kiwi allergy case not accompanied by multiple drug allergy with a history of latex allergy Cihan Örçen, Sureyyapasa Gogus Hastaliklari ve Gogus Cerrahisi EAH, Immunlogy and Allergy Department, Turkey 1363 Epicutaneous immunotherapy (EPIT) for peanut allergy modifies igg4 responses to major peanut allergens Stef J Koppelman, DBV Technologies, France 1364 Long term outcomes of oral immunotherapy for cow s milk allergy Ezgi Ulusoy, Ege University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Allergy and Immunology, Turkey 1365 Soti for wheat allergy in a one-year-old girl: a case report of a modified protocol. Marianna Tziotou, Department of Allergy, Sotiria General Hospital, Greece 1372 An interesting case of adult-onset food allergy Ismet Bulut, Süreyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital,Training Clinic of Adult Immunology and Allergy Diseases, Turkey 1373 An late-onset multiple food allergy case Cihan Örçen, Sureyyapasa Gogus Hastaliklari ve Gogus Cerrahisi EAH, Immunology and Allergy Department, Turkey 1374 A late adult-onset egg allergy case Cihan Örçen, Sureyyapasa Gogus Hastaliklari ve Gogus Cerrahisi EAH, Immunology and Allergy departmet, Turkey POSTERS Thematic Poster Session (TPS 54) The spectrum of adult food allergy Poster Exhibition Chairs: Clare Mills, United Kingdom Isabel Skypala, United Kingdom 1375 A multiple fruit allergy clinical case co-sensitization or cross-reactivity? Ana Castro Neves, Hospital Dona Estefânia, Portugal 1376 Jackfruit allergy An increasing exotic problem linked to the oral allergy syndrome Rhea A Bansal, St Helier Immunology Department, United Kingdom 1377 Kiwi allergy a case series Leonor Carneiro-Leão, Serviço de Imunoalergologia, Centro Hospitalar de São João, Portugal 1378 Kounis syndrome; an underdiagnosed entity. Natalia Magalí Giménez Licitra, 12 de Octubre University Hospital, Spain 1379 Interspecie cross reactivity beyond parvalbumin in allergy food: a case report between tuna and grouper. Virginia Bellido-Linares, Allergy Unit. University Hospital Virgen Macarena, Spain 157

158 POSTERS 20 JUNE 2017, 12:00-13: A case report of a patient allergic to mushrooms. Adriana Mendoza, Hospital Central de la Defensa Gomez Ulla, Spain 1381 High allergy to guar gum and to xanthan gum Michel Bouvier, Clinique Charcot, France 1382 Mustard allergy: diagnostic and identification of specific allergens by immunoblotting. Justine Courtois, CRIG, Belgium 1383 Differences and similarities in two cases of mugwort-mustard allergy syndrome Giuseppe Cataldo, School and Division of Allergy and Clinical Immunology, Italy 1384 Disease progression of lipid transfer protein syndrome: clinical case Ana Luisa Moura, Coimbra Hospital and University Centre, Portugal 1385 Development of food allergy to fish in elderly patient Olga I. Sidorovich, NRC Institute of Immunology, Russia 1386 A late adult-onset multiple food allergy case Cihan Örçen, Süreyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital,Training Clinic of Adult Immunology and Allergy Diseases, Turkey 1387 An interesting adult-onset food allergy case related to an asthma patient who has experienced laryngeal edema after eating arugula Cihan Örçen, Süreyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital,Training Clinic of Adult Immunology and Allergy Diseases, Turkey 1388 A late adult-onset food allergy case Cihan Örçen, Sureyyapasa Gogus Hastaliklari ve Gogus Cerrahisi EAH, Immunology and Allergy department, Turkey 1389 An interesting food allergy case displaying angioedema associated with hazelnut consumption Cihan Örçen, Süreyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital,Training Clinic of Adult Immunology and Allergy Diseases, Turkey 1390 Two adult-onset food allergy cases with wheat flour allergy Ismet Bulut, Sureyyapasa Gogus Hastaliklari ve Gogus Cerrahisi EAH, Immunology and Allergy Department, Turkey 1391 An adult-onset food allergy case with egg allergy Ismet Bulut, Süreyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital,Training Clinic of Adult Immunology and Allergy Diseases, Turkey 1392 An interesting case of adult-onset kiwi allergy not accompanied by latex allergy Cihan Örçen, Süreyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital,Training Clinic of Adult Immunology and Allergy Diseases, Turkey Thematic Poster Session (TPS 55) Allergens and antigens Poster Exhibition POSTERS Chairs: Karin Hoffmann-Sommergruber, Austria Reto Crameri, Switzerland 1393 Characterization of a PhL p 6 mutant with increased structural stability Wai Tuck Soh, University of Salzburg, Austria 1394 Evaluation of allergenic relationship between humulus japonicus and humulus lupulus pollens Chang-Gyu Jung, Department of Allergy and Clinical Immunology, Ajou University School of Medicine, South Korea 1395 Carbohydrate composition of house dust mite allergen extracts and its relevance for ige binding Steffen Augustin, Research and Development, Allergopharma GmbH & Co KG, Germany 1396 House dust mite component allergens as diagnostic markers Kyung Hee Park, Yonsei University, South Korea 1399 Inhalation antigens sensitisation in Czech hypersensitivity pneumonitis patients Martina Vasakova, Thomayer Hospital and 1st Medical School Charles University, Czech Republic 1400 A sensitive two-site immunoassay for quantification of japanese cedar pollen allergen, Cry j 1. Bryan Smith, Indoor Biotechnologies, United States 1401 The influence of the East Asian mushrooms ganoderma lucidum and lentinula edodes and the belarussian mushroom boletus edulis on immune cell function A Hancharou, Republican Research-Practical Center for Epidemiology and Microbiology, Belarus 1402 Uptake, maintenance and dissemination of oral polio vaccine (OPV) virus by periplaneta americana cockroaches Okikiola Morenike Olajide, Ahmadu Bello University, Nigeria 1397 The COMPARE allergen database: a comprehensive Protein Allergen resource Gregory S Ladics, DuPont Haskell Global Centers for Health and Environmental Sciences, United States 1398 Extracts freeze dried and stable purified allergens from HDM for diagnostic, research and immunotherapy purposes Sonja Kesselmans, Citeq BV, The Netherlands 1403 Major peach allergen pru p 3 has structural features similar to saposins María Garrido-Arandia, Centre for Plant Biotechnology and Genomics, Technical University of Madrid, Spain 1404 Assessing potency of various peanut allergens in germ-free murine model using Ara h1, Ara h2, and Ara h3 Nathan Lawrence Marsteller, University of Nebraska-Lincoln, United States Full abstract author lists are available on the official Congress website.

159 POSTERS 20 JUNE 2017, 12:00-13: Different sensitizations in the lombardia region (Italy) Davide Paolo Caimmi, CHRU de Montpellier, Allergy Unit and Cystic Fibrosis center, France Thematic Poster Session (TPS 56) Autoimmunity Chair: Cristiana Stellato, Italy 1406 Increased risk of developing depressive and anxiety disorders in patients with systemic lupus erythematosus: a matched case-control study Kun Lin Lu, Department of Pediatrics, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taiwan 1407 The role of dysregulation of the immune system in the formation of immunodeficiencies and autoimmune disorders L. P. Sizyakina, Rostov State Medical University, Russia 1408 Sputum anti-neutrophil cytoplasmic antibodies in eosinophilic granulomatosis and polyangiitis patients with respiratory involvement Manali Mukherjee, McMaster University, Canada Poster Exhibition 1413 Circulating ACPA-specific immune complexes in RA patients promote proliferation and cytokine secretion from fibroblastlike synoviocytes Xiao-Jun Li, Institute of Clinical Laboratory Science, Jinling Hospital, School of Medicine, Nanjing University, Nanjing , China, China 1414 The prevalence of autoantibodies in patients with chronic hepatitis B and C. Sükran Köse, Izmir Tepecik Training and Research Hospital, Turkey 1415 Clinical significance of circulating serum XIST in patients with rheumatoid arthritis Li-Ping Zhang, Department of Laboratory Science, Nanjing LiSHui District Hospital, China 1409 Role of 18F-FDG PET/CT in the assessment of disease activity and progression in takayasu s arteritis Maja Stojanovic, Clinic of Allergy and Immunology, Clinical Center of Serbia, Serbia 1410 Vasculitis in rheumatoid arthritis /RA/ Plamen Hristov Yakovliev, Medical college of Thracian university, Bulgaria 1411 Success of rituximab in a case of coronary arteritis and IgG4 related aortitis. Letizia Barbieri, Department of Translational Medical Sciences, University of Naples Federico II, Italy 1412 Overexpression of arginine transporter CAT-1 is associated with hypoxia-induced fibroblast-like synoviocytes hyperplasia in rheumatoid arthritis. Ying Lu, Shanghai East Hospital, Tongji University School of Medicine, China 1416 Investigation of IL-17 producing CD26-/low memory treg cells in patients with psoriasis Behnaz Esmaeili, Tehran University of Medical sciences, Iran 1417 Recalcitrant cutaneous sarcoidosis - paradoxical worsening with anti-tnfa therapy despite a dramatic improvement in pulmonary function Miriam Fitzgerald, Chelsea & Westminster Hospital, United Kingdom 1418 Overall disability sum score (ODSS) for clinical assessment of neurological involvement in eosinophilic granulomatosis with polyangiitis. Maddalena Marconato, School of Allergology and Clinical Immunology, University of Padova, Italy POSTERS Late Breaking Thematic Poster Session (LB TPS 7) Airborne allergens and air pollution Poster Exhibition 1623 Impact of outdoor molds on daily short-acting beta2 agonists (saba) sales in central france area for 5 years Denis M Caillaud, University Hospital, Auvergne University, France 1624 Towards developing personal allergy symptom forecasting system in Baltic states Olga Ritenberga, University of Latvia, Latvia 1625 Aerobiological, biogeographical, and meteorological features of the November 2016 fatal thunderstorm asthma event in Melbourne, Australia Janet Mary Davies, Queensland University of Technology, Australia 1626 Sensitization to peach tree pollen in Madrid Maria Luisa Somoza, Allergy Service. Infanta Leonor University Hospital, Spain 1627 Diagnosis and treatment of allergic patients to tree pollen in Lviv region, Ukraine S. Zubchenko, Danylo Halyckiy Lviv Medical Univercity, Ukraine 1628 Approaches to molecular diagnosis of allergy to pollen of weeds Svitlana Zubchenko, Danylo Halytsky Lviv National Medical University, Ukraine 159

160 POSTERS 20 JUNE 2017, 12:00-13: Respiratory symptoms associated with the inhalation of Cladosporium, Alternaria and Aspergillus Mold Spores in Zimbabwean patients Elopy Nimele Sibanda, Asthma, Allergy and Immune Dysfunction Clinic, Harare, Zimbabwe, National Universities of Science and Technology, Bulawayo, Zimbabwe Department of Pathophysiology, Infectiology and Allergy Research, Medical University of Vienna, Austria, Zimbabwe 1630 Alternaria spores counts during 2016 in Seville, Spain Cristina Lopez-Ruiz, Allergy Unit. University Hospital Virgen Macarena, Spain 1631 Peach tree pollen is highly prevalent in areas with extensive peach cultivar Laura Victorio, Allergy Servicie, Hospital Clínico Universitario Virgen de la Arrixaca, Spain 1632 Allergy medications sales: An useful surrogate marker for pollinosis health impacts in Alentejo, Portugal? Ana R Costa, Instituto de Ciências da Terra, Universidade de Évora, Portugal 1633 Spatial distribution of pollen-induced symptoms within a large Metropolitan area - A pilot study Barbora Werchan, Charité-Universitätsmedizin Berlin, Germany 1634 Diagnostic study of serum specific IgE versus skin prick test in diagnosing sensitization to house dust mites and cockroach allergens in patients with allergic asthma and/or rhinitis in Indonesia Suriani Alimuddin, Division of Allergy and Immunology, Indonesia 1635 Study of aero-allergen sensitization in subjects with nasobronchial allergy in a tertiary care centre from india. Madhavi Kadambi Vijayasarathi, Narayana Hrudayalaya, India 1636 The efficacy and safety of birch pollen allergen extract in the diagnosis of birch pollen allergy Jian-Qing Gu, Peking Union Medical College Hospital, China 1637 Small and handy - The personal particle sampler Matthias Werchan, Foundation German Pollen Information Service, Germany 1638 Allergen production and demographic increase in Dermatophagoides farinae mass reared population Neri Orsi Battaglini, Anallergo, Italy 1639 Comparison of the level of seven different indoor allergens in five different cities of Iran Fatemeh Mardani, Student Research committee, Mashhad University of Medical Sciences, Iran Late Breaking Thematic Poster Session (LB TPS 8) Immunology and allergooncology Poster Exhibition POSTERS 1640 AllergoOncology: folate receptor alpha as a therapeutic target in breast carcinomas using recombinant antibodies Anthony Cheung, King s College London, United Kingdom 1641 Inhibition of nasal allergic remodeling by JNJ Lin Li, China-Japan Union Hospital of Jilin University, China 1642 Release of neutrophil extracellular traps as a main trigger for asthma onset Coraline Radermecker, GIGA-R, Belgium 1643 Specific IgE plasma levels for definite cat antigens correlates with total IgE in russian patients with cat allergy Anna Sergeevna Dolgova, Central Research Institute of Epidemiology, Russia 1644 Epithelial dynamics in IL-4-stimulated human nasal epithelial cells Jin Won Kim, Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Korea, South Korea 1645 Binding of the active vitamin A metabolite retinoic acid impairs immunogenicity of the major cows milk allergen Bos D 5 Karin Hufnagl, Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Austria 1646 Comparison of allergic airway inflammation induction potency of Dermatophagoides Farinae, D. pteronyssinus and Tyrophagus putrescentiae Ju Yeong Kim, Department of Environmental Medical Biology, Institute of Tropical Medicine and Arthropods of Medical Importance Resource Bank, Yonsei University College of Medicine, South Korea 1647 A SHIP-1 antagonist does not increase CD63 upregulation of human blood basophils Pernille Rasmussen, Aarhus University, Denmark 1648 Immunomodulation of anticancer immune response in mouse prostate cancer model Nunu Mitskevich, Ivane Javakhishvili tbilisi State University, Georgia 1649 Allergic immune- reactivity to japanese cedar pollen in donors with different rates of pollen exposure Veronique Schulten, La Jolla Institute, United States 1650 The adaptor molecule MyD88: an inhibitory pathway of the allergic response induced by aspergillus fumigatus spores Pauline Percier-Lehebel, Scientific Institute of Public Health, Belgium 1651 Bacterial CpG-DNA prevents asthma by expanding lung interstitial regulatory macrophages from local and splenic reservoir monocytes Catherine Sabatel, University of Liege, Belgium Full abstract author lists are available on the official Congress website.

161 POSTERS 20 JUNE 2017, 12:00-13: Facilitated allergen binding of venom allergens via CD23 mediated by CCD-specific IgE Michaela Miehe, Aarhus University, Denmark 1653 Allergooncology: Functional evaluation of SF-25 IgE and IgG1 antibodies as novel candidates to activate human effector cells for cancer immunotherapy Giulia Pellizzari, King s College of London, United Kingdom 1654 Evaluating therapeutic IgE antibody toxicity using in vivo rat models and an ex vivo human basophil assay Heather J Bax, King s College London, United Kingdom 1655 Allergooncology: A tnfa/mcp-1/il-10 axis is associated with tumour antigen-specific ige-dependent monocyte-mediated functions against cancer Mano Nakamura, King s College London, United Kingdom 1656 Fc?-receptors and toll like receptor expression on monocyte from patients in chronic lymphocytic leukemia Tamar Tsertsvadze, Iv.Javakhishvili Tbilisi State University, Georgia Late Breaking Thematic Poster Session (LB TPS 9) Asthma in children and adults Poster Exhibition 1657 Manufacturers offer fake solutions for house dust mite allergic patients - An insight into market of bedding products with reference to current medical guidelines Karolina Dumycz, Medical University of Warsaw, Poland 1658 Serum quantitative specific IgE level of house dust mites and its relationship with the severity of allergic asthma patients in indonesia Agus Joko Susanto, Allergy and Clinical Immunology Moewardi Hospital, Indonesia 1659 The status of children admitted to the pediatric allergy policlinic due to excersize associated dipnea Hulya Ercan Saricoban, Yeditepe University Faculty of Medicine,Pediatric Immunology and Allergy, Turkey 1660 Clinical correlation of acute inflammatory marker in asthmatic children Ilknur Bostanci, Health Sciences, Dr. Sami Ulus Maternity and Children Research and Training Hospital, Ankara, Turkey, Department of Pediatric Allergy and Immunology, Turkey 1661 Characteristics of acute exacerbation in korean adult asthmatics between respiratory viruses detected cases and not detected cases Myung Shin Kim, Soonchunhyang university Gumi hospital, South Korea 1662 Patient with chronic asthma and treatment poor response associated to benzodiacepines chronic administration Joan Domenech Witek, Hospital General de Elda, Spain 1663 The role of allergens in the progression of obesity and hyperglycemia in asthma patients Galyna Vladimirovna Yeryomenko, Kharkiv National Medical University, Ukraine 1665 Serum specific IgE-sensitization to inhalant allergens in asthma and allergic rhinitis patients in Jakarta, Indonesia Iris Rengganis, University of Indoneisa - Dr. Cipto Mangunkusumo Hospital, Indonesia 1667 Evolutionary particularities in respiratory allergy associated with Cystic Fibrosis in children Bogdan Stana, Emergency Children Hospital, Romania 1668 Patterns of comorbidity of asthma and cardiovascular diseases Temyrzhan Temyrlanovich Nurpeissov, SRI of Cardiology and internal diseases, Kazakhstan 1669 The effect of vitamin D on the clinical outcome of children with asthma and vitamin D deficiency Rasoul Nasiri Kalmarzi, Kurdistan university of medical sciences, Iran 1670 Food allergy in children with bronchial asthma Ecaterina Stasii, State Medical and Pharmaceutical University, Moldova 1671 Tobacco cessation in asthmatic patients Marta Martins Batista, Hospital de São Bernardo, Portugal 1672 Evaluation of sensitization to der P 1 and der P 2 in a pediatric population of the north of portugal Sara Peixoto, Pediatric Department of Centro Hospitalar de Trás-os-Montes e Alto Douro (CHTMAD), Portugal 1673 Asthma predictive index in wheezy infants with chalmydia and mycoplasma pneumoniae infection Abdülkadir Koçak, osmangazi university faculty of medicine, Turkey 1674 Parental perceptions of salbutamol use and clinical response in children with asthma Christina J Jones, Brighton & Sussex Medical School, United Kingdom 1675 Prevalence Of Asthma-Like Symptoms And Allergic Diseases In Preschool Children And Risk Factors. Natalia Shakhova, Altai State Medical University, Russia POSTERS 1666 A Delphi approach to development of standard questionnaire to investigate asthma in Korean children Jaehyeon Jang, CHA University School of Medicine, South Korea 161

162 SPEAKER INDEX A Aakula, Matilda...77 Aalberse, Rob C...72 Aarestrup, Fernando Monteiro...129, 145 Aasmoe, Lisbeth Abadalkareem, Rana Abadoglu, Oznur Abbring, Suzanne...64 Abedi, Yasmin Hamzavi Abe, Masako Aberer, Werner...89, 99, 124 Abramidze, Tamar Acevedo, Margarita Acosta, Gabriela Sánchez Adcock, Ian...37 Afify, Sheriene Moussa Agache, Ioana...37, 44, 52, 71 Agarwal, Amit...81 Agner, Tove...76, 103 Agostini, Carlo...46 Aguiar, RITA Aguilera, Raquel E Ahmed, Hussien Ahmetaj, Luljeta Ahmetaj Ahumada, Velky Aitoro, Rosita...65 Akarcan, Sanem Eren Akbarzadeh, Reza...42 Akdis, Cezmi...61, 71, 87, 96 Akdis, Mübeccel...51, 75, 88 Akin, Cem...96 Aktas, Özge Öztürk...67 Albanesi, Marcello...48 Al-Dqour, Mohammad Riyad Al-Enezi, Mohammad Alenius, Harri...61 Alessandri, Claudia...55, 72, 125 Alevizopoulos, Kostas...56 Alfaya, Teresa Aliakhnovich, Natalia Alimuddin, Suriani Alizadeh, Zahra Al-Jebouri, Mohemid M Allaert, Francois Allegri, Pia...66 Allen, Katie...47, 57, 69, 95 Allen, Katrina J...65 Al-Shammari, Hamed Altunbulakli, Can...64 Alul, Maria Alvarez-Perea, Alberto... 31, 77, 128, 134, 143 Alvaro, Montserrat...73, 89, 98, 157 Alves, Cátia...55, 104 Amaral, Luis Amat, Flore...40, 78 Amerigo, Dario Antolin...41, 151 Amosova, Kristina Andiappan, Anand Kumar Andreev, Sergey...72 Angelina, Alba...53 Angier, Elizabeth...32, 95 Annesi-Maesano, Isabella...90, 138 Antolín-Amérigo, Darío...80, 124 Antonio, Moreno-Fernandez Anton-Paduraru, Dana-Teodora Antunes, Celia Antunes...78, 118 Apausa, María Del Pilar Cuesta Apfelbacher, Christian Joachim...31, 79, 88, 145 Apoil, Pol André Apostolovic, Danijela...55 Aramburu, Teresa Aranda, Carolina Sanchez...47 Arani, Marzieh Heidarzadeh Aranzabal, María Ascensión Arasi, Stefania Araujo, Galber R...72 Argiz, Laura Ariens, Lieneke Francis Marleen Arif, Rihane Arregui, Arturo Velasco Arslan, Zafer Artac, Hasibe Arts, Babette Arzt, Lisa Asano, Masayo...93 Asher, Ilan...92 Ashley, Sarah Elizabeth...39 Astafieva, Natalia Grigorievna Asturias, Juan Andrés...56 Astvatsatourov, Anatoli...46 Atanaskovic-Markovic, Marina...51, 61, 67 Augustin, Steffen Aydin, Ali...80 Aydin, Ömür...67 Aygören-Pürsün, Emel...139, 140 Azevedo, João B Babaie, Delara Babakhin, Alexander Alexandrovich. 81, 117, 127 Baccioglu, Ayse...80, 128, 144 Bacher, Petra...39 Bachert, Claus...38, 89, 93, 113 Backer, Vibeke...68, 112 Badas, Jenny...43 Bagnasco, Diego Bain, Calum...71 Bajraktarevic, Adnan Bakirtas, Arzu...45, 52 Balakirski, Galina Balikji, Stephanie Ballardini, Natalia Ballegaard, Anne-Sofie R Ballestar, Esteban Ballmer-Weber, Barbara...30, 45, 62 Bal, Suzanne Marleen...53, 64 Banerjee, Tushar Kanti...74, 130 Ban, Ga-Young...80 Bang, Berit Elisabeth...51 Bansal, Rhea A Barac, Aleksandra...66 Barayazarra, Susana Norma De Barbaud, Annick...42 Barber, Colin Mackenzie Barber, Domingo...45, 113, 125 Barbieri, Letizia Barbouche, Mohamed-Ridha...46 Barcik, Weronika...40 Baretto, Richard Lawrence Barni, Simona...79 Barrionuevo, Esther...80 Bartel, Sabine...64 Bartkowiak-Emeryk, Malgorzata...77 Bartoll, Esther Basagaña, Maria Bashkatova, Elena Batard, Thierry...67 Batista, Marta Martins , 140, 150, 161 Batmaz, Sehra Birgül Battaglini, Neri Orsi Bavbek, Sevim...96, 105 Bax, Heather J Baynova, Krasimira Bazarova, Sayyora A...54, 55, 90, 137 Bazire, Raphaëlle...73 Beck, Sarah C Beggs, Paul...82, 90 Beken, Burcin Bellach, Johanna Bellido-Linares, Virginia Belmonte, Jordina...49, 118 Beltyukov, Evgeny Benito-Garcia, Filipe...55, 124 Benito-Villalvilla, Cristina...91 Benson, Mikael...31, 69 Berce, Vojko...65 Berger, William Bergmann, Karl-Christian...69, 105 Bergroth, Eija...77 Bergström, Anna...62 Berings, Margot...46, 53 Bermingham, Max Bernad, Amalia Alonso...49 Berrios, Rosialzira Natasha Vera Berthold, Malin Berti, Alvise...47 Beyer, Kirsten...77, 89, 157 Bhowmik, Moumita Bianchini, Rodolfo...53 Biedermann, Tilo...30, 51, 141 Biletska, Sofiia Billo, Nils E Biló, Beatrice...41, 45, 63 Bilsen, Jolanda Hubertina Maria Van...39 Bindels, Patrick...75 Bindslev-Jensen, Carsten... 45, 91, 97, 112 Bingol, Aysen Birben, Esra

163 SPEAKER INDEX Bircher, Andreas...29, 44 Bisyuk, Yuri...81 Bjermer, Leif...38, 51 Björkander, Sophia Blaiss, Michael S...70 Blanca-López, Natalia...80, 113 Blanco, Carlos...53 Blankestijn, Mark Alexander...104, 105 Blay, Frédéric De...72 Blazowski, Lukasz...122, 135 Blin, Patrick Blom, Lars Heede Blom, W. Marty...77, 105 Blumchen, Katharina Blumenstock, Jesse Alexander...98 Boarini, Carolina Rodrigues Bochenek, Grazyna Bodajko-Grochowska, Anna...65, 121 Bodinier, Marie Boer, Douwe De...66 Bogomolov, Artemii Boguslavskaya, Julia...74 Bohle, Barbara...62, 68 Böhm, Teresa Manon Sophie Alice Bokanovic, Danijela Bona, Danilo Di...137, 153 Bonadonna, Patrizia...29, 45, 96 Bonaguro, Roberta...50 Boni, Elisa Bonini, Matteo...89, 103, 117 Bonini, Sergio...38 Boonpiyathad, Tadech Bork, Konrad Borovik, Tatiana E Boscolo, Maria Assunta Bosnic-Anticevich, Sinthia...89 Bossé, Isabelle Bostanci, Ilknur...94, 152, 161 Bougault, Valérie...75 Bousquet, Jean...46, 52, 71, 89, 149 Bouvier, Michel Bova, Maria Boyman, Onur...51, 64, 96 Bozkurt, Banu...52, 66 Bradatan, Elena Bradford, Eric S Brandström, Josef...72 Braunstahl, Gert-Jan...69 Bredenoord, Arjan...70 Brehmer, Detlef...92 Breitrueck, Nils Yannick Brinia, Aikaterini Brockow, Knut...29, 44, 89 Broderick, Lori...88 Broesby-Olsen, Sigurd...96, 106 Brosseron, Lise...43 Brough, Helen Annaruth...98 Brozek, Grzegorz Marek...47 Bruin-Weller, Marjolein Saskia de...54, 103 Brusselle, Guy Brzoza, Zenon Buckley, Darren Bulgakova, Vilya...50, 94, 106 Bulut, Gokten...72 Bulut, Ismet...154, 157, 158 Burman, Janne...99 Busse, William...63, 102 Buters, Jeroen Titus...45, 69, 78, 102 Buyuktiryaki, Betul C Cabanillas, Beatriz Cabrera, Martha...50, 130 Caillaud, Denis M...118, 159 Caimmi, Davide Paolo...73, 138, 149,153, 159 Calderon, Juan Carlos Calderón, Moisés Calder, Virginia...52, 75 Callesen, Katrine T...74 Caminiti, Lucia...67 Campana, Raffaela...67, 129 Campanón-Toro, Maria Valle Campo, Paloma...40, 46, 63, 70, 93, 94 Canonica, G. Walter...89 Cantillo, Jose Fernando...78 Cañas, José Antonio...54 Caraballo, Luis...64 Cárdenas, Remedios Cardeñosa, Aida Gomez Cardona, Victoria...76, 89, 114, 135 Carello, Rossella Carlsen, Kai-Håkon...75, 103 Carne, Emily Carneiro-Leão, Leonor Rosário , 155, 157 Carolina, Figueroa-Zorrilla Carpio-Escalona, Laura Victoria Carter, Melody C Caruso, Cristiano...68, 120 Carvalho, Sara...125, 138 Casale, Thomas B...91 Casanovas, Miguel Castagnoli, Riccardo Castells, Mariana...51, 82, 153 Castillo, José A...48 Castillo, Maria Jose Castro, Arantza Vega Castro, Eunice Dias De...80 Cataldo, Giuseppe Caubet, Jean-Christoph Caubet Cauwenberge, Paul van...63 Çekiç, Sükrü...43 Celebioglu, Ebru...67 Çelik, Gülfem Elif...29, 92, 96, 143 Celik, Ilknur Kulhas.125, 131, 134, 135, 139, 153 Celik, Velat...74 Cernadas, Josefina Rodrigues...29, 48, 51 çetinkaya, Pinar Gür...56, 73, 154 Chabane, Habib...97 Chaker, Adam...96 Chang, Fang-Yu Chan, Sanny K Charpin, Denis Chatain, Catharina...124, 125 Chatzipetrou, Alexia Cheng, Lei Chen, Zhuo...78, 81, 149 Cheung, Anthony Chiarella-Privette, Gian Marco...123, 134 Chipps, Bradley...70 Chiriac, Anca E...144, 148 Chivato, Tomás...69, 117 Cho, Hyunseok...66 Choi, Byoung Whui...94 Choi, Jinyoung Choi, Jun-Pyo...56 Choi, Youngwoo...92 Chorda, Carolina Perales Cho, Sung-Woo...49 Christoff, George Christoff Christopoulou, Georgia Chu, Chia-Yu Chu, Chun-Hui Chung, Eun Hee...74 Churyukina, Ella Vitalievna...127, 155 Chytiroglou, Evangelia Cianferoni, Antonella Cicardi, Marco...39, 97 Ciccarelli, Fedra Cichocka-Jarosz, Ewa...41 Cinetto, Francesco...79 Cingi, Cemal...46 Cinicola, Bianca Laura Cipriani, Francesca Clot, Bernard...69 Coattrenec, Yann Cohen, Noam A Colakovska, Valentina Cvejoska Colamarco, Gabriel Antonio Coman, Isabel Cornejo-García, José Antonio...99 Coronado, Sandra Corps, Claire Correia, Magna...80, 143 Corry, David B...63 Corsi, Alice...90, 142 Cortellini, Gabriele Coskun, Raif...66 Cosme, Joana...90, 123, 138, 143 Costa, Ana R Costache, Irina Veronica Courtois, Justine...125, 158 Cousin, Mathias...77 Couso, Veronica Lopez Couto, Mariana...75, 148 Cox, Michael J...46, 61 Crameri, Reto Crespo, Antonia Rojas...67 Cruz, Alvaro Cudowska, Beata

164 SPEAKER INDEX Cui, Na...94, 128, 145, 146 Custovic, Adnan...62, 95 Cvetkovski, Biljana...119, 143 Cybulska, Agnieszka...54 Czarnecka-Operacz, Magdalena D Daele, Paul L.A. Van...91 Dahlén, Sven-Erik...38, 51, 149 Dalgiç, Ceyda Tunakan...43, 93, 151 D Amato, Gennaro...39, 45, 90 Darlenski, Razvigor...29 D Auria, Enza...145, 151 Davies, Janet Mary Dávila, Ignacio...81, 143 Davis, John D Delayre-Orthez, Carine...72, 126 Delgado, Luís...97 Deliu, Matea Demirel, Fevzi...125, 140, 153 Demir, Semra...48, 114, 154 Demko, Irina Vladimirovna Dempster, John Denisova, Anita Robertovna...99 Denman, Sarah Depner, Martin Dermendzhiev, Svetlan Devantier, Anne Devidze, Madona Devillier, Philippe...68, 129 Dhong, Hun-Jong Diamant, Zuzana...38, 63, 68, 104 Díaz, Elisa Haroun Diez-Rivero, Carmen María...72 Dimitrova, Denitsa...48, 55 Dioszeghy, Vincent...42 Doan, Serge...52, 75 Dolgova, Anna Sergeevna...126, 160 Dölle, Sabine Domínguez-Ortega, Javier Douagui, Habib...76 Doulaptsi, Maria Downs, Melanie Drannik, G Dreßler, Melanie Drunen, Cornelis van...31, 69, 106 Dua, Shelley Dubiela, Pawel...55 DuBuske, Lawrence...81 Dumycz, Karolina...74, 161 Durango, Cira Rosario García De...66 Durham, Stephen...52, 71 Dziadzio, Magdalena...123, 146 E Ebo, Didier G...96 Eckert, Laurent...53, 141 Edwards, Michael...44 Egea, Eduardo...55 Eifan, Aarif O...78 Eigenmann, Philippe A...74, 87, 156 Ekström, Sandra Elinder, Camilla Söderqvist Elkhalifa, Shuayb...43, 67 El-Korashi, Lobna Abdel Aziz Eller, Esben...66 Elliott, Susan J Ellis, Anne K...92 El-Shanawany, Isobel...75 El-Shanawany, Tariq Eltan, Sevgi Bilgic Emeryk, Andrzej...99 Emminger, Waltraud Entrala, Ana Ereshko, Oxana A Ergin, Melek...94 Eriksson, Marianne...80 Erjefalt, Jonas...61 Erkekol, Ferda Öner Erkocoglu, Mustafa Escobar, Leticia Maday Pedraza Escribese, Maria M...53 Esfidvajani, Alireza Shafiei Esmaeili, Behnaz Español, Ines Torrado...123, 140 Eussen, Simone R.B.M...73 Eyerich, Stefanie...38 F Fabbri, Leonardo M...98 Farhan, Abdal Jabbar Farinha, Sofia Martins Farkas, Henriette...97, 140, 154 Farzan, Niloufar...81 Fassakhov, Rustem Fauquert, Jean-Luc...75, 103 Fazekas, Judit Febriana, Sri Awalia...43 Feleszko, Wojciech Fereidouni, Mohammad Fernandes, Mara...79, 123 Fernandes, Rosa-Anita...123, 128 Fernandez, Carmen Carolina Fernández, Diego Gutiérrez...67, 142 Fernández, Javier...93 Fernandez-Rivas, Maria Montserrat.. 47, 102, 113 Fernandez, Tahia Diana...99 Ferrando, Matteo Ferreira, Alice Ferreira, Ruben Duarte Ferrer, Ana Montoro Ferrer, Marta...94, 141 Feuerman, Oren Mark...46 Figueroa-Zorrilla, Carolina Filep, Stephanie Finotto, Susetta...98 Fitzgerald, Miriam Fitzsimons, Roisin Fleisher, Thomas...62 Flodström, Charlotta Flohr, Carsten...68, 88 Florea, Catalina Focke-Tejkl, Margarete Fokkens, Wytske...61 Fong, Andrew Timothy...73 Fox, Adam...92 Francisco, Ana Margarita Montoro De Frei, Remo...38, 126 Frew, Anthony...57, 95, 97 Frossard, Mikaël Fujii, Yosuke...79 Fukuda, Ken...75 Furuta, Atsuko Fussbroich, Daniela Fyhrquist, Nanna...39, 90, 126 G Gadermaier, Gabriele...49 Gaisina, Alina R Gajdanowicz, Pawel Galán, Carmen...49, 78, 118 Gallardo, Eladia Alarcon Galvin, Audrey Dunn Gambineri, Eleonora...82, 102 Garcia, Antonio Nieto...69, 150 Garcia-Granero, Diego Blanco Garcia, Juliana Fóes Bianchini...67, 123 Garcia-Larsen, Vanessa...95 García-Moral, Alba Garcia-Nunez, Ignacio...124, 144 García, Olaya Alvarez...130, 131 Gardner, James...29, 138 Garib, Victoria...49 Garrido-Arandia, María...40, 158 Garrido, Jaume Martí...93 Garriga-Baraut, Teresa Garritsen, Floor...54, 64 Garvey, Lene Heise...37, 44 Gaspar, María Vázquez De La Torre Gasse, Athina L. Van Gawlik, Radoslaw Gawryjolek, Julia...130, 157 Gayraud, Jacques...97 Genuneit, Jon...31, 40, 81, 99, 100 Georgountzou, Anastasia...72 Gergovska, Malena Germany...37 Gevaert, Philippe...52, 87, 113 Ghiglioni, Daniele Giovanni...49 Ghiordanescu, Ileana Maria Giacco, Stefano Del...75, 103 Giangrande, Nicola...144, 153 Giménez-Arnau, Ana...53, 97, 155 Ginkel, Cornelia Doriene Van...65 Giovanna, Cynthia Giovanna Araujo Sánchez.139 Giovannini-Chami, Lisa Glatz, Martin

165 SPEAKER INDEX Gokmen, Nihal Mete...49, 139 Goksör, Emma...99 Golebski, K...78 Gomez, Francisca...73 Gomez, Maximiliano...46, 49 Goncalo, Margarida González-Cavero, Lourdes González, Miguel...53 Gonzalez-Moreno, Ana...126, 144 Gonzalo-Garijo, María Angela Gonzalo-Garijo, María Ángeles Goossens, An...76 Gordon, Julian Gore, Claudia Gornicki, Jaroslaw Górska, Aleksandra Gotovina, Jelena...56 Grabenhenrich, Linus B...47 Gracia, Ibon Eguiluz...52, 64, 71 Gracia, Ibon Eguiluz Gracia Eguiluz...91 Graessel, Anke...53, 71 Granger, Vanessa...98 Grattan, Clive...29, 41, 91, 103 Graversen, Katrine B Greco, Dario...69 Greve, Jens Grewal, Anjum...50 Grimshaw, Kate...29, 95, 102, 133 Grivcheva-Panovska, Vesna Grzella, Anne-Nele Guagnini, Fabio Guan, Kai Guerra-Vilaplana, Dolores Guilarte, Mar Gu, Jian-Qing Gulen, Theo Guleva, Dimitrina Gumunyu, Eulitty Gunaydin, Nursen Cigerci...80 Guo, Mindy Ming-Huey Guo, Yinshi Gutermuth, Jan...42, 71 Gutiérrez, Diana Carolina Ochoa Guvenir, Hakan...43, 74, 79 H Haahtela, Tari...37, 63 Haar, Nienke ter...88 Habazi, Murad...142, 143 Haccuria, Amaryllis Hadler, Meike Hage, Marianne van...55, 88, 102 Haimerl, Pascal...78 Haka, Jaana...40 Hakl, Roman Halken, Susanne.38, 44, 61, 71, 92, 102, 121 Hamalainen, Niina Hamelmann, Eckard Hammad, Hamida...94 Hämynen, Inka...77 Hancharou, A...55, 126, 158 Han, Doo Hee Hanif, Tanzeela Harada, Laurie...71 Haralappa, Haralappa Paramesh Häring, Franziska...78 Harsini, Sara...142, 151 Havlucu, Yavuz Hawarden, Di...76 Hawrylowicz, Catherine...63 Hayen, S. M Heaney, Liam...38, 51 Heath, Matthew D...56, 72 Heederik, Dick...45 Heffler, Enrico...45, 54, 87 Heidelberg, Cecilie Thon...73 Heijink, Irene Heine, Holger...91 Helbling, Arthur...63 Hellings, Peter...52, 61, 63, 89, 112 Hemmer, Wolfgang...45, 113, 135 Hendriks, Rudi W...87 Henning, Rainer...67 Hermans, Maud...90, 139 Hernandez, Mercedes Ramirez Herranz, Javier Cuesta...42 Herrero-Lifona, Leticia...93 Hess, Julia Hetherington, Kathy...89 Hierro, Beatriz...43 Higenbottam, Tim...56 Hijnen, DirkJan Hinds, David...94 Hjalmarsson, Eric Hoffmann, Hans Jürgen...40, 135 Hoffmann, Hans-Jürgen... 32, 96, 113, 122 Hoffmann-Sommergruber, Karin... 77, 97, 158 Hofman, Zonne Lm...97 Holdstock, Victoria Holloway, John...62 Hong, Haiyu...65 Hopkins, Claire...38 Horiuchi, Tatsuo...93 Høst, Arne...47, 95 Hostrup, Morten...57 Hourihane, Jonathan...30 Hout, Rob Van Den Hovi, Petteri...47 Hoxha, Malvina Hoxha, Mehmet...154, 155 Hox, Valerie...31, 38, 65 Hristova, Diana Mitkova Huang, Jing-Long...52, 133 Huang, Shu-Jung Huang, Yvonne J...62 Hufnagl, Karin Hulshof, Lies Hung, Chi-Yen Hung, Chung-Chieh...50 Hur, Gyu Young Hussain, Maryam Hutchinson, Katrina...78 Hu, Xiaolan I Ibáñez, Ethel Iglesias, Jesús Macías Ignatova, Galina Igreja, Ana Isabel Ikeda, Masanori...99 Il chukova, Olga Vladimirovna Ilina, Natalia...28 Imaoka, Michiyoshi Indiveri, Martina Intapiboon, Porntip Intravaia, Rossella...90, 125 Ishida, Waka...66 Isik, Rana S Ispayeva, Zhannat Ivkovic-Jurekovic, Irena Izquierdo-Dominguez, Adriana...80 Izquierdo, Lisa...93 J Jabs, Frederic...40 Jacobsen, Lars...30, 42, 71 Jacome, Amyra Ali Azamar...90, 118 Jacquet, Alain...56 Jahnsen, Frode...75 Jain, Subir...122, 127 Jakob, Thilo...45 Janeva, Elena Jovanovska...48 Jang, Gwang-Cheon...80 Jang, Jaehyeon Janukonyte, Jurgita Jaqueti, Paloma Jares, Edgardo...46 Jartti, Tuomas...65, 102, 126 Jarvinen, Kirsi M...47 Jedynak-Wasowicz, Urszula Jeebhay, Mohamed...76 Jensen, Annika N Jensen, Bettina Margrethe... 64, 96, 104, 139 Jensen-Jarolim, Erika...53, 121 Jeong, Kyoung Yong Jeong, Kyunguk...73 Jeong, Kyu-Tae Jeon, Sea-Yuong...65 Jesenak, Milos Jiang, Nan Nan Jiang, Wujun...99, 121 Jimenez-Lopez, Jose C Jin, Peng...66 Jiusan, Lorena...43 Johansson, S.G.O...62 Johnson, Philip Johnston, Sebastian...46 Jones, Anya C

166 SPEAKER INDEX Jones, Christina Jane...50, 161 Jong, Esther De Jong, Nicolette de...29, 39 Jordakieva, Galateja Jung, Chang-Gyu Jungewelter, Soile Jung, Hye Lim Jung, Sungsu Jurado-Escobar, Raquel Jutel, Marek...28, 76, 87, 88 K Kabesch, Michael...69, 80 Käck, Ulrika Kaidashev, Igor...80, 81 Kalayci, Ömer...44, 45, 69 Kallio, Sampo Kalmarzi, Rasool Nasiri...41 Kalmarzi, Rasoul Nasiri Kalm-Stephens, Pia Kalogjera, Livije Kalpaklioglu, A. Fusun...93, 120 Kamaev, Andrei...28 Kamchaisatian, Wasu Kam, Pieter Jan De...71, 127 Kang, Min-Gyu Kang, Sung-Yoon Kansen, Hannah M Kao, Hui Fang Karaca, Neslihan Edeer Karakaya, Gul Karak, Partha Karaman, Sait Karimova, Maleyka Knyaz...43, 139 Kari, Osmo...37, 52, 152 Karjalainen, Jussi...51, 137 Kasuga, Saki...48 Kato, Izumi Katsaounou, Paraskevi...118, 138 Kaulsay, Ranbir...119, 149 Kauppila, Tiina...92 Kauppi, Paula Kaur, Gurjit Kecelj, Barbara Kecelj, Mojca Keller, Theresa...77 Kelly, Suzanne Kempinski, Karol...132, 155 Kere, Juha...37 Keren, Metin Kespohl, Sabine...73 Kessel, Aharon Kesselmans, Sonja Khachapuridze, Darejan...139, 148 Khaitov, Musa...28 Khaitov, Rakhim...28 Khaltaev, Nikolai Khanferyan, Roman...56, 81 Khanh, Bui Van Khurana-Hershey, Gurjit...39 Kiadeh, Shaghayegh Sadat Nourani Hassan.118 Kiely, Mairead...95 Kiewiet, Gea...50 Kikkawa, Tomonobu Kilic, Ayse...73 Kiliç, Sara Sebnem...43 Kilimajer, Jonathan Kim, Beom Joon...99 Kim, Cheol-Woo Kim, Edwin H Kim, Hyun Jee Kim, Jihyun Kim, Jin-Tack Kim, Jin Won Kim, Jong Deok...79 Kim, Jong Ouk Kim, Ju Yeong Kim, Kyu Han Kim, Mi-Ae Kim, Min-Hye Kim, Minji Kim, Min Jung Kim, Myung Shin Kim, Sang-Heon...48 Kim, Seon Tae Kim, So RI...64 Kim, Sujeong Kim, Sunyoung...80 Kim, Woo Kyung Kim, Yoon Hee Kim, Yoon Seob Kim, Young-Min Kinaciyan, Tamar...43, 114 Kippelen, Pascale...68, 103 Kirjavainen, Pirkka V...40 Kishimoto, Tatsuma...66 Kitsioulis, Nikolaos Aggelis Klangkalya, Natchanun Klatzmann, David...51 Kleij, Hanneke Van Der...56 Kleine-Tebbe, Jörg...62, 90, 113 Klimek, Ludger...31, 37, 38, 65 Klingebiel, Caroline...104, 146 Knipping, Karen Knol, Edward...32, 51, 87, 96, 113 Knulst, André...30, 62 Koçak, Abdülkadir...142, 161 Kocatürk, Emek...141, 154 Koch, Sonja...54 Kocwin, Marcelina...54 Kohalmi, Kinga Viktória Kohno, Kunie Koh, Young-Il Kolho, Kaija-Leena...88 Kolkhir, Pavel Koloskova, Olesya Komala, Adi Surya Kondo, Tomio Koning, Frits...30 Konishcheva, Anna...78 Konstantakopoulou, Maria...43 Konstantinopoulos, Anastasios Panagiotis Konstantinou, George N...106, 136 Kopac, Peter Koppelman, Stef J Koren, Ana Korošec, Peter Köse, Sükran Kosnik, Mitja Kos, Snjezana Kostadinova, Atanaska I Kostikas, Konstantinos...48, 51 Kostoudi, Sofia...50 Kowal, Krzysztof Kowalski, Marek...61, 153 Kralimarkova, Tanya Zdravkova Krause, Karoline Kreyberg, Ina...50 Krohn, Inge Kortekaas...72, 98, 145 Krones, Tanja...71 Krstic, Maja Kudryavtseva, Asya...74 Kukkonen, Anna Kaarina...70, 75 Kull, Inger...29, 133 Kündig, Thomas...88 Kuo, Ho-Chang Kurchenko, A Kurowski, Marcin...61, 75, 103 Kuwabara, Yu Kwong, Christina...52 Kwon, Ji-Won Kyslova, Iuliia L Labella, Marina Lachmann, Helen...88 Lack, Gideon...37, 112 Lacwik, Piotr...92 Ladics, Gregory S Laffert, Bernd Laghai, Valentina Laisuan, Wannada Laitinen, Kirsi Lambert, Katrina Anne Lamprecht, Juergen...93 Lan, Feng Lang, Claudia...131, 156 Lange, Joanna...67 Lan, Yu-Tung Larché, Mark...88 Larenas-Linnemann, Désirée...95 Larionova, Anneli...50 Larsen, Anders Ingemann...74 Latour, Patricia...46 Latysheva, Elena...28 Lauerma, Antti...61, 64, 155 Lau, Susanne...69, 76, 87, 97 Lavrova, Tatiana E

167 SPEAKER INDEX Lazarenko, Lyudmila Leonidovna Lazarušic, Nataša Karamarkovic Lee, Byung Jae Lee, Eun Lee, Jae Ho Lee, Jeongmin Lee, Jiho Lee, Ji Young Lee, Jungsoo Lee, Seung Eun...123, 137 Lee, Yong Chul...64 Lefevre, Sébastien...66, 128, 152, 154 Leffler, Jonatan...91 Lehtimäki, Jenni...50 Leishangthem, Anita...56 Lemanske, Robert...62 Leonardi, Andrea...52, 75, 93 Leonardi, Lucia Leru, Polliana Mihaela Le, Thu Thi Kieu...47 Leung, Agnes Sze-Yin Leung, Donald...62, 112 Leung, Nicki Y H...55 Leung, Ting Fan...99, 133 Levin, Michael...76, 88 Lewkowich, Ian Paul...54 Liau, Jia Li Licitra, Natalia Magalí Giménez Lidholm, Jonas Lieberman, Phil Liippo, Jussi...76 Li, Lin...129, 146, 160 Lillo, María Del Carmen...98 Lim, Dae Hyun Linauskiene, Kotryna Linceviciute, Skaiste Lindström, Irmeli...74 Lin, Li-Lun...77 Linneberg, Allan...94 Lipinska-Ojrzanowska, Agnieszka Anna Lishchuk-Yakymovych, K Litzman, Jiri Liu, Chuanhe Liu, Guanghui Liu, Juan...91 Liuzzo, Maria Teresa Li, Xiao-Jun Li, Yong Lleshi, Leonora Hana Loffredo, Stefania...41 Lombardi, Vincent...53, 106 Longhurst, Hilary...97 Longhurst, Hilary J Lonnberg, Tapio Loo, Aurora Van De Lopata, Andreas Ludwig...40, 62, 72 Lopes, Cristina Lopes, Joana Barradas...67, 152 Lopez-Ruiz, Cristina Lopez-Salgueiro, Ramon Loukides, Stylianos...63 Lourenço, Olga...118, 138 Lourenço, Tatiana...123, 152, 154 Lozano, Karen Lozano-Ojalvo, Daniel...77 Luengo, Olga Lukacs, Nick Lu, Kun Lin Lunding, Lars...64 Lundin, Susanne...53 Lund, Kjetil Børve Lunjani, Nonhlanhla Luo, Wenting Luukkainen, Annika...54, 148 Lu, Ying M Mabelane, Tshegofatso Maciulaityte, Ingrida...80 Maddox, Daniel E Mahlab-Guri, Keren Makarova, Svetlana Makatsori, Melina...56 Mäkelä, Mika...37, 62 Makrinioti, Heidi Makrinioti, Heidi Makrinioti Malling, Hans-Jørgen...30 Malmberg, Pekka...62 Manolaraki, Ioanna Manole, Felicia...120, 146 Mäntylä, Jarkko Manuyakorn, Wiparat...67 Marcelino, João...106, 113 Marchisotto, Mary Jane...76 Marconato, Maddalena Mardani, Fatemeh Mari, Adriano...49, 104, 107, 150 Markevych, Iana...65 Marques, María Andreína Marques-Mejías, María Andreína Marriage, Deborah Marsland, Alexander...91 Marsland, Benjamin...61, 62 Marsteller, Nathan Lawrence Martens, Katleen Marth, Katharina...119, 148 Martikainen, Maria-Viola Martín-Cruz, Leticia...55 Martin, Elena Rodriguez Martinez, Cinthia Aracelis De La Cruz Martini, Matteo...90, 134 Martín-Serrano, Angela...48 Martins, Luís Lourenço Marton, Corina Veronica...128, 136 Mascarenhas, Maria Isabel...93 Mascialino, Barbara...79, 98 Mata, Estefanía Moreno...124, 151 Matheus, Dorimar Cristina Brugaletta.. 43, 131 Mathioudakis, Alexander...52 Matricardi, Paolo...32, 62, 76, 104, 150 Matsuda, Masaya Matsyura, Oksana Mattila, Pekka...90 Matysiak, Klaudia Maurer, Marcus... 41, 91, 97, 103, 141, 155 Mayorga, Cristobalina...92, 96, 153 Mazinani, Marzieh...79, 151 Mccusker, Christine T...77 Mckenna, Olivia Eve McSorley, Henry...64 Mecheri, Salah...76 Medellín, Dasha Roa...90 Mederos, Elena Melchiors, Birgitte Louise Bech Melén, Erik...80, 123 Mendez-Barbero, Nerea Mendoza, Adriana Meng, Cuida Meng, Xun...78 Mera, Leticia...55 Merras-Salmio, Laura...75 Metbulut, Azize Pinar Metsälä, Johanna...47 Meucci, Elisa...152, 153 Meyer, Rosan...69 Michaelis, Louise J...98 Miehe, Michaela Miehlke, Stephan...77 Migueres, Michel...42 Mijakoski, Dragan...73 Mikkelsen, Kari Eilidh Milito, Cinzia...79 Mills, Clare...30, 45, 62, 76, 157 Milota, Tomas...43 Mincham, Kyle T Mincheva, Roxana...94 Mingomataj, Ervin Minov, Jordan Miranda, Ernesto Enrique Misirlioglu, Emine Dibek Mitskevich, Nunu Mitthamsiri, Wat...42 Mizuyoshi, Tomomi...56 Mjösberg, Jenny...61, 87 Moed, Heleen...92 Mogensen, Ida...40 Mo, Ji-Hun...66 Molin, Magnus Montecchiani, Vittoria Montero, Ana Maria Burgos Montoro-Ferrer, Ana Moon, Ji-Yong...48 Moreno-Fernandez, Antonio Moreno, Vanesa Sánchez...42 Mori, Akio Mori, Francesca Morillo, Rocio Candon...92 Morisset, Martine Morita, Hideaki...71,

168 SPEAKER INDEX Mortz, Charlotte G...29, 51, 74 Moscato, Gianna...45, 51, 144 Mose, Anja Pahlow...39, 97, 125 Mösges, Ralph...31, 63, 68, 95, 122 Mosnaim, Giselle...76 Moura, Ana Luisa...154, 158 Mousavinasab, Fatemahsadat Movsisyan, Mariam R Mueller, Geoffrey Andrew...50 Mueller, Ralf...44 Mueller-Rompa, Susanne Elfriede Karolina Mukherjee, Manali Müller, Ralf...39 Müller, Sabine Muraro, Antonella..37, 38, 44, 62, 71, 90, 112 Murthee, Kavitha Garuna...43 Mustakov, Tihomir B Musumeci, Sonia Mutius, Erika von...46 N Nabe, Takeshi Nabilou, Susan Nacaroglu, Hikmet Tekin Nadeau, Kari Christine...38 Nagaraju, K Nahm, Dong-Ho Nakamura, Mano Nakamura, Toshinori Namazova-Baranova, Leyla...28 Namork, Ellen Namork...56 Nam, Young-Hee...48 Nam, Yu Ran Nanjappa, Nagesh Chowdahalli Näsänen-Gilmore, Pieta...40 Nassiri, Maria...66 Natoli, Valentina Naumova, Olha Navarro, Ana Neeland, Melanie R...39 Neskorodova, Katerina Nesterova, Irina V...47 Neto, Herberto Jose Chong Neumann, Karolina-Theresa Neumeyr, Daniela...92 Neves, Ana Castro...131, 138, 157 Ngajilo, Dorothy...74 Nguyen-Ngoc-Quynh, Le Niederberger, Verena...38, 67 Niedoszytko, Marek Niedoszytko...66 Niemi, Merja...56 Niggemann, Bodo...65, 95 Niihara, Hiroyuki Nikoueinejad, Hassan...42 Nocerino, Rita...101, 126 Nony, Emmanuel...56, 90 Noronha, Lizanne Novakova, Plamena Ivanova Novosad, Jakub...48 Novotna, Bronislava...67 Nowak-Wegrzyn, Anna...30 Nuñez, Ignacio García...124, 137 Nurmatov, Ulugbek B Nurpeissov, Temyrzhan Temyrlanovich Nuttall, Tim...44 O Obeso, David Odebode, Adeyinka Odijk, Jenny van...39 Ödling, Maria...99 Offermann, Nadine...49, 135 Ohashi-Doi, Katsuyo O Hehir, Robyn E Oh, Eun-Yi Oh, Jae-Won Ohnmacht, Caspar Ojeda, Iván Chérrez...41 Okamoto, Kaoru Olajide, Okikiola Morenike Olgac, Muge Olgaç, Müge Oliveria, John-Paul...98 Oliver, Maria Ollert, Markus...32, 63, 113 O Mahony, Liam...38, 69, 91 Omarjee, Bashir Ong, Hsiao Hui Onieva, Montserrat López Oosterlinck, Patricia Oosterloo, Berthe Cornelie...50 Örçen, Cihan...125, 157, 158 Ornelas, Cristina...93, 134 Oropeza, Athamaica Ruiz Os-Medendorp, Harmieke Van Ottman, Noora Oude-Elberink, Hanneke...63, 104 Ozceker, Deniz...117, 122 Özdemir, Ebru Ozdemir, Pinar Gokmirza P Paciência, Inês...78 Padua, Ines...77, 106 Page, Clive...38 Pali-Schöll, Isabella...108, 136 Palladino, Angela Palladino, Chiara Palomares, María Francisca...42 Palomares, Oscar...56, 96 Panahova, Tahira Panaitescu, Carmen...122, 137 Pantera, Barbara Paolocci, Giulia...73 Papadopoulos, Nikolaos...61, 69, 97 Paparo, Lorella...101, 134 Papia, Francesco Pappu, Rajita...64 Park, Chang Ook Park, Hae-Sim Park, Jin-Sung Park, Joon Soo Park, Jung-Won Park, Kyung Hee Park, Miguel...80 Park, Mi Kyung Park, Yang Park, Yong Mean Pastorello, Elide...30, 106, 121 Patella, Vincenzo Patel, Nandinee B...79 Patient, Karine Pauli, Gabrielle...49 Paulikaite, Gintare Pawankar, Ruby...78 Pawelczyk, Malgorzata Ewa...48 Peden, David B...39 Pedersen, Lene Mølgaard Pedini, Veronica...79, 142 Peixoto, Sara...90, 134, 161 Pekkanen, Juha...40, 47 Peldan, Päivi...40 Pelkonen, Anna Pellizzari, Giulia Penas-Aguilera, Andreu Peng, Yang...66 Pentland, Julie Percier-Lehebel, Pauline Peredelskaya, Marina Perego, Francesca Perez-Alzate, Diana Pérez, Beatriz Veleiro...41 Pérez, Margarita Tomás Perez-Riverol, Amilcar Pérez-Sánchez, Natalia...49 Perkin, Michael...31, 68, 102 Perko, Karmen Pesonen, Maria Petrovskaya, Maria Pfaar, Oliver...30, 38, 63, 91 Pham, Duy Le...55 Picardi, Giuseppe...48, 120 Pichler, Werner...48, 81, 89 Piekkala, Anni...79 Pinero-Saavedra, Macarena Pinto, José Rosado Pinto, Nicole...99 Piñero-Saavedra, Macarena Pita, Joana Pite, Helena...48, 94, 149 Pitsios, Constantinos...57, 126, 132 Plado, Silvi Plank, Maximilian W...53 Plesca, Doina Anca Poel, Lauri-Ann van der...95 Pohorská, Jitka Polak, Dominika Pomés, Anna

169 SPEAKER INDEX Poncet, Pascal...55 Popa-Colbu, Petronela...74 Popescu, Andreea Ioana Popescu, Florin Dan...120, 143 Popov, Todor...71 Porcel, Isabel Fernandez De Alba Porebski, Grzegorz Porras, Wendy Vargas Porr, Corina...142, 152 Pouessel, Guillaume...66 Poulsen, Lars K...37, 62, 75, 97 Poza-Guedes, Paloma Pozo, Cesar Fireth...119, 141, 149 Prado, Manuel Jorge Rial...46, 123 Pranger, Christina Lisa Prasad, Rajniti Prazma, Charlene M Price, David...88, 149 Prieto, Ana...93 Prnjavorac, Besim Protudjer, Jennifer Lisa Penner...47 Prozorovscaia, Daniela Pruzinec, Peter Puente-Maestu, Luis Puerta, Leonardo Pugin, Benoit...89 Pujols, Laura Pulvirenti, Federica...79 Q Qian, Cheng...42 Qiao, Yongkang Qualizza, Rosanna Quinti, Isabella Quirce, Santiago...51, 73, 82 R Rabin, Ronald...38 Radenkova-Saeva, Julia Petrunov...80 Radermecker, Coraline Radice, Anna Radwan, Amr Rama, Tiago...78 Raptis, George...50 Rasmussen, Pernille Rauber, Michèle Myriam...41 Raulf, Monika Ravelli, Alberto...30 Rebane, Ana...78 Ree, Alessandra Van...65 Ree, Ronald van...70, 76, 90 Reier-Nilsen, Tonje Reiß, Nadine...41 Rengganis, Iris Renkonen, Risto...31, 53, 151 Renner, Ellen Renz, Harald Repka, Susana...46 Revyakina, Vera A...94, 130 Rezende, Isabel Rhyner, Claudio...31, 40, 106 Ribeiro, Filipa Lourenço Ribo, Paula Ricci, Anna Giulia Ricciardi, Luca...91 Ridolo, Erminia...42 Riedl, Marc Rijt, Leonie Sara Van Ring, Johannes...32, 76 Ristevska, Tara Ritenberga, Olga Rizzo, Francesca...46 Roa-Medellín, Dasha Roberts, Graham...32, 44, 51, 104 Rodinkova, Victoria...49, 81, 135, 138 Rodrigues, Alexandra Rodriguez, Jairo Antonio Rodriguez, Maria José Rodriguez, Raquel M Rojas, Jorge Roland, Pascale Nicaise Romain, Thomas Romeira, Ana Margarida...43 Rondon, Carmen...90 Roponen, Marjut...55 Rosace, Domenico Rose, Horst...114, 156 Rosita, Aitoro Rosmaninho, Isabel Rossberg, Siri...50 Rothenberg, Marc...87 Roth-Walter, Franziska...92 Rouzaire, Paul...70 Ruano, Francisco Javier Rudenko, Michael...31, 93, 129 Rueter, Kristina...114, 138 Rufo, João Cavaleiro Russkamp, Dennis...41 Ryan, Dermot...32, 45, 112 Ryder, Valerie...32 Rytilä, Paula S Sabatel, Catherine Sackesen, Cansin...72, 79, 89, 133 Saglani, Sejal...69 Saguer, Inmaculada Martinez Saha, Mouli Sahni, Vyanka Sajjadieh, Mohammad Reza Sheikh Sala-Cunill, Anna...67 Salava, Alexander Saloga, Joachim...39 Sampson, Sampson A...98 Sánchez, Andres Sanchez-Borges, Mario...63 Sanchez-Garcia, Silvia...45, 89, 137 Sánchez-Guerrero, Inmaculada M Sánchez-Jareño, Marta...49 Sánchez, Jorge...91, 118 Sánchez-López, Jaime...68, 122 Sanchez, Soledad Sanchez Sander, Ingrid...49 Santos, Alexandra F...37, 39, 70, 72 Santos, Patricia López De Los...73 Sapan, Nihat...49 Saricoban, Hulya Ercan Sari, Nurul Iman Nilam...74 Sasaki, Mari Savolainen, Johannes Scadding, Glenis...148, 149 Scala, Enrico...73 Scalone, Gino Schalkwjik, Joost...44 Schiener, Maximilian...41 Schleimer, Robert...95, 113 Schmid-Grendelmeier, Peter...87, 96 Schmid, Johannes Martin Schmidt, Felicitas Maria...47 Schmidt-Weber, Carsten...37, 68, 71 Schoos, Ann-Marie Malby Schranz, Jennifer...41 Schrautzer, Christoph...41 Schreiber, Jens Schryver, Els De...70 Schulten, Veronique...73, 160 Schuyler, Alexander J...72 Schwarze, Jürgen...53, 69, 75 Scott, Laura Allison...47 Sediva, Anna...79, 139 Segboer, Christine...70 Šelb, Julij Selcuk, Ali Sella, Juliana Augusta Selva, Blanca...56 Semedo, Filipa Matos...49, 93 Sentsova, Tatyana...55 Seoane-Rodriguez, Marta Sepiashvili, Revaz Seppä, Ville-Pekka...40 Seppo, Antti E Sergeeva, Galina Raisovna Severino, Maurizio Sexton, Daniel J...41, 140 Sexton, Dan J...41, 97 Seys, Sven F...55, 64, 79 Sfika, Ifigeneia Sfrent-Cornateanu, Roxana...42 Shahali, Youcef Shahid, Polina Sha, Jichao...93, 119 Shakerian, Leila...42, 142 Shakhova, Natalia Shamji, Mohamed H...30, 40, 53, 114 Shamlou, Somayeh Sharif, Hanan Al Sharikadze, Olena...68 Sharma, Manuprita

170 SPEAKER INDEX Sheikhi, Abdolkarim Shek, Lynette...52 Shershakova, Nadezhda Nikolaevna Shilovskiy, Igor Petrovich...100, 132 Shimizu, Mayu Shinohara, Miwa...74, 148 Shoormasti, Raheleh Shokouhi Sibanda, Elopy Nimele Sidorovich, Olga I Siew, Leonard Quok Chean...99 Silano, Marco...88 Šilar, Mira Silva, Diana Simoes, Catarina...95 Simon, Dagmar...64 Simon, Hans-Uwe...70, 87 Sin, Betul Ayse Sin, Betül Ayse...41, 123 Singh, Jaswinder Siniavin, Andrei...43 Sinnige, Niels Sircar, Gaurab Sitkauskiene, Brigita...48 Sizyakina, L. P Skaarup, Søren Helbo...92 Skevaki, Chrysanthi...108, 150 Skypala, Isabel Janet...29, 47,73, 97, 157 Slavyanskaya, Tatiana...106, 123 Smirnov, Valerii Valerievich Smith, Bryan Smith, Helen...97 Smith, Pete Smith, Peter...93 Smit, Joost J Smits, Hermelijn...96 Smolinska, Sylwia Smulders, Tamar...65 Soares, Patricia...81 Sobrino, Miriam Sofiev, Mikhail...69 Sohn, Kyoung-Hee...99 Soh, Wai Tuck Sokolowska, Milena Sommereux, Lauren Aimee Somoza, Maria Luisa Song, Joo Young Sont, Jacob...89 Sorensen, Katy Soriano-Gomis, Victor...93 Soti, Andras Laszlo Soto-Retes, Lorena...93 Sousa-Pinto, Bernardo Sozener, Zeynep Celebi Specjalski, Krzysztof Spek, Flora B. de Waard-van der...29, 138 Spiewak, Radoslaw , 112, 122, 135, 152 Spuls, Phyllis...88 Stage, Brian Sonne...92 Stana, Bogdan Standl, Marie...64 Starchenka, Sviatlana...106, 151 Stasii, Ecaterina Staudacher, Heidi...88 Steelant, Brecht...78 Steffensen, Maria Abildgaard...42, 68 Steiner-Monard, Viviane Stellato, Cristiana Sterner, Therese Sthoeger, Zev...41 Stirbiene, Neringa Stjarne, Par...119, 149 Stockhammer, Debbi Stojanovic, Maja Stoleski, Saso Stolz, Frank Stosovic, Rajica Straumann, Alex...30, 70, 135 Stril, Jean-Louis Striz, Ilja...55 Strong, Katherine Anne...54 Sturm, Gunter...45, 63, 132 Sugiura, Shiro...42 Suh, Dong In...40 Sundukova, Mariia S Sun, Jin Lu Suojalehto, Hille...74 Surda, Pavol...52 Susanto, Agus Joko Sussman, Gordon...106, 154 Sutic, Anamarija Suzuki, Naofumi...48 Suzuki, Yasuhiro Svitich, Oxana Anatolievna...81, 151 Swiontek, Kyra Syrczova, Marina Alexandrovna Szklany, Kirsten Sztormowska, Marlena Magdalena Szyc, Anna T Taka, Styliani Taka Takazawa, Tomonori Tang, Mimi...40 Tan, Kai Sen Tannert, Line Kring Tanno, Luciana Tan, Rachel Sze Bing Tarzi, Michael Tatewaki, Masamitsu Taube, Christian...71 Tavakol, Marzieh Tebyriçá, João Negreiros...46 Tejera-Alhambra, Marta...56 Teng, Yaoshu...65, 72 Terhorst, Dorothea Terreehorst, Ingrid...51, 70, 124 Tey, Hong Liang Thibaudon, Michel...49, 138 Thomas, Iason Thomassen, Marte Renate...73 Thomas, Wayne...95 Tilles, Stephen...70 Timmermans, Frans...71, 76 Titova, Olga Titov, Leonid...81, 127, 128, 151 Tmusic, Vladimir Toit, George du...52 Toldra, Silvia...148, 152 Tomazic, Peter Valentin...31, 38, 70 Toniolo, Alice Tontini, Chiara...47, 129, 152 Topalušic, Iva...119, 124 Toppila-Salmi, Sanna... 46, 63, 95, 117, 119 Topuz, Bülent Torres, Maria Jose...29, 67, 89, 113 Tosic, Milan Toskala, Elina M...46, 119 Tost, Jorg Trendelenburg, Valérie Treudler, Regina...64 Trincão, David Pina...73 Trinh, Hoang Kim Tu...48, 117 Trollvik, Anne...29 Trusova, Olga V Tsai, Hui-Ju Tsakanova, Gohar Tsami, Maria...124, 144 Tsang, Sin Man Tscheppe, Angelika Tsertsvadze, Tamar Tsilochristou, Olympia...71, 89, 150 Tsolakis, Nikolaos Tufvesson, Ellen...54, 117 Turner, Paul J...65, 105 Tu, Yanyi...65 Tyrak, Katarzyna Ewa...48 Tziotou, Marianna...143, 157 U Uasuf, Carina G Uehara, Hiromi Ue, Kok Loong...91 Ueta, Mayumi...48 Ukhanova, Olga Petrovna Ukleja-Sokolowska, Natalia Ewa.118, 121, 122 Ulusoy, Ezgi...144, 157 Umanets, Tetiana Unal, Derya Untersmayr, Eva...38, 56, 72, 112 Uotila, Riikka Tuuli Ilona...50 Ureche, Corina Uriarte, Silvia A...68 Urrutia-Pereira, Marilyn...117, 128 Uter, Wolfgang...29, 51 Uysal, Pınar...55 Uzokov, Jamol V 170

171 SPEAKER INDEX Vaccaro, Mario Vachová, Martina...131, 152 Vadas, Peter...51 Vaia, Elleni Sofia...93 Valenta, Rudolf...76, 102 Valerieva, Anna...42, 154 Valero, Antonio...120, 155 Valovirta, Erkka...92, 104 Vantur, Romana Varga, Eva-Maria...30 Vasakova, Martina Vasileiadou, Styliana...65 Vasquez-Echeverri, Estefania Vassilopoulou, Emilia...39 Vazquez-Ortiz, Marta Vázquez-Revuelta, Paula...90, 152 Velazquez, Juan Raymundo Venter, Carina...30, 39, 70 Vera, Andrea Lissett Vera, Michelle Baldorado De Vereda, Andrea...92 Verhoeckx, Kitty Catharina Maria...55 Vermani, Maansi...49 Versluis, Astrid Versprille, Livia Wilod Vesel, Tina...73, 134 Veszeli, Nora Vetskova, Evelina Vezina, Louis-Philippe...67 Vichyanond, Pakit...52 Victorio, Laura Victor, Jefferson Russo...53 Victor, Susanne Vidal, Carmen...30, 42 Vieths, Stefan...38, 44, 71 Viinanen, Arja Vijayasarathi, Madhavi Kadambi Vijverberg, Susanne...54 Vilain, Anne-Christine Vilà-Nadal, Gemma...66 Villaseñor, Alma...39 Villesen, Hanne Hedegaard...40 Víquez, Carmen Riggioni...50 Virchow, Johann Christian...94 Vishneva, Elena Vítor, Artur Bonito Vitte, Joana Vlashki, Emilija...136, 148 Vogelberg, Christian Vonk, Marlotte M...42 Vos, Werner L Vuillermin, Peter J...65 Vultaggio, Alessandra...96, 106 Wai, Christine Yee Yan...56 Wallengren, Joanna...64 Walusiak-Skorupa, Jolanta...51, 73 Wang, Hai Chao Wang, Hsueh-Chun...72 Wang, Shu-Yue...80 Wang, Xiaoyan Wang, Yi...41 Wang, Yichao...66 Waserman, Susan...67 Wasilewska, Eliza Watkins, Sasha Watts, Timothy John Wavrin, Sophie...42 Wawrzenczyk, Adam Weber, Milena Weidinger, Stephan...44 Weller, Karsten...91 Werchan, Barbora Werchan, Matthias Werfel, Thomas...64, 103, 112 West, Christina E Weyermann, Maria White, Jonathan...44, 112 Wickham, Martin Sean John...50 Wickman, Magnus...88, 114 Wiednig, Michaela Wijk, Roy Gerth van...38, 92 Wildner, Sabrina Willcox, Mark Willemsen, Linette...39, 72 Winther, Lone...92, 103 Wiszniewska, Marta...74 Witek, Joan Domenech Woelke, Sandra...79 Wojtalewicz, Nathalie...57 Wolf, Hendrik Wolthers, Ole D Wong, Cecil Chua Wong, Chun Kwok Wong, Gary...52 Wong, H. C. George Wood, Robert...89 Woo, Yu Ri Worgall, Stefan...38 Worm, Margitta...45, 51, 88 Woszczek, Grzegorz...38, 55, 88 Wróblewska, Barbara...50 Wu, Jiakai X Xing, Yu Han...47 Xu, Yan Hua Yang, Song-I...78, 99 Yang, William Yang, Zhaowei...73 Yan, Yan Yap, Gaik Chin Yasakov, Dmitry Yassky, Emma Guttman...37 Yeh, Kuo-Wei...48 Ye, Ping Yeryomenko, Galyna Vladimirovna Yilmaz, Ebru Arik...72, 133 Yilmaz, Insu...94, 124, 131, 155 Yilmaz, Ozge...99 Ylitalo-Heikkilä, Maija Yoon, Jungwon Yorgancioglu, Arzu Yoshida, Naruo Yu, Hee Joon Yuk, Ji Eun Yum, Hyeyung Yun, Younghee Yu, Qiu-Ning...53 Z Zakzuk, Josefina Zanon-Moreno, Laura Zenic, Lucija Zhang, Li-Ping Zhang, Xu Zhao, Li...66 Zheng, Jun Zheng, Peiyan...54, 92 Zhernov, Yury V...43 Zhi, Yu Xiang Zidarn, Mihaela...99 Ziegler, Steven...63 Zielen, Stefan Zimmer, Julia...90 Zisaki, Vasiliki Zissler, Ulrich M...98 Živkovic, Jelena Zi, XiaoXue...66 Zubchenko, Svitlana Zuberbier, Torsten...87, 89, 96 Zurbano, Laura W Wagenaar, Laura Wagenmann, Martin...46, 70, 148 Wagner, Annette Wahn, Ulrich...46, 57, 68, 129 Y Yakovliev, Plamen Hristov Yanase, Yuhki Yang, Jack Yang, Misuk

172 SPONSORSHIP AND EXHIBITION SPONSORSHIP AND EXHIBITION THIS SECTION CONTAINS INFORMATION THAT IS PROMOTIONAL IN NATURE, DISTINCT FROM THE SCIENTIFIC/EDUCATIONAL ELEMENTS OF THE CONGRESS

173 SPONSORSHIP AND EXHIBITION COMPANY SPONSORED SYMPOSIUM Roadmap of Innovative and Registered Allergen Immunotherapy MONDAY, 19 June :45 15:15, Hall 3A CHAIRS Oliver Pfaar, Germany Dirk-Jan Opstelten, The Netherlands Introduction Insights to AIT Clinical Study Program Dirk-Jan Opstelten, The Netherlands The TAV Program Implications for the Allergologist in Europe Ludger Klimek, Germany Grass allergen immunotherapy Where we are Moisés Calderón, United Kingdom INDUSTRY Birch or Trees From Allergen Source to Immunological Active Compounds Krzysztof Kowal, Poland Clinical Development of Immunotherapy for Peanut Allergy Carsten Bindslev-Jensen, Denmark HAL Allergy Group, J.H. Oortweg 15-17, NL-2333 CH Leiden,

174 FOUNDER SPONSORS EAACI and the Local Organising Committee gratefully acknowledge the support of the 2017 Founder Sponsors. Founder Sponsors - Platinum Level Founder Sponsors - Gold Level Founder Sponsors - Silver Level INDUSTRY EAACI thanks its Founder Sponsors for supporting the EAACI Goes Green initiative

175 SPONSORSHIP AND EXHIBITION ALK Symposium Step into the future of paediatric respiratory allergic disease Tuesday 20 June 2017 at 10:30-12:00 hrs in Room 5A Chairs: Mika Mäkelä & Eckard H Hamelmann What can the HDM SLIT-tablet offer adolescents living with HDM allergic rhinitis? Speaker: Michael S Blaiss, United States HDM allergic asthma addressing the unmet needs in children and adolescents Speaker: Carmen Vidal, Spain INDUSTRY Benefits of early intervention to prevent asthma in children with hayfever Speaker: Graham Roberts, United Kingdom 175

176 SPONSORS Additional Sponsors Aimmune Therapeutics, Inc. AstraZeneca BIOMAY AG CSL Behring GmbH DBV Technologies FAES FARMA & The MENARINI GROUP GlaxoSmithKline Orion Pharma Sanofi Genzyme and Regeneron Shire International GmbH Teva Pharmaceudicals EAACI would like to thank: Laboratorios LETI, s.l.u. for their educational grant to support a Highlights Session and the Virtual Congress Hub Mylan for providing auto-injectors for the emergency Treatment of anaphylaxis throughout the venue Nestlé Health Science for their support of the Postgraduate Courses and the Annual Congress Scholarships Novartis for their support of the Congress app Orion Pharma for their support of the Beat Allergy Run & Walk PHILIPS for their educational grant to support a Highlights Session Uriach for their educational grant to support the Allergy Awareness Campaign INDUSTRY Disclosure of Transfers of Value Please visit to view the conditions and the scope of the support provided by EFPIA member companies to EAACI on a voluntary basis

177 SPONSORSHIP AND EXHIBITION Ready to think about allergy differently? Join us at the EAACI 2017 Stallergenes Greer company sponsored symposium Sunday, June 18, :30-17:00 Room 101 abc LONG TERM EVIDENCE OF SLIT: DO WE HAVE A BREAKTHROUGH IN 2017? Chaired by Ass. Prof. Linda Cox (USA) & Prof. Antonella Muraro (Italy) Introduction: Long term evidence of SLIT Prof. Antonella Muraro, Italy Allergic sensitization and the atopic march: natural progression and long term SLIT targets Prof. Paolo M. Matricardi, Germany How far does the clinical trial evidence takes us to prove SLIT s long term effects? Associate Prof. Linda Cox, US Finding the breakthrough in real world evidence? Profs. Stefan Zielen & Ulrich Wahn, Germany INDUSTRY Conclusion: Do we have a breakthrough in 2017? Associate Prof Linda Cox, US 177

178 COMPANY SPONSORED SYMPOSIA SUNDAY, 18 JUNE 2017 COMPANY SPONSORED SYMPOSIUM (CSS 1) 10:30-12:00 Thermo Fisher Scientific: The story of IgE The next 50 years Hall 1 Chair: S.G.O. Johansson, Sweden The molecular allergology revolution Components and microarrays in prediction of allergic diseases Marianne van Hage, Sweden IgE and IgG4 antibodies to specific proteins in allergy, asthma and eosinophilic esophagitis Thomas Platts-Mills, United States Food allergy-induced anaphylaxis allergen components and cofactors Victoria Cardona, Spain Diagnostic tools in insect venom allergy - State of the art and future directions Thilo Jakob, Germany COMPANY SPONSORED SYMPOSIUM (CSS 2) 13:30-15:00 Novartis Pharma AG: As if severe allergic asthma wasn t enough: associated and treatment-induced comorbidities Hall 3a Chair: Jean Bousquet, France Welcome and introduction Jean Bousquet, France Pathological mechanisms of allergy in asthma and comorbidities: a central role for IgE Oscar Palomares, Spain Uncovering nasal polyps, where are we? Claus Bachert, Sweden Navigating corticosteroid-induced comorbidities in patients with SAA Matthias Blüher, Germany Re-addressing SAA treatment: summarizing the omalizumab evidence in children and adults Nikos Papadopoulos, United Kingdom COMPANY SPONSORED SYMPOSIUM (CSS 3) 15:30-17:00 STALLERGENES GREER: Long term evidence of SLIT: do we have a breakthrough in 2017? Room 101 Chairs: Linda Cox, United States Antonella Muraro, Italy Introduction: Long term evidence of SLIT Antonella Muraro, Italy Allergic sensitization and the atopic march: natural progression and long term SLIT targets Paolo M. Matricardi, Germany INDUSTRY How far does the clinical trial evidence takes us to prove SLIT s long term effects? Linda Cox, United States Finding the breakthrough in real world evidence? Stefan Zielen, Germany & Ulrich Wahn, Germany Conclusion: Do we have a breakthrough in 2017? Linda Cox, United States 178

179 SPONSORSHIP AND EXHIBITION As if severe allergic asthma wasn t enough: associated and treatment-induced comorbidities Sunday, 18 June :30 15:00 Messukeskus Helsinki Hall 3a PROGRAMME Welcome and introduction Chair: Jean Bousquet, France Pathological mechanisms of allergy in asthma and comorbidities: a central role for IgE Oscar Palomares, Spain Uncovering nasal polyps, where are we? Claus Bachert, Sweden Navigating corticosteroid-induced comorbidities in patients with SAA Matthias Blüher, Germany Re-addressing SAA treatment: summarizing the omalizumab evidence in children and adults Nikos Papadopoulos, United Kingdom INDUSTRY Novartis Pharma AG 2017 CH-4002 Basel Switzerland Date of preparation: March 2017 GLRESP/XOL/0116c 179

180 COMPANY SPONSORED SYMPOSIA MONDAY, 19 JUNE 2017 COMPANY SPONSORED SYMPOSIUM (CSS 4) 10:45-12:15 Mylan: The allergic rhinitis challenge: perception, control and real-life effectiveness Hall 5a Chair: Erkka Valovirta, Finland Chairman s Introduction Erkka Valovirta, Finland Changing the perception of the AR problem: barriers and solutions Mike Bewick, United Kingdom A simplified way to manage AR: do you agree with the experts? Jean Bousquet, France AR control in real life: the next battle field Magnus Wickman, Sweden Discussion and wrap-up All COMPANY SPONSORED SYMPOSIUM (CSS 5) 13:45-15:15 HAL Allergy: Roadmap of Innovative and Registered Allergen Immunotherapy Hall 3a Chairs: Oliver Pfaar, Germany Dirk-Jan Opstelten, The Netherlands Introduction Insights to AIT Clinical Study Program Dirk-Jan Opstelten, The Netherlands The TAV Program Implications for the Allergologist in Europe Ludger Klimek, Germany Grass allergen immunotherapy Where we are Moisés Calderón, United Kingdom Birch or Trees From Allergen Source to Immunological Active Compounds Krzysztof Kowal, Poland Clinical Development of Immunotherapy for Peanut Allergy Carsten Bindslev-Jensen, Denmark COMPANY SPONSORED SYMPOSIUM (CSS 6) 15:45-17:15 Uriach: Consolidated strategies in the management of allergies Hall 3d Chairs: Torsten Zuberbier, Germany Marek L. Kowalski, Poland Chairs welcome and introduction Torsten Zuberbier, Germany; Marek L. Kowalski, Poland INDUSTRY What s new in ARIA and Urticaria guidelines? Torsten Zuberbier, Germany The added value of Rupatadine in children Paraskevi Xepapadaki, Greece Rupatadine: a safe choice in the treatment of allergies Joaquim Mullol, Spain Discussion and concluding remarks Moderated by Torsten Zuberbier, Germany and Marek L. Kowalski, Poland 180

181 SPONSORSHIP AND EXHIBITION Mylan is pleased to invite you to attend the symposium The allergic rhinitis challenge: perception, control and real-life effectiveness 10:45 12:15 Monday June 19 th Hall 5a TIME TITLE SPEAKER 10:45 10:50 Chairman s Introduction Erkka Valovirta, Finland 10:50 11:20 Changing the perception of the AR problem: barriers and solutions Mike Bewick, UK 11:20 11:50 A simplified way to manage AR: do you agree with the experts? Jean Bousquet, France 11:50 12:10 AR control in real life: the next battle field Magnus Wickman, Sweden INDUSTRY 12:10 12:15 Discussion and wrap-up All 181

182 COMPANY SPONSORED SYMPOSIA TUESDAY, 20 JUNE 2017 COMPANY SPONSORED SYMPOSIUM (CSS 7) 10:30-12:00 ALK: Step into the future of paediatric respiratory allergic disease Hall 5a Chairs: Mika Mäkelä, Finland Eckard Hamelmann, Germany What can the HDM SLIT-tablet offer adolescents living with HDM allergic rhinitis? Michael S Blaiss, United States HDM allergic asthma - addressing the unmet needs in children and adolescents Carmen Vidal, Spain Benefits of early intervention to prevent asthma in children with hayfever Graham Roberts, United Kingdom COMPANY SPONSORED SYMPOSIUM (CSS 8) 15:30-17:00 Allergopharma GmbH & Co. KG: FASIT (Future of the Allergists and Specific Immunotherapy) meets EAACI: Novel Patient Profiling, Promising Treatments and Regulatory Challenges Hall 3g Chairs: Marek Jutel, Poland Ulrich Wahn, Germany New Promising Perspectives in AIT Marek Jutel, Poland Molecular Approaches for AIT - the Peril of Phase III Trials Jörg Kleine-Tebbe, Germany The Use of AIT in Europe - Regulatory Aspects and Call for Harmonization Oliver Pfaar, Germany How can we offer High Quality Diagnostics for our Patients in the Future? Piotr Kuna, Poland COMPANY LUNCH SYMPOSIA SUNDAY, 18 JUNE 2017 COMPANY SPONSORED LUNCH SYMPOSIUM (CLS 1) 12:15-13:15 INDUSTRY Mylan: Asthma and Allergic Rhinitis: One Airway, One Disease, One Control Concept Chair: Mika Mäkelä, Finland Chairman s introduction Mika Mäkelä, Finland One airway one disease survey Glenis Scadding, United Kingdom Hall 5a One control concept David Price, United Kingdom One treatment concept Jean Bousquet, France Discussion and wrap-up Mika Mäkelä, Finland All 182

183 SPONSORSHIP AND EXHIBITION Mylan is pleased to invite you to attend the lunch symposium Asthma and Allergic Rhinitis: One Airway One Disease One Control Concept 12:15 13:15 Sunday June 18 th Hall 5a TIME TITLE SPEAKER 12:15 12:20 Chairman s introduction Mika Mäkelä, Finland 12:20 12:35 One airway one disease survey Glenis Scadding, UK 12:35 12:55 One control concept David Price, UK 12:55 13:10 One treatment concept Jean Bousquet, France INDUSTRY 13:10 13:15 Discussion and wrap-up Mika Mäkelä, Finland All 183

184 COMPANY SPONSORED SATELLITE SYMPOSIA SUNDAY, 18 JUNE 2017 COMPANY SPONSORED SATELLITE SYMPOSIUM (SAT 1) 17:30-19:00 Novartis Pharma AG: The future of urticaria advances in CSU research Hall 3a Chair: Marcus Maurer, Germany Welcome address Marcus Maurer, Germany Under the skin of CSU diagnostic and prognostic biomarkers in urticaria Martin Metz, Germany Keeping it real: a look at the latest real-world data in CSU management Alexander Marsland, United Kingdom Managing relapse in CSU Gordon Sussman, Canada Looking beyond CSU a round-up of recent research Marcus Maurer, Germany Questions from the audience All speakers Closing address Marcus Maurer, Germany COMPANY SPONSORED SATELLITE SYMPOSIUM (SAT 2) 17:30-19:00 FAES FARMA & The MENARINI GROUP Hall 3c COMPANY SPONSORED SATELLITE SYMPOSIUM (SAT 3) 17:30-19:00 Shire International GmbH: Hereditary angioedema: what does the future hold? Hall 3d Chairs: Marco Cicardi, Italy Hilary Longhurst, United Kingdom Faculty: Emel Aygören-Pürsün, Germany Welcome, and an introduction to hereditary angioedema (HAE) Marco Cicardi, Italy Challenges and current treatment options in the management of paediatric HAE patients Markus Magerl, Germany Future therapeutic options for the management of paediatric HAE patients Emel Aygören-Pürsün, Germany The future of HAE treatment: innovative therapies to address unmet needs Marco Cicardi, Italy Q&A and closing remarks All faculty/co-chairs INDUSTRY COMPANY SPONSORED SATELLITE SYMPOSIUM (SAT 4) 17:30-19:00 GlaxoSmithKline: The Asthma Journey Right Road, Right Destination Hall 3e Chair: Maritta Kilpeläinen, Finland The building blocks for optimal asthma treatment Maritta Kilpeläinen, Finland Laying the foundations for improvements in therapy: Shared decision-making Neil Martin, United Kingdom Drawing the blueprints for correct asthma diagnosis Peter Howarth, United Kingdom Raising outcomes in the treatment of severe eosinophilic asthma Neil Barnes, United Kingdom Surveying the evidence: Effectiveness of targeted therapies in the real world Andreas Heddini, United Kingdom Q&A and symposium close Maritta Kilpeläinen, Finland; Neil Barnes, United Kingdom 184

185 SPONSORSHIP AND EXHIBITION The future of urticaria advances in CSU research Sunday 18 June 2017, Hall 3a, Messukeskus, Helsinki, Finland EAACI 2017 The future of urticaria advances in CSU research Chair: Professor Marcus Maurer Speakers: Professor Martin Metz, Dr Alexander Marsland, Professor Gordon Sussman : Welcome address Presented by Professor Marcus Maurer : Under the skin of CSU diagnostic and prognostic biomarkers in urticaria Presented by Professor Martin Metz : Keeping it real: a look at the latest real-world data in CSU management Presented by Dr Alexander Marsland : Managing relapse in CSU Presented by Professor Gordon Sussman : Looking beyond CSU a round-up of recent research INDUSTRY Presented by Professor Marcus Maurer : Questions from the audience All speakers : Closing address Presented by Professor Marcus Maurer Highlights of The future of urticaria will be available in the CSU Knowledge Centre on epgonline.org following the symposium. Register on for free today to access the symposium materials. We will notify registered members as soon as this content is available. epgonline.org provides healthcare professionals worldwide with free access to a wealth of clinical content. Carefully developed and curated from trustworthy sources, information is conveniently organised by disease, medical specialty and information type. Content includes localised prescription drug information, disease-focused Learning Zones, treatment guidelines, drug and industry news, clinical trial information and journal article abstracts Symposium supported by funding from Novartis Pharma AG. This symposium is for healthcare professionals only 185

186 COMPANY SPONSORED SATELLITE SYMPOSIA COMPANY SPONSORED SATELLITE SYMPOSIUM (SAT 5) 17:30-19:00 Allergy Therapeutics plc.: The Best Therapies By Design Hall 3g The importance of defining the optimal dose Jörg Kleine-Tebbe, Germany Molecular fingerprinting of complex allergoids Erika Jensen-Jarolim, Austria Rationale for broad spectrum grass immunotherapy Uwe E. Berger, Austria Defining the plateau of the efficacy for Allergen Specific Immunotherapy Tim Higenbottam, United Kingdom COMPANY SPONSORED SATELLITE SYMPOSIUM (SAT 6) 17:30-19:00 Nestlé Health Science: Controversies on Special Products for Managing Cow s Milk Protein Allergy (CMPA) in Infants Safety and Suitability Room 101 Chairs: Antonella Muraro, Italy Arne Høst, Denmark Choosing the most appropriate dietary management for infant with CMPA Rosan Meyer, United Kingdom Not all extensively hydrolysed formulas intended for CMPA are the same Martinas Kuslys, Switzerland New guidelines ensuring safe products for infants with CMPA update from the EAACI Task Force on special products for CMPA Antonella Muraro, Italy; Arne Høst, Denmark MONDAY, 19 JUNE 2017 COMPANY SPONSORED SATELLITE SYMPOSIUM (SAT 7) 17:45-19:15 AstraZeneca: A Personalized Approach to Eosinophilic Asthma: Expert Perspectives in Clinical Practice Hall 3a Welcome and Introductions Ian Pavord, United Kingdom Challenges in Asthma Heterogeneity Leif Bjermer, Sweden Clinical and Patient Perspectives in Severe Eosinophilic Asthma Arnaud Bourdin, France The Evolving Science of Severe Asthma and Emerging Clinical Practices Ian Pavord, United Kingdom INDUSTRY Panel Discussion and Audience Q&A All COMPANY SPONSORED SATELLITE SYMPOSIUM (SAT 8) 17:45-19:15 DBV Technologies: Investigational Epicutaneous Immunotherapy: Shaping the Future of Treating Food Allergies Hall 3d Chair: Jonathan Hourihane, Ireland Welcome and Introductions Jonathan Hourihane, Ireland The Unique Immune Properties of the Skin Hugh A. Sampson, United States Clinical Development of EPIT in Food Allergies André C. Knulst, The Netherlands What Are the Expectations for Peanut Allergy Immunotherapy? Jonathan M. Spergel, United States Conclusions and Faculty Panel Discussion

187 Symposium SPONSORSHIP Invitation AND EXHIBITION EAACI Congress 2017 ALUMINIUM FREE COMPANY The Best Therapies By Design Sunday, 18th June :30 19:00 Helsinki, Finland Messukeskus, Hall 3G Chair Person: Stephen Durham Featured Speakers: Jörg Kleine-Tebbe The importance of defining the optimal dose Erika Jensen-Jarolim Molecular fingerprinting of complex allergoids Uwe Berger Rationale for broad spectrum grass immunotherapy Tim Higenbottam Defining the plateau of the efficacy for Allergen Specific Immunotherapy INDUSTRY NPM 02

188 COMPANY SPONSORED SATELLITE SYMPOSIA COMPANY SPONSORED SATELLITE SYMPOSIUM (SAT 9) 17:45-19:15 CSL Behring GmbH: The dawn of a new era of HAE Management Hall 3e Chairs: Timothy Craig, United States Marco Cicardi, Italy Welcome and introduction Marco Cicardi, Italy; Timothy Craig, United States Unmet medical needs in HAE management Markus Magerl, Germany Experience with C1-INH replacement therapy for HAE management Hilary Longhurst, United Kingdom COMPACT: Evidence for subcutaneous C1-INH for routine prevention Bruce Zuraw, United States Panel discussion All Closing remarks Marco Cicardi, Italy; Timothy Craig, United States COMPANY SPONSORED SATELLITE SYMPOSIUM (SAT 10) 17:45-19:15 Sanofi Genzyme and Regeneron: Evolving Concepts and Clinical Implications for Targeted Therapeutics in Asthma Patients with Overlapping Type 2 Comorbidities Room 103a Chair: William Busse, United States Welcome and Introduction William Busse, United States Clinical Insights into the Management of Patients with Multiple Comorbidities: Clinical Challenges, Best Practices, and Future Directions William Busse, United States High Burden of Disease in Patients with Multiple Type 2 Diseases and Associated Comorbidities David Price, United Kingdom Lessons Learned from Immune-Epithelial Interactions in the Skin and Implications for Airway Diseases Donald Leung, United States Exploring the Links Between Upper and Lower Airway Inflammation and Implications for The Clinic Claus Bachert, Belgium Asthma Immunology A clinical approach Klaus Rabe, Germany INDUSTRY Closing Remarks and Panel Q&A William Busse All 188

189 SPONSORSHIP AND EXHIBITION Celebrating the 50-year anniversary of the discovery of Immunoglobulin E Join us for a Company Sponsored Symposium The story of IgE The next 50 years on Sunday, June 18 from in Hall 1. Visit us in Booth #B12 to celebrate the milestone that led to 5 decades of diagnostic innovations in the treatment of allergy and asthma. INDUSTRY thermoscientific.com/phadia Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.

190 COMPANY SPONSORED SATELLITE SYMPOSIA COMPANY SPONSORED SATELLITE SYMPOSIUM (SAT 11) 17:45-19:15 Teva Pharmaceuticals Room 102 Chair: Vibeke Backer, Denmark Welcome and introduction Vibeke Backer, Denmark Severe asthma: idetifying those with the eosinophilic phenotype Dave Singh, What biomarkers are clinically important in the inflamed lung? Johann Christian Virchow, Germany Anti-IL-5 therapy: from clinical trials to clinical practice Guy Brusselle, Belgium Summary and close Vibeke Backer, Denmark TUESDAY, 20 JUNE 2017 COMPANY SPONSORED SATELLITE SYMPOSIUM (SAT 12) 17:30-19:00 Aimmune Therapeutics, Inc.: Meeting Patients Needs: Exploring a Path to an Approved Oral Treatment for Peanut Allergy Hall 3a Chair: Clare Mills, United Kingdom Chair s address Clare Mills, United Kingdom Why do patients and families need an approved oral therapy for peanut allergy? Sabine Schnadt, Germany How is oral immunotherapy evolving? Kirsten Beyer, Germany Defining success of oral immunotherapy for Health Care Practitioners Pablo Rodríguez del Río, Spain Chair s closing remarks COMPANY SPONSORED SATELLITE SYMPOSIUM (SAT 13) 17:30-19:00 Sanofi Genzyme and Regeneron: Advancing the Clinical Care of Patients With Persistent Atopic Dermatitis Hall 3g Chair: Thomas Bieber, Germany Welcome and Introduction Thomas Bieber, Germany INDUSTRY Clinical Challenges, Best Practices, and Future Directions Thomas Bieber, Germany The Predisposition of Patients Living With AD: Comorbidities and Atopic March Mark Boguniewicz, United States Emerging Therapeutic Strategies for Atopic Dermatitis Michael Cork, United Kingdom Looking Forward Defining Different AD Clinical Phenotypes: Biomarkers and Genotypes Associated With AD Endotypes Thomas Bieber, Germany Closing Remarks and Panel Q&A Thomas Bieber, Germany All 190

191 SPONSORSHIP AND EXHIBITION PhARF (Phadia Allergy Research Forum) was established in 1987 to honor the 20th anniversary of the discovery of IgE at Uppsala University. PhARF is organized by Uppsala University and sponsored by Thermo Fisher Scientific, ImmunoDiagnostics. The objective of PhARF is to encourage progress in allergy research internationally; by an annual Award offered to a young scientist who has made outstanding contribution to the field of IgE associated diseases through creative and independent research efforts. Currently, the Award amounts to USD 50,000. A Nomination Committee at Uppsala University is responsible for the selection of the nominees and the winner is chosen every year by a Scientific Committee, today comprised of the presidents of the major organizations within the field of allergy, asthma and immunology; EAACI, AAAAI and WAO. The 2017 PhARF Award The recipient will be announced at the: EAACI Opening Ceremony Date: Saturday, June 17 Time: Place: Session Room Hall 1, Helsinki INDUSTRY Linder & Co, 2017

192 COMPANY SPONSORED SATELLITE SYMPOSIA COMPANY SPONSORED SATELLITE SYMPOSIUM (SAT 14) 17:30-19:00 BIOMAY AG: Peptide carrier fusion vaccines: A new paradigm for allergen specific immunotherapy Room 103a Chairs: Marianne van Hage, Sweden Rudolf Valenta, Austria Welcome Rainer Henning, Austria Limitations of current allergen extract-based AIT Marianne van Hage, Sweden Design of recombinant AIT vaccines based on the peptide carrier fusion technology Rudolf Valenta, Austria Clinical evaluation of a grass pollen allergy vaccine based on the peptide carrier fusion technology Petra Zieglmayer, Austria Questions & Answers INDUSTRY KEY OPINION LEADER INSIGHTS SUNDAY, 18 JUNE 2017 KEY OPINION LEADER INSIGHTS SESSION (KOL 1) 15:00-15:30 DBV Technologies: Investigational Epicutaneous Immunotherapy: Shaping the Future of Treating Food Allergies Pro & Con Arena Epicutaneous Immunotherapy (EPIT): A Brief Overview Hugh A. Sampson, United States Investigating EPIT in Milk-Induced Eosinophilic Esophagitis Jonathan M. Spergel, United States Conclusions and Q&A HIGHLIGHTS SESSIONS MONDAY, 19 JUNE 2017 HIGHLIGHTS SESSION 15:20-15:35 Exposure prevention measures, its value to rhinitis and asthma patients Pro & Con Arena INDUSTRY Chairs: Philippe Gevaert, Enrico Heffler TUESDAY, 20 JUNE 2017 Unrestricted educational grant provided by PHILIPS HIGHLIGHTS SESSION 15:05-15:20 Highlights on Allergen Immunotherapy the treatment of the future Pro & Con Arena Chairs: Lars Jacobsen, Oliver Pfaar Unrestricted educational grant provided by Laboratorios LETI, s.l.u

193 Visit us at our booth A.12 SPONSORSHIP AND EXHIBITION Uriach Sponsored Symposium at the EAACI Congress 2017 CONSOLIDATED STRATEGIES IN THE MANAGEMENT OF ALLERGIES Helsinki Monday 19 June 15:45-17:15h Hall 3d Chairpersons Torsten Zuberbier, Germany Marek L. Kowalski, Poland Lectures What s new in ARIA and Urticaria guidelines? Torsten Zuberbier, Germany The added value of Rupatadine in children Paraskevi Xepapadaki, Greece Rupatadine: a safe choice in the treatment of allergies Joaquim Mullol, Spain INDUSTRY 193

194 Karkkipiste (ei osastopaikka) EXHIBITION FLOORPLAN 3g 3c 3f N.14 N.15 N.18 lokerikot 3b N.13 N.16 N.17 National Society Village 3e N.03 N.04 N.09 N.10 HALL 1 3a N.02 N.05 N.08 N.11 N.01N.06 N.07 N.12 3d Fazer Café to Exhibition GALLERY MAIN ENTRANCE Registration Area to Exhibition Meet & Eat A.07A.05 A.09A.08 A.01 A.02 Helsinki Café A.03 B.01 C.01 C.02 D.01 A.10 B.02 B.03 Street Kitchen B.04 C.04 C.03 D.02 INDUSTRY Pasta Sapore D.03 D.04 D.09 D.05 D.08 D.07 D.06 Shop Virtual Congress Hub & Seating Area E.01 E.02 A.12 B.05 D.11 C.05 B.09 B.06 D.10 D.12 B.08 B.07 B.10 C.06 C.07 D.13 D.14 D.16 D.17 Pro & Con Arena Conference Centre A.11 A.13 A.14 A.15 A.16 B.11 B.12 B.13 B.15 B.14 Meet & Eat D.18 D.19 D.24 D.20 D.23 D.21 D.27 D.26 D.28 D.29 Publishers Corner Poster Area Poster Area Exhibition opening hours: Sunday, 18 June :00-17:30 Monday, 19 June :00-17:30 Tuesday, 20 June :00-17:

195 EXHIBITOR LIST Company/Society Booth Company/Society Booth Founder Sponsors - Platinum Level Mylan B.01 Novartis Pharma AG A.11 Founder Sponsors - Gold Level ALK A.10 Allergopharma GmbH & Co. KG B.02 Allergy Therapeutics plc. B.10 HAL Allergy A.03 STALLERGENES GREER A.01 / A.08 / B.08 / C.01 Thermo Fisher Scientific B.12 Uriach A.12 Sanofi Genzyme and Regeneron D.01 Shire International GmbH C.07 / D.10 Siemens Healthcare GmbH D.05 SmartPractice A.16 Teva Pharmaceuticals E.01 Yilmaz Medikal A.05 Publishers BioMed Central D.29 Karger Publishers D.26 Wiley D.28 Wisepress Medical Bookshop D.27 Founder Sponsors - Silver Level Laboratorios LETI, s.l.u. B.03 Nestlé Health Science B.05 Exhibitors Abionic SA D.11 Aimmune Therapeutics, Inc. A.13 Anallergo S.p.A. D.23 AstraZeneca C.04 Bausch + Lomb A.07 Boehringer Ingelheim International GmbH D.02 BÜHLMANN Laboratories AG B.09 Chiesi B.15 CIRCASSIA D.12 Citeq Biologics A.14 CSL Behring GmbH B.11 DBV Technologies C.05 DIATER A.02 Dr. Fooke Laboratorien GmbH B.07 DST - Diagnostische Systeme & Technologien GmbH B.06 epgonline.org D.03 EUROIMMUN AG B.04 EXBIO Praha, a.s. D.24 FAES FARMA B.13 GlaxoSmithKline C.02 / C.03 Hangzhou Zheda Dixun biological Gene Engineering Co.,Ltd D.21 Hitachi Chemical Diagnostics Inc. D.04 Indoor Biotechnologies Ltd D.06 Inmunotek S.L. D.17 LINICAL B.14 LOFARMA SPA D.18 MacroArray Diagnostics D.09 MENARINI GROUP E.02 Nasaleze International Ltd. A.09 Nutricia A.15 Omega Diagnostics Ltd. D.07 Orion Pharma D.19 PHILIPS D.16 Red Maple Trials Inc. D.08 Societies ABEFORCAL N.04 Algerian Society of Allergology and Clinical Immunology N.01 American Academy of Allergy, Asthma & Immunology (AAAAI) D.13 APAAACI and APAPARI N.02 Azerbaijan Society for Allergy, Immunology and Immunorehabilitation N.03 Brazilian Association of Allergy and Immunology N.14 CIS Society of Allergology and Clinical Immunology N.05 EAACI Patient Organisations Committee N.12 GAAPP - Global Allergy & Asthma Patient Platforms D.20 Georgian Association of Allergology and Clinical Immunology (GAACI) N.06 Indian College of Allergy and Applied Immunology (ICAAI) N.15 Italian Association of Hospital and Territorial Allergists and Immunologists N.09 Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC) N.07 Italian Society of Pediatric Allergy and Immunology N.08 KIAAA Kosovo Immunology Asthma and Allergy Association N.18 Lithuanian Society of Allergy and Clinical Immunology N.10 Pediatric Allergy and Asthma Academy Society-CAAAD N.16 Russian Association of Allergologists and Clinical Immunologists (RAACI) N.19 The British Society for Allergy & Clinical Immunology (BSACI) N.11 Turkish National Society of Allergy and Clinical Immunology N.17 Ukrainian Society for Immunology, Allergology and Immunorehabilitation N.13 World Allergy Organization (WAO) D.14 INDUSTRY 195

196 EXHIBITOR EDITORIALS Abionic SA D.11 Biopôle, sect. Esplanade SE-A, Route de la Corniche 3 CH-1066, Epalinges Switzerland Telephone: Based on a disruptive nanotechnology, Abionic is committed to improving the world of allergy diagnostics through innovation by providing a rapid quantitative platform to medical practitioners. Aimmune Therapeutics, Inc. A Marina Boulevard, Suite Brisbane United States Telephone: Allergopharma GmbH & Co. KG B.02 Hermann-Körner-Straße Reinbek Germany Telephone: Allergopharma is one of the leading companies in the field of allergen immunotherapy (AIT). We provide innovative products for the causal treatment of IgE-mediated allergic diseases and we are one of the market leaders for subcutaneous AIT. Our portfolio includes a diverse spectrum of approved allergen products that meet high quality standards. We offer high-dose, hypoallergenic, standardized products for the specific immunotherapy of pollen and mite allergies. Furthermore, Allergopharma has a broad range of skin prick test and provocation test solutions for a precise diagnosis of IgE-mediated allergic conditions. Products of Allergopharma are available in more than 20 markets worldwide. INDUSTRY Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company s Characterized Oral Desensitization ImmunoTherapy (CODIT) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune s first investigational biologic product is being studied for the treament of peanut allergy utilizing the CODIT approach. This investigational product has received the FDA s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, please see ALK A.10 Bøge Allé Hørsholm Denmark Telephone: ALK is a research-driven global pharmaceutical company with the mission to improve quality of life for people with allergy by developing pharmaceutical products that target the actual cause of allergy. ALK is a leader in allergy immunotherapy (AIT) - a unique treatment whose protective immune response reduces and potentially halts the allergic reaction. To offer as many patients as possible a causal allergy treatment, AIT is available as sublingual tablets, subcutaneous injections and sublingual droplets. ALK also provides emergency allergy treatment for food and untreated venom allergy. ALK has approx employees with subsidiaries, production facilities and distributors worldwide. Allergy Therapeutics plc. B.10 Dominion Way BN 14 8 SA, Worthing, West Sussex United Kingdom Telephone: Allergy Therapeutics plc is a fully integrated pharmaceuticals company with a profitable core business and a unique development pipeline with the potential to transform allergy treatment. The company has its own European sales & marketing infrastructure, GMP manufacturing & R&D facilities with over 450 employees. The core business has profitable sales of 48.5 supporting the development of unique, next generation, disease modifying allergy vaccines. The new vaccines are ultra-short course injected. Established in 1934, Allergy Therapeutics was listed on the London Stock Exchange s AIM in November 2004 (AGY.L) Allergy Therapeutics has a long-term commitment to research and in particular development of innovative therapies for both the treatment and prevention of allergy-related conditions. American Academy of Allergy, Asthma & Immunology (AAAAI) D East Wells Street, Suite Milwaukee United States Telephone: The American Academy of Allergy, Asthma & Immunology (AAAAI) represents allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic and immunologic diseases. Established in 1943, the AAAAI has nearly 7,000 members in the United States, Canada and 72 other countries

197 SPONSORSHIP AND EXHIBITION Lorem Subcutaneous ipsum dolor AIT sit amet consectetuer Allergopharma - the specialist in diagnosis and therapy of allergic diseases Lorem ipsum dolor sit amet consectetuer adipiscing elit sed diam nonummy nibh euismod tincidunt Visit us at INDUSTRY A business of Allergopharma GmbH & Co. KG Germany 197

198 EXHIBITOR EDITORIALS Anallergo S.p.A. D.23 Viale Nilde Iotti Scarperia e San Piero Italy Telephone: Anallergo is a biotechnology company focusing in the field of therapies for allergic diseases such as rhinitis, conjunctivitis, asthma and atopic dermatitis. Anallergo is a fully integrated pharmaceutical company (Research & Development, Production, Sales). The research of advanced immunotherapies is our main driver. Our fields of research include high purity raw materials, new production process technology and new therapies. Our main projects are the following: Insect Venoms source material Inactivated bacterial process technology Advanced immunotherapies The brand new plant located in Tuscany(Italy) is ready to supply Sublingual Immunotherapy (SLIT), Subcutaneous Immunotherapy (SCIT) and Advanced Immunotherapies in Europe and to the international markets. AstraZeneca C.04 1 Francis Crick Ave CB2 0RE, Cambridge United Kingdom Telephone: AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Disease and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide BÜHLMANN Laboratories AG B.09 Baselstrasse Schönenbuch Switzerland Telephone: BÜHLMANN is a fully independent, globally active Swiss based company offering cellular allergen stimulation tests since These tests are based on in-vitro activation of basophiles upon specific allergen contact with determination of cell surface marker CD63 and CD203c via flow-cytometry, or secreted leukotrienes via ELISA. They provide functional results beyond the specific IgE methods and significantly improve detection of drug, venom and food allergies. BÜHLMANN, the only company offering more than 160 standardized allergens in combination with our BAT tests, is focused on the continuous development of new allergens to extend this exclusive panel. Chiesi B.15 Kungstensgatan Stockholm Sweden Telephone: Chiesi Farmaceutici S.p.A. Via Palermo 26/A Parma Italy. Nordic Contact: Chiesi, Kungstensgatan 38, Stockholm. Phone infonordic@chiesi.com CIRCASSIA D.12 Louisenstraße Bad Homburg Germany Telephone: INDUSTRY Boehringer Ingelheim International GmbH D.02 Binger Str Ingelheim Germany Telephone: Boehringer Ingelheim is one of the world s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates presently with a total of some 50,000 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim has over 90 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions in areas of high unmet patient need including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF). Circassia is a specialty biopharmaceutical company focused on respiratory disease and allergy. Our growing commercial organization promotes our innovative asthma management products directly to specialist physicians, and we have a broad pipeline of asthma, COPD and allergy treatments in development. Citeq Biologics A.14 Admiraal de Ruyterlaan GN Groningen The Netherlands Telephone: Citeq is a producer of allergen source material. Citeq was born based on a passion for mites and the research for how mites influence our daily lives. With over 20 years of experience and an extensive knowledge about mites Citeq is more than just a supplier of allergen source material. We strive for an academic collaboration with our customers in order to achieve the best possible results in research, diagnostics and immunotherapy

199 EXHIBITOR EDITORIALS CSL Behring GmbH B.11 Emil-von-Behring Str Marburg Germany Telephone: CSL Behring is a global biotherapeutics leader which is driven by its promise to save lives. Focused on serving patients needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn. The parent company, CSL Limited (ASX:CSL), headquartered in Melbourne, Australia, employs more than 17,000 people, delivering it s life-saving, life-changing therapies to people in more than 60 countries. DBV Technologies C avenue Pierre Brossolette Montrouge France Telephone: DBV Technologies is a clinical-stage biopharmaceutical company focused on changing the field of immunotherapy. We are committed to finding efficacious, safe, and patient-friendly therapies for food allergic patients, for whom there are no currently approved treatments. A Phase 3 trial for the treatment of peanut allergy and a Phase 2 trial for the treatment of milk allergy are currently ongoing. Satellite Symposium Controversies on Special Products for Managing Cow s Milk Protein Allergy (CMPA) in Infants Safety and Suitability Sunday 18 th June 17:30-19:00 Room 101abc Chairpersons: Antonella Muraro Italy Arne Høst Denmark Choosing the most appropriate dietary management for infants with CMPA. Rosan Meyer UK Not all extensively hydrolysed formulas intended for CMPA are the same. Martinas Kuslys Switzerland New guidelines ensuring safe products for infants with CMPA update from the EAACI Task Force on special products for CMPA. Antonella Muraro Italy Arne Høst Denmark INDUSTRY Follow us 199

200 EXHIBITOR EDITORIALS DIATER A.02 Avda. Gregorio Peces Barba 2, Parque Tecnológico de Leganés Madrid Spain Telephone: epgonline.org D.03 Royal Victoria House, The Pantiles TN2 5TE Tunbridge Wells United Kingdom Telephone: INDUSTRY Diater is a biopharmaceutical company specialized in allergies and focused in developing, manufacturing and marketing allergen extracts for the diagnosis and treatment of IgE-mediated allergic diseases. The company, which is headquartered in Madrid, was founded with private capital in 1999 and has been a part of Ferrer s group since Diater has been committed to innovation in allergic diseases. Currently, the company s products are present in over 40 countries around the world thanks to the solid strategic and business partnerships established throughout these years. Our goal is help to improve the health and quality of life of people with allergy. Dr. Fooke Laboratorien GmbH B.07 Habichtweg Neuss Germany Telephone: Dr. Fooke Laboratorien GmbH offers innovative high quality assays for allergy and autoimmune diagnostics. Dedicated to fulfill our customers needs, we use state of the art technologies for the development of flexible and reliable routine applications. DST - Diagnostische Systeme & Technologien GmbH B.06 Güterbahnhofstraße Schwerin Germany Telephone: DST Diagnostische Systeme und Technologien GmbH develops, produces and markets worldwide in-vitro-diagnostic (IVD) and other products for the determination of allergies and food intolerance. The product portfolio covers test systems for laboratory diagnostic as well as various products for point-of-care testing (POC). More than 600 in-house produced, purified and characterized allergens and -components are the base for all of DST s high-quality in vitro diagnostic products, which are all CE-marked. Further information and download: epgonline.org epgonline.org is the website for healthcare professionals, providing fast, convenient and free access to the medical information that healthcare professionals want where, when and how they want it. Carefully curated from trustworthy sources, information is conveniently organised by disease, medical specialty, content type and localised edition (in 9 languages). Content includes prescription drug information, treatment guidelines, drug and industry news, clinical trials, journal article abstracts and disease-focused Learning Zones funded by trusted partners in healthcare. epgonline.org is constantly evolving to reflect the needs of healthcare professionals, providing a service that truly empowers, influences behaviour and leads to better healthcare outcomes. epgonline.org is owned by EPG Health Media, part of group business EPG Communication Holdings. EUROIMMUN AG B.04 Seekamp Luebeck Germany Telephone: EUROIMMUN is an international provider of medical laboratory products with a growing focus on allergy diagnostics. The company s EUROLINE system encompasses more than 500 different allergens and allergen components and provides reliable screening assays for the efficient determination of specific IgE antibodies. The EUROLINE system comprises a comprehensive spectrum of indication-oriented and country-specific profiles, and includes component-resolved profiles for in-depth characterisation of allergy triggers. Specialised instruments and software provide efficient automation of analyses. EUROIMMUN s allergy range complements its products for autoimmune diagnostics, infection diagnostics and molecular diagnostics. EXBIO Praha, a.s. D.24 Nad Safinou II Vestec Czech Republic Telephone: EXBIO strives to exceed the most demanding customer expectations in the field of analytical cytometry. With 25 years of experience in manufacture of monoclonal antibodies EXBIO provides a comprehensive range of high quality products for research and diagnostic applications. Antibodies from a broad list of clones are available in many colors and also in premixed CE IVD cocktails. Flow cytometry kits are intended for analysis of allergy, phagocytosis, apoptosis, fertility, NK cells and cell cycle

201 EXHIBITOR EDITORIALS Committed to Advance Research in Respiratory Medicine in Areas of Unmet Medical Need Among Patients With Poorly Controlled Asthma and Nasal Polyposis EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY INDUSTRY VISIT US AT BOOTH #D Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. 03/2017 US-G-ILF SAGLB.DUP

202 EXHIBITOR EDITORIALS FAES FARMA B.13 Avenida Autonomia, Leioa (Bizkaia) Spain Telephone: Hitachi Chemical Diagnostics Inc. D.04 Whitebrook Park, Lower Cookham Road SL6 8YA Maidenhead United Kingdom Telephone: INDUSTRY FAES FARMA is a leading Spanish company which researches, produces and commercialization of pharmaceutical products and raw materials. It exports for over 60 countries. Maximum pharmacological quality in its products, is a core objective. FAES FARMA has the head office and R&D centre in Bilbao, Lab.Vitoria in Lisbon, production plants in both cities, and INGASO FARM. FAES FARMA has another 2 subsidiaries and 3 sales offices abroad, presente in 45 countries with over 800 employees. Bilastine, is the lastest novelty from FAES FARMA investigation. A new 2nd generation, non-sedating antihistamine already presente in more than 90 countries. GlaxoSmithKline C.02 / C Great West Road TW8 9GS Brentford United Kingdom Telephone: For more than 45 years, GSK has been helping patients with respiratory disease better manage their condition; to live every breath, and lead the life they want. Investing millions of pounds in research and development each year, and working in collaboration with the scientific community, we remain at the cutting-edge of scientific research into respiratory diseases. We research and develop innovative medicines aimed at helping to treat patients symptoms and reduce the risk of their disease worsening. (RF/RESP/0032/17) Date of preparation: March 2017 HAL Allergy A.03 J. H. Oortweg CH, Leiden The Netherlands Telephone: HAL Allergy Group is a modern leader and innovator in the field of biopharmaceuticals and located at the Bio Science Park in Leiden, The Netherlands. Our core business is the production of allergen extracts, both for therapeutic and diagnostic purposes as well as contract manufacturing with focus on biopharmaceutical products for preclinical and clinical studies. With offices in major European countries, HAL Allergy is one of the European top players, particularly in the field of allergy. Established in 1959 we have long experience in developing and producing therapies against pollen, house dust mite, and insect venom allergy. Hitachi Chemical Diagnostics manufactures and markets Allergen Specific IgE Assays which offer a unique approach to in-vitro multiplex allergy diagnosis worldwide. A panel of up to 36 allergens, specific to geographical location, can be simultaneously tested for allergic severity on a single serum sample. Panel testing provides more clinical information for each sample and is economical to perform. Test automation is provided through state of the art instrumentation. Indoor Biotechnologies Ltd D.06 Vision Court, Caxton Place CF23 8HA Cardiff United Kingdom Telephone: Indoor Biotechnologies manufactures purified natural and recombinant allergens, ELISA (including pre-coated) and multiplex immunoassay systems for allergen detection, dust sampling devices, and a home test for dustmite allergen detection. We provide allergen, endotoxin, mould and food antigen testing at laboratories in Cardiff, UK, Charlottesville, Virginia and Bangalore, India. A newly commissioned Environmental Testing Suite in Cardiff allows efficacy and safety testing of products and procedures for allergen and mould remediation including cleaning products, wipes, acaricides, mattress encasings and air purifying devices. Our mission is to improve patient care through research, education and developing cutting edge technologies that serve clients worldwide. Inmunotek S.L. D.17 Calle Punto Mobi, Alcalá de Henares Spain Telephone: Inmunotek is a pharmaceutical company based in Madrid (Spain), wich investigates, develops, manufactures and commercializes products in the field of Allergy and Immunology for the diagnosis and treatment of allergic respiratory diseases in human and veterinary patients. From the outset, our goal has been to offer innovative and competitive products of the highest quality, useful for professionals and safe and effective for the treatment of patients. To this end we have put together a highly professional and motivated team; we have outstanding facilities and a broad product portfolio. Inmunotek complies with GMPs, and their products are approved by the Spanish Drug Agency and several international regulatory agencies

203 EXHIBITOR EDITORIALS Karger Publishers D.26 Allschwilerstrasse Basel Switzerland Telephone: Founded 125 years ago, this Swiss-based family-owned publishing house combines highly sophisticated production technology with customized services for its authors, editors and readers. Karger Publishers titles in the fields of allergy and immunology include the scientific journals International Archives of Allergy and Immunology and Journal of Innate Immunity and the book series Chemical Immunology and Allergy. Published papers and book volumes are accessible online at with full-text search of articles, pay-per-view options and many other services. Laboratorios LETI, s.l.u. B.03 Gran Via Corts Catalanes, 184 7th floor Barcelona Spain Telephone: Laboratorios LETI is an independent and family-owned biopharmaceutical research company with a global presence of reference in specialized segments of health and wellness, a leader through innovation and development of prestige products and brands. In its different areas of expertise, it seeks to contribute products to society that add value to health care. Its headquarters are in Barcelona and its industrial plant and allergy research laboratory are in Tres Cantos (Madrid). It has subsidiaries in Germany, Portugal and since 2013 it is present in the US through Juventio LLC. LETI operates with exclusive distributors in several countries in Europe, Latin America and Africa HOLISTIC APPROACH IN ALLERGY Come and visit us at our booth B.03 and get ready to discover allergy treatment from a universal perspective. INDUSTRY Looking forward to welcoming you in Helsinki! 203

204 EXHIBITOR EDITORIALS LINICAL B.14 Hahnstrasse Frankfurt am Main Germany Telephone: Linical is a global, full service CRO incepted in With more than 630 employees we directly serve in more than 20 countries in Europe, North America and Asia-Pacific. Linical has gained significant experience in the planning, conduct and analysis of immunology and allergy clinical trials, both in adults and in paediatric populations. We are able to leverage know-how and expertise coupled with leading technology. MENARINI GROUP E.02 1, AVENUE DE LA GARE 1611 Luxembourg Luxembourg Telephone: The Menarini Group is the leading Italian pharmaceutical company in the world, a guarantee of internationally recognised quality. Present in over 100 countries across the globe, Menarini Group is rapidly becoming a top respiratory player, addressing patients needs in Allergy, COPD & Asthma. INDUSTRY LOFARMA SPA D.18 Viale Cassala Milano Italy Telephone: Lofarma SpA is since 1945 a reference point in allergy care in Italy and abroad. With its innovative made in Italy products, the Company is engaged in improving allergic patients life, offering new tools to respond to doctors needs.its wide products range includes the original monomeric carbamylated allergoid for specific Immunotherapy in tablets, drops, injections, the first oral nickel treatment, diagnostics, branded pharmaceutical products, innovative medical devices, food supplements.besides its relevant presence in Italy, Lofarma is constantly expanding towards new foreign countries, which together with Germany,South Korea,Russia,Greece,Albania,Portugal,Hungary,Spain,Mongolia,will soon be part of Lofarma s world. MacroArray Diagnostics D.09 Gutheil Schoder Gasse Vienna Austria Telephone: MacroArray Diagnostics is a Vienna based MedTech startup, and was founded in We develop, produce and distribute reagents and automation solutions for immunological research and diagnosis. From our RnD pipeline we will launch products for several diseases, starting with our allergy IVD test at EAACI We create the most advanced tools for medical practitioners and researchers to improve the diagnosis of immunological diseases. All our products are based on a patent-pending technology. They allow precise, reliable and affordable immunological profiling of each patient, while lowering the cost of diagnosis and treatment. Mylan B.01 Benzstrasse Bad Homburg Germany Telephone: Mylan is one of the world s leading global pharmaceutical companies committed to setting new standards in healthcare and our mission is to provide the 7billion people across the globe with access to high quality medicine. Our growing portfolio of more than 2,700 medicines include generic, brand name and over-the-counter-products. Our global R&D/ manufacturing platform includes more than 50 facilities, and we are one of the world s largest producers of active pharmaceutical ingredients. We market our products in more than 165 countries and territories. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world. Nasaleze International Ltd. A.09 Nunnery Mills Old Castletown Road IM2 1QA Douglas, Isle of Man, British Isles United Kingdom Telephone: Nasaleze International Ltd are manufactures and brand owners of a unique, patented dry nasal powder for the treatment of allergies. The product has numerous double blind placebo controlled studies to support the efficacy. It has no known side effects, can be used by children and pregnant women and as a combination therapy with drugs to enhance the efficacy. The product is sold all over the world, with companies such as Boots in the UK. Leading KOL s endorse the product for its non-drowsy and very fast acting efficacy. A Poster Presentation is being given by Prof Popov at the Congress 204

205 AstraZeneca Industry Evening Symposium A Personalized Approach to Eosinophilic Asthma: Expert Perspectives in Clinical Practice 19 June :45 19:15 Room: Hall 3a 17:45 17:50 Welcome and Introductions Ian Pavord (Chair) London, United Kingdom 17:50 18:15 Challenges in Asthma Heterogeneity Leif Bjermer Lund, Sweden 18:15 18:40 Clinical and Patient Perspectives in Severe Eosinophilic Asthma Arnaud Bourdin Montpellier, France 18:40 19:05 The Evolving Science of Severe Asthma and Emerging Clinical Practices Ian Pavord (Chair) London, United Kingdom INDUSTRY 19:05 19:15 Panel Discussion and Audience Q&A Light refreshments will be served during this event. This event is organised and sponsored by AstraZeneca AstraZeneca. Promomats Number: Z Preparation date: March 2017; Expiry date: July

206 EXHIBITOR EDITORIALS Nestlé Health Science B.05 Avenue Nestlé Vevey Switzerland Telephone: Omega Diagnostics Ltd. D.07 Omega House, Hillfoots Business Village FK12 5DQ Alva Scotland, United Kingdom Telephone: INDUSTRY Nestlé Health Science is a health-science company engaged in advancing the role of nutritional therapy to change the course of health for consumers, patients and its partners in healthcare. Its portfolio of nutrition solutions, diagnostics, devices and drugs, targets a number of health areas, such as inborn errors of metabolism, pediatric and acute care, obesity care, healthy aging as well as gastrointestinal and brain health. In the field of food allergy, we aim to provide safe hypoallergenic products and tools for healthcare professionals to facilitate an earlier accurate diagnosis and use of appropriate products in line with existing guidelines. Novartis Pharma AG A.11 Novartis Campus, Asklepios Basel Switzerland Telephone: Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion (USD 8.4 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. Nutricia A.15 WTC Schiphol Airport Schiphol Boulevard BG Amsterdam The Netherlands Telephone: Nutricia Advanced Medical Nutrition is division of Danone and our mission is to establish medical nutrition as an integral part of healthcare. Nutricia s broad portfolio is designed to improve clinical outcomes and restore quality of life for patients of all ages. In paediatrics, Nutricia brings proven solutions for children and their carers in cow s milk allergy, faltering growth, neuro-disability, and metabolic conditions. Omega Diagnostics develop, manufacture and sell allergy tests for over 600 allergens. It has more than 20 years experience in the development of products for the diagnosis of allergic diseases. During this time, the company has gained a substantial understanding and knowledge in the production and standardisation of allergen extracts. This supports its current product offering and is being applied in the development of new in-vitro diagnostic products and systems. Orion Pharma D.19 Orionintie 1 A Espoo Finland Telephone: Orion is a globally operating Finnish developer of pharmaceuticals and diagnostic tests a builder of well-being already since Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. It is continuously developing new drugs and treatment methods. The core therapy areas of Orion s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion has discovered and patented a device-metered dry powder inhaler. Orion and Finland both celebrate their centenaries in Read more about Orion s centenary here orion-centenary-begins/ PHILIPS D.16 Amstelplein BC Amsterdam The Netherlands Telephone: Philips Air is a leading supplier of air purifiers, humidifiers and dehumidifiers as well as air quality sensors for indoor use. The air purifiers are equipped with filters that remove 99+% of fine-dust from the air, including air-borne biological species like viruses, bacteria, mold and pollen. Models also effectively reduce indoor levels of oxidative gasses like ozone (O3) and nitrogen dioxide (NO2) and hazardous components like formaldehyde and benzene. Devices are intended to operate in rooms of homes and offices. Our air quality sensors give real-time feedback about indoor PM2.5 levels. They help people to understand the cause of high fine-dust exposures and thus to take relevant countermeasures. We look forward to your visit

207 SPONSORSHIP AND EXHIBITION Please join this satellite symposium hosted by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. Evolving Concepts and Clinical Implications for Targeted Therapeutics in Asthma Patients with Overlapping Type 2 Comorbidities MONDAY, JUNE 19 17:45 19:15 ROOM 103A MESSUKESKUS EXHIBITION AND CONVENTION CENTRE HELSINKI, FINLAND SPEAKER PANEL WILLIAM BUSSE, MD (CHAIR) UNIVERSITY OF WISCONSIN MADSION SCHOOL OF MEDICINE AND PUBLIC HEALTH, USA DAVID PRICE, MBB CHIR, MA, DRCOG, FRCGP UNIVERSITY OF ABERDEEN, SCOTLAND AND UNIVERSITY OF ADELAIDE, AUSTRALIA DONALD LEUNG, MD, PHD NATIONAL JEWISH HEALTH DENVER, CO, USA CLAUS BACHERT, MD, PHD PROFESSOR, UPPER AIRWAY RESEARCH LABORATORY AND DEPARTMENT OF OTORHINOLARYNGOLOGY UNIVERSITY OF GHENT, BELGIUM KLAUS RABE, MD, PHD UNIVERSITY OF KIEL, GERMANY Speakers will receive compensation for their participation in this event. INDUSTRY SAGLB.AST a 207

208 EXHIBITOR EDITORIALS Red Maple Trials Inc. D Conroy Rd Unit 110 K1G6C6 Ottawa Canada Telephone: Red Maple Trials provides specialty services in allergy, asthma and immunology clinical research, highlighted by our CRO Services, our next generation Allergen Challenge Theatre (environmental exposure chamber), our Cat Challenge Chamber, and our Phase I infrastructure. Our clinical trial facilities are capable of executing on Phase I through IV studies, and our experienced team provides leading services in order to fulfill the challenging demands of our biopharmaceutical partners. Sanofi Genzyme and Regeneron D Kendell Street Cambridge United States Telephone: Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies. Shire International GmbH C.07 / D.10 Zählerweg Zug Switzerland Telephone: Siemens Healthcare GmbH D.05 Henkestrasse Erlangen Germany Telephone: Siemens Healthineers is one of the world s largest suppliers of technology to the healthcare industry and a leader in medical imaging, laboratory diagnostics and healthcare IT. All supported by a comprehensive portfolio of clinical consulting, training, and services available across the globe and tailored to customers needs. In fiscal 2015, Siemens Healthineers had around 44,000 employees worldwide and posted revenue worth 12.9 billion euros, and profits of more than 2.1 billion euros. Further information is available on the Internet at SmartPractice A E McDowell Road Phoenix United States Telephone: Our Dermatology Allergy division exists because patients deserve a diagnosis. Developed over the past 15 years, our multi-brand, multiproduct Dermatology Allergy division focuses on providing innovative products to help diagnose and treat patients with allergic contact dermatitis. SmartPractice is the manufacturer and exclusive worldwide distributor of ready to use patch tests, premium quality chamber & allergen products and the developed of the only patented precision allergen dispenser to standardize your patch testing clinic. Through our investments in technology, clinical science, and world-class service, SmartPractice is committed to all things contact dermatitis for physicians and patients. INDUSTRY Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs. We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics. STALLERGENES GREER A.01 / A.08 / B.08 / C Bernard Street 3rd Floor WC1N 1LE London United Kingdom Telephone: Stallergenes Greer is a global biopharmaceutical company specializing in the diagnosis and treatment of respiratory allergies through the development and commercialization of allergy immunotherapy products and services. Our purpose is to enable people with allergies to live normal lives. With more than 1,400 employees worldwide, a presence in 22 countries, and manufacturing facilities in both Europe and the United States, Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (registered office in the U.S.) and Stallergenes S.A.S. (registered office in France). With complementary strengths and joint heritage, Stallergenes Greer is driving a continuing leadership in Allergy Immunotherapy

209 SPONSORSHIP AND EXHIBITION CSL Behring sponsored Satellite Symposium THE DAWN OF A NEW ERA OF HAE MANAGEMENT PROGRAMME Monday 19 June, :45 19:15 Room: Hall 3e Chaired by Marco Cicardi, Italy; Timothy Craig, United States 17:45 17:50 Welcome and introduction Marco Cicardi, Italy; Timothy Craig, United States 17:50 18:05 Unmet medical needs in HAE management Markus Magerl, Germany 18:05 18:20 Experience with C1-INH replacement therapy for HAE management Hilary Longhurst, United Kingdom 18:20 18:40 COMPACT: Evidence for subcutaneous C1-INH for routine prevention Bruce Zuraw, United States 18:40 19:10 Panel discussion All 19:10 19:15 Closing remarks Marco Cicardi, Italy; Timothy Craig, United States INDUSTRY 209

210 EXHIBITOR EDITORIALS Teva Pharmaceuticals E.01 5 Basel St Petach Tikva Israel Telephone: Wiley D Garsington Road OX4 2DQ Oxford United Kingdom Telephone: INDUSTRY Teva is among the top 15 global pharmaceutical companies globally, delivering high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day. Teva produces a leading innovative treatment for multiple sclerosis and has late-stage development programs for a range of disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions. With its European headquarters in Amsterdam, the Netherlands, Teva is the world s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a broad range of products in nearly every therapeutic area. Teva draws on its specialty and generics capabilities to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva s net revenues in 2016 were $21.9 billion. For more information, visit Thermo Fisher Scientific B.12 Rapsgatan 7P, P.O. Box Uppsala Sweden Telephone: As the ImmunoDiagnostics experts within Thermo Fisher Scientific, we work to significantly improve the management of allergy, asthma and autoimmune disease. We do this by providing healthcare professionals with diagnostic technologies and clinical expertise. This results in better healthcare and quality of life for millions of patients and their families. Uriach A.12 Polígon Industrial Riera de Caldes, Av. Camí Reial, Palau-Solità i Plegamans (Barcelona) Spain Telephone: Uriach is a private Spanish pharmaceutical company based in the Barcelona area. In the pharmaceutical business for over 175 years, it is one of the leading domestic companies. Uriach has always been marked by a strong entrepreneurial character, with an emphasis on scientific and commercial innovation. Over 50 years of continuous devotion to R&D and a team of highly qualified professionals have allowed Uriach to commercialize our products in more than 70 countries. RUPATADINE, a new generation and potent antihistamine with PAF-Antagonist activity is Uriach s contribution to the treatment of allergic conditions. It s the knowledge age and it s Wiley s customers who lead the world s knowledge economy. Our customers drive progress by providing quality education, the right skills to fulfil global demand and scientific research to fuel innovation. Our customers care, their organizations succeed and the world benefits. Wiley develops digital education, learning, assessment and certification to help universities, businesses and individuals bridge between education and employment and achieve their ambitions. We partner with learned societies and support researchers to communicate discoveries that make a difference. Our digital content, books and 1600 online journals build on a 200 year heritage of quality publishing. Wisepress Medical Bookshop D Lyon Road SW19 2RL London United Kingdom Telephone: Wisepress.com, Europe s leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on World Allergy Organization (WAO) D E Wells St., Suite Milwaukee, WI United States Telephone: The World Allergy Organization (WAO) convenes professionals from all over the world to achieve WAO s mission to be a global resource and advocate in the field of allergy and asthma to advance excellence in clinical care, education, research, and training. As an umbrella organization, WAO has world-wide reach through its 97 member societies made up of regional and national allergy, asthma and clinical immunology societies. All programs and initiatives strive to be global in scope and work through collaborations and partnerships to provide venues and forums for international knowledge sharing and networking and to reach and work with emerging regions

211 SPONSORSHIP AND EXHIBITION As a Founder Sponsor of EAACI we proudly invite you to visit our COMPANY SPONSORED SYMPOSIUM FASIT meets EAACI Novel Patient Profiling, Promising Treatments and Regulatory Challenges Tuesday, June 20, h 17.00h, Hall 3g And: Visit us at our booth in the exhibition hall to get excellent information about allergy and specific immunotherapy. Chairs Marek Jutel / Poland Ulrich Wahn / Germany New promising perspectives in AIT Marek Jutel / Poland Molecular approaches for AIT the peril of phase III trials Jörg Kleine-Tebbe / Germany The use of AIT in Europe Regulatory aspects and call for harmonization Oliver Pfaar / Germany How can we offer high quality diagnostics for our patients in the future? Piotr Kuna / Poland We are looking forward to seeing you in Helsinki! Best regards, your Allergopharma-Team INDUSTRY A business of Allergopharma GmbH & Co. KG Germany 211

212 EXHIBITOR EDITORIALS Yilmaz Medikal A.05 Budak Mah. Hasırcı Samibey Cad. NO:12 ŞEHİTKAMİL Gaziantep Turkey Telephone: Serving in ophthalmology branch since 2006, our Company has been manufacturing medical devices comformable with ISO 13485:2003 and ISO 9001:2008 standards and according to 93/42/EEC Medical Devices Regulations. We as Yilmaz Medikal have the objective of increasing the demand products both in the domestic and foreign markets without any concessions of quality and trust. INDUSTRY 212

213 Please join a company-sponsored symposium hosted by Sanofi Genzyme and Regeneron Pharmaceuticals Advancing the Clinical Care of Patients With Persistent Atopic Dermatitis TUESDAY, JUNE 20 17:30 19:00 IN HALL 3G MESSUKESKUS EXHIBITION AND CONVENTION CENTRE, HELSINKI, FINLAND SPEAKER PANEL THOMAS BIEBER, MD, PHD, MDRA UNIVERSITY OF BONN, GERMANY MARK BOGUNIEWICZ, MD UNIVERSITY OF COLORADO SCHOOL OF MEDICINE, USA MICHAEL CORK, BSC, MB, PHD, FRCP UNIVERSITY OF SHEFFIELD, UK INDUSTRY Speakers will receive compensation for their participation in this event Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. All Rights Reserved. SAGLB.DUP b 213

214 HOTELS IN HELSINKI Please contact for further information. Please note that none of the hotels is officially categorised, there is no hotel rating system in Finland. appr. 6 km 6 appr. 8 km appr. 12 km PASILA RAILWAY STATION MAIN RAILWAY STATION Market Square Harbour appr. 16 km appr. 16 km appr. 15 km appr. 12 km 19 Break Sokos Hotel Flamingo 1 Crowne Plaza Helsinki 2 GLO Hotel Art 3 GLO Hotel Kluuvi 4 GLO Hotel Sello 5 Hilton Helsinki Kalastajatorppa Hotel Hilton Helsinki Strand Hotel 7 Holiday Inn Helsinki 8 Holiday Inn Helsinki City Centre 9 Holiday Inn Helsinki - West Ruoholahti 6 10 Hotel Indigo Helsinki - Boulevard 11 Next Hotel Rivoli Jardin 12 Original Sokos Hotel Vaakuna, Helsinki 13 Radisson Blu Aleksanteri Hotel 14 Radisson Blu Hotel Espoo 15 Radisson Blu Plaza Hotel Helsinki Radisson Blu Royal Hotel Helsinki Radisson Blu Seaside Hotel Helsinki Scandic Grand Marina 19 Scandic Marski 20 Scandic Paasi 21 Scandic Park Helsinki 22 Scandic Simonkenttä 23 Solo Sokos Hotel Torni 24 Original Sokos Hotel Pasila 25 not categorised Hotels Hotel Cumulus Hakaniemi Helsinki Hotel Cumulus Kaisaniemi Helsinki Hotel Cumulus Kallio Helsinki 28 Hotel Cumulus Meilahti Helsinki 29 Holiday Inn Helsinki - Vantaa Airport 30 Klaus K Hotel 31 Original Sokos Hotel Helsinki 32 Original Sokos Hotel Presidentti 33 Original Sokos Hotel Vantaa 34 Hotelli Seurahuone Helsinki

215 Come visit DBV at Booth C.05 Investigational Epicutaneous Immunotherapy: Shaping the Future of Treating Food Allergies Food allergies are an increasingly prevalent condition worldwide with no currently approved treatments. Epicutaneous immunotherapy (EPIT) seeks to change this with an ongoing Phase 3 clinical programme in peanut allergies. Join us Sunday for an overview of EPIT and food-induced eosinophilic esophagitis. Return on Monday for a broader discussion on EPIT s scientific foundation and clinical investigation into peanut allergy, including recent long-term Phase 2 study findings. Key Opinion Lead der Insight ts Session Sunday y, 18 June : :30 Messukeskus Expo and Convention Centre Pro & Con Arena Featured faculty: Hugh A. Sampson, MD, and Jonathan M. Spergel, MD, PhD Satellite Symposium Monday, 19 June :45 19:15 Messukeskus Expo and Convention Centre Hall 3d Light refreshments will be served. Featured faculty: Jonathan Hourihane, MD University College Cork Cork, Ireland André C. Knulst, MD, PhD University Medical Centre Utrecht Utrecht, the Netherlands Hugh A. Sampson, MD DBV Technologies Icahn School of Medicine at Mount Sinai New York, New York, USA Jonathan M. Spergel, MD, PhD Children s Hospital of Philadelphia Philadelphia, Pennsylvania, USA These programmes are sponsored by DBV and include data from DBV-sponsored clinical trials, some of which are ongoing. Epicutaneous immunotherapy has not been approved for marketing within or outside the European Union. DBV Technologies - Immeuble Astrée avenue Pierre Brossolette Montrouge - France 2017 DBV Technologies All rights reserved. March 2017/PA-1/EAACI

216 European Academy of Allergy and Clinical Immunology May 2018 Munich, Germany EAACI Congress 2018 Visit the website for more information Innovative Solutions for Allergy #eaaci2018